Product Name,Synonyms,CAS Number,M. Wt,Target,Pathway,Biological Activity,Formula,Solubility,Concentration,Research Area,Clinical Information,SMILES
BAY1125976,,1402608-02-9,383.45,Akt,PI3K/Akt/mTOR,"BAY1125976 is a selective allosteric Akt1/Akt2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively.",C23H21N5O,DMSO : 25 mg/mL (65.20 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(C1=NN2C(C=C1)=NC(C3=CC=C(C4(N)CCC4)C=C3)=C2C5=CC=CC=C5)N
Rogaratinib,BAY1163877,1443530-05-9,466.56,FGFR,Protein Tyrosine Kinase/RTK,"Rogaratinib (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. Rogaratinib inhibits FGFRs with IC50s of 11.2 nM (FGFR1), <1 nM (FGFR2), 18.5 nM (FGFR3), 127 nM (VEGFR3/FLT4), 201 nM (FGFR4), respectively[1][2].",C23H26N6O3S,DMSO : 5 mg/mL (10.72 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C1NCCN(CC2=C(COC)C(C3=CC4=CC(C)=CC(OC)=C4S3)=C5C(N)=NC=NN52)C1
Tomivosertib,eFT508,1849590-01-7,340.38,MNK; PD-1/PD-L1,Immunology/Inflammation; MAPK/ERK Pathway,"Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines[1]. Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance[2].",C17H20N6O2,DMSO : 4.35 mg/mL (12.78 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=C(C)C=C(NC2=NC=NC(N)=C2)C(N13)=O)NC43CCCCC4
AZD-5438,,602306-29-6,371.46,CDK,Cell Cycle/DNA Damage,"AZD-5438 is a potent CDK1, CDK2, and CDK9 inhibitor, with IC50s of 16 nM, 6 nM, and 20 nM in cell-free assays, respectively. AZD-5438 shows less inhibition activity against GSK3β, CDK5 and CDK6
[1].",C18H21N5O2S,DMSO : 100 mg/mL (269.21 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=S(C1=CC=C(NC2=NC(C3=CN=C(N3C(C)C)C)=CC=N2)C=C1)(C)=O
Varenicline (Tartrate),CP 526555-18,375815-87-5,361.35,ERK; nAChR; p38 MAPK,MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Neuronal Signaling; Stem Cell/Wnt,"Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation[1][2][3][4][5].",C17H19N3O6,DMSO : 14.29 mg/mL (39.55 mM; Need ultrasonic); H2O : 20 mg/mL (55.35 mM; ultrasonic and warming and heat to 60°C),10mM,Neurological Disease; Others; Cancer,Launched,O=C(O)[C@H](O)[C@@H](O)C(O)=O.C1(C2CC3CNC2)=C3C=C(N=CC=N4)C4=C1
XL 999,Tyrosine kinase-IN-1,705946-27-6,445.53,FGFR; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"XL999 is a multi-target tyrosine kinase inhibitor. XL999 has IC50 values for KDR, Flt-1, FGFR1 and PDGFRα of 4 nM, 20 nM, 4 nM and 2 nM, respectively. XL999 can be used in the research of cancer[1].",C26H28FN5O,DMSO : 50 mg/mL (112.23 mM; Need ultrasonic),10mM,Cancer; Cardiovascular Disease,Phase 2,O=C1NC2=C(C=C(NC3CCN(CC)CC3)C=C2)/C1=C(C4=CC=CC(F)=C4)/C5=NC=C(C)N5
PF 477736,PF 00477736,952021-60-2,419.48,Aurora Kinase; CDK; c-Fms; Checkpoint Kinase (Chk); FGFR; FLT3; RET; Src; VEGFR,Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK,"PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of Chk1, with a Ki of 0.49 nM, it is also a Chk2 inhibitor, with a Ki of 47 nM. PF 477736 shows <100-fold selectivity for Chk1 over VEGFR2, Fms, Yes, Aurora-A, FGFR3, Flt3,  and Ret (IC50=8 (Ki), 10, 14, 23, 23, 25, and 39 nM, respectively). PF 477736 can enhance Gemcitabine antitumor activity in vitro and in vivo[1][2].",C22H25N7O2,DMSO : 100 mg/mL (238.39 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 1,O=C([C@@H](C1CCCCC1)N)NC2=CC3=C(C(C=NNC4=O)=C(N3)C5=CN(N=C5)C)C4=C2
BFH772,,890128-81-1,439.39,VEGFR,Protein Tyrosine Kinase/RTK,"BFH772 is a potent oral VEGFR2 inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC50 value of 3 nM[1].",C23H16F3N3O3,DMSO : 100 mg/mL (227.59 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC(C(F)(F)F)=CC=C1)C2=CC=CC3=CC(OC4=NC=NC(CO)=C4)=CC=C32
AEE788,NVP-AEE 788,497839-62-0,440.58,Apoptosis; EGFR,Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"AEE788 is an inhibitor of the EGFR and ErbB2 with IC50 values of 2 and 6 nM, respectively.",C27H32N6,DMSO : 50 mg/mL (113.49 mM; Need ultrasonic),10mM,Cancer,Phase 2,C[C@H](C1=CC=CC=C1)NC2=C(C=C3C(C=C4)=CC=C4CN5CCN(CC)CC5)C(N3)=NC=N2
GSK3179106,,1627856-64-7,467.41,RET,Protein Tyrosine Kinase/RTK,"GSK3179106 is an orally active and selective RET kinase inhibitor with IC50s of 0.4 nM, 0.2 nM for human RET and rat RET, respectively. GSK3179106 has the potential for irritable bowel syndrome (IBS) through the attenuation of post-inflammatory and stress-induced visceral hypersensitivity[1].",C22H21F4N3O4,DMSO : ≥ 100 mg/mL (213.94 mM),10mM,Metabolic Disease; Inflammation/Immunology,Phase 1,O=C(NC1=NOC(C(C)(C)C(F)(F)F)=C1)CC2=CC=C(C(C(OCC)=C3)=CNC3=O)C=C2F
H3B-6527,,1702259-66-2,629.54,FGFR,Protein Tyrosine Kinase/RTK,"H3B-6527 is an orally active, highly selective and covalent FGFR4 inhibitor with an IC50 of <1.2 nM. H3B-6527 has at least 250-fold selectivity over FGFR1-3 with IC50s of 320 nM, 1290 nM and 1060 nM respectively. H3B-6527 has potent anti-cancer activity[1].",C29H34Cl2N8O4,DMSO : 2.5 mg/mL (3.97 mM; Need ultrasonic),2mM,Cancer,Phase 1,C=CC(NC1=CC(N2CCN(CC)CC2)=CC=C1NC3=NC=NC(N(C(NC4=C(Cl)C(OC)=CC(OC)=C4Cl)=O)C)=C3)=O
Fisogatinib,BLU-554,1707289-21-1,503.38,FGFR,Protein Tyrosine Kinase/RTK,"Fisogatinib (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 5 nM. Fisogatinib has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling[1][2].",C24H24Cl2N4O4,DMSO : 100 mg/mL (198.66 mM; Need ultrasonic),10mM,Cancer,Phase 2,C=CC(N[C@@H]1[C@H](NC2=NC=C3C=C(C4=C(Cl)C(OC)=CC(OC)=C4Cl)C=CC3=N2)COCC1)=O
M2698,MSC2363318A,1379545-95-5,449.86,Akt; Ribosomal S6 Kinase (RSK),MAPK/ERK Pathway; PI3K/Akt/mTOR,"M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with IC50s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity[1].",C21H19ClF3N5O,DMSO : 125 mg/mL (277.86 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(C1=CC=CC2=C(N[C@@H](C3=CC=C(Cl)C(C(F)(F)F)=C3)CN4CCC4)N=CN=C12)N
Axitinib,AG-013736,319460-85-0,386.47,PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and  PDGFRβ, respectively.",C22H18N4OS,DMSO : 20.83 mg/mL (53.90 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=C(SC2=CC3=C(C(/C=C/C4=CC=CC=N4)=NN3)C=C2)C=CC=C1)NC
GS-9901,,1640247-87-5,477.88,PI3K,PI3K/Akt/mTOR,"GS-9901 is a highly selective and orally active PI3Kδ inhibitor with an IC50 of 1 nM. GS-9901 has ≥100 fold selectivity for PI3Kα (IC50 of 750 nM), PI3Kβ (IC50 of 100 nM) and PI3Kγ (IC50 of 190 nM). GS-9901 can be used for the study of rheumatoid arthritis[1].",C22H17ClFN9O,DMSO : ≥ 250 mg/mL (523.14 mM),10mM,Inflammation/Immunology,Phase 1,NC1=NC(N)=NC(N[C@H](C2CC2)C(N3C4=CN=CC=C4)=NC5=C(F)C=CC(Cl)=C5C3=O)=C1C#N
Eganelisib,IPI-549,1693758-51-8,528.56,PI3K,PI3K/Akt/mTOR,Eganelisib (IPI549) is a potent and selective PI3Kγ inhibitor with an IC50 of 16 nM. Eganelisib shows >100-fold selectivity over other lipid and protein kinases[1].,C30H24N8O2,DMSO : 25 mg/mL (47.30 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=C2N=CC=CN2N=C1N)N[C@H](C3=CC4=C(C(N3C5=CC=CC=C5)=O)C(C#CC6=CN(C)N=C6)=CC=C4)C
Ritlecitinib,PF-06651600,1792180-81-4,285.35,Interleukin Related; JAK; STAT,Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ritlecitinib (PF-06651600) is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE)[1][2][3].",C15H19N5O,DMSO : 100 mg/mL (350.45 mM; Need ultrasonic),10mM,Inflammation/Immunology,Launched,C=CC(N1[C@@H](C)CC[C@@H](NC2=C3C(NC=C3)=NC=N2)C1)=O
Ritlecitinib (tosylate),PF-06651600 (tosylate),2192215-81-7,457.55,Interleukin Related; JAK; STAT,Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ritlecitinib (PF-06651600) tosylate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib tosylate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib tosylate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE)[1][2][3].",C22H27N5O4S,DMSO : 83.33 mg/mL (182.12 mM; ultrasonic and warming and heat to 60°C),10mM,Inflammation/Immunology,Launched,CC(C=C1)=CC=C1S(O)(=O)=O.C=CC(N2[C@@H](C)CC[C@@H](NC3=C4C(NC=C4)=NC=N3)C2)=O
Teglarinad (chloride),GMX1777; EB-1627,432037-57-5,672.60,NAMPT,Metabolic Enzyme/Protease,"Teglarinad chloride (GMX1777) is a proagent of GMX1778 (a nicotinamide phosphoribosyl transferase inhibitor). Teglarinad chloride exhibits antitumor activity in mice can be attributed to inhibition of NAMPT. Teglarinad chloride also enhances radiation efficacy, mediated by interference with DNA repair and antiangiogenesis[1][2].",C30H43Cl2N5O8,DMSO : 66.67 mg/mL (99.12 mM; Need ultrasonic),10mM,Cancer,Phase 1,N#CN/C(NC1=CC=[N+](C=C1)COC(OCCOCCOCCOCCOC)=O)=N/CCCCCCOC2=CC=C(C=C2)Cl.[Cl-]
Futibatinib,TAS-120,1448169-71-8,418.45,FGFR,Protein Tyrosine Kinase/RTK,"Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9?nM; V5651=1-3?nM; N550H=3.6?nM; E566G=2.4?nM)[1][2][3].",C22H22N6O3,DMSO : ≥ 29 mg/mL (69.30 mM),10mM,Cancer,Launched,O=C(C=C)N(C1)CC[C@@H]1N(N=C2C#CC3=CC(OC)=CC(OC)=C3)C4=C2C(N)=NC=N4
Bisantrene,CL216942,78186-34-2,398.46,Topoisomerase,Cell Cycle/DNA Damage,"Bisantrene is a highly effective antitumor agent, it exerts its cytotoxicity by affecting DNA intercalation. Bisantrene targets eukaryotic type II topoisomerases. Bisantrene is a substrate of MDR1[1][2][3][4].",C22H22N8,H2O : < 0.1 mg/mL (insoluble); DMSO : 1 mg/mL (2.51 mM; ultrasonic and warming and heat to 80°C),2mM,Cancer,Phase 2,C12=CC=CC=C1C(/C=N/NC3=NCCN3)=C4C(C=CC=C4)=C2/C=N/NC5=NCCN5
Bisantrene (dihydrochloride),CL-216942 (dihydrochloride),71439-68-4,471.39,Topoisomerase,Cell Cycle/DNA Damage,"Bisantrene dihydrochloride is a highly effective antitumor agent, it exerts its cytotoxicity by affecting DNA intercalation. Bisantrene dihydrochloride targets eukaryotic type II topoisomerases. Bisantrene dihydrochloride is a substrate of MDR1[1][2][3][4].",C22H24Cl2N8,H2O : 3.33 mg/mL (7.06 mM; ultrasonic and warming and heat to 60°C); DMSO : 5 mg/mL (10.61 mM; Need ultrasonic),10mM,Cancer,Phase 2,[H]Cl.[H]Cl.C12=CC=CC=C1C(/C=N/NC3=NCCN3)=C4C(C=CC=C4)=C2/C=N/NC5=NCCN5
CEP-40783,RXDX-106,1437321-24-8,588.56,c-Met/HGFR; TAM Receptor,Protein Tyrosine Kinase/RTK,"CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.",C31H26F2N4O6,DMSO : 3.12 mg/mL (5.30 mM; Need ultrasonic),2mM,Cancer,Phase 1,O=C(C1=CN(C(C)C)C(N(C2=CC=C(F)C=C2)C1=O)=O)NC3=CC=C(OC4=CC=NC5=CC(OC)=C(OC)C=C45)C(F)=C3
PF-06263276,,1421502-62-6,566.63,JAK; STAT,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"PF-06263276 (PF 6263276) is a potent and selective pan-JAK inhibitor, with IC50s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively. PF-06263276 inhibits pSTAT3 and TYK2 pathway. PF-06263276 has a protective effect against ear skin inflammation[1].",C31H31FN8O2,DMSO : 33.33 mg/mL (58.82 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 1,FC1=C(O)C=C(CC)C(C2=CC(NN=C3C4=NC5=C(CN(C(C6=NC=C(N7CCCCC7)N=C6)=O)CC5)N4)=C3C=C2)=C1
LY294002,,154447-36-6,307.34,Apoptosis; Autophagy; Casein Kinase; DNA-PK; PI3K,Apoptosis; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"LY294002 is a broad-spectrum inhibitor of PI3K with IC50s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively[1]. LY294002 also inhibits CK2 with an IC50 of 98 nM[2]. LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC50 of 1.4 μM. LY294002 is an apoptosis activator[3].",C19H17NO3,DMSO : 50 mg/mL (162.69 mM; Need ultrasonic); Ethanol : 50 mg/mL (162.69 mM; Need ultrasonic),10mM,Cancer; Infection,Phase 1,O=C1C=C(OC2=C1C=CC=C2C3=CC=CC=C3)N4CCOCC4
CA-170,,1673534-76-3,360.32,PD-1/PD-L1,Immunology/Inflammation,CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes[1][2].,C12H20N6O7,DMSO : 28.5 mg/mL (79.10 mM; Need ultrasonic and warming),10mM,Inflammation/Immunology; Cancer,Phase 1,C[C@@H](O)[C@@H](C(O)=O)NC(N[C@H](C1=NC([C@@H](N)CO)=NO1)CC(N)=O)=O
PD-166866,,192705-79-6,396.44,Autophagy; FGFR,Autophagy; Protein Tyrosine Kinase/RTK,PD166866 is a selective FGFR1 tyrosine kinase inhibitor with an IC50 of 52.4 nM.,C20H24N6O3,DMSO : 3.33 mg/mL (8.40 mM; ultrasonic and warming and heat to 60°C),2mM,Cancer,Phase 4,O=C(NC(C)(C)C)NC1=NC2=NC(N)=NC=C2C=C1C3=CC(OC)=CC(OC)=C3
E7090,,1622204-21-0,587.67,FGFR,Protein Tyrosine Kinase/RTK,"E7090 is an orally available, potent, and selective FGFR inhibitor with IC50s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/FGFR2/FGFR3/FGFR4, respectively[1].",C32H37N5O6,DMSO : 100 mg/mL (170.16 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(N1C=CC2=C1C=C(OCCOC)C(OC3=CC(NC(C4=CC=C(C5CCN(CCO)CC5)C=C4)=O)=NC=C3)=C2)NC
E7090 (succinate),,1879965-80-6,764.82,FGFR,Protein Tyrosine Kinase/RTK,"E7090 succinate is an orally available, selective and potent inhibitor of FGFR1, FGFR2 and  FGFR3 tyrosine kinase activities, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively[1].",C32H37N5O6.3/2C4H6O4,DMSO : 100 mg/mL (130.75 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(O)CCC(O)=O.O=C(N1C=CC2=C1C=C(OCCOC)C(OC3=CC(NC(C4=CC=C(C5CCN(CCO)CC5)C=C4)=O)=NC=C3)=C2)NC.[3/2]
Flurbiprofen axetil,,91503-79-6,330.35,AMPK; Apoptosis; COX; ERK; Interleukin Related; MEK; NF-κB; PPAR; STAT; TNF Receptor; Wnt,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt; Vitamin D Related/Nuclear Receptor,Flurbiprofen axetil is a non-selective COX inhibitor and a nonsteroidal anti-inflammatory agent with anti-inflammatory and analgesic effects. Flurbiprofen axetil inhibits basal-like breast cancer metastasis by inhibiting the MEK/ERK signaling pathway. Flurbiprofen axetil can promote neuroprotection after focal cerebral ischemia in rats by partially activating PPAR-γ. Flurbiprofen axetil alleviates cerebral ischemia/reperfusion injury by reducing inflammation in a transient global cerebral ischemia/reperfusion rat model. Flurbiprofen axetil can alleviate inflammatory responses and cognitive function in a mild cognitive impairment (MCI) SD rat model through the AMPKα/NF-κB signaling pathway[1][2][3][4][5].,C19H19FO4,DMSO : 250 mg/mL (756.77 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,O=C(OC(OC(C)=O)C)C(C)C1=CC=C(C2=CC=CC=C2)C(F)=C1
Temuterkib,LY3214996,1951483-29-6,453.56,ERK,MAPK/ERK Pathway; Stem Cell/Wnt,"Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.",C22H27N7O2S,DMSO : 16.67 mg/mL (36.75 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=C(C(C=C(C1=NC(NC2=CC=NN2C)=NC=C1)S3)=C3C4(C)C)N4CCN5CCOCC5
Onametostat,JNJ-64619178,2086772-26-9,483.36,Histone Methyltransferase,Epigenetics,"Onametostat (JNJ-64619178) is a selective, orally active and pseudo-irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 0.14 nM. Onametostat has potent activity in lung cancer[1][2].",C22H23BrN6O2,DMSO : 125 mg/mL (258.61 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 1,BrC1=C(N)N=C(C=C(CC[C@@H]2[C@@H](O)[C@@H](O)[C@H](N3C(N=CN=C4N)=C4C=C3)C2)C=C5)C5=C1
BMS-986158,,1800340-40-2,495.62,Epigenetic Reader Domain,Epigenetics,"BMS-986158 is a potent BET inhibitor with IC50s of 6.6 and 5 nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively[1].",C30H33N5O2,DMSO : 25 mg/mL (50.44 mM; ultrasonic and warming and heat to 60°C); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 2,OC(C)(C)C1=CC=C2C(N([C@H](C3=CC=CC=C3)C4CCOCC4)C5=C2N=CC(C6=C(C)N=NN6C)=C5)=C1
Roblitinib,FGF-401,1708971-55-4,506.56,FGFR,Protein Tyrosine Kinase/RTK,Roblitinib (FGF-401) is an orally active and highly selective FGFR4 inhibitor with an IC50 of 1.9 nM[1]. Roblitinib has antitumor activity[2].,C25H30N8O4,DMSO : 5 mg/mL (9.87 mM; ultrasonic and warming and heat to 60°C),2mM,Cancer,Phase 2,CN1CC(N(CC2=CC(CCCN3C(NC4=CC(NCCOC)=C(C#N)C=N4)=O)=C3N=C2C=O)CC1)=O
Nedisertib,Peposertib; M3814,1637542-33-6,481.91,BCRP; DNA-PK,Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel; PI3K/Akt/mTOR,"Nedisertib (Peposertib) is an orally active selective DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of less than 3 nM. Nedisertib also acts as a modulator of ABCG2, capable of reversing ABCG2-mediated multidrug resistance (MDR), thus providing new strategies for combination therapy. By inhibiting DNA double-strand break repair, Nedisertib can enhance the efficacy of chemotherapy and radiotherapy. Nedisertib exhibits antitumor activity[1][2][3].",C24H21ClFN5O3,DMSO : 50 mg/mL (103.75 mM; Need ultrasonic),10mM,Cancer,Phase 2,FC1=CC(Cl)=C([C@@H](C2=CC=C(N=N2)OC)O)C=C1C3=NC=NC4=C3C=CC(N5CCOCC5)=C4
Intoplicine,RP 60475,125974-72-3,348.44,Topoisomerase,Cell Cycle/DNA Damage,"Intoplicine (RP 60475), an antitumor derivative in the 7H-benzo[e]pyrido[4,3-b]indole series, is a DNA topoisomerase I and II inhibitor. Intoplicine strongly binds DNA (KA = 2 x 105 /M) and thereby increases the length of linear DNA[1][2].",C21H24N4O,DMSO : 80 mg/mL (229.59 mM; Need ultrasonic),10mM,Cancer,Phase 1,OC1=CC=C2C3=C(NC4=C3C(NCCCN(C)C)=NC=C4C)C=CC2=C1
Intoplicine (dimesylate),RP 60475 (dimesylate),133711-99-6,540.65,Topoisomerase,Cell Cycle/DNA Damage,"Intoplicine (RP 60475) dimesylate, an antitumor derivative in the 7H-benzo[e]pyrido[4,3-b]indole series, is a DNA topoisomerase I and II inhibitor. Intoplicine dimesylate strongly binds DNA (KA = 2 x 105 /M) and thereby increases the length of linear DNA[1][2].",C23H32N4O7S2,DMSO : 115 mg/mL (212.71 mM; Need ultrasonic); H2O : 100 mg/mL (184.96 mM; Need ultrasonic),10mM,Cancer,Phase 1,OC1=CC=C2C3=C(NC4=C3C(NCCCN(C)C)=NC=C4C)C=CC2=C1.CS(O)(=O)=O.CS(O)(=O)=O
PRN1371,,1802929-43-6,561.46,c-Fms; FGFR,Protein Tyrosine Kinase/RTK,"PRN1371 is a highly selective and potent FGFR1-4 and CSF1R inhibitor with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively[1].",C26H30Cl2N6O4,DMSO : 25 mg/mL (44.53 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C1C(C2=C(Cl)C(OC)=CC(OC)=C2Cl)=CC3=CN=C(NC)N=C3N1CCCN4CCN(C(C=C)=O)CC4
Simotinib,,944258-89-3,500.95,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Simotinib is a selective, specific, and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC50 of 19.9 nM. Antineoplastic activities[1].",C25H26ClFN4O4,DMSO : 100 mg/mL (199.62 mM; Need ultrasonic),10mM,Cancer,Launched,COC1=CC2=C(C(NC(C=C3)=CC(Cl)=C3F)=NC=N2)C=C1OCCN4CC5(CC5)C6(OCCO6)C4
TG 100801,,867331-82-6,580.08,FGFR; PDGFR; Src; VEGFR,Protein Tyrosine Kinase/RTK,"TG 100801 is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.",C33H30ClN5O3,DMSO : 5.56 mg/mL (9.58 mM; Need ultrasonic),2mM,Cancer,Phase 2,O=C(C1=CC=CC=C1)OC2=CC=C(Cl)C(C3=CC(C)=C(N=C(NC(C=C4)=CC=C4OCCN5CCCC5)N=N6)C6=C3)=C2
Linsitinib,OSI-906,867160-71-2,421.49,IGF-1R; Insulin Receptor,Protein Tyrosine Kinase/RTK,"Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC50s of 35 and 75 nM, respectively[1].",C26H23N5O,DMSO : 50 mg/mL (118.63 mM; Need ultrasonic),10mM,Cancer; Endocrinology,Phase 3,O[C@@]1(C)C[C@@H](C2=NC(C3=CC=C4C=CC(C5=CC=CC=C5)=NC4=C3)=C6C(N)=NC=CN62)C1
AZD-1480,,935666-88-9,348.77,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"AZD-1480 is an ATP-competitive inhibitor of JAK1 and JAK2 with IC50s?of 1.3 nM and <0.4?nM, respectively[1].",C14H14ClFN8,DMSO : 50 mg/mL (143.36 mM; Need ultrasonic),10mM,Cancer,Phase 2,ClC1=C(N=C(N=C1)N[C@@H](C)C2=NC=C(C=N2)F)NC3=NNC(C)=C3
Sepantronium (bromide),YM-155,781661-94-7,443.29,Autophagy; Survivin,Apoptosis; Autophagy,Sepantronium bromide (YM-155) is a survivin inhibitor with an IC50 of 0.54 nM[1].,C20H19BrN4O3,DMSO : 11.67 mg/mL (26.33 mM; ultrasonic and warming and heat to 60°C); H2O : 50 mg/mL (112.79 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1C2=C(C(C3=CC=CC=C31)=O)[N+](CC4=NC=CN=C4)=C(C)N2CCOC.[Br-]
BMS-754807,,1001350-96-4,461.49,IGF-1R; Insulin Receptor,Protein Tyrosine Kinase/RTK,"BMS-754807 is a potent and reversible IGF-1R/IR inhibitor (IC50=1.8 and 1.7 nM, respectively; Ki=<2 nM for both). BMS-754807 also shows potent activities against Met, RON, TrkA, TrkB, AurA, and AurB with IC50 values of 6, 44, 7, 4, 9, and 25 nM, respectively[1].",C23H24FN9O,DMSO : ≥ 100 mg/mL (216.69 mM),10mM,Cancer; Endocrinology,Phase 2,FC1=CC=C(NC([C@@]2(C)N(C(N=C3NC4=NNC(C5CC5)=C4)=NN6C3=CC=C6)CCC2)=O)C=N1
Sorafenib,Bay 43-9006,284461-73-0,464.83,Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR,Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].",C21H16ClF3N4O3,DMSO : ≥ 45 mg/mL (96.81 mM),10mM,Cancer,Launched,O=C(NC(C=C1)=CC=C1OC2=CC(C(NC)=O)=NC=C2)NC3=CC=C(Cl)C(C(F)(F)F)=C3
Sorafenib (tosylate),Bay 43-9006 (tosylate),475207-59-1,637.03,Apoptosis; Autophagy; Ferroptosis; FLT3; Raf; VEGFR,Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Sorafenib tosylate (Bay 43-9006 tosylate) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib tosylate is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib tosylate induces autophagy and apoptosis. Sorafenib tosylate has anti-tumor activity. Sorafenib tosylate is a ferroptosis activator[1].",C28H24ClF3N4O6S,DMSO : ≥ 100 mg/mL (156.98 mM),10mM,Cancer,Launched,O=S(C1=CC=C(C=C1)C)(O)=O.O=C(NC2=CC=C(C(C(F)(F)F)=C2)Cl)NC3=CC=C(OC4=CC(C(NC)=O)=NC=C4)C=C3
Vatalanib,PTK787; ZK-222584; CGP-79787,212141-54-3,346.81,VEGFR,Protein Tyrosine Kinase/RTK,Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM.,C20H15ClN4,DMSO : 62.5 mg/mL (180.21 mM; Need ultrasonic),10mM,Cancer,Phase 3,ClC1=CC=C(C=C1)NC2=NN=C(CC3=CC=NC=C3)C4=C2C=CC=C4
Linperlisib,YY-20394,1702816-75-8,588.69,PI3K,PI3K/Akt/mTOR,"Linperlisib (YY-20394) is a potent, orally bioavailable and selective inhibitor of PI3Kδ extracted from patent WO 2015055071 A1, compound 10; has an IC50 of 6.4 nM[1].",C28H37FN6O5S,DMSO : 100 mg/mL (169.87 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 4,CS(=O)(NC1=CC(C2=C3C=C(F)C=C(CN4CCC(C(C)(O)C)CC4)C3=NC(N5CCOCC5)=N2)=CN=C1OC)=O
OSI-930,,728033-96-3,443.44,Apoptosis; c-Fms; c-Kit; VEGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"OSI-930 is an orally selective inhibitor of Kit, KDR and CSF-1R (c-Fms) with IC50s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, Lck and low activity against PDGFRα/β, Flt-3 and Abl. OSI-930 has antitumor activity[1].",C22H16F3N3O2S,DMSO : 50 mg/mL (112.75 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(C1=C(NCC2=CC=NC3=CC=CC=C23)C=CS1)NC4=CC=C(OC(F)(F)F)C=C4
Cediranib,AZD2171,288383-20-0,450.51,Autophagy; PDGFR; VEGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Cediranib (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.",C25H27FN4O3,DMSO : 20 mg/mL (44.39 mM; Need ultrasonic),10mM,Cancer,Phase 3,FC1=C(OC2=C(C(C=C3OCCCN4CCCC4)=NC=N2)C=C3OC)C=CC5=C1C=C(C)N5
Amuvatinib,MP470; HPK 56,850879-09-3,447.51,Apoptosis; c-Kit; c-Met/HGFR; FLT3; PDGFR; RAD51; RET,Apoptosis; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK,"Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib (MP470) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair[1][2][3]. Antineoplastic activity[4].",C23H21N5O3S,DMSO : 50 mg/mL (111.73 mM; Need ultrasonic),10mM,Cancer,Phase 2,S=C(N1CCN(C2=C3OC4=CC=CC=C4C3=NC=N2)CC1)NCC5=CC=C6OCOC6=C5
Dovitinib (lactate),CHIR-258 lactate; TKI-258 lactate,692737-80-7,482.51,c-Kit; FGFR; FLT3; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively[1].",C24H27FN6O4,DMSO : 25 mg/mL (51.81 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(N1)C(C(NC2=C3)=NC2=CC=C3N4CCN(C)CC4)=C(N)C5=C1C=CC=C5F.O=C(O)C(C)O
Pazopanib,GW786034,444731-52-6,437.53,Autophagy; c-Kit; FGFR; PDGFR; VEGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.",C21H23N7O2S,DMSO : 50 mg/mL (114.28 mM; Need ultrasonic),10mM,Cancer,Launched,O=S(C1=CC(NC2=NC=CC(N(C3=CC4=NN(C(C)=C4C=C3)C)C)=N2)=CC=C1C)(N)=O
Masitinib,AB1010,790299-79-5,498.64,Apoptosis; c-Kit; FAK; FGFR; PDGFR; Src,Apoptosis; Protein Tyrosine Kinase/RTK,"Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity[1][2][4].",C28H30N6OS,DMSO : 100 mg/mL (200.55 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,O=C(NC1=CC=C(C(NC2=NC(C3=CC=CN=C3)=CS2)=C1)C)C4=CC=C(CN5CCN(CC5)C)C=C4
Masitinib (mesylate),AB-1010 mesylate,1048007-93-7,594.75,Apoptosis; c-Kit; FGFR; PDGFR; Src,Apoptosis; Protein Tyrosine Kinase/RTK,"Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity[1][2][4].",C29H34N6O4S2,DMSO : ≥ 30 mg/mL (50.44 mM); 1M HCl : 100 mg/mL (168.14 mM; ultrasonic and adjust pH to 1 with HCl),10mM,Cancer,Launched,O=C(NC1=CC=C(C(NC2=NC(C3=CC=CN=C3)=CS2)=C1)C)C4=CC=C(CN5CCN(CC5)C)C=C4.CS(=O)(O)=O
Everolimus,RAD001; SDZ-RAD,159351-69-6,958.22,Apoptosis; Autophagy; Bacterial; FKBP; mTOR,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; PI3K/Akt/mTOR,"Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].",C53H83NO14,DMSO : 50 mg/mL (52.18 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](OCCO)CC4)OC)C)=O)=O
Rapamycin,Sirolimus; AY-22989,53123-88-9,914.17,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; FKBP; Fungal; mTOR,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1[1]. Rapamycin is an autophagy activator, an immunosuppressant[2].",C51H79NO13,DMSO : 100 mg/mL (109.39 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O
Ixabepilone,BMS-247550; Aza-epothilone B,219989-84-1,506.70,Apoptosis; Bacterial; Microtubule/Tubulin,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,"Ixabepilone (BMS-247550) is an orally bioavailable microtubule inhibitor, which binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arrests cells in the G2-M phase of the cell cycle and induces tumor cell apoptosis.",C27H42N2O5S,DMSO : 83.33 mg/mL (164.46 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@H]([C@H]([C@H](CCC[C@]1(O[C@]1(C[C@H](N2)/C(C)=C/C3=CSC(C)=N3)[H])C)C)O)C)C(C)([C@H](CC2=O)O)C
CUDC-101,,1012054-59-9,434.49,EGFR; HDAC,Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"CUDC-101 is a potent inhibitor of HDAC, EGFR, and HER2 with IC50s of 4.4, 2.4, and 15.7 nM, respectively. CUDC-101 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.",C24H26N4O4,DMSO : 25 mg/mL (57.54 mM; Need ultrasonic),10mM,Cancer,Phase 1,C#CC1=CC=CC(NC2=NC=NC3=CC(OC)=C(C=C23)OCCCCCCC(NO)=O)=C1
Panobinostat,LBH589; NVP-LBH589,404950-80-7,349.43,Apoptosis; Autophagy; HDAC; HIV,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,"Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].",C21H23N3O2,DMSO : ≥ 100 mg/mL (286.18 mM),10mM,Cancer,Launched,O=C(/C=C/C1=CC=C(CNCCC2=C(NC3=C2C=CC=C3)C)C=C1)NO
Panobinostat (lactate),LBH589 (lactate); NVP-LBH589 (lactate),960055-56-5,439.50,Apoptosis; Autophagy; HDAC; HIV,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics,Panobinostat lactate is a potent and orally active non-selective HDAC inhibitor. Panobinostat lactate has antineoplastic activities. Panobinostat lactate effectively disrupts HIV latency. Panobinostat lactate induces cell apoptosis and autophagy. Panobinostat lactate can be used for the study of refractory or relapsed multiple myeloma[1][2][3][4][5].,C24H29N3O5,DMSO : 100 mg/mL (227.53 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,O=C(NO)/C=C/C1=CC=C(CNCCC2=C(C)NC3=C2C=CC=C3)C=C1.OC(C)C(O)=O
Motesanib,AMG 706,453562-69-1,373.45,c-Kit; VEGFR,Protein Tyrosine Kinase/RTK,"Motesanib (AMG 706) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret.",C22H23N5O,DMSO : ≥ 100 mg/mL (267.77 mM),10mM,Cancer,Phase 3,O=C(C1=CC=CN=C1NCC2=CC=NC=C2)NC3=CC(NCC4(C)C)=C4C=C3
Motesanib (Diphosphate),AMG 706 (Diphosphate),857876-30-3,569.44,c-Kit; VEGFR,Protein Tyrosine Kinase/RTK,"Motesanib Diphosphate (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret.",C22H29N5O9P2,DMSO : ≥ 110 mg/mL (193.17 mM); H2O : 5 mg/mL (8.78 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,O=C(C1=CC=CN=C1NCC2=CC=NC=C2)NC3=CC(NCC4(C)C)=C4C=C3.O=P(O)(O)O.O=P(O)(O)O
Midostaurin,PKC412; CGP 41251,120685-11-2,570.64,Apoptosis; c-Kit; NO Synthase; PKC; VEGFR,Apoptosis; Epigenetics; Immunology/Inflammation; Protein Tyrosine Kinase/RTK; TGF-beta/Smad,"Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM[1][2]. Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects[3].",C35H30N4O4,DMSO : 50 mg/mL (87.62 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=CC=CC=C1)N(C)[C@H]2[C@@H](OC)[C@@]3(C)N(C4=C5C=CC=C4)C6=C5C7=C(C(NC7)=O)C8=C6N(C9=CC=CC=C98)[C@@](O3)([H])C2
Saracatinib,AZD0530,379231-04-6,542.03,Autophagy; Src,Autophagy; Protein Tyrosine Kinase/RTK,"Saracatinib (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib shows high selectivity over other tyrosine kinases[1].",C27H32ClN5O5,DMSO : 50 mg/mL (92.25 mM; Need ultrasonic),10mM,Cancer,Phase 3,ClC1=CC=C2C(OCO2)=C1NC3=C4C(OC5CCOCC5)=CC(OCCN6CCN(C)CC6)=CC4=NC=N3
RAF265,CHIR-265,927880-90-8,518.41,Apoptosis; Autophagy; Raf; VEGFR,Apoptosis; Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,RAF265 is a potent and orally active  RAF/VEGFR2 inhibitor.,C24H16F6N6O,DMSO : ≥ 26 mg/mL (50.15 mM); Ethanol : 10 mg/mL (19.29 mM; Need ultrasonic),10mM,Cancer,Phase 2,FC(F)(C1=CN=C(N1)C2=NC=CC(OC3=CC=C4N(C(NC5=CC=C(C(F)(F)F)C=C5)=NC4=C3)C)=C2)F
GSK-690693,,937174-76-0,425.48,Akt; AMPK; Autophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC50s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation[1][2][3].",C21H27N7O3,DMSO : 20 mg/mL (47.01 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 1,CC(O)(C)C#CC1=NC=C(OC[C@@H]2CNCCC2)C3=C1N=C(C4=NON=C4N)N3CC
Sunitinib (Malate),SU 11248 (Malate),341031-54-7,532.56,Apoptosis; Autophagy; IRE1; Mitophagy; PDGFR; VEGFR,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK,"Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib Malate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].",C26H33FN4O7,H2O : 12.5 mg/mL (23.47 mM; ultrasonic and adjust pH to 3 with HCl); DMSO : ≥ 15 mg/mL (28.17 mM); H2O : 12.5 mg/mL (23.47 mM; ultrasonic and adjust pH to 3 with HCl); H2O : 3.33 mg/mL (6.25 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(NCCN(CC)CC)C1=C(NC(/C=C2C(NC3=C\2C=C(C=C3)F)=O)=C1C)C.O=C([C@H](CC(O)=O)O)O
Sunitinib,SU 11248,557795-19-4,398.47,Apoptosis; Autophagy; IRE1; Mitophagy; PDGFR; VEGFR,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Protein Tyrosine Kinase/RTK,"Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].",C22H27FN4O2,DMSO : 20.83 mg/mL (52.27 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NCCN(CC)CC)C1=C(NC(/C=C2C(NC3=C\2C=C(C=C3)F)=O)=C1C)C
Vandetanib,ZD6474,443913-73-3,475.35,Apoptosis; Autophagy; VEGFR,Apoptosis; Autophagy; Protein Tyrosine Kinase/RTK,"Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].",C22H24BrFN4O2,DMSO : 20.83 mg/mL (43.82 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,FC1=CC(Br)=CC=C1NC2=NC=NC3=CC(OCC4CCN(CC4)C)=C(C=C23)OC
Afatinib,BIBW 2992,850140-72-6,485.94,Akt; Apoptosis; Autophagy; c-Met/HGFR; EGFR; p38 MAPK,Apoptosis; Autophagy; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK,"Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer[1][2][3][4].",C24H25ClFN5O3,DMSO : 100 mg/mL (205.79 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NC1=C(C=C2C(C(NC3=CC(Cl)=C(C=C3)F)=NC=N2)=C1)O[C@H]4CCOC4)/C=C/CN(C)C
Afatinib (dimaleate),BIBW 2992MA2,850140-73-7,718.08,Akt; Apoptosis; Autophagy; c-Met/HGFR; EGFR; p38 MAPK,Apoptosis; Autophagy; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK,"Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer[1][2][3][4].",C32H33ClFN5O11,DMSO : ≥ 35 mg/mL (48.74 mM); H2O : 50 mg/mL (69.63 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NC1=C(C=C2C(C(NC3=CC(Cl)=C(C=C3)F)=NC=N2)=C1)O[C@H]4CCOC4)/C=C/CN(C)C.O=C(O)/C=C\C(O)=O.O=C(O)/C=C\C(O)=O
Omipalisib,GSK2126458; GSK458,1086062-66-9,505.50,Autophagy; mTOR; PI3K,Autophagy; PI3K/Akt/mTOR,"Omipalisib (GSK2126458) is an orally active and highly selective inhibitor of PI3K with Kis of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. Omipalisib has anti-cancer activity[1][2][3].",C25H17F2N5O3S,DMSO : 50 mg/mL (98.91 mM; Need ultrasonic),10mM,Cancer,Phase 1,COC1=NC=C(C=C1NS(C2=CC=C(C=C2F)F)(=O)=O)C3=CC=C(C4=C3)N=CC=C4C5=CN=NC=C5
Gusacitinib,ASN-002,1425381-60-7,460.53,JAK; Syk,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma[1][2].",C24H28N8O2,DMSO : 100 mg/mL (217.14 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 2,N#CCC1CCN(C2=NC(NC3=CC=C(N4CCC(O)CC4)C=C3)=C5C(C=NNC5=O)=N2)CC1
Repotrectinib,TPX-0005,1802220-02-5,355.37,Anaplastic lymphoma kinase (ALK); ROS Kinase; Trk Receptor,Neuronal Signaling; Protein Tyrosine Kinase/RTK,Repotrectinib (TPX-0005) is a potent ROS1 (IC50=0.07 nM) and TRK (IC50=0.83/0.05/0.1 nM for TRKA/B/C) inhibitor. Repotrectinib potently inhibits WT ALK (IC50=1.01 nM). Repotrectinib has anti-cancer activity[1][2].,C18H18FN5O2,DMSO : 25 mg/mL (70.35 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1NC[C@H](C)OC2=CC=C(F)C=C2[C@@H](C)NC3=NC4=C1C=NN4C=C3
Doramapimod,BIRB 796,285983-48-4,527.66,Autophagy; p38 MAPK; Raf,Autophagy; MAPK/ERK Pathway,"Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0.1 nM). Doramapimod also inhibits B-Raf with an IC50 of 83 nM[1][2].",C31H37N5O3,DMSO : 125 mg/mL (236.89 mM; Need ultrasonic); Ethanol : 33.33 mg/mL (63.17 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Phase 2,O=C(NC1=CC(C(C)(C)C)=NN1C2=CC=C(C)C=C2)NC3=C4C=CC=CC4=C(OCCN5CCOCC5)C=C3
Falnidamol,BIBX 1382,196612-93-8,387.84,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM). Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity[1][2].",C18H19ClFN7,DMSO : 31.25 mg/mL (80.57 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 1,ClC1=CC(NC2=NC=NC3=CN=C(NC(CC4)CCN4C)N=C23)=CC=C1F
Neflamapimod,VX-745,209410-46-8,436.26,Autophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,"Neflamapimod (VX-745) is a potent, blood-brain barrier penetrant, highly selective inhibitor of p38α inhibitor with an IC50 for p38α of 10 nM and for p38β of 220 nM. Neflamapimod (VX-745) possesses anti-inflammatory activity.",C19H9Cl2F2N3OS,DMSO : 13.08 mg/mL (29.98 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 2,O=C1N=CN(C(C=C2)=C1C3=C(Cl)C=CC=C3Cl)N=C2SC4=CC=C(F)C=C4F
Toceranib (phosphate),SU11654 (phosphate); PHA 291639E (phosphate),874819-74-6,494.45,c-Kit; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1] [2].",C22H28FN4O6P,DMSO : 2.46 mg/mL (4.98 mM; Need ultrasonic and warming),2mM,Cancer,Launched,O=C(NCCN1CCCC1)C2=C(NC(/C=C3C(NC4=C\3C=C(C=C4)F)=O)=C2C)C.O=P(O)(O)O
Regorafenib,BAY 73-4506,755037-03-7,482.82,Autophagy; c-Kit; FGFR; PDGFR; Raf; RET; Tie; VEGFR,Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity[1].",C21H15ClF4N4O3,H2O : < 0.1 mg/mL (insoluble); DMSO : 125 mg/mL (258.90 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NC1=CC=C(C(C(F)(F)F)=C1)Cl)NC2=CC=C(OC3=CC(C(NC)=O)=NC=C3)C=C2F
Regorafenib (monohydrate),BAY 73-4506 (monohydrate),1019206-88-2,500.83,Autophagy; c-Kit; FGFR; PDGFR; Raf; RET; Tie; VEGFR,Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity[1].",C21H17ClF4N4O4,DMSO : 50 mg/mL (99.83 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NC1=CC=C(C(C(F)(F)F)=C1)Cl)NC2=CC=C(OC3=CC(C(NC)=O)=NC=C3)C=C2F.O
BMS-690514,,859853-30-8,368.43,EGFR; VEGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"BMS-690514 is a potent and orally active inhibitor of EGFR and VEGFR; has IC50s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.",C19H24N6O2,DMSO : ≥ 25 mg/mL (67.86 mM),10mM,Cancer; Cardiovascular Disease,Phase 2,O[C@@H]1CN(CC[C@H]1N)CC2=C3C(NC4=CC=CC(OC)=C4)=NC=NN3C=C2
Brivanib (alaninate),BMS-582664,649735-63-7,441.46,Autophagy; VEGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ[1].",C22H24FN5O4,DMSO : 100 mg/mL (226.52 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(O[C@@H](COC1=CN2C(C(OC3=C(C4=C(NC(C)=C4)C=C3)F)=NC=N2)=C1C)C)[C@@H](N)C
Brivanib,BMS-540215,649735-46-6,370.38,Autophagy; VEGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Brivanib (BMS-540215) is an ATP-competitive inhibitor against VEGFR2 with an IC50 of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β[1].",C19H19FN4O3,DMSO : ≥ 50 mg/mL (135.00 mM),10mM,Cancer,Phase 3,FC1=C(OC2=NC=NN3C2=C(C(OC[C@H](O)C)=C3)C)C=CC4=C1C=C(C)N4
Foretinib,XL880; GSK1363089; GSK089; EXEL-2880,849217-64-7,632.65,c-Met/HGFR; VEGFR,Protein Tyrosine Kinase/RTK,Foretinib is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR. ,C34H34F2N4O6,DMSO : 75 mg/mL (118.55 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC=C(C(F)=C1)OC2=C3C=C(C(OCCCN4CCOCC4)=CC3=NC=C2)OC)C5(CC5)C(NC6=CC=C(C=C6)F)=O
KW-2449,,1000669-72-6,332.40,Apoptosis; Aurora Kinase; Bcr-Abl; FGFR; FLT3,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK,"KW-2449 is a multi-targeted kinase inhibitor of FLT3, ABL, ABLT315I and Aurora kinase with IC50s of 6.6, 14, 4 and 48 nM, respectively.",C20H20N4O,DMSO : ≥ 50 mg/mL (150.42 mM),10mM,Cancer,Phase 1,O=C(C1=CC=C(/C=C/C2=NNC3=C2C=CC=C3)C=C1)N4CCNCC4
Trovafloxacin (mesylate),,147059-75-4,512.46,Antibiotic; Bacterial; Topoisomerase,Anti-infection; Cell Cycle/DNA Damage,"Trovafloxacin mesylate is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin mesylate blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin mesylate is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC50 of 4 μM for PANX1 inward current. Trovafloxacin mesylate does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin mesylate leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1[1][2][3].",C21H19F3N4O6S,H2O : 20 mg/mL (39.03 mM; Need ultrasonic); DMSO : 116.67 mg/mL (227.67 mM; Need ultrasonic),10mM,Infection,Launched,O=C(C1=CN(C2=CC=C(F)C=C2F)C3=NC(N4C[C@@]5([H])[C@H](N)[C@@]5([H])C4)=C(F)C=C3C1=O)O.CS(=O)(O)=O
Tirbanibulin,KX2-391; KX-01,897016-82-9,431.53,Microtubule/Tubulin; Src,Cell Cycle/DNA Damage; Cytoskeleton; Protein Tyrosine Kinase/RTK,"Tirbanibulin (KX2-391) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.",C26H29N3O3,DMSO : 41.67 mg/mL (96.56 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(CC1=NC=C(C2=CC=C(OCCN3CCOCC3)C=C2)C=C1)NCC4=CC=CC=C4
8-Chloroadenosine,8-Cl-Ado,34408-14-5,301.69,AMPK; Autophagy; Nucleoside Antimetabolite/Analog,Autophagy; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR,"8-Chloroadenosine (8-Cl-Ado), a unique ribonucleoside analog, depletes endogenous ATP that subsequently induces the phosphorylation and activation of AMPK.  8-Chloroadenosine induces autophagic cell death. 8-Chloroadenosine effectively inhibited in vivo tumor growth in mice[1].",C10H12ClN5O4,DMSO : 125 mg/mL (414.33 mM; Need ultrasonic),10mM,Cancer,Phase 2,O[C@H]1[C@@H](O)[C@H](N2C(N=CN=C3N)=C3N=C2Cl)O[C@@H]1CO
Tirbanibulin (dihydrochloride),KX2-391 (dihydrochloride); KX-01 (dihydrochloride),1038395-65-1,504.45,Microtubule/Tubulin; Src,Cell Cycle/DNA Damage; Cytoskeleton; Protein Tyrosine Kinase/RTK,"Tirbanibulin (dihydrochloride) (KX2-391 (dihydrochloride)) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.",C26H31Cl2N3O3,H2O : 100 mg/mL (198.24 mM; Need ultrasonic); DMSO : 33.33 mg/mL (66.07 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(CC1=NC=C(C2=CC=C(OCCN3CCOCC3)C=C2)C=C1)NCC4=CC=CC=C4.Cl.Cl
Tirbanibulin (Mesylate),KX2-391 (Mesylate); KX01 (Mesylate),1080645-95-9,527.63,Microtubule/Tubulin; Src,Cell Cycle/DNA Damage; Cytoskeleton; Protein Tyrosine Kinase/RTK,"Tirbanibulin Mesylate (KX2-391 Mesylate) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.",C27H33N3O6S,DMSO : 100 mg/mL (189.53 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NCC1=CC=CC=C1)CC2=NC=C(C3=CC=C(OCCN4CCOCC4)C=C3)C=C2.CS(=O)(O)=O
AZD 6482,KIN-193,1173900-33-8,408.45,Autophagy; PI3K,Autophagy; PI3K/Akt/mTOR,AZD 6482 (KIN-193) is a potent and selective p110β inhibitor with an IC50 of 0.69 nM.,C22H24N4O4,DMSO : 50 mg/mL (122.41 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C1N2C(C([C@H](NC3=CC=CC=C3C(O)=O)C)=CC(C)=C2)=NC(N4CCOCC4)=C1
HKI-357,,848133-17-5,574.05,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 with IC50s of 34 nM and 33 nM, respectively. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation[1].",C31H29ClFN5O3,DMSO : 100 mg/mL (174.20 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)C2=C1)/C=C/CN(C)C
AV-412,MP412,451493-31-5,851.41,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"AV-412 (MP412) is an EGFR inhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively.",C41H44ClFN6O7S2,DMSO : ≥ 28 mg/mL (32.89 mM),10mM,Cancer,Phase 1,O=S(C1=CC=C(C)C=C1)(O)=O.C=CC(NC2=CC3=C(NC4=CC=C(F)C(Cl)=C4)N=CN=C3C=C2C#CC(N5CCN(C)CC5)(C)C)=O.O=S(C6=CC=C(C)C=C6)(O)=O
AV-412 (free base),MP-412 free base,451492-95-8,507.00,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively.",C27H28ClFN6O,DMSO : 50 mg/mL (98.62 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(C=C)NC1=CC2=C(NC3=CC=C(C(Cl)=C3)F)N=CN=C2C=C1C#CC(C)(C)N(CC4)CCN4C
MK-2206 (dihydrochloride),MK-2206 (2HCl),1032350-13-2,480.39,Akt; Apoptosis; Autophagy; Organoid,Apoptosis; Autophagy; PI3K/Akt/mTOR; Stem Cell/Wnt,"MK-2206 dihydrochloride (MK-2206 (2HCl)) is an orally active, BBB-penetrated allosteric AKT inhibitor with IC50s of 5 nM, 12 nM, and 65 nM for AKT1, AKT2, and AKT3, respectively. MK-2206 dihydrochloride induces autophagy[1][2].",C25H23Cl2N5O,DMSO : 12.5 mg/mL (26.02 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=C1N2C(C3=CC(C4=CC=CC=C4)=C(N=C3C=C2)C5=CC=C(C6(N)CCC6)C=C5)=NN1.Cl.Cl
Canertinib,CI-1033; PD-183805,267243-28-7,485.94,EGFR; Orthopoxvirus,Anti-infection; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,Canertinib (CI-1033;PD-183805) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM. Canertinib is active against vaccinia virus respiratory infection in mice[1][2][3][4].,C24H25ClFN5O3,Ethanol : 12.5 mg/mL (25.72 mM; Need ultrasonic); DMSO : 4.9 mg/mL (10.08 mM; Need warming),10mM,Cancer; Infection,Phase 2,O=C(NC1=C(C=C2C(C(NC3=CC=C(C(Cl)=C3)F)=NC=N2)=C1)OCCCN4CCOCC4)C=C
AZD7624,,1095004-78-6,491.56,Autophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,"AZD7624 is an inhaled p38 inhibitor, with potent anti-inflammatory activity.",C27H30FN5O3,DMSO : 62.5 mg/mL (127.15 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 2,O=C(NC1CC1)C2=CC(N3C(C(NC4(C5=CC=CC=C5OCCNC)CC4)=NC=C3)=O)=C(C)C(F)=C2
Canertinib (dihydrochloride),CI-1033 dihydrochloride; PD-183805 dihydrochloride,289499-45-2,558.86,EGFR; Orthopoxvirus,Anti-infection; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,Canertinib dihydrochloride (CI-1033 dihydrochloride) is a potent and irreversible EGFR inhibitor; inhibits cellular EGFR and ErbB2 autophosphorylation with IC50s of 7.4 and 9 nM. Canertinib dihydrochloride is active against vaccinia virus respiratory infection in mice[1][2][3][4].,C24H27Cl3FN5O3,H2O : 16.67 mg/mL (29.83 mM; Need ultrasonic); DMSO : 62.5 mg/mL (111.83 mM; Need ultrasonic),10mM,Cancer; Infection,Phase 2,C=CC(NC1=CC2=C(N=CN=C2C=C1OCCCN3CCOCC3)NC4=CC=C(C(Cl)=C4)F)=O.[H]Cl.[H]Cl
Estramustine,,2998-57-4,440.40,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"Estramustine is an antineoplastic agent. Estramustine depolymerizes microtnbules by binding to tubulin 1, exhibits antimitotic activity with an IC50 value of ~16 μM for mitosis of DU 145 cells. Estramustine blocks cells at mitosis in prostate tumor xenografts[1].",C23H31Cl2NO3,DMSO : 100 mg/mL (227.07 mM; Need ultrasonic),10mM,Cancer,Launched,C[C@@]12[C@](CC[C@@H]2O)([H])[C@@]3([H])[C@@](CC1)([H])C4=CC=C(OC(N(CCCl)CCCl)=O)C=C4CC3
Ensartinib,X-396,1370651-20-9,561.44,Anaplastic lymphoma kinase (ALK); c-Met/HGFR,Protein Tyrosine Kinase/RTK,"Ensartinib (X-396) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74  nM, respectively.",C26H27Cl2FN6O3,DMSO : 100 mg/mL (178.11 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=NN=C(N)C(O[C@@H](C2=C(Cl)C=CC(F)=C2Cl)C)=C1)NC3=CC=C(C(N4C[C@@H](C)N[C@@H](C)C4)=O)C=C3
Ensartinib (dihydrochloride),X-396 (dihydrochloride),2137030-98-7,634.36,Anaplastic lymphoma kinase (ALK); c-Met/HGFR,Protein Tyrosine Kinase/RTK,"Ensartinib dihydrochloride (X-396 dihydrochloride) is a potent and dual ALK/MET inhibitor with IC50s of <0.4 nM and 0.74 nM, respectively.",C26H29Cl4FN6O3,H2O : 33.33 mg/mL (52.54 mM; Need ultrasonic); DMSO : 35.71 mg/mL (56.29 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=NN=C(N)C(O[C@@H](C2=C(Cl)C=CC(F)=C2Cl)C)=C1)NC3=CC=C(C(N4C[C@@H](C)N[C@@H](C)C4)=O)C=C3.Cl.Cl
Semaxinib,SU5416,204005-46-9,238.28,VEGFR,Protein Tyrosine Kinase/RTK,Semaxinib (SU5416) is a potent and selective inhibitor of VEGFR (Flk-1/KDR) with an IC50 of 1.23 μM[1].,C15H14N2O,DMSO : 10 mg/mL (41.97 mM; ultrasonic and warming and heat to 60°C); DMF : 50 mg/mL (209.84 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC=CC=C/21)C2=C/C3=C(C)C=C(C)N3
VX-702,,745833-23-2,404.32,Autophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,"VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β[1].",C19H12F4N4O2,DMSO : ≥ 42 mg/mL (103.88 mM),10mM,Inflammation/Immunology,Phase 2,O=C(N)C1=CC=C(N=C1C2=CC=C(C=C2F)F)N(C3=C(C=CC=C3F)F)C(N)=O
Losmapimod,GSK-AHAB; GW856553X; SB856553,585543-15-3,383.46,Autophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,"Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively[1].",C22H26FN3O2,DMSO : 27.5 mg/mL (71.72 mM; Need ultrasonic); Ethanol : 33.33 mg/mL (86.92 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Phase 3,CC1=C(C2=NC=C(C(NCC(C)(C)C)=O)C=C2)C=C(C(NC3CC3)=O)C=C1F
PH-797804,,586379-66-0,477.30,Autophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,"PH-797804 is a ATP-competitive, selective p38α/p38β inhibitor (IC50=26 nM and Ki=5.8 nM for p38α; Ki=40 nM for p38β) and does not inhibit JNK2.",C22H19BrF2N2O3,DMSO : 50 mg/mL (104.76 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Phase 2,O=C(C1=CC=C(C(N2C(C)=CC(OCC3=CC=C(C=C3F)F)=C(C2=O)Br)=C1)C)NC
Dilmapimod,SB-681323; GW 681323,444606-18-2,456.42,Autophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,Dilmapimod (SB-681323) is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.,C23H19F3N4O3,DMSO : 125 mg/mL (273.87 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Phase 2,O=C1C=CC2=C(C3=CC=C(F)C=C3C)N=C(NC(CO)CO)N=C2N1C4=C(F)C=CC=C4F
Pamiparib,BGB-290,1446261-44-4,298.32,PARP,Cell Cycle/DNA Damage; Epigenetics,"Pamiparib (BGB-290) is an orally active, potent, highly selective PARP inhibitor, with IC50 values of 0.9 nM and 0.5 nM for PARP1 and PARP2, respectively. Pamiparib has potent PARP trapping, and capability to penetrate the brain, and can be used for the research of various cancers including the solid tumor[1][2].",C16H15FN4O,DMSO : 50 mg/mL (167.60 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1NN=C2CN(CCC3)[C@@]3(C)C(N4)=C2C5=C4C=C(F)C=C51
Pamapimod,Ro4402257; R1503,449811-01-2,406.38,Autophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,"Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment[1].",C19H20F2N4O4,DMSO : ≥ 34 mg/mL (83.67 mM),10mM,Inflammation/Immunology,Launched,O=C1C(OC2=CC=C(F)C=C2F)=CC3=CN=C(NC(CCO)CCO)N=C3N1C
Talmapimod,SCIO-469,309913-83-5,513.00,p38 MAPK,MAPK/ERK Pathway,"Talmapimod (SCIO-469) is an orally active, selective, and ATP-competitive p38α inhibitor with an IC50 of 9 nM. Talmapimod shows about 10-fold selectivity over p38β, and at least 2000-fold selectivity over a panel of 20 other kinases, including other MAPKs[1][2][3].",C27H30ClFN4O3,DMSO : ≥ 100 mg/mL (194.93 mM),10mM,Cancer,Phase 2,O=C(N(C)C)C(C1=CN(C)C2=C1C=C(C(N3[C@H](C)CN(CC4=CC=C(F)C=C4)[C@@H](C)C3)=O)C(Cl)=C2)=O
Fedratinib,TG-101348; SAR 302503,936091-26-8,524.68,Apoptosis; JAK,Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research[1][2].",C27H36N6O3S,DMSO : 125 mg/mL (238.24 mM; Need ultrasonic),10mM,Cancer,Launched,O=S(C1=CC=CC(NC2=NC(NC3=CC=C(C=C3)OCCN4CCCC4)=NC=C2C)=C1)(NC(C)(C)C)=O
Fedratinib (hydrochloride hydrate),TG-101348 (hydrochloride hydrate); SAR 302503 (hydrochloride hydrate),1374744-69-0,615.62,Apoptosis; JAK,Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib hydrochloride hydrate induces cancer cell apoptosis and has the potential for myeloproliferative disorders research[1][2].",C27H40Cl2N6O4S,DMSO : 100 mg/mL (162.44 mM; Need ultrasonic); H2O : 100 mg/mL (162.44 mM; Need ultrasonic),10mM,Cancer,Launched,[H]Cl.[H]O[H].[H]Cl.O=S(C1=CC=CC(NC2=NC(NC3=CC=C(C=C3)OCCN4CCCC4)=NC=C2C)=C1)(NC(C)(C)C)=O
AZD-8055,,1009298-09-2,465.54,Apoptosis; Autophagy; mTOR,Apoptosis; Autophagy; PI3K/Akt/mTOR,"AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM. AZD-8055 inhibits both mTORC1 and mTORC2[1].",C25H31N5O4,DMSO : 33.33 mg/mL (71.59 mM; Need ultrasonic),10mM,Cancer,Phase 1,OCC1=CC(C2=NC3=NC(N4CCOC[C@@H]4C)=NC(N5[C@@H](C)COCC5)=C3C=C2)=CC=C1OC
OSI-027,ASP7486,936890-98-1,406.44,Autophagy; mTOR,Autophagy; PI3K/Akt/mTOR,"OSI-027 (ASP7486) is a potent, selective, orally active and ATP-competitive mTOR kinase activity inhibitor with an IC50 of 4 nM. OSI-027 targets both mTORC1 and mTORC2 with IC50s of 22 nM and 65 nM, respectively[1][2].",C21H22N6O3,DMSO : 100 mg/mL (246.04 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C([C@H]1CC[C@H](C2=NC(C(N3)=CC4=C3C(OC)=CC=C4)=C5C(N)=NC=NN52)CC1)O
Terameprocol,EM-1421,24150-24-1,358.47,Apoptosis; COX; Survivin; TNF Receptor,Apoptosis; Immunology/Inflammation,"Terameprocol is an inhibitor targeting the Sp1 transcription factor, which can selectively inhibit the transcription of Sp1-dependent genes. Terameprocol exerts its effects by inhibiting Sp1-mediated gene transcription, such as reducing the expression of genes like CDC2, survivin and HMGB1, thereby arresting the cell cycle, inducing apoptosis, and suppressing the inflammatory response. Terameprocol exhibits anti-proliferative, pro-apoptotic, and anti-inflammatory activities and is currently mainly used in the research of diseases such as cancer and pulmonary arterial hypertension[1][2][3].",C22H30O4,DMSO : 100 mg/mL (278.96 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Phase 2,COC1=CC(C[C@H](C)[C@H](C)CC2=CC=C(OC)C(OC)=C2)=CC=C1OC
TAK-715,,303162-79-0,399.51,Casein Kinase; p38 MAPK; Wnt,Cell Cycle/DNA Damage; MAPK/ERK Pathway; Stem Cell/Wnt,"TAK-715 is an orally active and potent p38 MAPK inhibitor with IC50s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits casein kinase I (CK1δ/ε) to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model[1][2].",C24H21N3OS,DMSO : 50 mg/mL (125.15 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 2,O=C(C1=CC=CC=C1)NC2=NC=CC(C3=C(N=C(S3)CC)C4=CC=CC(C)=C4)=C2
Lexibulin,CYT-997,917111-44-5,434.53,Apoptosis; Microtubule/Tubulin; Reactive Oxygen Species (ROS),Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,Lexibulin (CYT-997) is a potent and orally active tubulin polymerisation inhibitor with IC50s of 10-100 nM in cancer cell lines; with potent cytotoxic and vascular disrupting activity in vitro and in vivo[1][2]. Lexibulin induces cell apoptosis and induces mitochondrial ROS generation in GC cells[3].,C24H30N6O2,DMSO : ≥ 100 mg/mL (230.13 mM),10mM,Cancer,Phase 2,CCC[C@H](NC1=C(C)C=NC(C2=CC=C(NC(NCC)=O)C(OC)=C2)=N1)C3=CN=CC=C3
SU14813,,627908-92-3,442.48,c-Kit; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.",C23H27FN4O4,DMSO : 44 mg/mL (99.44 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(/C(C1=C2)=C/C3=C(C(C(NC[C@H](O)CN4CCOCC4)=O)=C(N3)C)C)NC1=CC=C2F
SU14813 (maleate),,849643-15-8,558.56,c-Kit; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.",C27H31FN4O8,DMSO : 66.67 mg/mL (119.36 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC[C@@H](CN1CCOCC1)O)C2=C(NC(/C=C3C(NC4=C\3C=C(C=C4)F)=O)=C2C)C.O=C(/C=C\C(O)=O)O
Davunetide,,211439-12-2,824.92,Amyloid-β; Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton; Neuronal Signaling,"Davunetide is an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP), a neurotrophic factor that exists in the mammalian CNS. Davunetide possesses neuroprotective, neurotrophic and cognitive protective roperties. Davunetide, a microtubule-stabilizing peptide, interacts with and stabilises neuron-specific βIII-tubulin in vitro. Davunetide penetrates the blood-brain barrier and is non-toxic.  Davunetide inhibits Aβ aggregation and Aβ-induced neurotoxicity[1][2][3].",C36H60N10O12,H2O : 100 mg/mL (121.22 mM; Need ultrasonic); DMSO : 125 mg/mL (151.53 mM; Need ultrasonic),10mM,Neurological Disease,Phase 3,O=C(N(CCC1)[C@@H]1C(N[C@H](C(O)=O)CCC(N)=O)=O)[C@H]([C@@H](C)CC)NC([C@H](CO)NC([C@H](C(C)C)NC([C@H](CCC2)N2C([C@H](C)NC([C@@H](N)CC(N)=O)=O)=O)=O)=O)=O
Orantinib,SU6668; TSU-68,252916-29-3,310.35,Apoptosis; FGFR; PDGFR; VEGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with Kis of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and FGFR1, respectively.",C18H18N2O3,DMSO : 100 mg/mL (322.22 mM; Need ultrasonic),10mM,Cancer,Phase 3,CC1=C(/C=C2C3=CC=CC=C3NC/2=O)NC(C)=C1CCC(O)=O
(Z)-Orantinib,(Z)-SU6668; (Z)-TSU-68,210644-62-5,310.35,FGFR; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 μM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors[1][2].",C18H18N2O3,DMSO : 50 mg/mL (161.11 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(O)CCC1=C(C)NC(/C=C2C(NC3=C\2C=CC=C3)=O)=C1C
Telatinib,Bay 57-9352,332012-40-5,409.83,c-Kit; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit with IC50s of 6, 4, 15 and 1 nM, respectively.",C20H16ClN5O3,DMSO : ≥ 46 mg/mL (112.24 mM),10mM,Cancer,Phase 2,O=C(C1=NC=CC(COC2=NN=C(NC3=CC=C(Cl)C=C3)C4=C2OC=C4)=C1)NC
Telatinib (mesylate),Bay 57-9352 (mesylate),332013-26-0,505.93,c-Kit; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active VEGFR2, VEGFR3, PDGFα, and c-Kit inhibitor with IC50s of 6 nM, 4 nM, 15 nM and 1 nM, respectively[1].",C21H20ClN5O6S,DMSO : 250 mg/mL (494.14 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=NC=CC(COC2=NN=C(NC3=CC=C(Cl)C=C3)C4=C2OC=C4)=C1)NC.OS(=O)(C)=O
Varlitinib,ASLAN001; ARRY-334543,845272-21-1,466.94,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively[1].",C22H19ClN6O2S,DMSO : 33.33 mg/mL (71.38 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,C[C@H]1N=C(NC2=CC3=C(NC4=CC=C(OCC5=NC=CS5)C(Cl)=C4)N=CN=C3C=C2)OC1
ARRY-380 (analog),,937265-83-3,569.63,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"ARRY-380 analog, an inhibitor of EGFR (ErbB1), is extracted from patent WO2015153959A2, compound 249[1]. ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2[2].",C29H27N7O4S,DMSO : 100 mg/mL (175.55 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=S(CCNCC1=CC=C(C2=CC3=C(NC4=CC=C(OC5=CC6=NC=NN6C=C5)C(C)=C4)N=CN=C3C=C2)O1)(C)=O
Voreloxin,SNS-595; Vosaroxin; AG 7352,175414-77-4,401.44,Apoptosis; Topoisomerase,Apoptosis; Cell Cycle/DNA Damage,"Voreloxin (SNS-595; Vosaroxin; AG 7352) is a first-in-class topoisomerase II inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis.",C18H19N5O4S,DMSO : 2 mg/mL (4.98 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(C1=CN(C2=NC=CS2)C3=C(C=CC(N4C[C@H](OC)[C@@H](NC)C4)=N3)C1=O)O
Gatifloxacin,AM-1155; BMS-206584; PD135432,112811-59-3,375.39,Antibiotic; Bacterial; Topoisomerase,Anti-infection; Cell Cycle/DNA Damage,Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50=0.109 μg/ml)[1]. Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.,C19H22FN3O4,DMSO : 2 mg/mL (5.33 mM; Need ultrasonic); H2O : 1 mg/mL (2.66 mM; Need ultrasonic),2mM,Infection,Launched,CC1NCCN(C2=C(F)C=C3C(N(C4CC4)C=C(C(O)=O)C3=O)=C2OC)C1
Gatifloxacin (hydrochloride),AM-1155 (hydrochloride); BMS-206584 (hydrochloride); PD135432 (hydrochloride),121577-32-0,411.86,Antibiotic; Bacterial; Topoisomerase,Anti-infection; Cell Cycle/DNA Damage,Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml)[1]. Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.,C19H23ClFN3O4,DMSO : 4 mg/mL (9.71 mM; ultrasonic and warming and heat to 60°C); H2O : 10 mg/mL (24.28 mM; Need ultrasonic),10mM,Infection,Launched,CC1NCCN(C2=C(F)C=C3C(N(C4CC4)C=C(C(O)=O)C3=O)=C2OC)C1.Cl
5-Azacytidine,Azacitidine; 5-AzaC; Ladakamycin,320-67-2,244.20,Antibiotic; Autophagy; Bacterial; DNA Methyltransferase; Nucleoside Antimetabolite/Analog; Organoid,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Stem Cell/Wnt,5-Azacytidine (Azacitidine; 5-AzaC; Ladakamycin) is a nucleoside analogue of cytidine that specifically inhibits DNA methylation. 5-Azacytidine is incorporated into DNA to covalently trap DNA methyltransferases and contributes to reverse epigenetic changes[1][2]. 5-Azacytidine induces cell autophagy[4].,C8H12N4O5,DMSO : ≥ 31 mg/mL (126.95 mM); H2O : 25 mg/mL (102.38 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Infection,Launched,OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)N=C2)=O)O1
Edotreotide,DOTATOC; SDZ-SMT 487; SMT 487,204318-14-9,1421.64,Radionuclide-Drug Conjugates (RDCs),Antibody-drug Conjugate/ADC Related,"Edotreotide is a ligand that selectively targets SSTR2 and can competitively bind to the receptor. Edotreotide mediates the targeted delivery, while modificated with radionuclides (such as 90Y, 177Lu, and 68Ga) to SSTR-positive tumors and induces tumor cell apoptosis by releasing β rays. Edotreotide has strong tumor targeting and precise killing activity. Edotreotide is used in the synthesis of radionuclide-drug conjugates (RDCs) and is widely used in the field of neuroendocrine tumors (such as metastatic carcinoids, lung and thymus NETs)[1][2][3].",C65H92N14O18S2,H2O : 5 mg/mL (3.52 mM; ultrasonic and warming and heat to 60°C); DMSO : 100 mg/mL (70.34 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@H](NC([C@@](CSSC[C@@H](C(N[C@H](CO)[C@H](O)C)=O)NC([C@@]([C@H](O)C)([H])NC([C@@](CCCCN)([H])NC1=O)=O)=O)([H])NC([C@H](NC(CN2CCN(CCN(CC(O)=O)CCN(CC(O)=O)CC2)CC(O)=O)=O)CC3=CC=CC=C3)=O)=O)CC4=CC=C(O)C=C4)N[C@@H]1CC5=CNC6=C5C=CC=C6
Chloroquinoxaline sulfonamide,Chloroquinoxaline; NSC-339004,97919-22-7,334.78,Molecular Glues; Parasite; Topoisomerase,Anti-infection; Cell Cycle/DNA Damage; PROTAC,"Chloroquinoxaline sulfonamide (Chloroquinoxaline), a structural analogue of sulfaquinoxaline, is a topoisomerase II alpha/beta poison. Chloroquinoxaline sulfonamide is used to control coccidiosis in poultry, rabbit, sheep, and cattle[1]. Antitumor activity[2].",C14H11ClN4O2S,DMSO : 125 mg/mL (373.38 mM; Need ultrasonic),10mM,Cancer; Infection,Phase 2,ClC1=CC=CC2=NC(NS(=O)(C3=CC=C(N)C=C3)=O)=CN=C12
Gedatolisib,PKI-587; PF-05212384,1197160-78-3,615.73,mTOR; PI3K,PI3K/Akt/mTOR,"Gedatolisib (PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ, and mTOR with IC50s of 0.4 nM, 5.4 nM and 1.6 nM, respectively[1]. Gedatolisib is equally effective in both complexes of mTOR, mTORC1 and mTORC2[2].",C32H41N9O4,H2O : < 0.1 mg/mL (insoluble); DMSO : 4 mg/mL (6.50 mM; Need warming),2mM,Cancer,Phase 3,CN(C1CCN(C(C2=CC=C(NC(NC3=CC=C(C4=NC(N5CCOCC5)=NC(N6CCOCC6)=N4)C=C3)=O)C=C2)=O)CC1)C
Peldesine (dihydrochloride),BCX 34 (dihydrochloride),2772702-10-8,314.17,HIV; Nucleoside Antimetabolite/Analog,Anti-infection; Cell Cycle/DNA Damage,"Peldesine (BCX 34) dihydrochloride is a potent, competitive, reversible and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC50s of 36 nM, 5 nM, and 32 nM for human, rat, and mouse red blood cell (RBC) PNP, respectively. Peldesine dihydrochloride is also a T-cell proliferation inhibitor with an IC50 of 800 nM. Peldesine dihydrochloride has the potential for cutaneous T-cell lymphoma, psoriasis and HIV infection research[1][2][3][4].",C12H13Cl2N5O,H2O : 33.33 mg/mL (106.09 mM; Need ultrasonic); DMSO : 200 mg/mL (636.60 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Phase 1,Cl[H].O=C1C(NC=C2CC3=CC=CN=C3)=C2N=C(N)N1.Cl[H]
Ningetinib Tosylate,,1394820-77-9,728.79,c-Met/HGFR; TAM Receptor; VEGFR,Protein Tyrosine Kinase/RTK,"Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.",C38H37FN4O8S,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble); DMSO : 33.33 mg/mL (45.73 mM; Need ultrasonic),10mM,Cancer,Phase 2,CC1=CC=C(S(=O)(O)=O)C=C1.CC2=C(C(NC3=CC(F)=C(OC4=CC=NC5=C4C=CC(OCC(C)(O)C)=C5)C=C3)=O)C(N(C6=CC=CC=C6)N2C)=O
Ningetinib,,1394820-69-9,556.58,c-Met/HGFR; TAM Receptor; VEGFR,Protein Tyrosine Kinase/RTK,"Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.",C31H29FN4O5,DMSO : 12.5 mg/mL (22.46 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,CC1=C(C(NC2=CC(F)=C(OC3=CC=NC4=C3C=CC(OCC(C)(O)C)=C4)C=C2)=O)C(N(C5=CC=CC=C5)N1C)=O
Golidocitinib,AZD4205,2091134-68-6,489.57,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Golidocitinib (AZD4205) is a selective JAK1 inhibitor, with an IC50 of 73 nM, weakly inhibits JAK2 (IC50>14.7 μM), and shows little inhibition on JAK3 (IC50>30 μM)[1].",C25H31N9O2,DMSO : 100 mg/mL (204.26 mM; Need ultrasonic),10mM,Cancer,Phase 2,C[C@@H](N1CCN(C)CC1)C(NC2=C3C(C(C4=NC(NC5=CN(C)N=C5OC)=NC=C4)=CN3)=CC=C2)=O
Epertinib (hydrochloride),S-22611 (hydrochloride),2071195-74-7,596.48,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Epertinib (S-22611) hydrochloride is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER4 and HER2, with IC50s of 1.48 nM, 2.49 nM and 7.15 nM, respectively. Epertinib hydrochloride shows potent antitumor activity[1][2]. Epertinib (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.",C30H28Cl2FN5O3,DMSO : 125 mg/mL (209.56 mM; Need ultrasonic); H2O : 33.33 mg/mL (55.88 mM; Need ultrasonic),10mM,Cancer,Phase 2,CC#C/C(C1=CC2=C(NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)N=CN=C2C=C1)=N\OC[C@@H]5NCCOC5.Cl
Abrocitinib,PF-04965842,1622902-68-4,323.41,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Abrocitinib (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC50s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) exhibits less active effect on TYK2 (IC50, 1.253 μM), and inhibits phosphorylation of STAT1, STAT3 and STAT5 after stimulation. Effective in autoimmune disease[1].",C14H21N5O2S,DMSO : 100 mg/mL (309.21 mM; Need ultrasonic),10mM,Inflammation/Immunology,Launched,CN([C@H]1C[C@@H](NS(CCC)(=O)=O)C1)C2=C3C(NC=C3)=NC=N2
Nalmefene,,55096-26-9,339.43,Apoptosis; NF-κB; NO Synthase; Opioid Receptor; p38 MAPK; Reactive Oxygen Species (ROS); Toll-like Receptor (TLR),Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB,"Nalmefene is a BBB-penetrable opioid receptor modulator. Nalmefene is an antagonist of MOR and DOR, and a partial agonist of KOR. Nalmefene has anti-inflammatory and neuroprotective activities. Nalmefene can be used in the research of reducing alcohol-dependent disorders[1][2][3][4].",C21H25NO3,DMSO : 175 mg/mL (515.57 mM; Need ultrasonic),10mM,Inflammation/Immunology; Neurological Disease; Cardiovascular Disease,Launched,O[C@]12[C@@]34C5=C(C[C@@]2([H])N(CC6CC6)CC4)C=CC(O)=C5O[C@@]3([H])C(CC1)=C
Valopicitabine (dihydrochloride),NM283 (dihydrochloride),640725-71-9,429.30,HCV; HCV Protease; Nucleoside Antimetabolite/Analog,Anti-infection; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Valopicitabine (NM283) dihydrochloride is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination[1][2].",C15H26Cl2N4O6,DMSO : 100 mg/mL (232.94 mM; Need ultrasonic); H2O : 100 mg/mL (232.94 mM; Need ultrasonic),10mM,Infection,Phase 2,N[C@H](C(O[C@@H]1[C@H](O[C@H]([C@]1(C)O)N2C=CC(N)=NC2=O)CO)=O)C(C)C.[H]Cl.[H]Cl
Raltitrexed,ZD1694; D1694; ICI-D1694,112887-68-0,458.49,Nucleoside Antimetabolite/Analog; Thymidylate Synthase,Apoptosis; Cell Cycle/DNA Damage,"Raltitrexed is an antimetabolite agent used in chemotherapy, acting by inhibiting thymidylate synthase.",C21H22N4O6S,DMSO : ≥ 29 mg/mL (63.25 mM),10mM,Cancer,Launched,CC(NC1=O)=NC2=C1C=C(CN(C)C3=CC=C(C(N[C@H](C(O)=O)CCC(O)=O)=O)S3)C=C2
MK-2206,,1032349-77-1,443.93,Akt; Apoptosis; Autophagy; Organoid,Apoptosis; Autophagy; PI3K/Akt/mTOR; Stem Cell/Wnt,"MK-2206 is an orally active, highly potent and selective allosteric Akt inhibitor, with IC50s of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. Many breast cancer cell lines, and PIK3CA-mutant and cell lines with PTEN loss are sensitive to MK-2206. MK-2206 has anticancer activities[1][2].",C25H22ClN5O,DMSO : 100 mg/mL (225.26 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1NN=C2C3=C(N=C(C4=CC=C(C5(N)CCC5)C=C4)C(C6=CC=CC=C6)=C3)C=CN21.[H]Cl
Famitinib,SHR1020,1044040-56-3,410.48,Apoptosis; PDGFR; VEGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively[1]. Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis[2].",C23H27FN4O2,DMSO : 2.86 mg/mL (6.97 mM; ultrasonic and warming and heat to 60°C),2mM,Cancer,Phase 3,O=C1C2=C(NC(/C=C3C(NC4=C\3C=C(F)C=C4)=O)=C2C)CCN1CCN(CC)CC
Ponatinib (hydrochloride),AP24534 (hydrochloride),1114544-31-8,569.02,Autophagy; Bcr-Abl; FGFR; PDGFR; Src; VEGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively[1].",C29H28ClF3N6O,DMSO : 25 mg/mL (43.94 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Infection,Launched,O=C(C1=CC=C(C)C(C#CC2=CN=C3C=CC=NN23)=C1)NC4=CC=C(CN5CCN(CC5)C)C(C(F)(F)F)=C4.Cl
Pyrazoloacridine,NSC 366140; PD 115934,99009-20-8,367.40,Apoptosis; Topoisomerase,Apoptosis; Cell Cycle/DNA Damage,"Pyrazoloacridine (NSC 366140), an intercalating agent with anti-cancer activity, inhibits the activity of topoisomerases 1 and 2. Pyrazoloacridine (NSC 366140) exhibits an IC50 of 1.25 μM in K562 myeloid leukemia cells for 24 h treatment[1][2].",C19H21N5O3,DMSO : 16.67 mg/mL (45.37 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=[N+](C1=CC=C2C3=C1NC4=CC=C(OC)C=C4C3=NN2CCCN(C)C)[O-]
Tenofovir exalidex,CMX-157,911208-73-6,569.72,HBV; HIV; Nucleoside Antimetabolite/Analog,Anti-infection; Cell Cycle/DNA Damage,"Tenofovir exalidex (CMX157) is a lipid conjugate of the acyclic nucleotide analog Tenofovir with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant viruses. Tenofovir exalidex is active against all major subtypes of HIV-1 and HIV-2 in fresh human PBMCs and against all HIV-1 strains evaluated in monocyte-derived macrophages, with EC50s ranging between 0.2 and 7.2 nM. CMX157 is orally available and has no apparent toxicity. Tenofovir exalidex also shows antiviral activity against HBV[1][2][3].",C28H52N5O5P,DMSO : 100 mg/mL (175.52 mM; Need ultrasonic),2mM,Infection,Phase 2,NC1=C2N=CN(C[C@H](OCP(O)(OCCCOCCCCCCCCCCCCCCCC)=O)C)C2=NC=N1
Vorolanib,CM082; X-82,1013920-15-4,439.48,PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Vorolanib (CM082) is an orally active, potent multikinase VEGFR/PDGFR inhibitor. Vorolanib is a potent ATP-binding cassette (ABC) transporter inhibitor. Vorolanib is an angiogenesis inhibitor and has antitumor activity combined with ZD1839 (HY-50895)[1][2].",C23H26FN5O3,DMSO : 27 mg/mL (61.44 mM; Need ultrasonic),10mM,Cancer; Cardiovascular Disease,Phase 3,O=C1/C(C2=CC(F)=CC=C2N1)=C/C(NC(C)=C3C(N[C@@H]4CN(C(N(C)C)=O)CC4)=O)=C3C
Acrizanib,LHA510,1229453-99-9,445.40,VEGFR,Protein Tyrosine Kinase/RTK,"Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC50 of 17.4 nM for BaF3-VEGFR-2[1].",C20H18F3N7O2,DMSO : 41.67 mg/mL (93.56 mM; Need ultrasonic),10mM,Others,Phase 2,O=C(N1C2=CC=C(OC3=NC=NC(CNC)=C3)C=C2C=C1)NC4=NN(C)C(C(F)(F)F)=C4
Lazertinib,YH25448; GNS-1480,1903008-80-9,554.64,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Lazertinib (YH25448) is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer[1].",C30H34N8O3,DMSO : 3.33 mg/mL (6.00 mM; ultrasonic and warming and heat to 60°C),2mM,Cancer,Launched,C=CC(NC1=CC(NC2=NC=CC(N3N=C(C4=CC=CC=C4)C(CN(C)C)=C3)=N2)=C(OC)C=C1N5CCOCC5)=O
Pemigatinib,INCB054828,1513857-77-6,487.50,FGFR,Protein Tyrosine Kinase/RTK,"Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma[1][2].",C24H27F2N5O4,DMSO : 25 mg/mL (51.28 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,CCN(C(N(C(C(F)=C(OC)C=C1OC)=C1F)C2)=O)C(C2=CN3)=C4C3=NC(CN5CCOCC5)=C4
Imifoplatin,PT-112,1339960-28-9,485.23,Apoptosis; DNA Alkylator/Crosslinker,Apoptosis; Cell Cycle/DNA Damage,Imifoplatin (PT-112) is a platinum-based active molecule and a member of the phosphaplatins family. Imifoplatin can induce Apoptosis and exhibits antitumor activity[1][2][3].,C6H16N2O7P2Pt,H2O : 1.25 mg/mL (2.58 mM; Need ultrasonic),2mM,Cancer,Phase 2,O=[P]([O-][Pt+2]1([O-][P]2(O)=O)[NH2][C@@](CCCC3)([H])[C@]3([H])[NH2]1)(O2)O
Izencitinib,TD-1473; JNJ-8398,2051918-33-1,402.50,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Izencitinib (TD-1473) is an orally active, non-selective and gut-restricted JAK inhibitor. Izencitinib (TD-1473) can be used in the study for ulcerative colitis[1].",C22H26N8,DMSO : 50 mg/mL (124.22 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 3,CC1=CC(NC2=CC3=C(C=CC=N3)C(N[C@@H]4C[C@@H](CC5)N(CCC#N)[C@@H]5C4)=N2)=NN1
Ifidancitinib,ATI-50002; ATI-502,1236667-40-5,395.39,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ifidancitinib (ATI-50002) is an orally available, potent and selective inhibitor of JAK kinase 1/3 that disrupts γc cytokine signaling. Ifidancitinib is used in the research of allergy, asthma, and autoimmune diseases[1][2].",C20H18FN5O3,DMSO : 62.5 mg/mL (158.07 mM; Need ultrasonic),10mM,Inflammation/Immunology; Others,Phase 2,O=C1OC2=CC=C(NC3=NC(NC4=CC(C)=C(F)C(OC)=C4)=NC=C3C)C=C2N1
Itacnosertib,TP-0184,1628870-27-8,468.55,Akt; Anaplastic lymphoma kinase (ALK); FLT3; JAK; mTOR; PI3K; STAT; TGF-beta/Smad; TGF-β Receptor,Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; TGF-beta/Smad,"Itacnosertib (TP-0184) is the inhibitor for FLT3, ACVR1 (ALK2, IC50=8 nM) and JAK2 (IC50=8540 nM). Itacnosertib exhibits anti-leukemic activity[1][2].",C26H28N8O,DMSO : 12.5 mg/mL (26.68 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,CN1CCN(C2=CC=C(NC3=NC=CC(NC4=CC=CN=C4C5=NC=CC=C5)=N3)C=C2OC)CC1
Itacnosertib (hydrochloride),TP-0184 (hydrochloride),2409543-84-4,505.01,Akt; Anaplastic lymphoma kinase (ALK); FLT3; JAK; mTOR; PI3K; STAT; TGF-beta/Smad; TGF-β Receptor,Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; TGF-beta/Smad,"Itacnosertib hydrochloride (TP-0184 hydrochloride) is the inhibitor for FLT3, ACVR1 (ALK2, IC50=8 nM) and JAK2 (IC50=8540 nM). Itacnosertib hydrochloride exhibits anti-leukemic activity[1][2].",C26H29ClN8O,DMSO : 5.56 mg/mL (11.01 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,CN1CCN(C2=CC=C(NC3=NC=CC(NC4=CC=CN=C4C5=NC=CC=C5)=N3)C=C2OC)CC1.[H]Cl
Rezivertinib,BPI-7711,1835667-12-3,486.57,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib has excellent central nervous system (CNS) penetration and has antitumor activity[1][2].",C27H30N6O3,DMSO : 125 mg/mL (256.90 mM; Need ultrasonic),10mM,Cancer,Phase 3,C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1OCCN(C)C)=O
Momelotinib,CYT387,1056634-68-4,414.46,Apoptosis; Autophagy; JAK,Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Momelotinib (CYT387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50a of 11 nM and 18 nM,respectively. CYT387 shows much less activity against JAK3.",C23H22N6O2,DMSO : 10 mg/mL (24.13 mM; ultrasonic and warming and adjust pH to 3 with HCl and heat to 60°C),10mM,Cancer,Launched,O=C(C1=CC=C(C2=NC(NC3=CC=C(N4CCOCC4)C=C3)=NC=C2)C=C1)NCC#N
Momelotinib (sulfate),CYT387 (sulfate salt),1056636-06-6,610.62,Apoptosis; Autophagy; JAK,Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC50=155 nM).",C23H26N6O10S2,DMSO : 220 mg/mL (360.29 mM; Need ultrasonic); H2O : 100 mg/mL (163.77 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(NCC#N)C(C=C1)=CC=C1C2=NC(NC(C=C3)=CC=C3N4CCOCC4)=NC=C2.O=S(O)(O)=O.O=S(O)(O)=O
Vadimezan,DMXAA; ASA-404,117570-53-3,282.29,IFNAR; Influenza Virus; STING,Anti-infection; Immunology/Inflammation,"Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.",C17H14O4,DMSO : 10 mg/mL (35.42 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Infection,Phase 3,O=C(O)CC1=CC=CC(C2=O)=C1OC3=C2C=CC(C)=C3C
Tivozanib,AV-951; KRN951,475108-18-0,454.86,VEGFR,Protein Tyrosine Kinase/RTK,"Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy[1].",C22H19ClN4O5,DMSO : 25 mg/mL (54.96 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NC1=CC=C(C=C1Cl)OC2=CC=NC3=CC(OC)=C(C=C23)OC)NC4=NOC(C)=C4
Tivozanib (hydrochloride hydrate),AV-951 (hydrochloride hydrate); KRN951 (hydrochloride hydrate),682745-41-1,509.34,VEGFR,Protein Tyrosine Kinase/RTK,"Tivozanib hydrochloride hydrate is the hydrate hydrochloride form of Tivozanib (HY-10977). Tivozanib hydrochloride hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrochloride hydrate exhibits antitumor efficacy[1].",C22H22Cl2N4O6,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 125 mg/mL (245.42 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NC1=CC=C(C=C1Cl)OC2=CC=NC3=CC(OC)=C(C=C23)OC)NC4=NOC(C)=C4.Cl.O
Lenvatinib,E7080,417716-92-8,426.85,c-Kit; FGFR; PDGFR; RET; VEGFR,Protein Tyrosine Kinase/RTK,"Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows  potent antitumor activities[1][2].",C21H19ClN4O4,DMSO : 12.5 mg/mL (29.28 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(N)C1=C(C=C2N=CC=C(C2=C1)OC3=CC=C(C(Cl)=C3)NC(NC4CC4)=O)OC
Lenvatinib (mesylate),E7080 (mesylate),857890-39-2,522.96,c-Kit; FGFR; PDGFR; RET; VEGFR,Protein Tyrosine Kinase/RTK,"Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows  potent antitumor activities[1][2].",C22H23ClN4O7S,DMSO : 31.25 mg/mL (59.76 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=C(OC)C=C2N=CC=C(OC3=CC=C(NC(NC4CC4)=O)C(Cl)=C3)C2=C1)N.OS(=O)(C)=O
Amonafide,AS1413,69408-81-7,283.33,Topoisomerase,Cell Cycle/DNA Damage,Amonafide is a topoisomerase II inhibitor and DNA intercalator that induces apoptotic signaling by blocking the binding of Topo II to DNA.,C16H17N3O2,DMSO : 41.67 mg/mL (147.07 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C1N(C(C2=CC(N)=CC3=CC=CC1=C23)=O)CCN(C)C
(R)-Lisofylline,(R)-Lisophylline,100324-81-0,280.32,STAT,JAK/STAT Signaling; Stem Cell/Wnt,"(R)-Lisofylline ((R)-Lisophylline) is a (R)-enantiomer of the metabolite of Pentoxifylline with anti-inflammatory properties. (R)-Lisofylline is a lysophosphatidic acid acyltransferase inhibitor with an IC50 of 0.6 μM and interrupts IL-12 signaling-mediated STAT4 activation. (R)-Lisofylline has the potential for type 1 diabetes, autoimmune disorders research[1][2].",C13H20N4O3,DMSO : 100 mg/mL (356.74 mM; Need ultrasonic),10mM,Metabolic Disease; Inflammation/Immunology,Phase 2,O=C(N1CCCC[C@H](O)C)N(C)C2=C(N(C)C=N2)C1=O
ENMD-2076 (Tartrate),,1453868-32-0,525.56,Apoptosis; Aurora Kinase; FGFR; FLT3; PDGFR; Src; VEGFR,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK,"ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2,  Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.",C25H31N7O6,DMSO : 25 mg/mL (47.57 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C([C@@H]([C@H](C(O)=O)O)O)O.CC1=CC(NC2=NC(/C=C/C3=CC=CC=C3)=NC(N4CCN(CC4)C)=C2)=NN1
ENMD-2076,,934353-76-1,375.47,Apoptosis; Aurora Kinase; FGFR; FLT3; PDGFR; Src; VEGFR,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK,"ENMD-2076 is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2,  Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively. ",C21H25N7,DMSO : ≥ 31 mg/mL (82.56 mM),10mM,Cancer,Phase 2,CC1=CC(NC2=NC(/C=C/C3=CC=CC=C3)=NC(N4CCN(CC4)C)=C2)=NN1
MGCD-265 analog,,875337-44-3,517.60,Apoptosis; c-Met/HGFR; VEGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"MGCD-265 analog is a potent and oral active inhibitor of c-Met and VEGFR2 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity[1].",C26H20FN5O2S2,DMSO : ≥ 100 mg/mL (193.20 mM),10mM,Cancer,Phase 2,O=C(CC1=CC=CC=C1)NC(NC2=CC=C(C(F)=C2)OC3=C4C(C=C(S4)C5=CN(C=N5)C)=NC=C3)=S
PKI-179,,1197160-28-3,488.54,mTOR; PI3K,PI3K/Akt/mTOR,"PKI-179 is a potent and orally active dual PI3K/mTOR inhibitor, with IC50s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ and mTOR, respectively. PKI-179 also exhibits activity over E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 shows anti-tumor activity in vivo[1][2].",C25H28N8O3,DMSO : 100 mg/mL (204.69 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(NC1=CC=NC=C1)NC2=CC=C(C3=NC(N4C5CCC4COC5)=NC(N6CCOCC6)=N3)C=C2
PKI-179 (hydrochloride),,1463510-35-1,525.00,mTOR; PI3K,PI3K/Akt/mTOR,"PKI-179 hydrochloride is a potent and orally active dual PI3K/mTOR inhibitor, with IC50s of 8 nM, 24 nM, 74 nM, 77 nM, and 0.42 nM for PI3K-α, PI3K-β, PI3K-γ, PI3K-δ and mTOR, respectively. PKI-179 hydrochloride also exhibits activity over E545K and H1047R, with IC50s of 14 nM and 11 nM, respectively. PKI-179 hydrochloride shows anti-tumor activity in vivo[1][2].",C25H29ClN8O3,DMSO : 20 mg/mL (38.10 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(NC1=CC=NC=C1)NC2=CC=C(C3=NC(N4C5CCC4COC5)=NC(N6CCOCC6)=N3)C=C2.Cl
RO4929097,RG-4733,847925-91-1,469.40,Notch; γ-secretase,Neuronal Signaling; Stem Cell/Wnt,"RO4929097 (RG-4733) is an orally active γ secretase inhibitor with an IC50 of 4 nM, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively[1].",C22H20F5N3O3,DMSO : ≥ 49 mg/mL (104.39 mM),10mM,Neurological Disease; Cancer,Phase 2,O=C(C(C)(C(NCC(F)(C(F)(F)F)F)=O)C)N[C@H]1C2=CC=CC=C2C3=CC=CC=C3NC1=O
JNJ-38877618,,943540-74-7,374.35,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively.",C20H12F2N6,DMSO : 5 mg/mL (13.36 mM; Need ultrasonic),10mM,Cancer,Phase 1,FC(C1=CC=C2N=CC=CC2=C1)(F)C3=NN=C4C=CC(C5=CC=NC=C5)=NN43
Nintedanib esylate,BIBF 1120 (esylate),656247-18-6,649.76,FGFR; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.",C33H39N5O7S,DMSO : 66.67 mg/mL (102.61 mM; Need ultrasonic); Ethanol : 3.08 mg/mL (4.74 mM; Need ultrasonic); H2O : 16.67 mg/mL (25.66 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=CC(NC/2=O)=C(C=C1)C2=C(NC3=CC=C(N(C)C(CN4CCN(C)CC4)=O)C=C3)/C5=CC=CC=C5)OC.CCS(=O)(O)=O
KX2-361,KX-02,897016-26-1,405.46,Apoptosis; Microtubule/Tubulin; Src,Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Protein Tyrosine Kinase/RTK,KX2-361 (KX-02) is a Src-kinase and tubulin polymerization inhibitor. KX2-361 shows good oral bioavailability and readily crosses the BBB in mice. KX2-361 shows anti-tumor activity and induces apoptosis of Glioblastoma (GBM) cell[1].,C24H24FN3O2,DMSO : 10.71 mg/mL (26.41 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 1,O=C(NCC1=CC=CC(F)=C1)CC2=NC=C(C3=CC=C(N4CCOCC4)C=C3)C=C2
Naphazoline,Naphthazoline,835-31-4,210.27,Adrenergic Receptor; Interleukin Related; TNF Receptor; VEGFR,Apoptosis; GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Protein Tyrosine Kinase/RTK,"Naphazoline (Naphthazoline) is a potent α-adrenergic receptor agonist. Naphazoline reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF. Naphazoline can be used for non-bacterial conjunctivitis research[1][2].",C14H14N2,DMSO : 62.5 mg/mL (297.24 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cardiovascular Disease; Cancer,Launched,C1(CC2=C3C=CC=CC3=CC=C2)=NCCN1
Naphazoline (nitrate),Naphthazoline (nitrate),5144-52-5,273.29,Adrenergic Receptor; Interleukin Related; TNF Receptor; VEGFR,Apoptosis; GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Protein Tyrosine Kinase/RTK,"Naphazoline (Naphthazoline) nitrate is an α-adrenergic receptor agonist. Naphazoline nitrate reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline nitrate reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF. Naphazoline nitrate can be used for non-bacterial conjunctivitis research[1][2].",C14H15N3O3,DMSO : 100 mg/mL (365.91 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cardiovascular Disease; Cancer,Launched,O[N+]([O-])=O.C1(CC2=C3C=CC=CC3=CC=C2)=NCCN1
MK-8353,SCH900353,1184173-73-6,691.84,ERK,MAPK/ERK Pathway; Stem Cell/Wnt,"MK-8353 (SCH900353) is a potent, selective and orally available ERK1/2 inhibitor, with IC50s of 23.0 nM and 8.8 nM, respectively; MK-8353 has antitumor activity.",C37H41N9O3S,DMSO : 100 mg/mL (144.54 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C([C@@]1(SC)CN(CC(N2CC=C(C3=CC=C(C4=NN(C)C=N4)C=C3)CC2)=O)CC1)NC5=CC6=C(NN=C6C7=CC=C(OC(C)C)N=C7)C=C5
RGX-104 (hydrochloride),Abequolixron (hydrochloride),610318-03-1,632.54,LXR,Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,RGX-104 hydrochloride is a small-molecule LXR agonist that modulates innate immunity via transcriptional activation of the ApoE gene.,C34H34Cl2F3NO3,DMSO : 125 mg/mL (197.62 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 1,O=C(O)CC1=CC=CC(OCC[C@H](N(CC2=CC=CC(C(F)(F)F)=C2Cl)CC(C3=CC=CC=C3)C4=CC=CC=C4)C)=C1.Cl
AZD-7648,,2230820-11-6,380.40,Apoptosis; ATM/ATR; DNA-PK; PI3K,Apoptosis; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"AZD-7648 is a potent, orally active, selective DNA-PK inhibitor with an IC50 of 0.6 nM. AZD-7648 induces apoptosis and shows antitumor activity[1].",C18H20N8O2,DMSO : 5.83 mg/mL (15.33 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,CC1=CC2=NC=NN2C=C1NC3=NC=C(N(C)C(N4C5CCOCC5)=O)C4=N3
Elzovantinib,TPX-0022; CSF1R-IN-2,2271119-26-5,409.42,c-Fms; c-Met/HGFR; Src,Protein Tyrosine Kinase/RTK,"Elzovantinib (TPX-0022) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively[1].",C20H20FN7O2,DMSO : 25 mg/mL (61.06 mM; Need ultrasonic),10mM,Cancer,Phase 1,N#CC1=C2CN(CC)C(C=C3)=NC(N3N=C4N)=C4C(NC[C@H](C)OC2=CC=C1F)=O
LUT014,,2274819-46-2,528.49,ERK; p38 MAPK; Raf,MAPK/ERK Pathway; Stem Cell/Wnt,"LUT014 is a topical inhibitor targeting BRAF that cannot pass through the blood-brain barrier. LUT014 inhibits BRAF kinase and abnormally activates the MAPK/ERK signaling pathway, promoting the proliferation of epidermal keratinocytes, repairing skin barrier damage caused by radiation damage, and alleviating inflammatory responses. LUT014 is independent of RAS signaling and accelerates the repair and regeneration of damaged skin cells. LUT014 can be used to study radiation dermatitis, especially skin damage caused by breast cancer radiotherapy[1][2][3].",C27H19F3N8O,DMSO : 50 mg/mL (94.61 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 2,FC(F)(F)OC1=CC(NC2=NC=CC3=C2C=CC(C)=C3NC4=NC=CC=C4C5=C6N=CNC6=NC=N5)=CC=C1
IACS-010759,IACS-10759,1570496-34-2,562.56,Apoptosis; Mitochondrial Metabolism; Oxidative Phosphorylation,Apoptosis; Metabolic Enzyme/Protease,"IACS-010759 is an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 inhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 has the potential for relapsed/refractory AML and solid tumors research[1][2].",C25H25F3N6O4S,DMSO : 50 mg/mL (88.88 mM; Need ultrasonic),10mM,Cancer,Phase 1,FC(F)(F)OC1=CC=C(C2=NOC(C3=NN(CC4=CC(N5CCC(S(=O)(C)=O)CC5)=CC=C4)C(C)=N3)=N2)C=C1
IACS-010759 (hydrochloride),IACS-10759 (hydrochloride),1807523-99-4,599.02,Apoptosis; Mitochondrial Metabolism; Oxidative Phosphorylation,Apoptosis; Metabolic Enzyme/Protease,"IACS-010759 hydrochlorideis an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 hydrochlorideinhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 hydrochloride has the potential for relapsed/refractory AML and solid tumors research[1][2].",C25H26ClF3N6O4S,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 60 mg/mL (100.16 mM; Need ultrasonic),10mM,Cancer,Phase 1,FC(F)(F)OC1=CC=C(C2=NOC(C3=NN(CC4=CC(N5CCC(S(=O)(C)=O)CC5)=CC=C4)C(C)=N3)=N2)C=C1.Cl
Naporafenib,LXH254,1800398-38-2,502.49,Bcr-Abl; p38 MAPK; Raf,MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Naporafenib (LXH254) is a potent, selective, orally active, type II BRAF and CRAF inhibitor, with IC50 values of 0.072 and 0.21 nM against CRAF and BRAF, respectively[1][2].",C25H25F3N4O4,DMSO : 100 mg/mL (199.01 mM; Need ultrasonic),10mM,Cancer,Phase 3,CC1=CC=C(NC(C2=CC(C(F)(F)F)=NC=C2)=O)C=C1C3=CC(N4CCOCC4)=NC(OCCO)=C3
KO-947,,1695533-89-1,355.39,ERK,MAPK/ERK Pathway; Stem Cell/Wnt,KO-947 is a potent and selective inhibitor of ERK1/2 kinases with potential utility in MAPK pathway dysregulated tumors.,C21H17N5O,DMSO : 62.5 mg/mL (175.86 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C1NC2=CC(NN=C3C4=CC=NC=C4)=C3C=C2CN1CC5=CC=CC=C5
Lerociclib,G1T38,1628256-23-4,474.60,CDK,Cell Cycle/DNA Damage,"Lerociclib (G1T38) is a potent and selective inhibitor of CDK4/6, with IC50s of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.",C26H34N8O,10 mM in DMSO,10mM,Cancer,Phase 3,O=C1NCC2(N3C1=CC4=CN=C(NC5=NC=C(N6CCN(C(C)C)CC6)C=C5)N=C43)CCCCC2
Lerociclib (dihydrochloride),G1T38 (dihydrochloride),2097938-59-3,547.52,CDK,Cell Cycle/DNA Damage,"Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 1 nM and 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.",C26H36Cl2N8O,H2O : 5 mg/mL (9.13 mM; ultrasonic and warming and heat to 60°C),2mM,Cancer,Phase 3,O=C1NCC2(N3C1=CC4=CN=C(NC5=NC=C(N6CCN(C(C)C)CC6)C=C5)N=C43)CCCCC2.Cl.Cl
C188-9,TTI-101,432001-19-9,471.52,Apoptosis; STAT,Apoptosis; JAK/STAT Signaling; Stem Cell/Wnt,"C188-9 (TTI-101) is a STAT3 inhibitor, with a Kd of 4.7 nM. C188-9 inhibits G-CSF-induced STAT3 activation and STAT3-dependent gene expression. C188-9 induces apoptosis in AML cell lines and primary samples and inhibits colony formation by primary AML blasts[1][2][3][4].",C27H21NO5S,DMSO : 25 mg/mL (53.02 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=S(C1=CC=C(OC)C=C1)(NC2=C3C=CC=CC3=C(O)C(C4=C5C=CC=CC5=CC=C4O)=C2)=O
Zipalertinib,TAS6417; CLN-081,1661854-97-2,396.44,Apoptosis; EGFR,Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Zipalertinib (TAS6417; CLN-081) is a highly effective, orally active and pan-mutation-selective EGFR tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with IC50 values ranging from 1.1-8.0 nM[1][2].",C23H20N6O,DMSO : 22.73 mg/mL (57.34 mM; Need ultrasonic),10mM,Cancer,Phase 3,NC1=C2C(N3C(C(C)=C[C@@H](C3)NC(C=C)=O)=C2C4=CC5=CC=CC=C5N=C4)=NC=N1
Pralsetinib,BLU-667,2097132-94-8,533.60,RET,Protein Tyrosine Kinase/RTK,"Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor. Pralsetinib (BLU-667) inhibits WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion with IC50s of 0.4, 0.3, 0.4, 0.4, and 0.4 nM, respectively[1].",C27H32FN9O2,DMSO : ≥ 100 mg/mL (187.41 mM),10mM,Cancer,Launched,O=C([C@@]1(OC)CC[C@H](C2=NC(NC3=NNC(C)=C3)=CC(C)=N2)CC1)N[C@H](C4=CC=C(N5N=CC(F)=C5)N=C4)C
Ripretinib,DCC-2618,1442472-39-0,510.36,Apoptosis; c-Kit; FLT3; PDGFR; VEGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2)[1][2]. DCC-2618 exerts antineoplastic effect and induces apoptosis[3].",C24H21BrFN5O2,DMSO : 25 mg/mL (48.99 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NC1=CC(C2=CC3=C(C=C(NC)N=C3)N(CC)C2=O)=C(Br)C=C1F)NC4=CC=CC=C4
MAT2A inhibitor 2,,13299-99-5,365.85,Methionine Adenosyltransferase (MAT); NF-κB; p38 MAPK,Epigenetics; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB,MAT2A inhibitor 2 is an inhibitor of methionine adenosine transferase 2A (MAT2A) with oral activity. MAT2A inhibitor 2 can be used in osteoporosis study[1],C18H24ClN3O3,DMSO : 75 mg/mL (205.00 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C1C(C)=CC(C2=CC=CC(OC)=C2)=NN1CCN3CCOCC3.[H]Cl
Brepocitinib,PF-06700841,1883299-62-4,389.40,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Brepocitinib (PF-06700841) is a potent dual  Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively[1].",C18H21F2N7O,DMSO : 125 mg/mL (321.01 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 3,O=C([C@H]1C(F)(F)C1)N2C3CN(C4=NC(NC5=CN(C)N=C5)=NC=C4)CC2CC3
Brepocitinib (P-Tosylate),PF-06700841 (P-Tosylate),2140301-96-6,561.60,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Brepocitinib (PF-06700841) P-Tosylate is a potent dual  Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. Brepocitinib P-Tosylate also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively[1].",C25H29F2N7O4S,H2O : 2 mg/mL (3.56 mM; Need ultrasonic); DMSO : 50 mg/mL (89.03 mM; ultrasonic and warming and heat to 60°C),10mM,Inflammation/Immunology,Phase 3,O=C([C@H]1C(F)(F)C1)N2C3CN(C4=NC(NC5=CN(C)N=C5)=NC=C4)CC2CC3.O=S(C6=CC=C(C)C=C6)(O)=O
Ivarmacitinib,SHR0302,1445987-21-2,414.48,Apoptosis; JAK,Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ivarmacitinib (SHR0302) is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of Ivarmacitinib for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. Ivarmacitinib inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. Ivarmacitinib has anti-proliferative and anti-inflammatory effects[1][2].",C18H22N8O2S,DMSO : 31.25 mg/mL (75.40 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 3,O=C(N1C[C@@]2([H])[C@@](C[C@H](N(C)C3=C4C(NC=C4)=NC=N3)C2)([H])C1)NC5=NC(OC)=NS5
F-1,,2244775-31-1,519.02,Anaplastic lymphoma kinase (ALK); ROS Kinase,Protein Tyrosine Kinase/RTK,"F-1 is a potent ALK and ROS1 dual inhibitor, suppresses phospho-ALK and its relative downstream signaling pathways, with IC50s of 2.1 nM, 2.3 nM, 1.3 nM and 3.9 nM for ALKWT, ROS1WT, ALKL1196M and ALKG1202R, respectively[1].",C22H27ClN8O3S,DMSO : 125 mg/mL (240.84 mM; ultrasonic and warming and heat to 65°C),10mM,Cancer,Phase 3,O=S(NC1=C(NC2=NC(NC3=C(OC)N=C(N4CCN(C)CC4)C=C3)=NC=C2Cl)C=CC=C1)(C)=O
GSK2646264,,1398695-47-0,374.48,Aurora Kinase; GSK-3; JAK; LRRK2; Src; Syk; VEGFR,Autophagy; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.1. GSK2646264 also inhibits other kinases with pIC50 values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin[1].",C24H26N2O2,DMSO : 50 mg/mL (133.52 mM; ultrasonic and warming and heat to 60°C),10mM,Inflammation/Immunology,Phase 1,CC1=CC(COC2=C(C3=CC=C4CCNCCC4=C3)C(OC)=CC=C2)=NC=C1
Almonertinib,HS-10296,1899921-05-1,525.64,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Almonertinib (HS-10296) is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib is used for the research of the non-small cell lung cancer[1][2].",C30H35N7O2,DMSO : 80 mg/mL (152.20 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,COC(C=C(N(C)CCN(C)C)C(NC(C=C)=O)=C1)=C1NC2=NC(C3=CN(C4CC4)C5=C3C=CC=C5)=CC=N2
Almonertinib (mesylate),HS-10296 (mesylate),2134096-06-1,621.75,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer[1][2].",C31H39N7O5S,DMSO : 31.25 mg/mL (50.26 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,COC(C=C(N(C)CCN(C)C)C(NC(C=C)=O)=C1)=C1NC2=NC(C3=CN(C4CC4)C5=C3C=CC=C5)=CC=N2.CS(=O)(O)=O
Almonertinib (hydrochloride),HS-10296 (hydrochloride),2134096-03-8,562.11,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib hydrochloride shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib hydrochloride is used for the research of the non-small cell lung cancer[1][2].",C30H36ClN7O2,DMSO : 5 mg/mL (8.90 mM; Need ultrasonic); H2O : 12.5 mg/mL (22.24 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,COC(C=C(N(C)CCN(C)C)C(NC(C=C)=O)=C1)=C1NC2=NC(C3=CN(C4CC4)C5=C3C=CC=C5)=CC=N2.[H]Cl
Firmonertinib,Alflutinib; Furmonertinib; AST2818,1869057-83-9,568.59,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Firmonertinib (Alflutinib; Furmonertinib) is an orally active, mutant-selective, and highly brain penetrant EGFR inhibitor. Firmonertinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation[1].",C28H31F3N8O2,DMSO : 100 mg/mL (175.87 mM; Need ultrasonic),10mM,Cancer,Launched,C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OCC(F)(F)F)N=C1N(CCN(C)C)C)=O
N-Acetylputrescine hydrochloride,,18233-70-0,166.65,Endogenous Metabolite,Metabolic Enzyme/Protease,"N-Acetylputrescine hydrochloride is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine hydrochloride may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine hydrochloride can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine hydrochloride can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD)[1][2][3][4].",C6H15ClN2O,H2O : 200 mg/mL (1200.12 mM; Need ultrasonic); DMSO : ≥ 125 mg/mL (750.08 mM),10mM,Cancer; Neurological Disease,Phase 2,CC(NCCCCN)=O.Cl
Cantrixil,TRX-E-002-1,2135511-22-5,408.44,Apoptosis,Apoptosis,"Cantrixil (TRX-E-002-1), an active enantiomer of TRX-E-002, is a second-generation super-benzopyran (SBP) compound. Cantrixil increases phosphorylated c-Jun levels resulting in caspase-mediated apoptosis in ovarian cancer cells. Cantrixil has potent pan anti-cancer activity against a broad range of cancer phenotypes[1][2].",C24H24O6,DMSO : 100 mg/mL (244.83 mM; Need ultrasonic),10mM,Cancer,Phase 1,OC1=CC=C([C@H](C2=CC=C(O)C=C2)[C@H](C3=CC(OC)=C(O)C(OC)=C3)CO4)C4=C1C
Sotorasib,AMG-510,2296729-00-3,560.59,Ras,GPCR/G Protein; MAPK/ERK Pathway,"Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib leads to the regression of KRAS G12C?mutated locally advanced or metastatic non?small cell lung cancer (NSCLC)[1][2][3][4][5][6].",C30H30F2N6O3,DMSO : 50 mg/mL (89.19 mM; Need ultrasonic); H2O : 33.33 mg/mL (59.46 mM; ultrasonic and adjust pH to 11 with NaOH),10mM,Cancer,Launched,O=C(C=C)N1C[C@H](C)N(C2=NC(N(C3=C(C)C=CN=C3C(C)C)C4=C2C=C(F)C(C5=C(O)C=CC=C5F)=N4)=O)CC1
Sotorasib (racemate),AMG-510 (racemate),2252403-56-6,560.59,p38 MAPK; Ras,GPCR/G Protein; MAPK/ERK Pathway,"Sotorasib racemate (Compound A) is an orally active racemate of Sotorasib (HY-114277), a covalent inhibitor of KRAS G12C mutant which induces adaptive feedback activation of MAPK pathway. Sotorasib racemate also exerts inhibitor activity against KRAS G12C induced cancer and can be applied to cancer research[1].",C30H30F2N6O3,DMSO : 3.85 mg/mL (6.87 mM; Need ultrasonic),2mM,Cancer,Launched,O=C1N(C2=C(C)C=CN=C2C(C)C)C3=NC(C4=C(O)C=CC=C4F)=C(F)C=C3C(N5[C@@H](C)CN(C(C=C)=O)CC5)=N1
BPI-9016M,,1528546-94-2,460.43,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma[1][2].",C25H18F2N4O3,DMSO : 100 mg/mL (217.19 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(C1=CNC=C(C2=CC=C(F)C=C2)C1=O)NC3=CC=C(OC4=C5C(NCC5)=NC=C4)C(F)=C3
Tamnorzatinib,ONO-7475,1646839-59-9,562.57,TAM Receptor; Trk Receptor,Neuronal Signaling; Protein Tyrosine Kinase/RTK,"Tamnorzatinib (ONO-7475) is a potent, selective, and orally active Axl/Mer inhibitor with IC50 values of 0.7 nM and 1.0 nM, respectively. Tamnorzatinib sensitizes AXL-overexpressing EGFR-mutant NSCLC cells to the EGFR-TKIs, suppresses the emergence and maintenance of tolerant cells. Tamnorzatinib combines with Osimertinib (HY-15772) provides a bright promise for the study of EGFR-mutated non-small cell lung cancer (NSCLC).",C32H26N4O6,DMSO : 250 mg/mL (444.39 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=CC2=C(N(C3=CC=CC=C3)C1=O)CCCC2=O)NC4=NC=C(OC5=CC=NC6=CC(OC)=C(OC)C=C56)C=C4
Selpercatinib,LOXO-292,2152628-33-4,525.60,RET,Protein Tyrosine Kinase/RTK,"Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity[1][2].",C29H31N7O3,DMSO : 62.5 mg/mL (118.91 mM; Need ultrasonic),10mM,Cancer,Launched,N#CC1=C2C(C3=CC=C(N4CC(C5)N(CC6=CC=C(OC)N=C6)C5C4)N=C3)=CC(OCC(C)(O)C)=CN2N=C1
Camptothecin-20(S)-O-propionate,Camptothecin-20-O-propionate,194414-69-2,404.42,Topoisomerase,Cell Cycle/DNA Damage,"Camptothecin-20(S)-O-propionate (CZ48), the C20-propionate ester of CPT, is a highly effective anticancer agent. Camptothecin-20(S)-O-propionate (CZ48) is a topoisomerase-Ι inhibitor[1][2][3].",C23H20N2O5,DMSO : 9.09 mg/mL (22.48 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C1[C@](CC)(C2=C(C(N3CC4=CC5=CC=CC=C5N=C4C3=C2)=O)CO1)OC(CC)=O
Glumetinib,Gumarontinib; SCC244,1642581-63-2,459.48,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor with an IC50 of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity[1].",C21H17N9O2S,DMSO : 41.67 mg/mL (90.69 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=S(N1N=CC2=NC=C(C3=CN(C)N=C3)C=C21)(C4=CN=C5C=CC(C6=CN(C)N=C6)=CN54)=O
Selatinib,,1275595-86-2,565.06,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Selatinib is a reversible and orally active dual EGFR and ErbB2 inhibitor with IC50s of 13 nM and 22.5 nM, respectively. Selatinib has anticancer effects[1].",C29H26ClFN4O3S,DMSO : 100 mg/mL (176.97 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=S(C)CCNCC1=CC=C(O1)C2=CC3=C(N=CN=C3C=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5
Ethaselen,BBSKE,217798-39-5,422.20,TrxR,Metabolic Enzyme/Protease,"Ethaselen (BBSKE) is an orally active, selective thioredoxin reductase (TrxR) inhibitor with IC50s of 0.5 and 0.35 μM for the wild-type human TrxR1 and rat TrxR1, respectively. Ethaselen specifically binds to the unique selenocysteine-cysteine redox pair in the C-terminal active site of mammalian TrxR1. Ethaselen, an organoselenium compound, is a potent antitumor candidate that exerts potent inhibition on non-small cell lung cancer (NSCLC) by targeting TrxR[1][2].",C16H12N2O2Se2,DMSO : 12.5 mg/mL (29.61 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 1,O=C1N([Se]C2=CC=CC=C12)CCN3[Se]C4=CC=CC=C4C3=O
Fialuridine,FIAU; DRG-0098; NSC 678514,69123-98-4,372.09,DNA/RNA Synthesis; HBV; HSV; Nucleoside Antimetabolite/Analog; Orthopoxvirus,Anti-infection; Cell Cycle/DNA Damage,"Fialuridine (FIAU), a nucleoside analog, is a HSV-1 and HSV-2 inhibitor with Kis of 0.14 μM and 0.95 μM, respectively. Fialuridine shows anti-orthopoxvirus and anti-hepatitis B virus (HBV) activities. Fialuridine inhibits duck HBV DNA replication with IC50 values of 0.075 μM and 156 μM in human hepatoma cells and in chicken liver cells, respectively[1][2][3].",C9H10FIN2O5,DMSO : 100 mg/mL (268.75 mM; Need ultrasonic),10mM,Infection,Phase 2,O[C@H]1[C@H](F)[C@H](N2C(NC(C(I)=C2)=O)=O)O[C@@H]1CO
Dacomitinib (hydrate),PF-00299804 (hydrate); PF-299804 (hydrate),1042385-75-0,487.95,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC)[1].",C24H27ClFN5O3,DMF : 10 mg/mL (20.49 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(/C=C/CN1CCCCC1)NC2=CC3=C(C=C2OC)N=CN=C3NC4=CC=C(C(Cl)=C4)F.O
Bucillamine,SA96; Thiobutarit,65002-17-7,223.31,VEGFR,Protein Tyrosine Kinase/RTK,Bucillamine (SA96) is an orally active and potent sulfhydryl donor and antioxidant. Bucillamine is also an antirheumatic agent with antiangiogenic properties. Bucillamine can protect against Ischemia/reperfusion (I/R) injury in high-risk organ transplants. Bucillamine inhibits the production of VEGF. Bucillamine can be used for the research of choroidal neovascularization (CNV) and rheumatoid arthritis (RA)[1][2].,C7H13NO3S2,H2O : 5 mg/mL (22.39 mM; ultrasonic and warming and heat to 60°C),10mM,Inflammation/Immunology; Cardiovascular Disease,Phase 4,SC[C@@H](C(O)=O)NC(C(C)(S)C)=O
Butamirate (citrate),,18109-81-4,499.55,STAT,JAK/STAT Signaling; Stem Cell/Wnt,Butamirate citrate is an orally active antitussive agent that acts centrally through the receptors in the brainstem. Butamirate citrate also reduces the resistance in the airways by inhibiting bronchospasm and anti-inflammatory effect. Butamirate citrate inhibits glioblastoma (GBM) growth and STAT3 activity. Butamirate citrate can be used for the study of glioblastoma[1][2].,C24H37NO10,DMSO : 125 mg/mL (250.23 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 1,O=C(OCCOCCN(CC)CC)C(CC)C1=CC=CC=C1.O=C(CC(C(O)=O)(O)CC(O)=O)O
Mitonafide,NSC 300288,54824-17-8,313.31,DNA/RNA Synthesis,Cell Cycle/DNA Damage,"Mitonafide (NSC 300288) is a cytostatic agent. Mitonafide binds to double-stranded DNA through intercalation, and inhibits DNA and RNA synthesis. Mitonafide is an antitumor agent that can be used in the research of cancers, such as non-small cell lung cancer (NSCLC), leukemia[1][2][3].",C16H15N3O4,DMSO : 62.5 mg/mL (199.48 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1N(C(C2=CC([N+]([O-])=O)=CC3=CC=CC1=C23)=O)CCN(C)C
Apratastat,TMI-005,287405-51-0,414.50,MMP; TNF Receptor,Apoptosis; Metabolic Enzyme/Protease,"Apratastat (TMI-005) is an orally active, non-selective and reversible TACE/MMPs inhibitor, can inhibit inhibit the release of TNF-α. Apratastat has the potential to overcome radiotherapy-resistance in non-small cell lung cancer (NSCLC)[1][2]. Apratastat is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.",C17H22N2O6S2,DMSO : ≥ 100 mg/mL (241.25 mM),10mM,Cancer,Phase 2,CC1(C)[C@H](C(NO)=O)N(S(=O)(C2=CC=C(OCC#CCO)C=C2)=O)CCS1
ODM-203,,1430723-35-5,505.54,FGFR; VEGFR,Protein Tyrosine Kinase/RTK,"ODM-203 is an orally active and selective FGFR/VEGFR inhibitor with IC50 values of 6, 11, 16, 5, 9, 26 and 35 nM for FGFR3/1/2 and VEGFR3/2/1/4, respectively. ODM-203 has strong anti-tumour activity and activates immune responses in the tumour microenvironment[1].",C26H21F2N5O2S,DMSO : 66.67 mg/mL (131.88 mM; Need ultrasonic),10mM,Cancer,Phase 1,CN(N=C1)C=C1C2=CC=C3C(N=CN3C4=CC(C5=CC=C(F)C=C5F)=CC(NS(C6CC6)(=O)=O)=C4)=C2
Erlotinib (Hydrochloride),CP-358774 (hydrochloride); NSC 718781 (hydrochloride); OSI-774 (hydrochloride),183319-69-9,429.90,Autophagy; EGFR,Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Erlotinib Hydrochloride (CP-358774 Hydrochloride) inhibits purified EGFR kinase with an IC50 of 2 nM. Erlotinib (Hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.",C22H24ClN3O4,DMSO : 3.33 mg/mL (7.75 mM; ultrasonic and warming and heat to 60°C); H2O : < 0.1 mg/mL (insoluble),2mM,Cancer,Launched,COCCOC1=CC2=NC=NC(NC3=CC=CC(C#C)=C3)=C2C=C1OCCOC.[H]Cl
Pazopanib (Hydrochloride),GW786034 (Hydrochloride),635702-64-6,473.98,Autophagy; c-Fms; c-Kit; FGFR; PDGFR; VEGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.",C21H24ClN7O2S,DMSO : 10 mg/mL (21.10 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,CC1=CC=C(C=C1S(N)(=O)=O)NC2=NC=CC(N(C3=CC4=NN(C(C)=C4C=C3)C)C)=N2.Cl
BMS-599626 (Hydrochloride),AC480 (Hydrochloride),873837-23-1,567.01,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC50s of 20 and 30 nM, respectively. BMS-599626 Hydrochloride displays ~8-fold less potent to HER4 (IC50=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 Hydrochloride inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy[1][2].",C27H28ClFN8O3,DMSO : 100 mg/mL (176.36 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(OC[C@H]1NCCOC1)NC2=CN(C3=C2C)N=CN=C3NC4=CC5=C(C=C4)N(CC6=CC(F)=CC=C6)N=C5.Cl
MW-150,MW01-18-150SRM,1628502-91-9,381.47,Autophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,"MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. MW-150 inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia[1].",C24H23N5,DMSO : 40 mg/mL (104.86 mM; Need ultrasonic),10mM,Inflammation/Immunology; Neurological Disease,Phase 2,CN1CCN(C2=NN=C(C3=CC=C4C=CC=CC4=C3)C(C5=CC=NC=C5)=C2)CC1
PF-04217903,,956905-27-4,372.38,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"PF-04217903 is a potent ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met. PF-04217903 shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties[1][2].",C19H16N8O,Ethanol : < 1 mg/mL (ultrasonic) (insoluble); DMSO : 20 mg/mL (53.71 mM; Need ultrasonic),10mM,Cancer,Phase 1,OCCN1N=CC(C2=NC3=C(N=C2)N=NN3CC4=CC5=CC=CN=C5C=C4)=C1
PF-04217903 (mesylate),,956906-93-7,468.49,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"PF-04217903 mesylate is a potent ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM for human c-Met. PF-04217903 mesylate shows more than 1,000-fold selectivity relative to 208 kinases. Antiangiogenic properties[1][2].",C20H20N8O4S,DMSO : 50 mg/mL (106.73 mM; Need ultrasonic),10mM,Cancer,Phase 1,OCCN1N=CC(C2=NC3=C(N=C2)N=NN3CC4=CC5=CC=CN=C5C=C4)=C1.CS(=O)(O)=O
Vatalanib (dihydrochloride),PTK787 (dihydrochloride); ZK-222584 (dihydrochloride); CGP-797870 (dihydrochloride),212141-51-0,419.73,Apoptosis; VEGFR,Apoptosis; Protein Tyrosine Kinase/RTK,Vatalanib dihydrochloride (PTK787 dihydrochloride) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM.,C20H17Cl3N4,DMSO : 50 mg/mL (119.12 mM; ultrasonic and warming and heat to 80°C); H2O : 50 mg/mL (119.12 mM; Need ultrasonic),10mM,Cancer,Phase 3,ClC1=CC=C(C=C1)NC2=NN=C(C3=C2C=CC=C3)CC4=CC=NC=C4.[H]Cl.[H]Cl
SGX-523,,1022150-57-7,359.41,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"SGX523 is a exquisitely selective and ATP-competitive MET inhibitor. SGX523 potently inhibits MET with an IC50 of 4 nM and is >1,000-fold selective versus other protein kinases. Antitumor activity[1].",C18H13N7S,DMSO : 30 mg/mL (83.47 mM; Need ultrasonic),10mM,Cancer,Phase 1,CN1N=CC(C2=NN3C(SC4=CC5=C(N=CC=C5)C=C4)=NN=C3C=C2)=C1
2-Methoxyestradiol,2-ME2; NSC-659853,362-07-2,302.41,Apoptosis; Autophagy; Endogenous Metabolite; Microtubule/Tubulin; Reactive Oxygen Species (ROS),Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"2-Methoxyestradiol (2-ME2), an orally active endogenous metabolite of 17β-estradiol (E2), is an apoptosis inducer  and an angiogenesis inhibitor with potent antineoplastic activity. 2-Methoxyestradiol also destablize microtubules. 2-Methoxyestradio, also a potent superoxide dismutase (SOD) inhibitor and a ROS-generating agent, induces autophagy in the transformed cell line HEK293 and the cancer cell lines U87 and HeLa[1][2][3][4][5][6].",C19H26O3,H2O : < 0.1 mg/mL (insoluble); DMSO : 250 mg/mL (826.69 mM; Need ultrasonic),10mM,Cancer,Phase 2,OC1=CC2=C([C@]3(CC[C@@]4([C@H](CC[C@]4([C@@]3(CC2)[H])[H])O)C)[H])C=C1OC
AMG-208,,1002304-34-8,383.40,c-Met/HGFR; Cytochrome P450,Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,AMG-208 is an orally active c-Met/RON dual selective inhibitor with an IC50 of 9 nM for c-Met. AMG-208 is a CYP3A4 inhibitor with an IC50 of 32 μM. AMG-208 has anti-cancer activity[1][2][3].,C22H17N5O2,DMSO : 3.33 mg/mL (8.69 mM; Need ultrasonic),2mM,Cancer,Phase 2,COC1=CC=C2C(OCC3=NN=C4N3N=C(C=C4)C5=CC=CC=C5)=CC=NC2=C1
GSK1059615,,958852-01-2,333.36,Apoptosis; mTOR; PI3K,Apoptosis; PI3K/Akt/mTOR,"GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively.",C18H11N3O2S,DMSO : 5 mg/mL (15.00 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(S/C1=C\C2=CC=C3N=CC=C(C3=C2)C4=CC=NC=C4)NC1=O
Rigosertib (sodium),ON-01910 (sodium),592542-60-4,473.47,Apoptosis; PI3K; Polo-like Kinase (PLK),Apoptosis; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3K/Akt pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle[1][2]. Rigosertib sodium is a selective and non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM[3].",C21H24NNaO8S,H2O : ≥ 52 mg/mL (109.83 mM); DMSO : 150 mg/mL (316.81 mM; Need ultrasonic),10mM,Cancer,Phase 3,COC1=CC=C(C=C1NCC(O[Na])=O)CS(/C=C/C2=C(C=C(C=C2OC)OC)OC)(=O)=O
Cabozantinib (S-malate),XL184 (S-malate); BMS-907351 (S-malate),1140909-48-3,635.59,Apoptosis; VEGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.",C32H30FN3O10,DMSO : 100 mg/mL (157.33 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,O=C([C@H](CC(O)=O)O)O.O=C(NC1=CC=C(C=C1)OC2=CC=NC3=CC(OC)=C(C=C23)OC)C4(CC4)C(NC5=CC=C(C=C5)F)=O
Ponatinib,AP24534,943319-70-8,532.56,Autophagy; Bcr-Abl; FGFR; PDGFR; Src; VEGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively[1].",C29H27F3N6O,DMSO : 25 mg/mL (46.94 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,CC1=C(C=C(C=C1)C(NC2=CC(C(F)(F)F)=C(C=C2)CN3CCN(CC3)C)=O)C#CC4=CN=C5N4N=CC=C5
Vinorelbine (ditartrate),KW-2307; Nor-5'-anhydrovinblastine ditartrate,125317-39-7,1079.11,Autophagy; Microtubule/Tubulin,Autophagy; Cell Cycle/DNA Damage; Cytoskeleton,Vinorelbine (ditartrate) is an anti-mitotic agent which inhibits the proliferation of Hela cells with IC50 of 1.25 nM.,C53H66N4O20,DMSO : 175 mg/mL (162.17 mM; Need ultrasonic); H2O : 100 mg/mL (92.67 mM; Need ultrasonic),10mM,Cancer,Launched,CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C(C=C([C@@](C4=C5C(C=CC=C6)=C6N4)(CC(C=C(CC)C7)([H])CN7C5)C(OC)=O)C(OC)=C8)=C8N9C)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O
Ruserontinib,SKLB1028,1350544-93-2,443.55,Bcr-Abl; EGFR; FLT3,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Ruserontinib (SKLB1028) is an orally active multikinase inhibitor of EGFR, FLT3 and Abl, with an IC50 value of 55 nM for human FLT3, and has antitumor activity[1].",C24H29N9,DMSO : 250 mg/mL (563.63 mM; Need ultrasonic),10mM,Cancer,Phase 3,CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C4N=C(N(C4=N3)C(C)C)NC5=CC=CN=C5
JNJ-49095397,RV568,1220626-82-3,592.69,p38 MAPK; Src,MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms of p38 MAPK. JNJ-49095397 also inhibits SRC kinase family, specifically haematopoietic kinase (HCK) JNJ-49095397 shows potent anti-inflammatory effects and can be used for the research of chronic obstructive pulmonary disease (COPD) and asthma[1].",C34H36N6O4,DMSO : 100 mg/mL (168.72 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 2,O=C(NC1=NC=CC(COC2=C3C=CC=CC3=C(NC(NC4=CC(C(C)(C)C)=NN4C5=CC=C(C)C=C5)=O)C=C2)=C1)COC
Sabizabulin,VERU-111; ABI-231,1332881-26-1,377.39,Apoptosis; HPV; Microtubule/Tubulin,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,"VERU-111 (ABI-231) is a potent and orally active α and β tubulin inhibitor, which displays strong antiproliferative activity, with an average IC50 of 5.2 nM against panels of melanoma and prostate cancer cell lines. VERU-111 (ABI-231) suppresses tumor growth and metastatic phenotypes of cervical cancer cells via targeting HPV E6 and E7, and has potential for the treatment of prostate cancer[1][2][3].",C21H19N3O4,DMSO : 20 mg/mL (53.00 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(C1=CNC(C2=CNC3=C2C=CC=C3)=N1)C4=CC(OC)=C(OC)C(OC)=C4
KRN-633,,286370-15-8,416.86,VEGFR,Protein Tyrosine Kinase/RTK,"KRN-633 is a potent VEGFR inhibitor with IC50s of 170, 160 and 125 nM for VEGFR1, VEGFR2 and VEGFR3, respectively. ",C20H21ClN4O4,DMSO : 25 mg/mL (59.97 mM; Need ultrasonic),10mM,Cancer,Phase 1,ClC1=CC(OC2=NC=NC3=CC(OC)=C(C=C32)OC)=CC=C1NC(NCCC)=O
SB-743921 (hydrochloride),,940929-33-9,553.52,Kinesin,Cell Cycle/DNA Damage; Cytoskeleton,"SB-743921 hydrochloride is a potent inhibitor of the mitotic kinesin KSP (Eg5), with a Ki of 0.1 nM.",C31H34Cl2N2O3,DMSO : ≥ 100 mg/mL (180.66 mM); H2O : 10 mg/mL (18.07 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,ClC1=CC2=C(C(C(CC3=CC=CC=C3)=C([C@@H](C(C)C)N(C(C4=CC=C(C=C4)C)=O)CCCN)O2)=O)C=C1.Cl
BMS 777607,BMS 817378,1025720-94-8,512.89,c-Met/HGFR; TAM Receptor,Protein Tyrosine Kinase/RTK,"BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor kinases[1].",C25H19ClF2N4O4,DMSO : 83.33 mg/mL (162.47 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC=C(C(F)=C1)OC2=C(C(N)=NC=C2)Cl)C3=C(C=CN(C3=O)C4=CC=C(C=C4)F)OCC
"3,4',5-Trismethoxybenzophenone",,94709-12-3,272.30,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"3,4',5-Trismethoxybenzophenone (compound 16a) is a potent tubulin assembly inhibitor with an IC50 value of 2.6 μM[1].",C16H16O4,10 mM in DMSO,10mM,Cancer,Phase 2,O=C(C1=CC(OC)=CC(OC)=C1)C2=CC=C(OC)C=C2
Verubulin (hydrochloride),MPC-6827 (hydrochloride),917369-31-4,315.80,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"Verubulin hydrochloride (MPC-6827 hydrochloride) is a blood brain barrier permeable microtubule-disrupting agent, with potent and broad-spectrum in vitro and in vivo cytotoxic activities. Verubulin hydrochloride (MPC-6827 hydrochloride) exhibits potent anticancer activity in human MX-1 breast and other mouse xenograft cancer models. Verubulin hydrochloride (MPC 6827 hydrochloride) is a promising candidate for the treatment of multiple cancer types[1][2].",C17H18ClN3O,DMSO : 62.5 mg/mL (197.91 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,CC1=NC(N(C2=CC=C(OC)C=C2)C)=C3C=CC=CC3=N1.Cl
Lorlatinib,PF-06463922,1454846-35-5,406.41,Anaplastic lymphoma kinase (ALK); Apoptosis; ROS Kinase,Apoptosis; Protein Tyrosine Kinase/RTK,"Lorlatinib (PF-06463922) is a selective, orally active, brain-penetrant and ATP-competitive ROS1/ALK inhibitor with anticancer activity. Lorlatinib has Kis of <0.025 nM, <0.07 nM, and 0.7 nM for ROS1, wild type ALK, and ALKL1196M, respectively. Lorlatinib targets to EML4-ALK, and inhibits ALK phosphorylation with IC50s of 15-43 nM (ALKL1196), 14-80 nM (ALKG1269A), 38-50 nM (ALK1151Tins), 77-113 nM (ALKG1202R), respectively[1][2][3].",C21H19FN6O2,DMSO : ≥ 28 mg/mL (68.90 mM),10mM,Cancer,Launched,CN1C(C#N)=C2C(CN(C)C(C3=C([C@@H](C)OC4=C(N)N=CC2=C4)C=C(F)C=C3)=O)=N1
Aurintricarboxylic acid,,4431-00-9,422.34,Apoptosis; Influenza Virus; MicroRNA; P2X Receptor; Topoisomerase,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Membrane Transporter/Ion Channel,"Aurintricarboxylic acid is a nanomolar-potency, allosteric antagonist with selectivity towards αβ-methylene-ATP-sensitive P2X1Rs and P2X3Rs, with IC50s of 8.6 nM and 72.9 nM for rP2X1R and rP2X3R, respectively[1]. Aurintricarboxylic acid is a potent anti-influenza agent by directly inhibiting the neuraminidase[2]. Aurintricarboxylic acid is an inhibitor of topoisomerase II and apoptosis[3]. Aurintricarboxylic acid is a selective inhibitor of the TWEAK-Fn14 signaling pathway[4]. Aurintricarboxylic acid also acts as a cystathionine-lyase (CSE) inhibitor with an IC50 of 0.6 μM[5]. Aurintricarboxylic acid is a modifier of miRNAs that regulate miRNA function, with an IC50 of 0.47 μM[6].",C22H14O9,H2O : < 0.1 mg/mL (ultrasonic) (insoluble); DMSO : 125 mg/mL (295.97 mM; Need ultrasonic); NH4OH : 10 mg/mL (23.68 mM; Need ultrasonic),10mM,Infection; Inflammation/Immunology; Neurological Disease,Phase 2,O=C(C=C/1)C(C(O)=O)=CC1=C(C2=CC(C(O)=O)=C(O)C=C2)\C3=CC(C(O)=O)=C(O)C=C3
Umbralisib,TGR-1202; RP5264,1532533-67-7,571.55,Casein Kinase; PI3K,Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib can be used for haematological malignancies reseach[1][2][3][4].",C31H24F3N5O3,DMSO : 25 mg/mL (43.74 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1C(C2=CC=CC(F)=C2)=C([C@@H](N3N=C(C4=CC=C(OC(C)C)C(F)=C4)C5=C(N)N=CN=C53)C)OC6=CC=C(F)C=C16
Umbralisib (hydrochloride),TGR-1202 hydrochloride; RP5264 hydrochloride,1532533-78-0,608.01,Casein Kinase; PI3K,Cell Cycle/DNA Damage; PI3K/Akt/mTOR; Stem Cell/Wnt,"Umbralisib (TGR-1202) hydrochloride is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC50 of 22.2 nM and 6.0 μM, respectively. Umbralisib hydrochloride exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib hydrochloride can be used for haematological malignancies reseach[1][2][3][4].",C31H25ClF3N5O3,DMSO : ≥ 150 mg/mL (246.71 mM),10mM,Cancer,Launched,O=C1C(C2=CC=CC(F)=C2)=C([C@@H](N3N=C(C4=CC=C(OC(C)C)C(F)=C4)C5=C(N)N=CN=C53)C)OC6=CC=C(F)C=C16.[H]Cl
Serabelisib,MLN1117; INK1117; TAK-117,1268454-23-4,363.37,PI3K,PI3K/Akt/mTOR,Serabelisib (MLN1117) is a selective p110α inhibitor with an IC50 of 15 nM.,C19H17N5O3,DMSO : 6.4 mg/mL (17.61 mM; Need ultrasonic and warming),10mM,Cancer,Phase 2,O=C(C1=CN=C2C=CC(C3=CC=C(OC(N)=N4)C4=C3)=CN21)N5CCOCC5
Sulfatinib,Surufatinib; HMPL-012,1308672-74-3,480.58,FGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Sulfatinib (Surufatinib) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC50s of in a range of 1 to 24 nM.",C24H28N6O3S,DMSO : ≥ 100 mg/mL (208.08 mM),10mM,Cancer,Launched,O=S(CC1=CC=CC(NC2=NC=CC(OC3=CC4=C(NC(C)=C4)C=C3)=N2)=C1)(NCCN(C)C)=O
Oxatomide,KW-4354,60607-34-3,426.55,5-HT Receptor; Apoptosis; COX; Histamine Receptor; P2X Receptor; p38 MAPK; PERK,Apoptosis; Cell Cycle/DNA Damage; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Neuronal Signaling,"Oxatomide (KW-4354) is an orally active dual antagonist of the H1-histamine receptor and the P2X7 receptor, as well as an inhibitor of serotonin. Oxatomide possesses antihistaminic, antiallergic and anti-inflammatory activities. Oxatomide can be used in the research of allergic diseases[1][2][3][4].",C27H30N4O,DMSO : 250 mg/mL (586.10 mM; Need ultrasonic),10mM,Inflammation/Immunology,Launched,O=C1NC2=CC=CC=C2N1CCCN3CCN(C(C4=CC=CC=C4)C5=CC=CC=C5)CC3
AZD8186,,1627494-13-6,457.47,PI3K,PI3K/Akt/mTOR,"AZD8186 is a PI3K inhibitor, which potently inhibits PI3Kβ (IC50=4 nM) and PI3Kδ (IC5050=12 nM) with selectivity over PI3Kα (IC50=35 nM) and PI3Kγ (IC50=675 nM).",C24H25F2N3O4,DMSO : ≥ 35 mg/mL (76.51 mM),10mM,Cancer,Phase 2,O=C(C1=CC([C@H](NC2=CC(F)=CC(F)=C2)C)=C3C(C(C=C(N4CCOCC4)O3)=O)=C1)N(C)C
DS-7423,,1222104-37-1,520.51,mTOR; PI3K,PI3K/Akt/mTOR,"DS-7423 is a dual PI3K and mTOR inhibitor, with IC50 values of 15.6 nM, 34.9 nM for PI3Kα and mTOR, respectively. DS-7423 possesses anti-tumor activity[1][2].",C22H27F3N10O2,DMSO : 100 mg/mL (192.12 mM; Need ultrasonic),10mM,Cancer,Phase 1,CC(N1[C@H](C)CN(C2=NC3=C(N4CCOCC4)N=C(C5=CN=C(N)N=C5)N=C3N2CC(F)(F)F)CC1)=O
Pamufetinib,TAS-115,1190836-34-0,518.56,c-Met/HGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Pamufetinib (TAS-115) is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.",C27H23FN4O4S,DMSO : 25 mg/mL (48.21 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,O=C(C1=C(OC)C=C2N=CC=C(OC3=CC=C(NC(NC(CC4=CC=CC=C4)=O)=S)C=C3F)C2=C1)NC
Pamufetinib (mesylate),TAS-115 (mesylate),1688673-09-7,614.66,c-Met/HGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Pamufetinib (TAS-115) mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.",C28H27FN4O7S2,DMSO : 75 mg/mL (122.02 mM; Need ultrasonic),10mM,Cancer,Phase 3,CS(=O)(O)=O.O=C(C1=C(OC)C=C2N=CC=C(OC3=CC=C(NC(NC(CC4=CC=CC=C4)=O)=S)C=C3F)C2=C1)NC
Imofinostat,ABT-301; MPT0E028; TMU-C-0012,1338320-94-7,344.38,Akt; Apoptosis; HDAC,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR,"Imofinostat (ABT-301; MPT0E028) is an orally active and selective HDAC inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively. Imofinostat has a weak inhibitory effect on HDAC8 (IC50 of 2.5 ??μM), but no inhibitory effect on HDAC4 (IC50>10 μM). Imofinostat reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. Imofinostat has a broad-spectrum antitumor activity, including colorectal cancer, B-cell lymphoma, non-small cell lung carcinoma (NSCLC), and pancreatic cancer, while also showing therapeutic potential in non-tumor diseases like emphysema and pulmonary fibrosis[1][2][3][14][5][6].",C17H16N2O4S,DMSO : 100 mg/mL (290.38 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 1,O=C(/C=C/C1=CC2=C(C=C1)N(CC2)S(=O)(C3=CC=CC=C3)=O)NO
Chiauranib,Ibcasertib; CS2164,1256349-48-0,435.47,Aurora Kinase; c-Fms; c-Kit; PDGFR; VEGFR,Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK,"Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects[1].",C27H21N3O3,DMSO : 62.5 mg/mL (143.52 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(NC1=CC=CC=C1N)C2=C3C=CC(OC4=CC=NC5=CC(OC)=CC=C54)=CC3=CC=C2
(R)-Odafosfamide,OBI-3424; TH-3424; (R)-AST-3424,2097713-68-1,460.42,DNA Alkylator/Crosslinker,Cell Cycle/DNA Damage,"(R)-Odafosfamide (OBI-3424) is a proagent that is selectively converted by AKR1C3 (aldo-keto reductase 1C3) to a potent DNA-alkylating agent. (R)-Odafosfamide can be used for hepatocellular carcinoma, castrate-resistant prostate cancer, and acute lymphoblastic leukemia (ALL) research[1].",C21H25N4O6P,DMSO : 50 mg/mL (108.60 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=P(N1CC1)(N2CC2)O[C@@H](C3=CC=C([N+]([O-])=O)C(OC4=CC=CC(C(N(C)C)=O)=C4)=C3)C
Decernotinib,VX-509; VRT-831509,944842-54-0,392.38,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Decernotinib is a potent, orally active JAK3 inhibitor, with Kis of 2.5, 11, 13 and 11 nM for JAK3, JAK1, JAK2, and TYK2, respectively.",C18H19F3N6O,DMSO : ≥ 50 mg/mL (127.43 mM),10mM,Inflammation/Immunology,Phase 3,C[C@](C(NCC(F)(F)F)=O)(CC)NC1=NC(C2=CNC3=NC=CC=C32)=NC=C1
Bozitinib,PLB-1001; CBT-101; Vebreltinib,1440964-89-5,424.38,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].",C20H15F3N8,DMSO : 50 mg/mL (117.82 mM; Need ultrasonic),10mM,Cancer,Phase 3,CN1N=C2C=C(F)C(C(C3=NN=C4C=CC(C5=CN(C6CC6)N=C5)=NN43)(F)F)=CC2=C1
Samotolisib,LY3023414,1386874-06-1,406.48,Autophagy; DNA-PK; mTOR; PI3K,Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Samotolisib (LY3023414) potently and selectively inhibits class I PI3K isoforms, DNA-PK, and mTORC1/2 with IC50s of 6.07 nM, 77.6 nM, 38 nM, 23.8 nM, 4.24 nM and 165 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, DNA-PK and mTOR, respectively. Samotolisib potently inhibits mTORC1/2 at low nanomolar concentrations[1][2].",C23H26N4O3,DMSO : 50 mg/mL (123.01 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(N1C[C@@H](OC)C)N(C)C2=C1C3=CC(C4=CC(C(C)(O)C)=CN=C4)=CC=C3N=C2
DRF-1042,,200619-13-2,408.40,ADC Payload; Topoisomerase,Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage,DRF-1042 is an orally active derivative of Camptothecin. DRF-1042 acts to inhibit DNA topoisomerase I. DRF-1042 shows good anticancer activity against a panel of human cancer cell lines including multi-agent resistance (MDR) phenotype[1][2].,C22H20N2O6,DMSO : 50 mg/mL (122.43 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C1[C@](CC)(C2=C(C(N3C(C4=CC5=CC=CC=C5N=C4C3=C2)OCCO)=O)CO1)O
Chromium picolinate,Chromium (III) picolinate; Cr(Pic)3,14639-25-9,418.30,Apoptosis; p38 MAPK,Apoptosis; MAPK/ERK Pathway,Chromium picolinate (Chromium (III) picolinate) is a compound that has oral activity. Chromium picolinate induces apoptosis. Chromium picolinate is the activator of p38 MAPK. Chromium picolinate has antioxidant activity. Chromium picolinate can be used in research on type 2 diabetes[1][2][3][4].,C18H12CrN3O6,DMSO : 7.81 mg/mL (18.67 mM; Need ultrasonic),10mM,Metabolic Disease,Launched,O=C1[O-][Cr+3]([N]2=C(C=CC=C2)C3=O)([O-]3)([N]4=C(C=CC=C4)C5=O)([O-]5)[N]6=C1C=CC=C6
Acalisib,GS-9820; CAL-120,870281-34-8,401.40,PI3K,PI3K/Akt/mTOR,Acalisib is a potent and selective PI3Kδ inhibitor with an IC50 of 12.7 nM.,C21H16FN7O,DMSO : 125 mg/mL (311.41 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)C)=NC5=C1C=C(F)C=C5
Entrectinib,NMS-E628; RXDX-101,1108743-60-7,560.64,Anaplastic lymphoma kinase (ALK); Autophagy; ROS Kinase; Trk Receptor,Autophagy; Neuronal Signaling; Protein Tyrosine Kinase/RTK,"Entrectinib (NMS-E628) is an orally active, BBB-penetrated and centrally active inhibitor of TrkA/B/C, ROS1 and ALK, with IC50 values of 1, 3, 5, 12 and 7 nM, respectively. Entrectinib induces apoptosis and cycle arrest in cancer cells, has antitumor activity, and attenuates bleomycin-induced lung fibrosis in mice[1][2][3].",C31H34F2N6O2,DMSO : ≥ 31 mg/mL (55.29 mM),10mM,Cancer,Launched,O=C(NC1=NNC2=C1C=C(CC3=CC(F)=CC(F)=C3)C=C2)C4=C(NC5CCOCC5)C=C(N6CCN(C)CC6)C=C4
Muramyl dipeptide,MDP,53678-77-6,492.48,NOD-like Receptor (NLR); p38 MAPK,Immunology/Inflammation; MAPK/ERK Pathway,"Muramyl dipeptide (MDP) is a synthetic immunoreactive peptide, consisting of N-acetyl muramic acid attached to a short amino acid chain of L-Ala-D-isoGln. Muramyl dipeptide is an inducer of bone formation through induction of Runx2. Muramyl dipeptide directly enhances osteoblast differentiation by up-regulating Runx2 gene expression through MAPK pathways. Muramyl dipeptide is a NLRP1 agonist[1][2].",C19H32N4O11,H2O : 50 mg/mL (101.53 mM; Need ultrasonic); DMSO : 100 mg/mL (203.05 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Phase 3,CC(N[C@@H](C=O)[C@H]([C@H](O)[C@H](O)CO)O[C@H](C)C(N[C@@H](C)C(N[C@@H](C(N)=O)CCC(O)=O)=O)=O)=O
Brigatinib,AP-26113,1197953-54-0,584.09,Anaplastic lymphoma kinase (ALK),Protein Tyrosine Kinase/RTK,"Brigatinib (AP-26113) is a highly potent, selective and orally active ALK inhibitor, with an IC50 of 0.6 nM. Brigatinib can be used for research of NSCLC[1].",C29H39ClN7O2P,DMSO : 2 mg/mL (3.42 mM; Need ultrasonic); Ethanol : 10 mg/mL (17.12 mM; Need ultrasonic and warming),2mM,Cancer,Launched,CN1CCN(C2CCN(C3=CC=C(NC4=NC=C(Cl)C(NC5=CC=CC=C5P(C)(C)=O)=N4)C(OC)=C3)CC2)CC1
Bimiralisib,PQR309,1225037-39-7,411.38,mTOR; PI3K,PI3K/Akt/mTOR,"Bimiralisib (PQR309) is a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor with IC50s of 33 nM, 451 nM, 661 nM, 708 nM and 89 nM for PI3Kα, PI3Kδ, PI3Kβ, PI3Kγ and mTOR, respectively. Bimiralisib is an mTORC1 and mTORC2 inhibitor.",C17H20F3N7O2,DMSO : ≥ 50 mg/mL (121.54 mM),10mM,Cancer,Phase 2,NC1=NC=C(C2=NC(N3CCOCC3)=NC(N4CCOCC4)=N2)C(C(F)(F)F)=C1
AZD-8835,,1620576-64-8,469.54,PI3K,PI3K/Akt/mTOR,"AZD8835 is a potent and selective inhibitor of PI3Kα and PI3Kδ with IC50s of 6.2 and 5.7 nM, respectively.",C22H31N9O3,DMSO : 12.5 mg/mL (26.62 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(N1CCC(C2=NN(CC)C(C3=NC(C4=NN=C(C(C)(C)C)O4)=C(N)N=C3)=N2)CC1)CCO
Nazartinib,EGF816,1508250-71-2,495.02,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Nazartinib (EGF816) is a covalent mutant-selective EGFR inhibitor, with Ki and Kinact of 31 nM and 0.222 min 1 on EGFR(L858R/790M) mutant, respectively.",C26H31ClN6O2,DMSO : ≥ 242 mg/mL (488.87 mM),10mM,Cancer,Phase 3,O=C(C1=CC(C)=NC=C1)NC2=NC3=CC=CC(Cl)=C3N2[C@H]4CN(C(/C=C/CN(C)C)=O)CCCC4
Phenyl acetate,,122-79-2,136.15,Endogenous Metabolite,Metabolic Enzyme/Protease,"Phenyl acetate is an endogenous metabolite and a metabolite of 2-phenylethylamine, which can be found in urine. Phenyl acetate regulates the metabolism of glutamine. In addition, Phenyl acetate can be used as a detection index for certain diseases, such as depression[1][2].",C8H8O2,DMSO : 250 mg/mL (1836.21 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Neurological Disease,Phase 2,CC(OC1=CC=CC=C1)=O
Gozanertinib,,1226549-49-0,533.62,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Gozanertinib is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM and 48 nM for EGFRWT and EGFRL858R/T790M, respectively. Gozanertinib can occupy the ATP-binding site. Gozanertinib has significant antitumor efficacy[1].",C32H31N5O3,DMSO : 250 mg/mL (468.50 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(NC1=CC=CC(C2=C(C3=CC=CC=C3)OC4=NC=NC(N[C@@H](C5=CC=CC=C5)CO)=C42)=C1)/C=C/CN(C)C
Vindesine (sulfate),,59917-39-4,852.00,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,Vindesine sulfate is a potent tubulin inhibitor with an Ki of 0.110 μM. Vindesine sulfate shows anti-proliferation effect in vitro. Vindesine sulfate shows antitumor effect in vivo[1].,C43H57N5O11S,DMSO : 250 mg/mL (293.43 mM; Need ultrasonic),10mM,Cancer,Launched,O=S(O)(O)=O.CC[C@@]12[C@@]3([H])[C@@]4(CCN3CC=C2)C5=CC([C@@]6(C7=C(CC[N@]8C[C@@](C[C@](O)(C8)CC)([H])C6)C9=CC=CC=C9N7)C(OC)=O)=C(OC)C=C5N([C@@]4([H])[C@](O)([C@@H]1O)C(N)=O)C
Pulrodemstat (benzenesulfonate),CC-90011 (benzenesulfonate); LSD1-IN-7 (benzenesulfonate),2097523-60-7,609.64,Histone Demethylase,Epigenetics,"CC-90011 benzenesulfonate is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC50 of 0.25 nM. CC-90011 benzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. CC-90011 benzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity[1].",C30H29F2N5O5S,DMSO : 50 mg/mL (82.02 mM; Need ultrasonic),10mM,Cancer,Phase 2,N#CC1=CC=C(C(N=C(N2CCC(N)CC2)N3C)=C(C4=CC=C(OC)C(F)=C4)C3=O)C=C1F.O=S(C5=CC=CC=C5)(O)=O
AMG319,,1608125-21-8,385.40,PI3K,PI3K/Akt/mTOR,AMG319 is a potent and selective PI3Kδ kinase inhibitor with IC50 of 18 nM.,C21H16FN7,DMSO : 50 mg/mL (129.74 mM; Need ultrasonic),10mM,Cancer,Phase 2,C[C@H](NC1=C2N=CNC2=NC=N1)C3=CC4=CC=C(F)C=C4N=C3C5=NC=CC=C5
Mavelertinib,PF-06747775,1776112-90-3,415.42,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Mavelertinib is a selective, orally available and irreversible EGFR tyrosine kinase inhibitor (EGFR TKI), with IC50s of 5, 4, 12 and 3 nM for Del, L858R, and double mutants T790M/L858R and T790M/Del, respectively. Mavelertinib can be used for the research of non-small-cell lung cancer (NSCLC)[1][2][3][4].",C18H22FN9O2,DMSO : 47.5 mg/mL (114.34 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,C=CC(N[C@@H]1CN(C2=NC(NC3=CN(C)N=C3OC)=C4N=CN(C)C4=N2)C[C@H]1F)=O
Pimozide,R6238,2062-78-4,461.55,Adrenergic Receptor; Dopamine Receptor; Parasite; STAT,Anti-infection; GPCR/G Protein; JAK/STAT Signaling; Neuronal Signaling; Stem Cell/Wnt,"Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5.",C28H29F2N3O,H2O : < 0.1 mg/mL (insoluble); DMSO : 16.67 mg/mL (36.12 mM; Need ultrasonic),10mM,Cancer; Neurological Disease; Endocrinology,Launched,O=C1NC2=CC=CC=C2N1C3CCN(CCCC(C4=CC=C(F)C=C4)C5=CC=C(F)C=C5)CC3
Adagrasib,MRTX849,2326521-71-3,604.12,Ras,GPCR/G Protein; MAPK/ERK Pathway,"Adagrasib (MRTX849) is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. Adagrasib covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction[1][2].",C32H35ClFN7O2,DMSO : 25 mg/mL (41.38 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,N#CC[C@@H]1N(C(C(F)=C)=O)CCN(C2=C3C(CN(C4=C5C(Cl)=CC=CC5=CC=C4)CC3)=NC(OC[C@H]6N(C)CCC6)=N2)C1
Cabozantinib,XL184; BMS-907351,849217-68-1,501.51,Apoptosis; c-Kit; c-Met/HGFR; FLT3; TAM Receptor; VEGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis[1][2].",C28H24FN3O5,DMSO : 25 mg/mL (49.85 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1(CC1)C(NC2=CC=C(F)C=C2)=O)NC3=CC=C(C=C3)OC4=C5C=C(OC)C(OC)=CC5=NC=C4
Flonoltinib,JAK2/FLT3-IN-1,2387765-27-5,467.58,Apoptosis; FLT3; JAK,Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Flonoltinib is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib has anti-cancer activity[1].",C25H34FN7O,DMSO : 35 mg/mL (74.85 mM; Need ultrasonic),10mM,Cancer,Phase 2,OCCN(C1CCN(C2=CC=C(NC3=NC=C(C)C(C4=CN(C(C)C)N=C4)=N3)C=C2F)CC1)C
Flonoltinib (TFA),JAK2/FLT3-IN-1 (TFA),2928093-29-0,581.61,Apoptosis; FLT3; JAK,Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Flonoltinib TFA is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib TFA has anti-cancer activity[1].",C27H35F4N7O3,H2O : 33.33 mg/mL (57.31 mM; Need ultrasonic),10mM,Cancer,Phase 2,OCCN(C1CCN(C2=CC=C(NC3=NC=C(C)C(C4=CN(C(C)C)N=C4)=N3)C=C2F)CC1)C.O=C(O)C(F)(F)F
Idelalisib,CAL-101; GS-1101,870281-82-6,415.42,Autophagy; PI3K,Autophagy; PI3K/Akt/mTOR,"Idelalisib (CAL-101; GS-1101) is a highly selective and orally bioavailable p110δ inhibitor with an IC50 of 2.5 nM, showing 40- to 300-fold selectivity for p110δ over other PI3K class I enzymes.",C22H18FN7O,DMSO : ≥ 59.7 mg/mL (143.71 mM),10mM,Cancer,Launched,O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)CC)=NC5=C1C(F)=CC=C5
Gandotinib,LY2784544,1229236-86-5,469.94,FGFR; FLT3; JAK; VEGFR,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC50 of 4, 25, 32, 44, and 95 nM.",C23H25ClFN7O,DMSO : 33.33 mg/mL (70.92 mM; Need ultrasonic),10mM,Cancer,Phase 2,CC1=NNC(NC2=NN3C(C(CN4CCOCC4)=C2)=NC(C)=C3CC5=CC=C(C=C5F)Cl)=C1
Cediranib (maleate),AZD-2171 maleate,857036-77-2,566.58,Autophagy; PDGFR; VEGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.",C29H31FN4O7,DMSO : ≥ 45 mg/mL (79.42 mM); H2O : 2 mg/mL (3.53 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(O)/C=C\C(O)=O.FC1=C(OC2=C(C(C=C3OCCCN4CCCC4)=NC=N2)C=C3OC)C=CC5=C1C=C(C)N5
Sapitinib,AZD-8931,848942-61-0,473.93,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Sapitinib (AZD-8931) is a reversible, ATP competitive EGFR inhibitor of with IC50s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively.",C23H25ClFN5O3,DMSO : ≥ 33 mg/mL (69.63 mM),10mM,Cancer,Phase 2,O=C(CN1CCC(OC2=CC3=C(NC4=CC=CC(Cl)=C4F)N=CN=C3C=C2OC)CC1)NC
Daunorubicin (hydrochloride),Daunomycin (hydrochloride); RP 13057 (hydrochloride); Rubidomycin (hydrochloride),23541-50-6,563.98,ADC Payload; Antibiotic; Apoptosis; Autophagy; Bacterial; DNA/RNA Synthesis; Topoisomerase,Antibody-drug Conjugate/ADC Related; Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage,"Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin hydrochloride is also an anthracycline antibiotic. Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor[1][2][4][5].",C27H30ClNO10,H2O : ≥ 34 mg/mL (60.29 mM); DMSO : 50 mg/mL (88.66 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Infection; Neurological Disease,Launched,O=C(C(C(OC)=CC=C1)=C1C2=O)C3=C2C(O)=C(C[C@@](O)(C(C)=O)C[C@@H]4O[C@@]5([H])C[C@H](N)[C@H](O)[C@H](C)O5)C4=C3O.[H]Cl
Cobimetinib,GDC-0973; XL518,934660-93-2,531.31,Apoptosis; MEK,Apoptosis; MAPK/ERK Pathway,"Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral MEK1 inhibitor with an IC50 of 4.2 nM for MEK1.",C21H21F3IN3O2,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 50 mg/mL (94.11 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,OC1([C@H]2NCCCC2)CN(C1)C(C3=C(C(F)=C(C=C3)F)NC4=C(C=C(C=C4)I)F)=O
Cobimetinib (hemifumarate),GDC-0973 (hemifumarate); XL-518 (hemifumarate),1369665-02-0,589.25,Apoptosis; MEK,Apoptosis; MAPK/ERK Pathway,"Cobimetinib hemifumarate is a novel selective MEK1 inhibitor, and the IC50 value against MEK1 is 4.2 nM.",C21H21F3IN3O2.1/2C4H4O4,DMSO : 50 mg/mL (84.85 mM; Need ultrasonic),10mM,Cancer,Launched,OC1(CN(C(C2=C(NC3=C(F)C=C(I)C=C3)C(F)=C(F)C=C2)=O)C1)[C@H]4NCCCC4.O=C(/C=C/C(O)=O)O
Golvatinib,E-7050,928037-13-2,633.69,c-Met/HGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Golvatinib (E-7050) is a potent dual inhibitor of both c-Met and VEGFR2 kinases with IC50s of 14 and 16 nM, respectively.",C33H37F2N7O4,DMSO : 50 mg/mL (78.90 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC=C(C=C1F)OC2=CC(NC(N3CCC(CC3)N4CCN(CC4)C)=O)=NC=C2)C5(CC5)C(NC6=CC=C(C=C6)F)=O
Cenisertib,AS-703569; R-763,871357-89-0,451.54,Akt; Aurora Kinase; Bcr-Abl; FLT3; STAT,Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3. Cenisertib induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia[1][2][3].",C24H30FN7O,DMSO : 250 mg/mL (553.66 mM; Need ultrasonic),10mM,Cancer,Phase 1,[H][C@@]1([C@H]([C@H]2C(N)=O)NC3=NC(NC4=CC=C(C(C)=C4)N5CCN(CC5)C)=NC=C3F)C[C@]2(C=C1)[H]
Taletrectinib,DS-6051b; AB-106; IBI-344,1505515-69-4,551.61,ROS Kinase,Protein Tyrosine Kinase/RTK,"Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants[1][2].",C29H34FN5O5,DMSO : 50 mg/mL (90.64 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(O)CCCCC(O)=O.C[C@@H](NC1=NN2C(C=C1)=NC=C2C3=CC=C(OC[C@H](N)C)C=C3)C4=CC=CC(F)=C4
CPL304110,,1627826-19-0,446.54,FGFR,Protein Tyrosine Kinase/RTK,"CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3), with IC50 values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectively[1].",C25H30N6O2,DMSO : 100 mg/mL (223.94 mM; Need ultrasonic),10mM,Cancer,Phase 1,CN(CC1)CCN1C2=CC3=C(N=C(C4=NNC(CCC5=CC(OC)=CC(OC)=C5)=C4)N3)C=C2
Crenolanib,CP-868596,670220-88-9,443.54,Autophagy; FLT3; PDGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively.",C26H29N5O2,DMSO : 25 mg/mL (56.36 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,NC1CCN(C2=CC=CC3=C2N=C(N4C5=CC=C(C=C5N=C4)OCC6(COC6)C)C=C3)CC1
Galunisertib,LY2157299,700874-72-2,369.42,TGF-β Receptor,TGF-beta/Smad,Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.,C22H19N5O,DMSO : 100 mg/mL (270.69 mM; Need ultrasonic),10mM,Cancer,Phase 3,CC1=CC=CC(C2=NN3C(CCC3)=C2C4=CC=NC5=C4C=C(C=C5)C(N)=O)=N1
Ralimetinib dimesylate,LY2228820 dimesylate,862507-23-1,612.74,Apoptosis; Autophagy; p38 MAPK,Apoptosis; Autophagy; MAPK/ERK Pathway,"Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.",C26H37FN6O6S2,DMSO : 61 mg/mL (99.55 mM; Need ultrasonic and warming); H2O : ≥ 33.33 mg/mL (54.40 mM),10mM,Cancer; Inflammation/Immunology,Phase 2,FC1=CC=C(C=C1)C2=C(NC(C(C)(C)C)=N2)C3=NC4=C(C=C3)N=C(N)N4CC(C)(C)C.OS(C)(=O)=O.OS(C)(=O)=O
Apitolisib,GDC-0980; GNE 390; RG 7422,1032754-93-0,498.60,Apoptosis; mTOR; PI3K,Apoptosis; PI3K/Akt/mTOR,"Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and mTOR kinase (TORC1/2) inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with a Ki of 17 nM for mTOR.",C23H30N8O3S,DMSO : 14.29 mg/mL (28.66 mM; Need ultrasonic),10mM,Cancer,Phase 2,C[C@@H](C(N1CCN(CC1)CC2=C(C3=NC(C4=CN=C(N=C4)N)=NC(N5CCOCC5)=C3S2)C)=O)O
ABT-751,E7010,141430-65-1,371.41,Apoptosis; Autophagy; Microtubule/Tubulin,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton,"ABT-751 (E7010) is a novel, highly orally bioavailable sulfonamides antimitotic compound and tubulin binder. It prevents tubulin aggregation by binding to the colchicine site on β-tubulin, leading to cell cycle arrest in G2/M phase and inducing apoptosis, thus effectively preventing cell division. ABT-751 induces autophagy by inhibiting the AKT/MTOR signaling pathway. ABT-751 showed significant inhibition against various types of cancer cells, including lung, gastric, colon, and breast cancer[1][2][3][4][5][6][7][8].",C18H17N3O4S,DMSO : 100 mg/mL (269.24 mM; Need ultrasonic),10mM,Cancer,Phase 2,COC1=CC=C(C=C1)S(=O)(NC2=C(N=CC=C2)NC3=CC=C(C=C3)O)=O
Dacomitinib,PF-00299804; PF-299804,1110813-31-4,469.94,Apoptosis; EGFR,Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively[1].",C24H25ClFN5O2,DMSO : 38.89 mg/mL (82.76 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(/C=C/CN1CCCCC1)NC2=CC3=C(C=C2OC)N=CN=C3NC4=CC=C(C(Cl)=C4)F
Gunagratinib,ICP-192,2211082-53-8,423.47,FGFR,Protein Tyrosine Kinase/RTK,"Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer[1]. Gunagratinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups[1][2].",C22H25N5O4,DMSO : 100 mg/mL (236.14 mM; Need ultrasonic),10mM,Cancer,Phase 2,CNC1=C(C(N)=O)C(C#CC2=CC(OC)=CC(OC)=C2)=NN1[C@]3([H])CN(CC3)C(C=C)=O
Sovilnesib,AMG 650,2410796-79-9,564.65,Kinesin; Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"Sovilnesib (AMG 650) is a potent, orally active kinesin-like protein KIF18A inhibitor with an IC50 value of 0.071 μM. Sovilnesib can be used for the research of cancer[1][2].",C26H34F2N6O4S,DMSO : 100 mg/mL (177.10 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(NC1=NC(N2CCC(F)(F)CC2)=NC(C)=C1)C3=CC=C(NS(=O)(CCO)=O)C=C3N(CC4)CCC54CC5
Sunvozertinib,DZD9008,2370013-12-8,584.08,Btk; EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Sunvozertinib (DZD9008) is a potent ErbBs (EGFR, Her2, especially mutant forms) and BTK inhibitor. Sunvozertinib shows IC50s of 20.4, 20.4, 1.1, 7.5, and 80.4 nM for EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, and Her2 Exon20 YVMA, and EGFR WT A431, respectively (patent WO2019149164A1, example 52)[1].",C29H35ClFN7O3,DMSO : 50 mg/mL (85.60 mM; ultrasonic and warming and heat to 80°C),10mM,Cancer,Launched,C=CC(NC1=C(N2C[C@@H](CC2)N(C)C)C=C(C(NC3=NC=CC(NC4=C(C=C(C(Cl)=C4)F)C(C)(O)C)=N3)=C1)OC)=O
Tunlametinib,HL-085,1801756-06-8,491.25,MEK,MAPK/ERK Pathway,"Tunlametinib is a highly selective, orally active MEK1/2 inhibitor (IC50=1.9 nM, MEK1). Tunlametinib blocks the RAS-RAF-MEK-ERK signaling pathway, arrests tumor cell cycle and promotes apoptosis. Tunlametinib potently inhibits the proliferation of RAS/RAF mutant cancer cells (such as BRAF V600E, KRAS G12C mutant cells). Tunlametinib shows synergistic anti-tumor effects with BRAF/KRASG12C/SHP2 inhibitors, Docetaxel (HY-B0011). Tunlametinib can be used to study targeted therapy for RAS/RAF mutation-driven malignancies (such as melanoma, colorectal cancer, and non-small cell lung cancer)[1][2].",C16H12F2IN3O3S,DMSO : 100 mg/mL (203.56 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(C1=CC2=C(C(F)=C1NC3=CC=C(C=C3F)I)N=CS2)NOCCO
Vepafestinib,TAS0953/HM06,2129515-96-2,474.55,Apoptosis; RET,Apoptosis; Protein Tyrosine Kinase/RTK,"Vepafestinib (TAS0953/HM06) is a next-generation brain-penetrant, selective and orally active RET inhibitor with an IC50 value of 0.33 nM. Vepafestinib inhibits the phosphorylation of RET and its downstream signaling pathways, thus blocking the growth and signal transduction of tumor cells and inducing cell cycle arrest and apoptosis. Vepafestinib can be used in the research of various RET-driven cancers, such as non-small cell lung cancer, thyroid cancer and other disease areas[1].",C26H30N6O3,DMSO : 50 mg/mL (105.36 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=C(C#CCN2CCOCC2)N(C3(C)CC3)C4=NC=NC(N)=C41)NC5=CC=C(COC)C=C5
MK-8033,,1001917-37-8,471.53,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"MK-8033 is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs)[1][2].",C25H21N5O3S,DMSO : ≥ 46 mg/mL (97.55 mM),10mM,Cancer,Phase 1,O=S(NCC1=CC=CC=N1)(CC2=CC=C3C(C(C4=CC(C5=CN(N=C5)C)=CN=C4C=C3)=O)=C2)=O
MK-8033 (hydrochloride),,1283000-43-0,507.99,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"MK-8033 hydrochloride is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs)[1][2].",C25H22ClN5O3S,DMSO : 5.88 mg/mL (11.58 mM; Need ultrasonic); H2O : 7.14 mg/mL (14.06 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=S(CC1=CC=C2C(C(C3=CC(C4=CN(C)N=C4)=CN=C3C=C2)=O)=C1)(NCC5=NC=CC=C5)=O.Cl
CP-547632,,252003-65-9,532.40,FGFR; VEGFR,Protein Tyrosine Kinase/RTK,"CP-547632 is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 has antitumor efficacy[1].",C20H24BrF2N5O3S,DMSO : ≥ 115 mg/mL (216.00 mM),10mM,Cancer,Phase 2,O=C(NC1=C(C(N)=O)C(OCC2=C(F)C=C(Br)C=C2F)=NS1)NCCCCN3CCCC3
CP-547632 (hydrochloride),,252003-71-7,568.86,FGFR; VEGFR,Protein Tyrosine Kinase/RTK,"CP-547632 hydrochloride is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy[1].",C20H25BrClF2N5O3S,DMSO : 33.33 mg/mL (58.59 mM; ultrasonic and warming and heat to 60°C); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Phase 2,O=C(NC1=C(C(N)=O)C(OCC2=C(F)C=C(Br)C=C2F)=NS1)NCCCCN3CCCC3.[H]Cl
LY2874455,,1254473-64-7,444.31,FGFR,Protein Tyrosine Kinase/RTK,"LY2874455 is a pan-FGFR inhibitor with IC50s of 2.8, 2.6, 6.4, 6 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively.",C21H19Cl2N5O2,DMSO : 50 mg/mL (112.53 mM; Need ultrasonic),10mM,Cancer,Phase 2,ClC1=CN=CC(Cl)=C1[C@@H](C)OC2=CC=C(NN=C3/C=C/C4=CN(CCO)N=C4)C3=C2
Regorafenib (Hydrochloride),BAY 73-4506 (hydrochloride),835621-07-3,519.28,Autophagy; PDGFR; Raf; RET; VEGFR,Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[1].",C21H16Cl2F4N4O3,DMSO : ≥ 5.6 mg/mL (10.78 mM); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,ClC1=C(C(F)(F)F)C=C(NC(NC2=C(F)C=C(OC3=CC=NC(C(NC)=O)=C3)C=C2)=O)C=C1.Cl
Infigratinib,BGJ-398; NVP-BGJ398,872511-34-7,560.48,Apoptosis; FGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"Infigratinib (BGJ-398; NVP-BGJ398) is a potent inhibitor of the FGFR family with IC50s of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.",C26H31Cl2N7O3,DMSO : 12 mg/mL (21.41 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Cancer,Launched,ClC1=C(C(Cl)=C(C=C1OC)OC)NC(N(C2=CC(NC3=CC=C(C=C3)N4CCN(CC4)CC)=NC=N2)C)=O
Infigratinib phosphate,BGJ-398 phosphate; NVP-BGJ398 (phosphate),1310746-10-1,658.47,FGFR,Protein Tyrosine Kinase/RTK,"Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the FGFR family with IC50 of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.",C26H34Cl2N7O7P,DMSO : 8.75 mg/mL (13.29 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=P(O)(O)O.ClC1=C(C(Cl)=C(C=C1OC)OC)NC(N(C2=CC(NC3=CC=C(C=C3)N4CCN(CC4)CC)=NC=N2)C)=O
Tesevatinib,XL-647; EXEL-7647; KD-019,781613-23-8,491.39,EGFR; Src; VEGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Tesevatinib (XL-647) is an orally available, blood-brain barrier-penetrant inhibitor of the epidermal growth factor receptor (EGFR). Tesevatinib significantly reduces cellular viability, with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Tesevatinib also inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM). Tesevatinib can inhibit tumor proliferation and exhibits antitumor activity[1][2].",C24H25Cl2FN4O2,DMSO : 100 mg/mL (203.50 mM; Need ultrasonic),10mM,Cancer,Phase 3,[H][C@@]12[C@@](C[C@@H](COC3=CC4=C(C(NC5=C(F)C(Cl)=C(Cl)C=C5)=NC=N4)C=C3OC)C2)([H])CN(C)C1
ASP3026,,1097917-15-1,580.74,Akt; Anaplastic lymphoma kinase (ALK); Apoptosis; Caspase; IGF-1R; JNK; PARP; ROS Kinase; STAT,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC50 value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. ASP3026 can be used in anti-tumor research[1][2][3][4].",C29H40N8O3S,DMSO : 20 mg/mL (34.44 mM; Need ultrasonic),10mM,Cancer,Phase 1,COC(C=C(N1CCC(N2CCN(C)CC2)CC1)C=C3)=C3NC4=NC=NC(NC5=C(S(C(C)C)(=O)=O)C=CC=C5)=N4
Sapanisertib,INK-128; MLN0128; TAK-228,1224844-38-5,309.33,Autophagy; mTOR,Autophagy; PI3K/Akt/mTOR,"Sapanisertib (INK-128; MLN0128; TAK-228) is an orally available, ATP-dependent mTOR1/2 inhibitor with an IC50 of 1 nM for mTOR kinase.",C15H15N7O,DMSO : 55 mg/mL (177.80 mM; Need ultrasonic),10mM,Cancer,Phase 2,NC1=NC=NC2=C1C(C3=CC4=C(C=C3)OC(N)=N4)=NN2C(C)C
Fexagratinib,AZD4547; ADSK091,1035270-39-3,463.57,FGFR,Protein Tyrosine Kinase/RTK,"Fexagratinib (AZD4547; ADSK091) is a potent inhibitor of the FGFR family with IC50s of 0.2 nM, 2.5 nM, 1.8 nM, and 165 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.",C26H33N5O3,DMSO : 125 mg/mL (269.65 mM; Need ultrasonic),10mM,Cancer,Phase 3,C[C@H](C1)N[C@@H](C)CN1C2=CC=C(C(NC3=NNC(CCC4=CC(OC)=CC(OC)=C4)=C3)=O)C=C2
BGT226 (maleate),NVP-BGT226 (maleate),1245537-68-1,650.60,Apoptosis; Autophagy; mTOR; PI3K,Apoptosis; Autophagy; PI3K/Akt/mTOR,"BGT226 (NVP-BGT226 maleate) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ) /mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells[1][2].",C32H29F3N6O6,DMSO : 62.5 mg/mL (96.07 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,COC1=CC=C(C=N1)C2=CC=C(C3=C2)N=CC(N4C)=C3N(C4=O)C5=CC=C(C(C(F)(F)F)=C5)N6CCNCC6.OC(/C=C\C(O)=O)=O
BGT226,NVP-BGT226,915020-55-2,534.53,Autophagy; mTOR; PI3K,Autophagy; PI3K/Akt/mTOR,"BGT226 (NVP-BGT226) is a PI3K (with IC50s of 4 nM, 63 nM and 38 nM for PI3Kα, PI3Kβ and PI3Kγ)/mTOR dual inhibitor which displays potent growth-inhibitory activity against human head and neck cancer cells[1][2].",C28H25F3N6O2,DMSO : 10 mg/mL (18.71 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=C(N1C2=CC=C(N3CCNCC3)C(C(F)(F)F)=C2)N(C)C4=C1C5=CC(C6=CC=C(OC)N=C6)=CC=C5N=C4
Capmatinib,INC280; INCB28060,1029712-80-8,412.42,Apoptosis; c-Met/HGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase[1][2][3].",C23H17FN6O,DMSO : 5 mg/mL (12.12 mM; ultrasonic and warming and heat to 60°C); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,O=C(NC)C1=CC=C(C2=NN3C(N=C2)=NC=C3CC4=CC=C5N=CC=CC5=C4)C=C1F
Capmatinib (dihydrochloride),INC280 (dihydrochloride); INCB28060 (dihydrochloride),1197376-85-4,485.34,Apoptosis; c-Met/HGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"Capmatinib (INC280; INCB28060) dihydrochloride is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride is largely metabolized by CYP3A4 and aldehyde oxidase[1][2][3].",C23H19Cl2FN6O,DMSO : 5.83 mg/mL (12.01 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(NC)C1=CC=C(C2=NN3C(N=C2)=NC=C3CC4=CC=C5N=CC=CC5=C4)C=C1F.Cl.Cl
Capmatinib (dihydrochloride hydrate),INC280 (dihydrochloride hydrate); INCB-28060 (dihydrochloride hydrate),1865733-40-9,503.36,Apoptosis; c-Met/HGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"Capmatinib (INC280; INCB28060) dihydrochloride hydrate is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib dihydrochloride hydrate can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib dihydrochloride hydrate potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib dihydrochloride hydrate is largely metabolized by CYP3A4 and aldehyde oxidase[1][2][3].",C23H21Cl2FN6O2,DMSO : 20.83 mg/mL (41.38 mM; ultrasonic and warming and heat to 60°C); H2O : 3.33 mg/mL (6.62 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NC)C1=CC=C(C2=NN3C(N=C2)=NC=C3CC4=CC=C5N=CC=CC5=C4)C=C1F.O.Cl.Cl
NHWD-870,,2115742-03-3,491.59,Apoptosis; Epigenetic Reader Domain,Apoptosis; Epigenetics,"NHWD-870 is a potent, orally active and selective BET family bromodomain inhibitor and only binds bromodomains of BRD2, BRD3, BRD4 (IC50=2.7 nM), and BRDT. NHWD-870 has potent tumor suppressive efficacies and suppresses cancer cell-macrophage interaction. NHWD-870 increases tumor apoptosis and inhibits tumor proliferation[1].",C29H29N7O,DMSO : 62.5 mg/mL (127.14 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,CN1N=CC2=CC3=C(N([C@H](C4=CC=CC=C4)C5CCOCC5)C6=CC(C7=C(C)N=NN7C)=CN=C63)C=C12
TAK-733,,1035555-63-5,504.23,MEK,MAPK/ERK Pathway,TAK-733 is a potent and selective MEK allosteric site inhibitor with an IC50 of 3.2 nM.,C17H15F2IN4O4,DMSO : ≥ 33 mg/mL (65.45 mM),10mM,Cancer,Phase 1,O=C1C(C(NC2=CC=C(I)C=C2F)=C(F)C(N3C)=O)=C3N=CN1C[C@@H](O)CO
Avatrombopag (maleate),AKR-501 (maleate); E5501 (maleate); YM477 (maleate),677007-74-8,765.73,Cytochrome P450; ERK; STAT; Thrombopoietin Receptor,Immunology/Inflammation; JAK/STAT Signaling; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Stem Cell/Wnt,"Avatrombopag (AKR-501) maleate is an orally active, non-peptide thrombopoietin receptor (TPO receptor) agonist (EC50: 3.3 nM). Avatrombopag maleate mimics the biological activity of TPO. Avatrombopag maleate increases platelet production by activating intracellular signaling systems and promotes the production of platelets and megakaryocytes from hematopoietic precursor cells. Avatrombopag maleate is a substrate for cytochrome P450 (CYP) 2C9 and CYP3A [1][2][3].",C33H38Cl2N6O7S2,DMSO : 175 mg/mL (228.54 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Launched,O=C(C1CCN(C2=NC=C(C(NC3=NC(C4=CC(Cl)=CS4)=C(N5CCN(C6CCCCC6)CC5)S3)=O)C=C2Cl)CC1)O.O=C(O)/C=C\C(O)=O
Debio 0932,CUDC-305,1061318-81-7,442.58,HSP,Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Debio 0932 (CUDC-305) is an orally active HSP90 inhibitor, with IC50s of 100 and 103 nM for HSP90α and HSP90β, respectively[1].",C22H30N6O2S,DMSO : 75 mg/mL (169.46 mM; Need ultrasonic),10mM,Cancer,Phase 1,NC1=NC=CC2=C1N=C(SC3=C(N(C)C)C=C(OCO4)C4=C3)N2CCNCC(C)(C)C
Mubritinib,TAK-165,366017-09-6,468.47,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,Mubritinib (TAK-165) is a potent and selective EGFR2/HER2 inhibitor with an IC50 of 6 nM.,C25H23F3N4O2,DMSO : 50 mg/mL (106.73 mM; Need ultrasonic),10mM,Cancer,Phase 1,FC(C1=CC=C(/C=C/C2=NC(COC3=CC=C(CCCCN4N=NC=C4)C=C3)=CO2)C=C1)(F)F
Mitoxantrone,Mitozantrone; NSC 301739,65271-80-9,444.48,Apoptosis; Endogenous Metabolite; Orthopoxvirus; PKC; Topoisomerase,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; TGF-beta/Smad,"Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity[1][2][3][4]. Mitoxantrone also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively[5].",C22H28N4O6,DMSO : 35 mg/mL (78.74 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Infection,Launched,O=C1C2=C(C(NCCNCCO)=CC=C2NCCNCCO)C(C3=C(O)C=CC(O)=C13)=O
Mitoxantrone (dihydrochloride),Mitozantrone (dihydrochloride); NSC 301739 (dihydrochloride),70476-82-3,517.40,Apoptosis; Endogenous Metabolite; Orthopoxvirus; PKC; Topoisomerase,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease; TGF-beta/Smad,"Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity[1][2][3][4]. Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively[5].",C22H30Cl2N4O6,DMSO : 31.25 mg/mL (60.40 mM; Need ultrasonic); H2O : 100 mg/mL (193.27 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,O=C1C2=C(C(NCCNCCO)=CC=C2NCCNCCO)C(C3=C(O)C=CC(O)=C13)=O.[H]Cl.[H]Cl
Fimepinostat,CUDC-907,1339928-25-4,508.55,Apoptosis; HDAC; PI3K,Apoptosis; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR,"Fimepinostat (CUDC-907) potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes with an IC50 of  19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.",C23H24N8O4S,DMSO : 43.75 mg/mL (86.03 mM; ultrasonic and warming and heat to 60°C); DMF : 5 mg/mL (9.83 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=CN=C(N(CC2=CC3=NC(C4=CC=C(OC)N=C4)=NC(N5CCOCC5)=C3S2)C)N=C1)NO
Gemcitabine elaidate,CP-4126; CO-101; Gemcitabine 5'-elaidate,210829-30-4,527.64,Apoptosis; Autophagy; Nucleoside Antimetabolite/Analog,Apoptosis; Autophagy; Cell Cycle/DNA Damage,Gemcitabine elaidate (CP-4126) is lipophilic pro-agent of Gemcitabine. Gemcitabine elaidate is converted to Gemcitabine by esterases in order to be phosphorylated.  Gemcitabine elaidate exhibits anti-tumor activity[1][2].,C27H43F2N3O5,DMSO : ≥ 100 mg/mL (189.52 mM),10mM,Cancer,Launched,O[C@@H](C(F)(F)[C@H](N1C(N=C(C=C1)N)=O)O2)[C@H]2COC(CCCCCCC/C=C/CCCCCCCC)=O
Gemcitabine elaidate (hydrochloride),CP-4126 (hydrochloride); CO-101 (hydrochloride); Gemcitabine 5'-elaidate (hydrochloride),2918768-08-6,564.11,Apoptosis; Autophagy; Nucleoside Antimetabolite/Analog,Apoptosis; Autophagy; Cell Cycle/DNA Damage,Gemcitabine elaidate (CP-4126) hydrochloride is lipophilic pro-agent of Gemcitabine. Gemcitabine elaidate hydrochloride is converted to Gemcitabine by esterases in order to be phosphorylated.  Gemcitabine elaidate hydrochloride exhibits anti-tumor activity[1][2].,C27H44ClF2N3O5,DMSO : 100 mg/mL (177.27 mM; Need ultrasonic),10mM,Cancer,Phase 2,O[C@@H](C(F)(F)[C@H](N1C(N=C(C=C1)N)=O)O2)[C@H]2COC(CCCCCCC/C=C/CCCCCCCC)=O.[H]Cl
Tretazicar,CB 1954,21919-05-1,252.18,DNA Alkylator/Crosslinker; Quinone Reductase,Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Tretazicar (CB 1954), an antitumor proagent, is highly selective against the Walker 256 rat tumour line. Tretazicar is enzymatically activated to generate a bifunctional agent, which can form DNA-DNA interstrand cross-links. Tretazicar in rat cells involves the reduction of its 4-nitro group to a 4-hydroxylamine by the enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1)[1][2].",C9H8N4O5,DMSO : 125 mg/mL (495.68 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(N)C1=CC(N2CC2)=C([N+]([O-])=O)C=C1[N+]([O-])=O
Amsacrine,m-AMSA; acridinyl anisidide,51264-14-3,393.46,Autophagy; Topoisomerase,Autophagy; Cell Cycle/DNA Damage,"Amsacrine (m-AMSA; acridinyl anisidide) is an inhibitor of topoisomerase II, and acts as an antineoplastic agent which can intercalates into the DNA of tumor cells.",C21H19N3O3S,DMSO : 100 mg/mL (254.16 mM; Need ultrasonic),10mM,Cancer,Launched,CS(=O)(NC1=CC=C(NC2=C(C=CC=C3)C3=NC4=CC=CC=C42)C(OC)=C1)=O
Amsacrine (hydrochloride),m-AMSA hydrochloride; acridinyl anisidide hydrochloride,54301-15-4,429.92,Autophagy; Topoisomerase,Autophagy; Cell Cycle/DNA Damage,"Amsacrine hydrochloride (m-AMSA hydrochloride; acridinyl anisidide hydrochloride) is an inhibitor of topoisomerase II, and acts as an antineoplastic agent which can intercalates into the DNA of tumor cells.",C21H20ClN3O3S,DMSO : 62.5 mg/mL (145.38 mM; Need ultrasonic),10mM,Cancer,Launched,CS(=O)(NC1=CC=C(NC2=C(C=CC=C3)C3=NC4=CC=CC=C42)C(OC)=C1)=O.[H]Cl
β-Lapachone,ARQ-501; NSC-26326,4707-32-8,242.27,"Apoptosis; Autophagy; Indoleamine 2,3-Dioxygenase (IDO); Topoisomerase",Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"β-Lapachone (ARQ-501;NSC-26326) is a naturally occurring O-naphthoquinone, acts as a topoisomerase I inhibitor, and induces apoptosis by inhibiting cell cycle progression.",C15H14O3,DMSO : 25 mg/mL (103.19 mM; Need ultrasonic); Ethanol : 8.33 mg/mL (34.38 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=C2OC(C)(C)CC1)C(C3=C2C=CC=C3)=O
Batabulin,T138067,195533-53-0,371.26,Apoptosis; Microtubule/Tubulin,Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,"Batabulin (T138067) is an antitumor agent, which binds covalently and selectively to a subset of the β-tubulin isotypes, thereby disrupting microtubule polymerization. Batabulin affects cell morphology and leads to cell-cycle arrest ultimately induces apoptotic cell death[1].",C13H7F6NO3S,Ethanol : 100 mg/mL (269.35 mM; Need ultrasonic); DMSO : 100 mg/mL (269.35 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=S(C1=C(F)C(F)=C(F)C(F)=C1F)(NC2=CC=C(OC)C(F)=C2)=O
Batabulin (sodium),T138067 (sodium),195533-98-3,393.24,Apoptosis; Microtubule/Tubulin,Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,"Batabulin sodium (T138067 sodium) is an antitumor agent, which binds covalently and selectively to a subset of the β-tubulin isotypes, thereby disrupting microtubule polymerization. Batabulin sodium affects cell morphology and leads to cell-cycle arrest ultimately induces apoptotic cell death[1].",C13H6F6NNaO3S,DMSO : 125 mg/mL (317.87 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=S(C1=C(F)C(F)=C(F)C(F)=C1F)([N-]C2=CC=C(OC)C(F)=C2)=O.[Na+]
Belotecan,CKD-602 (free base),256411-32-2,433.50,Apoptosis; Topoisomerase,Apoptosis; Cell Cycle/DNA Damage,"Belotecan (CKD-602 free base) is a DNA topoisomerase I inhibitor. Belotecan induces cell apoptosis and cell-cycle arrest. Belotecan is a camptothecin analogue with anti-tumor effects, it can be used for the research of cancer[1].",C25H27N3O4,DMSO : 12.5 mg/mL (28.84 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C(CCNC(C)C)C5=CC=CC=C5N=C4C3=C2)=O
Belotecan (hydrochloride),CKD-602,213819-48-8,469.96,Topoisomerase,Cell Cycle/DNA Damage,"Belotecan hydrochloride (CKD-602 hydrochloride), a Topoisomerase I inhibitor, is a synthetic camptothecin derivative.",C25H28ClN3O4,DMSO : 12.5 mg/mL (26.60 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C(CCNC(C)C)C5=CC=CC=C5N=C4C3=C2)=O.[H]Cl
Bendamustine,SDX-105 (free base),16506-27-7,358.26,Apoptosis; DNA Alkylator/Crosslinker,Apoptosis; Cell Cycle/DNA Damage,"Bendamustine (SDX-105 free base), a purine analogue, is a DNA cross-linking agent. Bendamustine activates DNA-damage stress response and apoptosis. Bendamustine has potent alkylating, anticancer and antimetabolite properties[1].",C16H21Cl2N3O2,DMSO : 100 mg/mL (279.13 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(O)CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C
Oclacitinib,PF-03394197,1208319-26-9,337.44,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,Oclacitinib is a novel JAK inhibitor. Oclacitinib is most potent at inhibiting JAK1 (IC50=10 nM).,C15H23N5O2S,DMSO : 5 mg/mL (14.82 mM; ultrasonic and warming and heat to 60°C),10mM,Inflammation/Immunology,Launched,CN([C@H]1CC[C@@H](CC1)CS(NC)(=O)=O)C2=C3C(NC=C3)=NC=N2
Oclacitinib (monomaleate),PF-03394197 (monomaleate),1640292-55-2,453.51,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,Oclacitinib maleate (PF-03394197 maleate) is a novel JAK inhibitor. Oclacitinib maleate (PF-03394197 maleate) is most potent at inhibiting JAK1 (IC50=10 nM).,C19H27N5O6S,DMSO : 250 mg/mL (551.26 mM; Need ultrasonic); H2O : 25 mg/mL (55.13 mM; Need ultrasonic),10mM,Inflammation/Immunology,Launched,O=S(C[C@H]1CC[C@H](N(C)C2=C3C(NC=C3)=NC=N2)CC1)(NC)=O.O=C(O)/C=C\C(O)=O
Mobocertinib,TAK-788; AP32788,1847461-43-1,585.70,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research[1][2].,C32H39N7O4,DMSO : 25 mg/mL (42.68 mM; ultrasonic and warming and heat to 80°C),10mM,Cancer,Launched,O=C(C1=CN=C(NC2=CC(NC(C=C)=O)=C(N(CCN(C)C)C)C=C2OC)N=C1C3=CN(C)C4=C3C=CC=C4)OC(C)C
Mobocertinib (succinate),TAK-788 (succinate); AP32788 (succinate),2389149-74-8,703.78,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research[1][2].,C36H45N7O8,DMSO : 125 mg/mL (177.61 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=CN=C(NC2=CC(NC(C=C)=O)=C(N(CCN(C)C)C)C=C2OC)N=C1C3=CN(C)C4=C3C=CC=C4)OC(C)C.O=C(O)CCC(O)=O
Roginolisib,MSC2360844; IOA-244,1305267-37-1,526.58,PI3K,PI3K/Akt/mTOR,"Roginolisib (MSC2360844; IOA-244) is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. Roginolisib shows highly selective against a panel of 278 additional kinases[1].",C26H27FN4O5S,DMSO : 100 mg/mL (189.90 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 2,O=C(C1=NN(C2=CC=C(CN3CCOCC3)C=C2)C(C4=CC=CC(F)=C45)=C1CS5(=O)=O)N6CCOCC6
Roginolisib (hemifumarate),MSC2360844 (hemifumarate); IOA-244 (hemifumarate),1621688-31-0,584.62,PI3K,PI3K/Akt/mTOR,"Roginolisib (MSC2360844) hemifumarate is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. Roginolisib hemifumarate shows highly selective against a panel of 278 additional kinases[1].",C26H27FN4O5S.1/2C4H4O4,DMSO : 100 mg/mL (171.05 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 2,O=C(C1=NN(C2=CC=C(CN3CCOCC3)C=C2)C(C4=CC=CC(F)=C45)=C1CS5(=O)=O)N6CCOCC6.OC(/C=C/C(O)=O)=O
Carmustine,BCNU,154-93-8,214.05,DNA Alkylator/Crosslinker,Cell Cycle/DNA Damage,"Carmustine is an antitumor chemotherapeutic agent, which works by akylating DNA and RNA.",C5H9Cl2N3O2,DMSO : 100 mg/mL (467.18 mM; Need ultrasonic); H2O : 100 mg/mL (467.18 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NCCCl)N(CCCl)N=O
Chlorambucil,CB-1348; WR-139013,305-03-3,304.21,DNA Alkylator/Crosslinker,Cell Cycle/DNA Damage,"Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease[1][2][3][4].",C14H19Cl2NO2,DMSO : ≥ 100 mg/mL (328.72 mM),10mM,Cancer,Launched,O=C(O)CCCC1=CC=C(N(CCCl)CCCl)C=C1
Valecobulin,CKD-516,1188371-47-2,536.60,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,Valecobulin (CKD516) is a valine proagent of (S516) and a vascular disrupting agent (VDA). Valecobulin is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors[1][2].,C26H28N6O5S,DMSO : 125 mg/mL (232.95 mM; Need ultrasonic),10mM,Cancer,Phase 2,CC(C)[C@H](N)C(NC1=NC(C2=CC=C(C(C3=CC(OC)=C(OC)C(OC)=C3)=O)C(N4N=CN=C4)=C2)=CS1)=O
Valecobulin (hydrochloride),CKD-516 (hydrochloride),1240321-53-2,573.06,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,Valecobulin hydrochloride (CKD-516 hydrochloride) is a valine proagent of S516 (HY-130233) and a vascular disrupting agent (VDA). Valecobulin hydrochloride is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors[1][2].,C26H29ClN6O5S,H2O : 50 mg/mL (87.25 mM; Need ultrasonic); DMSO : 125 mg/mL (218.13 mM; Need ultrasonic),10mM,Cancer,Phase 2,CC(C)[C@H](N)C(NC1=NC(C2=CC=C(C(C3=CC(OC)=C(OC)C(OC)=C3)=O)C(N4N=CN=C4)=C2)=CS1)=O.Cl
Crolibulin,EPC2407,1000852-17-4,417.26,Apoptosis; Microtubule/Tubulin,Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,"Crolibulin (EPC2407) is a tubulin polymerization inhibitor, with potent apoptosis induction and cell growth inhibition. Crolibulin has anti-tumor activity. Crolibulin also has cardiovascular toxicity and neurotoxicity[1][2][3].",C18H17BrN4O3,DMSO : 125 mg/mL (299.57 mM; Need ultrasonic and warming),10mM,Cancer; Cardiovascular Disease,Phase 2,N#CC1=C(N)OC2=C(N)C(N)=CC=C2[C@H]1C3=CC(OC)=C(OC)C(Br)=C3
Cytarabine,Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C,147-94-4,243.22,Apoptosis; Autophagy; DNA/RNA Synthesis; Endogenous Metabolite; HSV; Nucleoside Antimetabolite/Analog; Orthopoxvirus,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Cytarabine, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM. Cytarabine has antiviral effects against HSV. Cytarabine shows anti-orthopoxvirus activity.",C9H13N3O5,DMSO : 17.3 mg/mL (71.13 mM; Need ultrasonic and warming); H2O : 48 mg/mL (197.35 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,O=C1N=C(C=CN1[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)N
Cytarabine (hydrochloride),Cytosine β-D-arabinofuranoside hydrochloride; Cytosine Arabinoside hydrochloride; Ara-C hydrochloride,69-74-9,279.68,Autophagy; DNA/RNA Synthesis; HSV; Nucleoside Antimetabolite/Analog,Anti-infection; Autophagy; Cell Cycle/DNA Damage,"Cytarabine hydrochloride, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC50 of 16 nM. Cytarabine hydrochloride has antiviral effects against HSV.",C9H14ClN3O5,H2O : ≥ 100 mg/mL (357.55 mM); DMSO : 50 mg/mL (178.78 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,O=C1N=C(C=CN1[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)N.Cl
Batoprotafib,TNO155,1801765-04-7,421.95,Phosphatase; SHP2,Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,"Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 μM). Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors[1].</br>",C18H24ClN7OS,DMSO : 66.67 mg/mL (158.00 mM; Need ultrasonic),10mM,Cancer,Phase 2,N[C@@H]1[C@H](C)OCC12CCN(C3=NC(N)=C(SC4=C(Cl)C(N)=NC=C4)N=C3)CC2
RBN-2397,,2381037-82-5,523.43,PARP,Cell Cycle/DNA Damage; Epigenetics,"RBN-2397 is a potent, accross species and orally active NAD+ competitive inhibitor of PARP7 (IC50<3 nM). RBN-2397 selectively binds to PARP7 (Kd=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors[1][2].",C20H23F6N7O3,DMSO : 200 mg/mL (382.10 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1C(C(F)(F)F)=C(N[C@@H](C)COCCC(N2CCN(C3=NC=C(C(F)(F)F)C=N3)CC2)=O)C=NN1
Epirubicin,4'-Epidoxorubicin,56420-45-2,543.52,Antibiotic; Apoptosis; DNA/RNA Synthesis; Topoisomerase,Anti-infection; Apoptosis; Cell Cycle/DNA Damage,"Epirubicin (4'-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase[1]. Epirubicin inhibits DNA and RNA synthesis. Epirubicin is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity[2].",C27H29NO11,DMSO : 125 mg/mL (229.98 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=C2C(O)=C3[C@@H](O[C@@]4([H])C[C@H](N)[C@@H](O)[C@H](C)O4)C[C@@](C(CO)=O)(O)CC3=C1O)C5=CC=CC(OC)=C5C2=O
Epirubicin (hydrochloride),4'-Epidoxorubicin (hydrochloride),56390-09-1,579.98,Antibiotic; Apoptosis; DNA/RNA Synthesis; Topoisomerase,Anti-infection; Apoptosis; Cell Cycle/DNA Damage,"Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase[1]. Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity[2].",C27H30ClNO11,DMSO : 25 mg/mL (43.10 mM; Need ultrasonic); H2O : 50 mg/mL (86.21 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1=C2C(O)=C3[C@@H](O[C@@]4([H])C[C@H](N)[C@@H](O)[C@H](C)O4)C[C@@](C(CO)=O)(O)CC3=C1O)C5=CC=CC(OC)=C5C2=O.Cl
Estramustine (phosphate sodium),,52205-73-9,564.35,Apoptosis; Microtubule/Tubulin,Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,"Estramustine phosphate sodium, an estradiol analog, is an orally active antimicrotubule chemotherapy agent. Estramustine phosphate sodium depolymerises microtubules by binding to microtubule associated proteins (MAPs) and/or to tubulin. Estramustine phosphate sodium can interfere mitosis, trigger cell death and induce apoptosis, which can be used for the research of cancer like prostate cancer[1][2][3].",C23H30Cl2NNa2O6P,H2O : 62.5 mg/mL (110.75 mM; Need ultrasonic); DMSO : 5 mg/mL (8.86 mM; Need ultrasonic),10mM,Cancer; Endocrinology; Inflammation/Immunology,Launched,O=C(N(CCCl)CCCl)OC1=CC2=C(C=C1)[C@@]3([H])CC[C@@]4(C)[C@](CC[C@@H]4OP(O[Na])(O[Na])=O)([H])[C@]3([H])CC2
Etoposide,VP-16; VP-16-213,33419-42-0,588.56,Antibiotic; Apoptosis; Autophagy; Bacterial; Mitophagy; Topoisomerase,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage,"Etoposide (VP-16; VP-16-213) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy[1].",C29H32O13,DMSO : ≥ 39 mg/mL (66.26 mM),10mM,Cancer; Infection,Launched,O=C1OC[C@]2([H])[C@H](O[C@H]3[C@@H]([C@H]([C@@H]4O[C@H](C)OC[C@H]4O3)O)O)C5=C(C=C6OCOC6=C5)[C@@H](C7=CC(OC)=C(O)C(OC)=C7)[C@]21[H]
Etoposide phosphate,BMY-40481,117091-64-2,668.54,Apoptosis; Autophagy; Bacterial; Topoisomerase,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage,"Etoposide phosphate (BMY-40481) is a potent anti-cancer chemotherapy agent and a selective topoisomerase II inhibitor to prevent re-ligation of DNA strands. Etoposide phosphate is the phosphate ester proagent of etoposide and is considered as active equivalent to Etoposide. Etoposide phosphate induces cell cycle arrest, apoptosis, and autophagy.",C29H33O16P,DMSO : 100 mg/mL (149.58 mM; ultrasonic and warming and heat to 80°C); H2O : 100 mg/mL (149.58 mM; Need ultrasonic),10mM,Cancer; Infection; Neurological Disease,Launched,O=C1OC[C@]2([H])[C@H](O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO4)O3)O[C@@H]4C)O)O)C5=C(C=C6OCOC6=C5)[C@@H](C7=CC(OC)=C(OP(O)(O)=O)C(OC)=C7)[C@]21[H]
Exatecan,DX-8951,171335-80-1,435.45,ADC Payload; Topoisomerase,Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage,"Exatecan (DX-8951) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL), and can be used in cancer research.",C24H22FN3O4,DMSO : 20 mg/mL (45.93 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C5C6=C(CC[C@@H]5N)C(C)=C(F)C=C6N=C4C3=C2)=O
Exatecan (mesylate),DX8951f,169869-90-3,531.55,ADC Payload; Topoisomerase,Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage,"Exatecan mesylate (DX8951f) is a DNA topoisomerase I inhibitor, with an IC50 of 2.2 μM (0.975 μg/mL). Exatecan mesylate can be used in cancer research.",C25H26FN3O7S,H2O : 10 mg/mL (18.81 mM; ultrasonic and warming and heat to 60°C); DMSO : 3.45 mg/mL (6.49 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,O=S(C)(O)=O.O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C5C6=C(CC[C@@H]5N)C(C)=C(F)C=C6N=C4C3=C2)=O
Dxd,Exatecan derivative for ADC,1599440-33-1,493.48,ADC Payload; Topoisomerase,Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage,"Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).",C26H24FN3O6,DMSO : 40 mg/mL (81.06 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C5C6=C(CC[C@@H]5NC(CO)=O)C(C)=C(F)C=C6N=C4C3=C2)=O
Ganciclovir,BW 759; 2'-Nor-2'-deoxyguanosine,82410-32-0,255.23,Antibiotic; CMV; HSV; Nucleoside Antimetabolite/Analog,Anti-infection; Cell Cycle/DNA Damage,"Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain[1][2][3].",C9H13N5O4,DMSO : 60 mg/mL (235.08 mM; Need ultrasonic); H2O : 1.67 mg/mL (6.54 mM; Need ultrasonic),10mM,Infection; Cancer,Launched,O=C1NC(N)=NC2=C1N=CN2COC(CO)CO
Ganciclovir (sodium),BW 759 (sodium); 2'-Nor-2'-deoxyguanosine (sodium),107910-75-8,277.21,Antibiotic; CMV; HSV; Nucleoside Antimetabolite/Analog,Anti-infection; Cell Cycle/DNA Damage,"Ganciclovir (BW 759) sodium, a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir sodium also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir sodium inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir sodium has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain[1][2][3].",C9H12N5NaO4,DMSO : 5 mg/mL (18.04 mM; Need ultrasonic); H2O : 50 mg/mL (180.37 mM; Need ultrasonic),10mM,Infection; Cancer,Launched,OCC(OCN1C=NC2=C1N=C(N)N=C2O[Na])CO
Rabacfosadine,GS-9219; VDC-1101,859209-74-8,526.53,Nucleoside Antimetabolite/Analog,Cell Cycle/DNA Damage,"Rabacfosadine (GS-9219), a novel proagent of the nucleotide analogue PMEG, is designed as a cytotoxic agent that preferentially targets lymphoid cells.",C21H35N8O6P,DMSO : 100 mg/mL (189.92 mM; Need ultrasonic),10mM,Cancer,Phase 2,CCOC([C@H](C)NP(N[C@@H](C)C(OCC)=O)(COCCN1C=NC2=C(NC3CC3)N=C(N)N=C12)=O)=O
Indibulin,ZIO 301; D 24851,204205-90-3,389.83,Apoptosis; Checkpoint Kinase (Chk); Microtubule/Tubulin,Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,"Indibulin (ZIO 301), an orally applicable inhibitor of tubulin assembly, shows potent anticancer activity with a minimal neurotoxicity. Indibulin reduces inter-kinetochoric tension, produces aberrant spindles, activates mitotic checkpoint proteins Mad2 and BubR1, and induces mitotic arrest and apoptosis[1].",C22H16ClN3O2,DMSO : 50 mg/mL (128.26 mM; Need ultrasonic),10mM,Cancer; Neurological Disease,Phase 2,O=C(NC1=CC=NC=C1)C(C2=CN(CC3=CC=C(Cl)C=C3)C4=C2C=CC=C4)=O
SC-43,,1400989-25-4,431.80,Apoptosis; Phosphatase; SHP1; STAT,Apoptosis; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"SC-43, a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis. SC-43 has anti-fibrotic and anticancer effects[1][2].",C21H13ClF3N3O2,DMSO : 250 mg/mL (578.97 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC=CC(OC2=CC=C(C#N)C=C2)=C1)NC3=CC=C(Cl)C(C(F)(F)F)=C3
Lomustine,CCNU; NSC 79037,13010-47-4,233.70,Apoptosis; Autophagy; DNA Alkylator/Crosslinker,Apoptosis; Autophagy; Cell Cycle/DNA Damage,"Lomustine (CCNU; NSC 79037) is a DNA alkylating agent, with antitumor activity.",C9H16ClN3O2,DMSO : ≥ 100 mg/mL (427.90 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,O=C(NC1CCCCC1)N(CCCl)N=O
LY2334737,,892128-60-8,389.39,Enterovirus; Nucleoside Antimetabolite/Analog,Anti-infection; Cell Cycle/DNA Damage,LY2334737 is an nucleoside analog and is an orally active proagent of Gemcitabine. LY2334737 exhibits inhibitory activity against enterovirus A71 (EV-A71) infection. LY2334737 has antiviral and anticancer effects[1][2].,C17H25F2N3O5,DMSO : ≥ 100 mg/mL (256.81 mM),10mM,Cancer; Infection,Phase 1,OC[C@@H]1[C@H](C(F)(F)[C@H](N2C(N=C(C=C2)NC(C(CCC)CCC)=O)=O)O1)O
Maytansine,NSC 153858,35846-53-8,692.20,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,Maytansine is a highly potent microtubule-targeted compound that induces mitotic arrest and kills tumor cells at subnanomolar concentrations[1].,C34H46ClN3O10,DMSO : 100 mg/mL (144.47 mM; Need ultrasonic),10mM,Cancer,Launched,C[C@]12[C@@]([C@@H]([C@]3([H])C[C@]([C@@H](/C=C/C=C(CC4=CC(N(C(C[C@@H]2OC([C@H](C)N(C)C(C)=O)=O)=O)C)=C(C(OC)=C4)Cl)\C)OC)(NC(O3)=O)O)C)([H])O1
6-Mercaptopurine,Mercaptopurine; 6-MP,50-44-2,152.18,Autophagy; Endogenous Metabolite; Nucleoside Antimetabolite/Analog,Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,6-Mercaptopurine is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive drug.,C5H4N4S,DMSO : 35.71 mg/mL (234.66 mM; Need ultrasonic),10mM,Cancer,Launched,S=C1NC=NC2=C1NC=N2
6-Mercaptopurine hydrate,Mercaptopurine hydrate; 6-MP hydrate,6112-76-1,170.19,Nucleoside Antimetabolite/Analog,Cell Cycle/DNA Damage,6-Mercaptopurine hydrate (Mercaptopurine hydrate; 6-MP hydrate) is a purine analogue which acts as an antagonist of the endogenous purines and has been widely used as antileukemic agent and immunosuppressive agent.,C5H6N4OS,DMSO : 50 mg/mL (293.79 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,S=C1NC=NC2=C1NC=N2.O
Tuxobertinib,BDTX-189,2414572-47-5,561.03,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. Tuxobertinib shows KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity[1].",C29H29ClN6O4,DMSO : 41.67 mg/mL (74.27 mM; Need ultrasonic),10mM,Cancer,Phase 1,C=CC(NC1=CC2=C(NC3=CC=C(OCC4=NC=CC=C4)C(Cl)=C3)N=CN=C2C=C1OCCN5CCOCC5)=O
Miltefosine,HePC; Hexadecyl phosphocholine,58066-85-6,407.57,Akt; HIV; Parasite,Anti-infection; PI3K/Akt/mTOR,"Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid agent acting by inhibiting the PI3K/Akt activity[1][2][3][4]. Miltefosine is an inhibitor of CTP-phosphocholine cytidyltransferase (CCT)[5].",C21H46NO4P,DMSO : 3.33 mg/mL (8.17 mM; ultrasonic and warming and heat to 60°C); H2O : 33.33 mg/mL (81.78 mM; ultrasonic and warming and heat to 60°C),10mM,Infection; Cancer,Launched,O=P(OCC[N+](C)(C)C)(OCCCCCCCCCCCCCCCC)[O-]
MKC-1,Ro-31-7453,125313-92-0,400.39,Akt; Apoptosis; Microtubule/Tubulin; mTOR,Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; PI3K/Akt/mTOR,MKC-1 (Ro-31-7453) is an orally active and potent cell cycle inhibitor with broad antitumor activity. MKC-1 inhibits the Akt/mTOR pathway. MKC-1 arrests cellular mitosis and induces cell apoptosis by binding to a number of different cellular proteins including tubulin and members of the importin β family[1][2][3].,C22H16N4O4,DMSO : ≥ 50 mg/mL (124.88 mM),10mM,Cancer,Phase 2,O=C(C(C1=CN(C)C2=C1C=CC=C2)=C3C4=CN(C)C5=C4C=CC([N+]([O-])=O)=C5)NC3=O
Nelarabine,506U78; GW 506U78; Nelzarabine,121032-29-9,297.27,Apoptosis; Nucleoside Antimetabolite/Analog,Apoptosis; Cell Cycle/DNA Damage,Nelarabine (506U78) is a nucleoside analogue and can be used for the research of T cell acute lymphoblastic leukemia (T-ALL)[1].,C11H15N5O5,DMSO : 100 mg/mL (336.39 mM; Need ultrasonic); H2O : 10 mg/mL (33.64 mM; Need ultrasonic),10mM,Cancer,Launched,OC[C@@H]1[C@@H](O)[C@H](O)[C@H](N2C=NC3=C(OC)N=C(N)N=C23)O1
Nimustine (hydrochloride),ACNU,55661-38-6,309.15,AP-1; Apoptosis; DNA Alkylator/Crosslinker; DNA/RNA Synthesis; JNK; p38 MAPK,Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; MAPK/ERK Pathway,"Nimustine hydrochloride (ACNU) is the hydrochloride salt form of Nimustine (HY-13703). Nimustine hydrochloride is an alkylating agent, which induces DNA double-strand breaks (DSBs) and inter-strand crosslinks (ICLs), thereby activating the DNA damage response (DDR) signaling pathway. Nimustine hydrochloride activates p38 MAPK/JNK signaling pathway, and exhibits antitumor activity[1][2].",C9H14Cl2N6O2,DMSO : 62.5 mg/mL (202.17 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NCC1=CN=C(C)N=C1N)N(CCCl)N=O.[H]Cl
SN-38,7-Ethyl-10-hydroxycamptothecin,86639-52-3,392.40,ADC Payload; Autophagy; Drug Metabolite; Topoisomerase,Antibody-drug Conjugate/ADC Related; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254)[1][2][3][4][5].",C22H20N2O5,DMSO : 25 mg/mL (63.71 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C(CC)C5=CC(O)=CC=C5N=C4C3=C2)=O
Phenoxodiol,Idronoxil; Dehydroequol; Haginin E,81267-65-4,240.25,Apoptosis; Caspase; Topoisomerase,Apoptosis; Cell Cycle/DNA Damage,"Phenoxodiol (Idronoxil), a synthetic analog of Genestein, activates the mitochondrial caspase system, inhibits XIAP (an apoptosis inhibitor), and sensitizes the cancer cells to Fas-mediated apoptosis. Phenoxodiol also inhibits DNA topoisomerase II by stabilizing the cleavable complex. Phenoxodiol induces cell cycle arrest in the G1/S phase of the cell cycle and upregulates p21WAF1 via a p53 independent manner[1][2].",C15H12O3,DMSO : ≥ 100 mg/mL (416.23 mM),10mM,Cancer,Phase 3,OC1=CC=C2C=C(C3=CC=C(O)C=C3)COC2=C1
Pirarubicin (Hydrochloride),THP Hydrochloride,95343-20-7,664.10,Antibiotic; Autophagy; Bacterial; Topoisomerase,Anti-infection; Autophagy; Cell Cycle/DNA Damage,"Pirarubicin Hydrochloride is an anthracycline antibiotics, acts as a topoisomerase II inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors.",C32H38ClNO12,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 20.83 mg/mL (31.37 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,O=C1C2=C(C=CC=C2OC)C(C3=C(O)C4=C([C@@H](O[C@@]5([H])C[C@H](N)[C@H](O[C@@]6([H])OCCCC6)[C@H](C)O5)C[C@@](C(CO)=O)(O)C4)C(O)=C31)=O.Cl
Pixantrone,BBR 2778,144675-97-8,557.51,Topoisomerase,Cell Cycle/DNA Damage,"Pixantrone (BBR 2778) dimaleate is a topoisomerase II inhibitor and DNA intercalator, with anti-tumor activity.",C25H27N5O10,H2O : 8.33 mg/mL (14.94 mM; ultrasonic and warming and heat to 60°C); DMSO : 50 mg/mL (89.68 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(O)/C=C\C(O)=O.O=C(O)/C=C\C(O)=O.O=C(C1=C(NCCN)C=CC(NCCN)=C12)C3=C(C=NC=C3)C2=O
TML-6,,1462868-88-7,523.62,Amyloid-β; Keap1-Nrf2; mTOR; NF-κB,Neuronal Signaling; NF-κB; PI3K/Akt/mTOR,"TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-oxidative Nrf2 gene. TML-6 has the potential for Alzheimer’s disease (AD) research[1].",C30H37NO7,DMSO : 120 mg/mL (229.17 mM; Need ultrasonic),10mM,Neurological Disease,Phase 1,O=C(N(CC)CC)CC(C)(C(/C=C/C1=CC=C(OC)C(OC)=C1)=O)C(/C=C/C2=CC=C(OC)C(OC)=C2)=O
Procarbazine (Hydrochloride),,366-70-1,257.76,DNA Alkylator/Crosslinker,Cell Cycle/DNA Damage,"Procarbazine Hydrochloride is an orally active alkylating agent, with anticancer activity. Procarbazine Hydrochloride can be used in Hodgkin's disease research[1][2].",C12H20ClN3O,H2O : 100 mg/mL (387.96 mM; Need ultrasonic); DMSO : 16.67 mg/mL (64.67 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(NC(C)C)C1=CC=C(CNNC)C=C1.Cl
Quinagolide (hydrochloride),CV205-502 hydrochloride,94424-50-7,432.02,Akt; Dopamine Receptor,GPCR/G Protein; Neuronal Signaling; PI3K/Akt/mTOR,"Quinagolide hydrochloride (CV205-502 hydrochloride) is a selective and orally active dopamine D2 receptor agonist. Quinagolide hydrochloride is an inhibitor of prolactin. Quinagolide hydrochloride down-regulates AKT levels and its phosphorylation. Quinagolide hydrochloride shows antitumor effects, it can be used for the research of cancer[1][2].",C20H34ClN3O3S,DMSO : 3.85 mg/mL (8.91 mM; Need ultrasonic),2mM,Cancer; Neurological Disease,Launched,OC1=C2C(C[C@](N(CCC)C[C@@H](NS(N(CC)CC)(=O)=O)C3)([H])[C@@]3([H])C2)=CC=C1.Cl
Avotaciclib (hydrochloride),BEY1107 (hydrochloride),,317.73,Apoptosis; CDK,Apoptosis; Cell Cycle/DNA Damage,Avotaciclib (BEY1107) hydrochloride is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib hydrochloride can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib hydrochloride can be used in the research of cancer such as pancreatic cancer and lung cancer[1][2].,C13H12ClN7O,DMSO : 14.29 mg/mL (44.98 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,OC1=C(N=C(C=C1)C2=NC(N)=NC=C2)C3=CC=NC(N)=N3.Cl
Befotertinib,D-0316,1835667-63-4,567.61,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,Befotertinib (D-0316) is an orally active EGFR tyrosine kinase inhibitor. Befotertinib can inhibit the proliferation of tumor cells. Befotertinib can be used in the research of EGFR T790M-positive non-small cell lung cancer (NSCLC)[1][2].,C29H32F3N7O2,DMSO : 50 mg/mL (88.09 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 4,O=C(NC1=CC(NC2=NC(C3=CN(CC(F)(F)F)C4=C3C=CC=C4)=CC=N2)=C(C=C1N(CCN(C)C)C)OC)C=C
Rubitecan,RFS 2000; 9-Nitrocamptothecin,91421-42-0,393.35,Topoisomerase,Cell Cycle/DNA Damage,"Rubitecan (RFS 2000), a Camptothecin derivative, is an orally active topoisomerase I inhibitor with broad antitumor activity, and induces protein-linked DNA single-strand breaks, thereby blocking DNA and RNA synthesis in dividing cells[1][2][3].",C20H15N3O6,DMSO : 62.5 mg/mL (158.89 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=C([N+]([O-])=O)C=CC=C5N=C4C3=C2)=O
Vevorisertib,ARQ 751,1416775-46-6,586.73,Akt; Ser/Thr Protease,Metabolic Enzyme/Protease; PI3K/Akt/mTOR,"Vevorisertib (ARQ 751) is an orally active, potent and selective pan-AKT serine/threonine kinase inhibitor against AKT1 (IC50=0.55 nM), AKT2 (IC50=0.81 nM), and AKT3 (IC50=1.31 nM). Vevorisertib, as a single agent or in combination with other anti-cancer agents, can be used for the research of solid tumors with PIK3CA / AKT / PTEN mutations[1][2][3][4].",C35H38N8O,DMSO : 6.67 mg/mL (11.37 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 1,NC1=C(C=CC=N1)C2=NC3=CC=C(C4=CC(N(CC5)CCC5N(C)C(C)=O)=CC=C4)N=C3N2C6=CC=C(C7(CCC7)N)C=C6
Vevorisertib (trihydrochloride),ARQ 751 (trihydrochloride),1416775-08-0,696.11,Akt,PI3K/Akt/mTOR,"Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC50 values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. Vevorisertib trihydrochloride can be used for the research of cancer[1].",C35H41Cl3N8O,H2O : 25 mg/mL (35.91 mM; ultrasonic and warming and heat to 60°C); DMSO : 150 mg/mL (215.48 mM; Need ultrasonic),10mM,Cancer,Phase 1,NC1=C(C=CC=N1)C2=NC3=CC=C(C4=CC(N(CC5)CCC5N(C)C(C)=O)=CC=C4)N=C3N2C6=CC=C(C7(CCC7)N)C=C6.[H]Cl.[H]Cl.[H]Cl
Teniposide,VM26,29767-20-2,656.65,Topoisomerase,Cell Cycle/DNA Damage,"Teniposide is a podophyllotoxin derivative, acts as a topoisomerase II inhibitor, and used as a chemotherapeutic agent.",C32H32O13S,DMSO : ≥ 30 mg/mL (45.69 mM),10mM,Cancer,Launched,O=C1OC[C@]2([H])[C@H](O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO4)O3)O[C@@H]4C5=CC=CS5)O)O)C6=C(C=C7OCOC7=C6)[C@@H](C8=CC(OC)=C(O)C(OC)=C8)[C@]21[H]
Topotecan (hydrochloride),SKF 104864A (hydrochloride); NSC 609669 (hydrochloride),119413-54-6,457.91,Apoptosis; Autophagy; Topoisomerase,Apoptosis; Autophagy; Cell Cycle/DNA Damage,Topotecan Hydrochloride (SKF 104864A Hydrochloride) is a Topoisomerase I inhibitor with potent antineoplastic activities.,C23H24ClN3O5,H2O : 33.33 mg/mL (72.79 mM; Need ultrasonic); DMSO : 100 mg/mL (218.38 mM; Need ultrasonic),10mM,Cancer,Launched,[H]Cl.O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=C(CN(C)C)C(O)=CC=C5N=C4C3=C2)=O
Troxacitabine,BCH 4556; L-OddC; SPD 758,145918-75-8,213.19,Nucleoside Antimetabolite/Analog,Cell Cycle/DNA Damage,Troxacitabine is nucleoside analog with potent anticancer activity.,C8H11N3O4,DMSO : 20 mg/mL (93.81 mM; Need ultrasonic),10mM,Cancer,Phase 2,NC1=NC(N(C=C1)[C@@H]2CO[C@H](CO)O2)=O
XL019,,945755-56-6,444.53,Apoptosis; JAK,Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"XL019 is a potent, orally active, and selective JAK2 inhibitor, with IC50s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively. XL019 shows 50-fold or greater selectivity for JAK2, versus a panel of over 100 serine/threonine and tyrosine kinases, including other members of the JAK family. XL019 potently inhibits STAT3 and STAT5 phosphorylation in cells harboring either JAK2V617F or wild-type JAK2[1][2].",C25H28N6O2,DMSO : 25 mg/mL (56.24 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C([C@H]1NCCC1)NC2=CC=C(C3=NC(NC4=CC=C(N5CCOCC5)C=C4)=NC=C3)C=C2
Vinblastine (sulfate),Vincaleukoblastine sulfate salt,143-67-9,909.05,Autophagy; Microtubule/Tubulin; nAChR,Autophagy; Cell Cycle/DNA Damage; Cytoskeleton; Membrane Transporter/Ion Channel; Neuronal Signaling,Vinblastine sulfate is a cytotoxic alkaloid used against various cancer types. Vinblastine sulfate inhibits the formation of microtubule and suppresses nAChR with an IC50 of 8.9 μM.,C46H60N4O13S,DMSO : ≥ 44 mg/mL (48.40 mM); H2O : 50 mg/mL (55.00 mM; Need ultrasonic),10mM,Cancer,Launched,[H][C@@]12C[C@@](C3=C(OC)C=C(N([C@]4([H])[C@@]56[C@]7([H])[C@](C=CCN7CC6)(CC)[C@@H](OC(C)=O)[C@@]4(C(OC)=O)O)C)C5=C3)(C(OC)=O)C(NC8=C9C=CC=C8)=C9CC[N@](C2)C[C@](O)(CC)C1.OS(=O)(O)=O
Roxatidine,,78273-80-0,306.41,Caspase; Histamine Receptor; NF-κB; p38 MAPK,Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Neuronal Signaling; NF-κB,"Roxatidine is an active metabolite of Roxatidine acetate hydrochloride, is an orally active histamine H2-receptor antagonist. Roxatidine, an anti-ulcer agent, suppresses histamine release (thus inhibiting proton secretion) and inhibits the production of VEGF-1, an important marker of inflammation and angiogenesis. Anti-allergic inflammatory effect. Roxatidine is promising for research of gastric and duodenal ulcers[1][2][3].",C17H26N2O3,DMSO : 100 mg/mL (326.36 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 2,O=C(NCCCOC1=CC=CC(CN2CCCCC2)=C1)CO
Evixapodlin,GS-4224; PD-1/PD-L1-IN 7,2374856-75-2,691.61,HBV; PD-1/PD-L1,Anti-infection; Immunology/Inflammation,Evixapodlin (GS-4224) is a human PD-1/PD-L1 protein/protein interaction inhibitor with an IC50 of 0.213 nM. Evixapodlin has anticancer and antiviral functions[1].,C34H36Cl2N8O4,DMSO : 50 mg/mL (72.30 mM; Need ultrasonic),10mM,Cancer; Infection,Phase 1,ClC1=C(C(C=CC=C2C(C=N3)=NC(OC)=C3CNC[C@H](CC4)NC4=O)=C2Cl)C=CC=C1C(C=N5)=NC(OC)=C5CNC[C@H](CC6)NC6=O
AG-270,,2201056-66-6,489.57,Methionine Adenosyltransferase (MAT),Epigenetics; Metabolic Enzyme/Protease,"AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC50 of 14 nM[1].",C30H27N5O2,DMSO : 4 mg/mL (8.17 mM; ultrasonic and warming and heat to 60°C),2mM,Cancer,Phase 1,O=C1C(C2=CC=C(OC)C=C2)=C(NC3=NC=CC=C3)NC4=C(C5=CCCCC5)C(C6=CC=CC=C6)=NN14
Zanzalintinib,XL092,2367004-54-2,528.53,c-Met/HGFR; TAM Receptor; VEGFR,Protein Tyrosine Kinase/RTK,"Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research[1][2].",C29H25FN4O5,DMSO : 16.67 mg/mL (31.54 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,O=C(C1=CC2=C(OC3=CC=C(NC(C4(CC4)C(NC5=CC=C(C=C5)F)=O)=O)C=C3)C=CN=C2C=C1OC)NC
limertinib,ASK120067,1934259-00-3,546.06,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,limertinib (ASK120067) is a potent and orally active inhibitor of EGFRT790M  (IC50:0.3 nM) with selectivity over EGFRWT (IC50:6.0 nM). limertinib is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC)[1].,C29H32ClN7O2,DMSO : 41.67 mg/mL (76.31 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(NC1=CC(NC2=NC=C(C(NC3=CC4=C(C=CC=C4)C=C3)=N2)Cl)=C(C=C1N(CCN(C)C)C)OC)C=C
Taselisib,GDC-0032; RG-7604,1282512-48-4,460.53,PI3K,PI3K/Akt/mTOR,"Taselisib (GDC-0032) is a potent PI3K inhibitor targets PIK3CA mutations, with Kis of 0.12 nM, 0.29 nM, 0.97 nM, and 9.1 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.",C24H28N8O2,DMSO : 25 mg/mL (54.29 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,CC(C)N1C(C2=CN3C(C(C(OCC3)=C4)=CC=C4C5=CN(C(C)(C(N)=O)C)N=C5)=N2)=NC(C)=N1
Simufilam,PTI-125,1224591-33-6,259.35,Amyloid-β; iGluR; mTOR; Tau Protein,Membrane Transporter/Ion Channel; Neuronal Signaling; PI3K/Akt/mTOR,"Simufilam (PTI-125) is an orally active FLNA modulator. Simufilam restores NMDAR signaling and Arc expression. Simufilam inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. 
Simufilam can be used for research of Alzheimer's disease[1][2][3].",C15H21N3O,DMSO : 50 mg/mL (192.79 mM; Need ultrasonic),10mM,Neurological Disease,Phase 3,O=C1N(CC2=CC=CC=C2)C3(CCN(C)CC3)NC1
Simufilam (hydrochloride),PTI-125 (hydrochloride),2480226-07-9,295.81,Amyloid-β; iGluR; mTOR; Tau Protein,Membrane Transporter/Ion Channel; Neuronal Signaling; PI3K/Akt/mTOR,"Simufilam hydrochloride (PTI-125 hydrochloride) is an orally active FLNA modulator. Simufilam hydrochloride restores NMDAR signaling and Arc expression. Simufilam hydrochloride inhibits overactive mTOR signaling by restoring the normal conformation of FLNA, improves insulin sensitivity, reduces Aβ42-induced neuroinflammation and tau protein hyperphosphorylation. Simufilam hydrochloride can be used for research of Alzheimer's disease[1][2][3].",C15H22ClN3O,H2O : 100 mg/mL (338.05 mM; Need ultrasonic); DMSO : 125 mg/mL (422.57 mM; ultrasonic and warming and heat to 60°C),10mM,Neurological Disease,Phase 3,O=C1N(CC2=CC=CC=C2)C3(CCN(C)CC3)NC1.[H]Cl
Napabucasin,BBI608,83280-65-3,240.21,STAT,JAK/STAT Signaling; Stem Cell/Wnt,Napabucasin (BBI608) is a STAT3 inhibitor which blocks stem cell activity in cancer cells.,C14H8O4,DMSO : 4.44 mg/mL (18.48 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble); Ethanol : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); N-Methylpyrrolidone (NMP) : 16.67 mg/mL (69.40 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(C1=C2OC(C(C)=O)=C1)C3=C(C2=O)C=CC=C3
Epitinib,HMPL-813,1203902-67-3,430.50,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Epitinib is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib can be used for the research of cancer[1][2]. Epitinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.",C24H26N6O2,10 mM in DMSO,10mM,Cancer,Phase 1,O=C(N1CCN(CC)CC1)NC2=CC3=C(NC4=CC=CC(C#C)=C4)N=CN=C3C=C2OC
Epitinib (succinate),HMPL-813 (succinate),2252334-12-4,548.59,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Epitinib succinate is an orally active and selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib succinate can be used for the research of cancer[1][2]. Epitinib (succinate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.",C28H32N6O6,DMSO : 12.5 mg/mL (22.79 mM; ultrasonic and warming and heat to 60°C); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 1,O=C(CCC(O)=O)O.O=C(N1CCN(CC)CC1)NC2=CC3=C(NC4=CC=CC(C#C)=C4)N=CN=C3C=C2OC
Zeteletinib,BOS-172738; DS-5010,2216753-97-6,500.47,PDGFR; RET,Protein Tyrosine Kinase/RTK,"Zeteletinib (BOS-172738; DS-5010) is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib shows exquisite potency for the wild type RET, RETV804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib has potent antitumor activity[1][2][3].",C25H23F3N4O4,DMSO : 100 mg/mL (199.81 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(CC1=CC=C(C2=CN=C3C=C(C(OC)=CC3=C2)OC)N=C1)NC4=CC(C(C)(C(F)(F)F)C)=NO4
Opnurasib,JDQ-443; NVP-JDQ443,2653994-08-0,526.03,PERK; Ras,Cell Cycle/DNA Damage; GPCR/G Protein; MAPK/ERK Pathway,"Opnurasib (JDQ-443) (NVP-JDQ443) is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity[1][2].",C29H28ClN7O,DMSO : 80 mg/mL (152.08 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(C=C)N1CC2(C1)CC(N3N=C(C4=CC=C5C(C=NN5C)=C4)[C@]([C@]6=C(Cl)C(C)=CC7=C6C=NN7)=C3C)C2
Oritinib,SH-1028,2035089-28-0,539.67,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Oritinib (SH-1028), an irreversible third-generation EGFR TKI, overcomes T790M-mediated resistance in non-small cell lung cancer. Oritinib (SH-1028), a mutant-selective inhibitor of EGFR kinase activity, inhibits EGFRWT, EGFRL858R, EGFRL861Q, EGFRL858R/T790M, EGFRd746-750 and EGFRd746-750/T790M kinases, with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM, respectively[1].",C31H37N7O2,DMSO : 125 mg/mL (231.62 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(NC1=CC(NC2=NC(C3=C(CCCC4)N4C5=C3C=CC=C5)=CC=N2)=C(C=C1N(CCN(C)C)C)OC)C=C
BMS-582949 (hydrochloride),,912806-16-7,442.94,Autophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,"BMS-582949 hydrochloride is an orally active and highly selective p38α MAPK inhibitor, with an IC50 of 13 nM. BMS-582949 hydrochloride displays a significantly improved pharmacokinetic profile and is effective in inflammatory disease[1].",C22H27ClN6O2,DMSO : 25 mg/mL (56.44 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 2,O=C(NCCC)C1=CN(N=CN=C2NC3=CC(C(NC4CC4)=O)=CC=C3C)C2=C1C.[H]Cl
PD153035,SU-5271; AG1517; ZM 252868,153436-54-5,360.21,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"PD153035 (SU-5271; AG1517; ZM 252868) is a potent EGFR inhibitor with Ki and IC50 of 6 and 25 pM, respectively.",C16H14BrN3O2,DMSO : 33.33 mg/mL (92.53 mM; Need ultrasonic),10mM,Cancer,Phase 1,COC1=C(C=C(C2=C1)N=CN=C2NC3=CC(Br)=CC=C3)OC
Plinabulin,NPI-2358,714272-27-2,336.39,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,Plinabulin (NPI-2358) is a vascular disrupting agen (VDA) against tubulin-depolymerizing with an IC50 of 9.8 nM against HT-29 cells[1]. Plinabulin binds the colchicine binding site of β-tubulin preventing polymerization and has potent inhibitory to tumor cells[2].,C19H20N4O2,DMSO : 50 mg/mL (148.64 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(N/C1=C\C2=C(NC=N2)C(C)(C)C)/C(NC1=O)=C/C3=CC=CC=C3
Onalespib,AT13387,912999-49-6,409.52,HSP,Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Onalespib (AT13387) is a potent and cross the blood-brain barrier heat-shock-protein-90 (Hsp90) inhibitor. Onalespib inhibits the proliferation, survival and migration. Onalespib decreases the expression of EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, P-S6 protein. Onalespib shows antitumor activity. Onalespib has the potential for the research of non-small cell lung cancer (NSCLC)[1][2][3].",C24H31N3O3,DMSO : 50 mg/mL (122.09 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,OC1=CC(O)=C(C(C)C)C=C1C(N2CC(C=CC(CN3CCN(C)CC3)=C4)=C4C2)=O
BLU-945,ZL-2313,2660250-10-0,556.70,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC)[1][2][3].",C28H37FN6O3S,DMSO : 100 mg/mL (179.63 mM; Need ultrasonic),10mM,Cancer,Phase 1,CC(C1=CC=C(N2[C@@H]([C@H](C2)CS(C)(=O)=O)C)C3=C1C=C(NC4=NC(N5C[C@@H]([C@@H](CC5)OC)F)=NC=C4)N=C3)C
Migoprotafib,GDC-1971,2377352-49-1,454.53,ERK; p38 MAPK; Phosphatase; SHP2,MAPK/ERK Pathway; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Migoprotafib (GDC-1971) (compound 199) is a SHP2 inhibitor. Migoprotafib inhibits the MAPK/ERK signaling pathway, and exhibits antitumor activity[1][2].",C25H26N8O,DMSO : 100 mg/mL (220.01 mM; Need ultrasonic),10mM,Cancer,Phase 1,N[C@H]1C2(CCN(C3=CN=C(C(N4C5=CC=CN=C5CCC4)=NN6)C6=N3)CC2)OC7=CC=CC=C71
Enbezotinib,TPX-0046,2359649-81-1,424.43,RET,Protein Tyrosine Kinase/RTK,"Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer[1].",C21H21FN6O3,DMSO : 100 mg/mL (235.61 mM; ultrasonic and warming and heat to 80°C),10mM,Cancer,Phase 2,FC(C=C1CN2C3=NC4=C5C=NN4C=C3O[C@]6([H])[C@@]2([H])CCC6)=CN=C1O[C@@H](C)CNC5=O
Iruplinalkib,WX-0593,1854943-32-0,569.08,Akt; Anaplastic lymphoma kinase (ALK); BCRP; ERK; ROS Kinase; STAT,JAK/STAT Signaling; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Iruplinalkib (WX-0593) is an orally active and selective ALK/ROS1 inhibitor. Iruplinalkib can effectively inhibit tyrosine autophosphorylation of ALK and mutant ALK, EGFR, with the IC50 between 5.38 and 16.74 nM. Iruplinalkib is also a suppressive agent of the transporter  MATE1, MATE2K, P-gp  and BCRP. Iruplinalkib can be used in the study of non-small cell lung cancer[1][2].",C29H38ClN6O2P,DMSO : 10 mg/mL (17.57 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=P(C)(C)C1=C(NC2=NC(NC3=CC=C(N4CCC5(CCN(CC5)C)CC4)C=C3OC)=NC=C2Cl)C=CC=C1
Povorcitinib,INCB54707,1637677-22-5,507.46,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,Povorcitinib (INCB54707) is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib is used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP)[1][2].,C23H22F5N7O,DMSO : 250 mg/mL (492.65 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 3,N#CCC1(N2C=C(C3=C(C)NN=C3C)C=N2)CN(C4=C(C=C(C(F)=C4)C(N[C@@H](C)C(F)(F)F)=O)F)C1
Povorcitinib (phosphate),INCB54707 (phosphate),1637677-33-8,605.45,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,Povorcitinib (INCB54707) phosphate is a potent and selective JAK1 inhibitor that effectively reduces abscesses and inflammatory nodules. Povorcitinib phosphate can be used to study cutaneous lupus erythematosus (CLE) and lichen planus (LP) (information extracted from patent WO2021076124A1)[1].,C23H25F5N7O5P,DMSO : 100 mg/mL (165.17 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 3,O=P(O)(O)O.N#CCC1(N2C=C(C3=C(C)NN=C3C)C=N2)CN(C4=C(C=C(C(F)=C4)C(N[C@@H](C)C(F)(F)F)=O)F)C1
Tinengotinib,TT 00420,2230490-29-4,394.86,Aurora Kinase; FGFR; VEGFR,Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK,"Tinengotinib (TT00420) is an orally active, spectrally selective small molecule kinase inhibitor targeting Aurora A/B (IC50=1.2-3.3 nM), FGFR1/2/3 (IC50=1.5-3.5 nM), VEGFRs, JAK1/2 and CSF1R. Tinengotinib blocks Aurora kinase-mediated cell cycle progression (inducing G2/M arrest), inhibits FGFR/JNK-JUN signaling pathway and activates MEK/ERK-dependent apoptotic pathway. Tinengotinib has the activity of anti-tumor proliferation, inducing apoptosis, inhibiting angiogenesis and regulating tumor microenvironment. Tinengotinib can be used in the study of triple-negative breast cancer (TNBC), gallbladder cancer and tumor immune microenvironment[1][2].",C20H19ClN6O,DMSO : 50 mg/mL (126.63 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,ClC1=C(C2=NC3=C(C)NN=C3NC4=C2C=NC(N5CCOCC5)=C4)C=CC=C1
MAX-40279,,2070931-57-4,438.52,FGFR; FLT3,Protein Tyrosine Kinase/RTK,MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032)[1].,C22H23FN6OS,DMSO : ≥ 25 mg/mL (57.01 mM),10mM,Cancer; Inflammation/Immunology,Phase 2,FC1=CC(OC)=C(C2=C(C)SC3=C2N=C(NC4=CN(C5CCNCC5)N=C4)N=C3)C=C1
MAX-40279 (hemiadipate),,2388506-44-1,584.66,FGFR; FLT3,Protein Tyrosine Kinase/RTK,MAX-40279 hemiadipate is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 hemiadipate has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032)[1].,C22H23FN6OS.1/2C6H10O4,DMSO : 25 mg/mL (42.76 mM; ultrasonic and warming and heat to 60°C); DMF : 10 mg/mL (17.10 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Inflammation/Immunology,Phase 2,O=C(O)CCCCC(O)=O.FC1=CC(OC)=C(C2=C(C)SC3=C2N=C(NC4=CN(C5CCNCC5)N=C4)N=C3)C=C1
AMXI-5001,,2170491-77-5,457.46,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"AMXI-5001 is a potent, orally active, and dual parp1/2 and microtubule polymerization inhibitor. MXI-5001 exhibits selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC50s than existing clinical PARP1/2 inhibitors. AMXI-5001 induces complete regression of established tumors, including exceedingly large tumors[1].",C25H20FN5O3,DMSO : 50 mg/mL (109.30 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=C(NC1=NC2=C(N1)C=C(C3=C(F)C=CC(CC4=NNC(C5=C4C=CC=C5)=O)=C3)C=C2)OCC
AMXI-5001 (hydrochloride),,,493.92,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"AMXI-5001 hydrochloride is a potent, orally active, and dual parp1/2 and microtubule polymerization inhibitor. MXI-5001 hydrochloride exhibits selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC50s than existing clinical PARP1/2 inhibitors. AMXI-5001 hydrochloride induces complete regression of established tumors, including exceedingly large tumors[1].",C25H21ClFN5O3,DMSO : 100 mg/mL (202.46 mM; Need ultrasonic),10mM,Cancer,Phase 2,[H]Cl.O=C(NC1=NC2=C(N1)C=C(C3=C(F)C=CC(CC4=NNC(C5=C4C=CC=C5)=O)=C3)C=C2)OCC
PF-03814735,,942487-16-3,474.48,Aurora Kinase; VEGFR,Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK,"PF-03814735 is a potent, orally available, ATP-competitive and reversible aurora A and aurora B inhibitor with IC50s of 0.8 and 0.5 nM, respectively.",C23H25F3N6O2,DMSO : ≥ 100 mg/mL (210.76 mM),10mM,Cancer,Phase 1,O=C(CNC(C)=O)N1[C@@H]2C3=C(C=C(NC4=NC(NC5CCC5)=C(C(F)(F)F)C=N4)C=C3)[C@H]1CC2
Palomid 529,P529,914913-88-5,406.43,Apoptosis; mTOR,Apoptosis; PI3K/Akt/mTOR,Palomid 529 is a potent inhibitor of mTORC1 and mTORC2 complexes.,C24H22O6,DMSO : 100 mg/mL (246.04 mM; Need ultrasonic),10mM,Cancer,Phase 1,COC1=C(OCC2=CC=C(C=C2)OC)C=C3C(C4=C(C(O3)=O)C=C(C(C)O)C=C4)=C1
Kaempferol,Kempferol; Robigenin,520-18-3,286.24,Apoptosis; Autophagy; Endogenous Metabolite; Estrogen Receptor/ERR; HIV; Mitophagy; Parasite,Anti-infection; Apoptosis; Autophagy; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,"Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer[1][2][3][4].",C15H10O6,DMSO : 20 mg/mL (69.87 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 1,OC1=C2C(OC(C3=CC=C(O)C=C3)=C(O)C2=O)=CC(O)=C1
BAY 2666605,,2275774-60-0,352.28,Phosphodiesterase (PDE),Metabolic Enzyme/Protease,"BAY 2666605 is an orally active PDE3A and PDE3B inhibitor with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 is a PDE3A-SLFN12 complex inducer (WO2019025562A1; example 135)[1].",C17H12F4N2O2,DMSO : 250 mg/mL (709.66 mM; Need ultrasonic),10mM,Cancer,Phase 1,FC(F)(C1=C(C2=CC=C(C=C2)F)C=CC(C([C@@H](O3)C)=NNC3=O)=C1)F
MRTX0902,,2654743-22-1,388.47,Ras; SOS1,GPCR/G Protein; MAPK/ERK Pathway,MRTX0902 is an orally active and potent SOS1 inhibitor with an IC50 of 46 nM (WO2021127429A1; Example 12-10)[1].,C22H24N6O,DMSO : 12.5 mg/mL (32.18 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,C[C@H](C1=C(C(C#N)=CC=C1)C)NC2=NN=C(C)C3=C2C=C(N4CCOCC4)N=C3
NT219,,1198078-60-2,412.26,Insulin Receptor; STAT,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,NT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 (IRS1/2) and STAT3. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation. NT219 has the potential for the research of cancer diseases[1].,C16H14BrNO5S,DMSO : ≥ 100 mg/mL (242.57 mM),10mM,Cancer,Phase 2,OC(C=C1CNC(/C=C/C2=C(C(O)=C(C=C2)O)Br)=S)=C(C(O)=C1)O
Genistein,NPI 031L,446-72-0,270.24,Apoptosis; Autophagy; EGFR; Endogenous Metabolite,Apoptosis; Autophagy; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,"Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.",C15H10O5,DMSO : ≥ 100 mg/mL (370.04 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 4,OC1=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=CC(O)=C1
Aspirin,Acetylsalicylic acid; ASA,50-78-2,180.16,Apoptosis; Autophagy; Caspase; COX; Mitophagy; NF-κB; p38 MAPK; Virus Protease,Anti-infection; Apoptosis; Autophagy; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB,"Aspirin (Acetylsalicylic acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis[1][2][3][4][5][6].",C9H8O4,DMSO : 100 mg/mL (555.06 mM; Need ultrasonic); H2O : 3.12 mg/mL (17.32 mM; ultrasonic and warming and heat to 37°C),10mM,Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease,Launched,OC(C1=C(OC(C)=O)C=CC=C1)=O
CP-724714,,383432-38-0,469.55,Apoptosis; EGFR,Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"CP-724714 is a potent, selective and orally active ErbB2 (HER2) tyrosine kinase inhibitor, with an IC50 of 10 nM. CP-724714 displays a marked selectivity against EGFR kinase (IC50=6400 nM). CP-724714 potently inhibits ErbB2 receptor autophosphorylation in intact cells. Antitumor activities[1][2].",C27H27N5O3,DMSO : ≥ 50 mg/mL (106.48 mM),10mM,Cancer,Phase 2,O=C(COC)NC/C=C/C1=CC2=C(N=CN=C2C=C1)NC3=CC=C(C(C)=C3)OC4=CC=C(N=C4)C
ABN401,,2242563-15-9,566.66,Apoptosis; c-Met/HGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"ABN401 is an orally active and selective ATP-competitive c-MET inhibitor with an IC50 of 10 nM. ABN401 is cytotoxic to MET-addicted cancer cells with the IC50 of 2-43 nM. ABN401 has bioavailability in rats and dogs of 42.1-56.2% and 27.4-37.7%, respectively. ABN401 has antitumor activity[1][2].",C29H34N12O,DMSO : 10 mg/mL (17.65 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,CN1N=CC(C2=CN=C3C(N(CC4CN(C5=NC=C(C6=CC=C(CN7CCN(C)CC7)C=C6)C=N5)CCO4)N=N3)=N2)=C1
Tepotinib,EMD-1214063,1100598-32-0,492.57,Autophagy; c-Met/HGFR,Autophagy; Protein Tyrosine Kinase/RTK,"Tepotinib (EMD-1214063) is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC50 of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib inhibits c-Met phosphorylation and induces autophagy. Tepotinib has antitumor effects[1][2][3].",C29H28N6O2,DMSO : 8.75 mg/mL (17.76 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,N#CC1=CC=CC(C(C=CC2=O)=NN2CC3=CC=CC(C4=NC=C(C=N4)OCC5CCN(CC5)C)=C3)=C1
PF-07265807,,2412356-57-9,591.57,c-Met/HGFR; TAM Receptor,Protein Tyrosine Kinase/RTK,"PF-07265807 is a potent TAM and c-Met kinase inhibitor with IC50 values of 6.1 nM, 13.2 nM and 21.6 nM for AXL, MER and TYRO3, respectively. PF-07265807 can be used for researching anticancer[1].",C29H27F2N7O5,DMSO : 200 mg/mL (338.08 mM; Need ultrasonic),10mM,Cancer,Phase 1,OC[C@@H](C)NC1=NNC2=NC=CC(OC3=C(C=C(C=C3)NC(C(C(N4C5=CC=C(C=C5)F)=O)=CN(C(C)C)C4=O)=O)F)=C12
Ansornitinib,ANG-3070,1448874-96-1,540.61,PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, and gastrointestinal fibrotic diseases[1].",C30H32N6O4,DMSO : 40 mg/mL (73.99 mM; ultrasonic and warming and heat to 80°C),10mM,Inflammation/Immunology; Cardiovascular Disease,Phase 2,CN(CC1)CCN1CC(N(C)C(C=C2)=CC=C2N/C(C3=CC=CC=C3)=C4C5=CC=C(C(OC)=O)N=C5NC/4=O)=O
Lirafugratinib,RLY-4008,2549174-42-5,509.53,FGFR,Protein Tyrosine Kinase/RTK,"Lirafugratinib (RLY-4008) is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC50 of 3 nM. Lirafugratinib covalently binds to Cys491. Lirafugratinib targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs[1].",C28H24FN7O2,DMSO : 62.5 mg/mL (122.66 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=C(C(C)=C)NC1=CC=C(C2=C(C3=C(N)N=CN=C3N2C)C4=CC(F)=C(OC5=NC=CC(C)=N5)C=C4)C=C1
Lirafugratinib (hydrochloride),RLY-4008 (hydrochloride),2688040-45-9,546.00,FGFR,Protein Tyrosine Kinase/RTK,"Lirafugratinib (RLY-4008) hydrochloride is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC50 of 3 nM. Lirafugratinib hydrochloride covalently binds to Cys491. Lirafugratinib hydrochloride targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs[1].",C28H25ClFN7O2,DMSO : 125 mg/mL (228.94 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C(C)=C)NC1=CC=C(C2=C(C3=C(N)N=CN=C3N2C)C4=CC(F)=C(OC5=NC=CC(C)=N5)C=C4)C=C1.Cl
Exarafenib,RAF/KIN_2787,2639957-39-2,521.58,p38 MAPK; Raf,MAPK/ERK Pathway,"Exarafenib (RAF/KIN_2787) is an orally-available, selective pan-RAF inhibitor. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. Exarafenib has anticancer activity[1][2].",C26H34F3N5O3,DMSO : 100 mg/mL (191.73 mM; Need ultrasonic),10mM,Cancer,Phase 1,CC1=CC=C(NC(N2C[C@@H](CC2)CC(F)(F)F)=O)C=C1C3=CC(N[C@H](C)CO)=NC(N4CCOCC4)=C3
Anamorelin,RC-1291; ONO-7643,249921-19-5,546.70,GHSR,GPCR/G Protein,"Anamorelin (RC-1291) is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin can be used in the research of anorexia and cancer cachexia[1][2].",C31H42N6O3,DMSO : 100 mg/mL (182.92 mM; Need ultrasonic),10mM,Cancer; Endocrinology,Launched,[H][C@](CC1=CNC2=CC=CC=C21)(NC(C(C)(C)N)=O)C(N3CCC[C@@](C(N(C)N(C)C)=O)(CC4=CC=CC=C4)C3)=O
Anamorelin (hydrochloride),RC-1291 (hydrochloride); ONO-7643 (hydrochloride),861998-00-7,583.16,GHSR,GPCR/G Protein,"Anamorelin (RC-1291) hydrochloride is an orally active Ghrelin receptor agonist with an EC50 of 0.74 nM. Anamorelin hydrochloride can promote appetite, increase body weight, and stimulate the secretion of growth hormone and insulin-like growth factor-1. Anamorelin hydrochloride can be used in the research of anorexia and cancer cachexia[1][2].",C31H43ClN6O3,DMSO : ≥ 100 mg/mL (171.48 mM); H2O : 50 mg/mL (85.74 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Endocrinology,Launched,[H][C@](CC1=CNC2=CC=CC=C21)(NC(C(C)(C)N)=O)C(N3CCC[C@@](C(N(C)N(C)C)=O)(CC4=CC=CC=C4)C3)=O.[H]Cl
Golotimod,SCV 07; Gamma-D-glutamyl-L-tryptophan,229305-39-9,333.34,Bacterial; STAT,Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt,"Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod (SCV-07) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod (SCV-07) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2)[1][2][3].",C16H19N3O5,H2O : 125 mg/mL (374.99 mM; Need ultrasonic); DMSO : 50 mg/mL (150.00 mM; Need ultrasonic),10mM,Infection; Inflammation/Immunology; Cancer,Phase 2,O=C(CC[C@@](N)(C(O)=O)[H])N[C@]([H])(C(O)=O)CC1=CNC2=C1C=CC=C2
Golotimod (hydrochloride),SCV 07 (hydrochloride); Gamma-D-glutamyl-L-tryptophan (hydrochloride),1029401-59-9,369.80,Bacterial; STAT,Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt,"Golotimod hydrochloride (SCV 07 hydrochloride), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod hydrochloride (SCV 07 hydrochloride) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod hydrochloride (SCV 07 hydrochloride) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2)[1][2][3].",C16H20ClN3O5,H2O : 150 mg/mL (405.62 mM; Need ultrasonic),10mM,Infection; Inflammation/Immunology; Cancer,Phase 2,O=C(CC[C@@](N)(C(O)=O)[H])NC([H])(C(O)=O)CC1=CNC2=C1C=CC=C2.Cl
Bentamapimod,AS 602801,848344-36-5,457.55,JNK,MAPK/ERK Pathway,"Bentamapimod (AS 602801) is an ATP-competitive JNK inhibitor with IC50 of 80 nM, 90 nM, and 230 nM for JNK1, JNK2, and JNK3, respectively.",C25H23N5O2S,DMSO : 8.33 mg/mL (18.21 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,N#CC(C1=NC(OCC2=CC=C(C=C2)CN3CCOCC3)=NC=C1)C4=NC5=CC=CC=C5S4
Ombrabulin,AVE8062; AC7700,181816-48-8,402.44,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"Ombrabulin (AVE8062) is a derivative of CA-4 phosphate, which is known to exhibit antivascular effects through selective disruption of the tubulin cytoskeleton of endothelial cells.",C21H26N2O6,DMSO : 100 mg/mL (248.48 mM; Need ultrasonic),10mM,Cancer; Cardiovascular Disease,Phase 3,O=C(NC1=CC(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)=CC=C1OC)[C@@H](N)CO
Palifosfamide,Isophosphoramide mustard; IPM; ZIO-201,31645-39-3,221.02,DNA Alkylator/Crosslinker; Drug Metabolite,Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Palifosfamide is a novel DNA alkylator and the active metabolite of ifosfamide, with antitumor activity.",C4H11Cl2N2O2P,DMSO : 125 mg/mL (565.56 mM; Need ultrasonic); H2O : 14.29 mg/mL (64.65 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=P(NCCCl)(NCCCl)O
Teneligliptin (hydrobromide),MP-513 (hydrobromide),906093-29-6,628.86,AMPK; Apoptosis; Dipeptidyl Peptidase; Interleukin Related; JNK; NF-κB; NOD-like Receptor (NLR); p38 MAPK; Reactive Oxygen Species (ROS),Apoptosis; Epigenetics; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR,"Teneligliptin (MP-513) hydrobromide is an orally active and selective dipeptidyl peptidase 4 (DPP-4) inhibitor (IC50s: 0.37 and 0.29 nM for the human and rat DPP-4, respectively). Teneligliptin hydrobromide  improves blood glucose levels and can be used in researches related to type 2 diabetes mellitus[1][2][3][4][5][6][7][8].",C22H30N6OS.5/2HBr,H2O : ≥ 200 mg/mL (318.04 mM); DMSO : ≥ 100 mg/mL (159.02 mM),10mM,Metabolic Disease; Neurological Disease; Cardiovascular Disease,Launched,O=C(N1CSCC1)[C@H]2NC[C@@H](N3CCN(C4=CC(C)=NN4C5=CC=CC=C5)CC3)C2.[2.5 HBr]
Teneligliptin (hydrobromide hydrate),MP-513 (hydrobromide hydrate),1572583-29-9,426.58,AMPK; Apoptosis; Interleukin Related; JNK; NF-κB; NOD-like Receptor (NLR); p38 MAPK; Reactive Oxygen Species (ROS); Toll-like Receptor (TLR),Apoptosis; Epigenetics; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR,"Teneligliptin (MP-513) hydrobromide hydrate is an orally active and selective dipeptidyl peptidase 4 (DPP-4) inhibitor (IC50s: 0.37 and 0.29 nM for the human and rat DPP-4, respectively). Teneligliptin hydrobromide hydrate improves blood glucose levels and can be used in researches related to type 2 diabetes mellitus[1][2][3][4][5][6][7][8].",C22H30N6OS,H2O : ≥ 100 mg/mL (234.42 mM),10mM,Metabolic Disease; Neurological Disease; Cardiovascular Disease,Launched,O=C([C@H]1NC[C@@H](N2CCN(C3=CC(C)=NN3C4=CC=CC=C4)CC2)C1)N5CSCC5.[x H2O].[5/2 HBr]
Namitecan,ST-1968,372105-27-6,434.44,Topoisomerase,Cell Cycle/DNA Damage,"Namitecan is a potent topoisomerase I inhibitor, with antitumor property.",C23H22N4O5,DMSO : 250 mg/mL (575.45 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C(/C=N/OCCN)C5=CC=CC=C5N=C4C3=C2)=O
Ralometostat,TNG908,2760481-53-4,409.50,Histone Methyltransferase,Epigenetics,TNG908 is a MTAP synergistic PRMT5 inhibitor. TNG908 crosses the blood-brain barrier and is orally active. TNG908 could be used in cancer research[1].,C21H23N5O2S,DMSO : 100 mg/mL (244.20 mM; Need ultrasonic),10mM,Cancer,Phase 2,CC1=CC(NC(C(N2[C@@H](C3=CC=C(SC=N4)C4=C3)CC[C@@H](C2)C)=O)=O)=CN=C1N
Daraxonrasib,RMC-6236; RAS-IN-2,2765081-21-6,811.05,PERK; Ras,Cell Cycle/DNA Damage; GPCR/G Protein; MAPK/ERK Pathway,"RMC-6236 is an orally active, non-covalent RAS (ON) inhibitor. RMC-6236 disrupts the interaction of wild-type or mutant RAS proteins with the RAS binding domain of BRAF, with EC50 values ranging from 28-220 nM for wild-type KRAS, NRAS, HRAS, and multiple oncogenic RAS variants. RMC-6236 inhibits pERK. RMC-6236 has anti-tumor activity against KRAS mutant tumors[1][2][3].",C44H58N8O5S,DMSO : 100 mg/mL (123.30 mM; Need ultrasonic),10mM,Cancer,Phase 3,CC(COC([C@H]1NN(C([C@H](CC2=NC3=CS2)NC([C@H]4C[C@@H]4C)=O)=O)CCC1)=O)(C)CC5=[C@@](N(CC)C6=C5C=C3C=C6)[C@@]7=C([C@H](C)OC)N=CC(N8CCN(C)CC8)=C7
Tivumecirnon,FLX475,2174938-78-2,543.41,CCR,GPCR/G Protein; Immunology/Inflammation,"Tivumecirnon (FLX475) is an orally active, selective CCR4 antagonist. Tivumecirnon blocks the binding of CCR4 to its ligands, CCL17 and CCL22, thereby reducing Treg infiltration into the tumor microenvironment. Tivumecirnon has antitumor activity[1][2][3][4].",C24H27Cl2F3N6O,DMSO : 100 mg/mL (184.02 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 2,C[C@H](C1=C(C=C(C=C1)Cl)Cl)N2C3=NC(N4CC([C@H]5CCCN(C5)CCO)C4)=CN=C3C(C(F)(F)F)=N2
Pumecitinib,PG-011,2401057-12-1,400.46,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,Pumecitinib is a Janus kinase (JAK) inhibitor with anti-inflammatory activity[1].,C17H20N8O2S,DMSO : 125 mg/mL (312.14 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Inflammation/Immunology,Phase 2,N#CCC1(CN(S(=O)(C(C)C)=O)C1)N2N=C(C(C3=C4C=CNC4=NC=N3)=C2)N
Zongertinib,BI 1810631,2728667-27-2,535.60,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors[1][2][3].",C29H29N9O2,DMSO : 30.77 mg/mL (57.45 mM; ultrasonic and warming and adjust pH to 7 with 1 M HCL and heat to 60°C),10mM,Cancer,Launched,O=C(NC1CCN(CC1)C2=NC=C3N=CN=C(C3=N2)NC4=CC=C(C(C)=C4)OC5=CC(N=CN6C)=C6C=C5)C=C
Verubulin,MPC 6827,827031-83-4,279.34,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"Verubulin (MPC-6827) is a highly potent and broad-spectrum microtubule blocker. Verubulin has antitumor activity against breast cancer, melanoma, and ovarian cancer. Verubulin can be used in non-small cell lung cancer research[1][2][3].",C17H17N3O,DMSO : 100 mg/mL (357.99 mM; Need ultrasonic),10mM,Cancer,Phase 2,CC1=NC(N(C2=CC=C(OC)C=C2)C)=C3C=CC=CC3=N1
Rosabulin,STA 5312,501948-05-6,400.45,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,Rosabulin (STA 5312) is a potent and orally active microtubule inhibitor that inhibits microtubule assembly. Rosabulin has broad-spectrum anti-tumor activity[1].,C22H16N4O2S,DMSO : 50 mg/mL (124.86 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(NC1=CC(C)=NS1)C(C2=C3C=CC=CN3C(CC4=CC=C(C#N)C=C4)=C2)=O
Elacytarabine,CP 4055,188181-42-2,507.66,Nucleoside Antimetabolite/Analog,Cell Cycle/DNA Damage,Elacytarabine (CP 4055) is a lipid-conjugated derivative of the nucleoside analog cytarabine. Elacytarabine (CP 4055) is an antineoplastic agent with cytotoxicity in solid tumors.,C27H45N3O6,DMSO : 125 mg/mL (246.23 mM; Need ultrasonic); Ethanol : 4 mg/mL (7.88 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,CCCCCCCC/C=C/CCCCCCCC(OC[C@H]([C@@H](O)[C@@H]1O)O[C@H]1N2C(N=C(N)C=C2)=O)=O
Homoharringtonine,Omacetaxine mepesuccinate; HHT,26833-87-4,545.62,STAT,JAK/STAT Signaling; Stem Cell/Wnt,Homoharringtonine (Omacetaxine mepesuccinate;HHT) is a cytotoxic alkaloid with antitumor properties which acts by inhibiting translation elongation.,C29H39NO9,DMSO : ≥ 50 mg/mL (91.64 mM); H2O : 1.4 mg/mL (2.57 mM; Need ultrasonic),10mM,Cancer,Launched,[H][C@@]12[C@](CCC3)(C=C(OC)[C@]2(OC([C@](CCCC(O)(C)C)(O)CC(OC)=O)=O)[H])N3CCC4=CC5=C(OCO5)C=C14
Cevipabulin,TTI-237,849550-05-6,464.82,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"Cevipabulin (TTI-237) is an oral, microtubule-active antitumor compound and inhibits the binding of [3H] vinblastine to tubulin, with an IC50 of 18-40 nM for cytotoxicity in human tumor cell line[1][2].",C18H18ClF5N6O,DMSO : 100 mg/mL (215.14 mM; Need ultrasonic),10mM,Cancer,Phase 1,C[C@@]([H])(C(F)(F)F)NC1=C(C2=C(F)C=C(OCCCNC)C=C2F)C(Cl)=NC3=NC=NN13
Cevipabulin fumarate,TTI-237 fumarate,849550-67-0,580.89,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"Cevipabulin fumarate (TTI-237 fumarate) is an oral, microtubule-active, antitumor compound and inhibits the binding of [3H]NSC 49842 to tubulin, with an IC50 of 18-40 nM for cytotoxicity in human tumor cell line[1][2].",C22H22ClF5N6O5,H2O : 1.43 mg/mL (2.46 mM; ultrasonic and warming and heat to 60°C); DMSO : 50 mg/mL (86.07 mM; Need ultrasonic),10mM,Cancer,Phase 1,C[C@@H](C(F)(F)F)NC1=C(C2=C(F)C=C(OCCCNC)C=C2F)C(Cl)=NC3=NC=NN13.O=C(O)/C=C/C(O)=O
R1487 (Hydrochloride),,449808-64-4,424.83,Autophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,"R1487 Hydrochloride is a highly potent and selective p38α inhibitor, with Kd values of 0.2 nM and 29 nM for p38α and p38β, respectively[1].",C19H19ClF2N4O3,DMSO : 20.83 mg/mL (49.03 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 1,O=C1C(OC2=CC=C(F)C=C2F)=CC3=CN=C(NC4CCOCC4)N=C3N1C.Cl
Doxorubicin (hydrochloride),Hydroxydaunorubicin (hydrochloride); ADR,25316-40-9,579.98,ADC Payload; AMPK; Antibiotic; Apoptosis; Autophagy; Bacterial; HBV; HIV; Mitophagy; Topoisomerase,Antibody-drug Conjugate/ADC Related; Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR,"Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride; ADR), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy[1][2][3].",C27H30ClNO11,DMSO : 25 mg/mL (43.10 mM; ultrasonic and warming and heat to 60°C); H2O : 50 mg/mL (86.21 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Infection,Launched,COC1=C2C(C(C(C(O)=C(C[C@](C(CO)=O)(O)C[C@@H]3O[C@@]4([H])C[C@H](N)[C@H](O)[C@H](C)O4)C3=C5O)=C5C2=O)=O)=CC=C1.[H]Cl
Zotiraciclib,TG02; SB1317,1204918-72-8,372.46,CDK; FLT3; JAK,Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Zotiraciclib (TG02) is an orally active potent inhibitor of CDK2, JAK2 and FLT3 with IC50 values of 13, 73, and 56 nM, respectively. Zotiraciclib can be used for the research of advanced leukemias and multiple myeloma[1][2].",C23H24N4O,DMSO : 100 mg/mL (268.49 mM; Need ultrasonic),10mM,Cancer,Phase 2,CN1CC2=CC(NC3=NC(C4=CC(OCC/C=C/C1)=CC=C4)=CC=N3)=CC=C2
Icotinib (Hydrochloride),BPI-2009H,1204313-51-8,427.88,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Icotinib Hydrochloride (BPI-2009) is a potent and specific EGFR inhibitor with an IC50 of 5 nM; also inhibits mutant EGFRL858R, EGFRL858R/T790M, EGFRT790M and EGFRL861Q. Icotinib (Hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.",C22H22ClN3O4,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 25 mg/mL (58.43 mM; Need ultrasonic),10mM,Cancer,Launched,C#CC1=CC(NC2=C(C=C(OCCOCCOCCO3)C3=C4)C4=NC=N2)=CC=C1.[H]Cl
Icotinib,BPI-2009,610798-31-7,391.42,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Icotinib (BPI-2009) is a potent and specific EGFR inhibitor with an IC50 of 5 nM; also inhibits mutant EGFRL858R, EGFRL858R/T790M, EGFRT790M and EGFRL861Q. Icotinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.",C22H21N3O4,DMSO : ≥ 155 mg/mL (395.99 mM),10mM,Cancer,Launched,C#CC1=CC(NC2=C(C=C(OCCOCCOCCO3)C3=C4)C4=NC=N2)=CC=C1
Dactolisib (Tosylate),BEZ235 (Tosylate); NVP-BEZ 235 (Tosylate),1028385-32-1,641.74,Autophagy; mTOR; PI3K,Autophagy; PI3K/Akt/mTOR,"Dactolisib Tosylate (BEZ235 Tosylate) is a dual PI3K and mTOR kinase inhibitor with IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.",C37H31N5O4S,H2O : < 0.1 mg/mL (insoluble); DMSO : 34 mg/mL (52.98 mM; Need ultrasonic and warming),10mM,Cancer,Phase 3,CN(C1=C2C3=CC(C4=CC5=CC=CC=C5N=C4)=CC=C3N=C1)C(N2C6=CC=C(C=C6)C(C)(C#N)C)=O.CC7=CC=C(S(=O)(O)=O)C=C7
PF-04691502,,1013101-36-4,425.48,Autophagy; mTOR; PI3K,Autophagy; PI3K/Akt/mTOR,"PF-04691502 is a potent and selective inhibitor of PI3K and mTOR.  PF-04691502 binds to human PI3Kα, β, δ, γ and mTOR with Kis of 1.8, 2.1, 1.6, 1.9 and 16 nM, respectively.",C22H27N5O4,DMSO : 50 mg/mL (117.51 mM; Need ultrasonic),10mM,Cancer,Phase 2,OCCO[C@@H]1CC[C@@H](N2C(N=C(N)N=C3C)=C3C=C(C4=CC=C(OC)N=C4)C2=O)CC1
Buparlisib (Hydrochloride),BKM120 (Hydrochloride); NVP-BKM120 (Hydrochloride),1312445-63-8,446.85,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Buparlisib Hydrochloride (BKM120 Hydrochloride) is a pan-class I PI3K inhibitor, with IC50 of 52 nM/166 nM/116 nM/262 nM for p110α/p110β/p110δ/p110γ, respectively.",C18H22ClF3N6O2,DMSO : ≥ 50 mg/mL (111.89 mM),10mM,Cancer,Phase 3,NC(N=C1)=CC(C(F)(F)F)=C1C2=NC(N3CCOCC3)=NC(N4CCOCC4)=C2.[H]Cl
Ipatasertib,GDC-0068; RG7440,1001264-89-6,458.00,Akt; Apoptosis; Organoid,Apoptosis; PI3K/Akt/mTOR; Stem Cell/Wnt,"Ipatasertib (GDC-0068) is an orally active, highly selective and ATP-competitive pan-Akt inhibitor with IC50 values of 5, 18, 8 nM for Akt1/2/3, respectively. Ipatasertib synchronously activates FoxO3a and NF-κB through inhibition of Akt leading to p53-independent activation of PUMA. Ipatasertib also induces apoptosis in cancer cells and inhibits tumor growth in xenograft mouse models[1][2].",C24H32ClN5O2,H2O : 3.57 mg/mL (7.79 mM; ultrasonic and warming and heat to 60°C); DMSO : 100 mg/mL (218.34 mM; Need ultrasonic),10mM,Cancer,Phase 3,ClC1=CC=C([C@@H](CNC(C)C)C(N2CCN(C3=C([C@H](C)C[C@H]4O)C4=NC=N3)CC2)=O)C=C1
Ipatasertib (dihydrochloride),GDC-0068 (dihydrochloride); RG-7440 (dihydrochloride),1396257-94-5,530.92,Akt; Organoid,PI3K/Akt/mTOR; Stem Cell/Wnt,"Ipatasertib dihydrochloride (GDC-0068 dihydrochloride) is a highly selective and ATP-competitive pan-Akt inhibitor with IC50s of 5, 18 and 8 nM for Akt1, Akt2 and Akt3, respectively.",C24H34Cl3N5O2,H2O : ≥ 41 mg/mL (77.22 mM); DMSO : 100 mg/mL (188.35 mM; Need ultrasonic),10mM,Cancer,Phase 3,ClC1=CC=C([C@@H](CNC(C)C)C(N2CCN(C3=C([C@H](C)C[C@H]4O)C4=NC=N3)CC2)=O)C=C1.[H]Cl.[H]Cl
TAK-285,,871026-44-7,547.96,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"TAK-285 is a potent, selective, ATP-competitive and orally active HER2 and EGFR(HER1) inhibitor with IC50 of 17 nM and 23 nM, respectively. TAK-285 is >10-fold selectivity for HER1/2 than HER4, and less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. TAK-285 has effective antitumor activity[1]. TAK-285 can cross the blood-brain barrier (BBB)[2].",C26H25ClF3N5O3,DMSO : ≥ 50 mg/mL (91.25 mM),10mM,Cancer,Phase 1,ClC(C=C(NC1=NC=NC2=C1N(CCNC(CC(C)(C)O)=O)C=C2)C=C3)=C3OC4=CC=CC(C(F)(F)F)=C4
Ganetespib,STA-9090,888216-25-9,364.40,Apoptosis; HSP,Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,Ganetespib (STA-9090) is a heat shock protein 90 (HSP90) inhibitor which exhibits potent cytotoxicity in a wide variety of hematological and solid tumor cell lines. Ganetespib has antiangiogenic effects in colorectal cancer mediated through inhibition of HIF-1α and STAT3[1][2][3][4][5][6].,C20H20N4O3,DMSO : ≥ 100 mg/mL (274.42 mM),10mM,Cancer,Phase 3,CN1C2=CC=C(N3C(NN=C3C4=CC(C(C)C)=C(O)C=C4O)=O)C=C2C=C1
Zidesamtinib,NVL-520; NUV-520,2739829-00-4,419.45,ROS Kinase,Protein Tyrosine Kinase/RTK,"Zidesamtinib (NVL-520) is a potent, selective, orally active and brain-penetrant inhibitor of diverse ROS1 fusions and resistance mutations, with IC50s of 0.7 and 7.9 nM for wild-type ROS1 and ROS1 G2032R, respectively, and spares TRK inhibition. Zidesamtinib can be used for the research of cancer[1].",C22H22FN7O,DMSO : 50 mg/mL (119.20 mM; ultrasonic and warming and heat to 65°C),10mM,Cancer,Phase 2,CCN1C2=C(C=N1)CC3=NN(C)N=C3C4=CC=C(F)C=C4[C@H](OC5=C(N)N=CC2=C5)C
c-Kit-IN-1,,1225278-16-9,489.47,c-Kit; c-Met/HGFR,Protein Tyrosine Kinase/RTK,c-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with IC50s of <200 nM.,C26H21F2N5O3,DMSO : 100 mg/mL (204.30 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1(CC1)C(NC2=CC=CC=C2)=O)NC3=CC(F)=C(OC4=CC=NC(C5=CN(C)N=C5)=C4)C=C3F
Alpelisib,BYL-719,1217486-61-7,441.47,PI3K,PI3K/Akt/mTOR,"Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC50s of 5/250/290/1200 nM, respectively. Antineoplastic activity[1][2][3].",C19H22F3N5O2S,DMSO : 83.33 mg/mL (188.76 mM; Need ultrasonic),10mM,Cancer,Launched,CC(N=C(S1)NC(N2CCC[C@H]2C(N)=O)=O)=C1C3=CC(C(C)(C(F)(F)F)C)=NC=C3
Alpelisib (hydrochloride),BYL-719 (hydrochloride),1584128-91-5,477.93,PI3K,PI3K/Akt/mTOR,"Alpelisib hydrochloride (BYL-719 hydrochloride) is a potent, orally active, and selective PI3Kα inhibitor with IC50s of 5 nM, 250 nM, 290 nM and 1200 nM for p110α, p110γ, p110δ, and p110β, respectively. Alpelisib hydrochloride (BYL-719 hydrochloride) shows antineoplastic activity[1][2].",C19H23ClF3N5O2S,10 mM in DMSO,10mM,Cancer,Launched,CC(N=C(S1)NC(N2CCC[C@H]2C(N)=O)=O)=C1C3=CC(C(C)(C(F)(F)F)C)=NC=C3.Cl
GSK2636771,,1372540-25-4,433.42,PI3K,PI3K/Akt/mTOR,"GSK2636771 is a potent, selective and orally bioavailable inhibitor of PI3Kβ with a Ki of 0.89 nM and an IC50 of 5.2 nM, showing 900-fold selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms.",C22H22F3N3O3,DMSO : 16.67 mg/mL (38.46 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,CC1=NC2=C(C(O)=O)C=C(C=C2N1CC3=CC=CC(C(F)(F)F)=C3C)N4CCOCC4
Vistusertib,AZD2014,1009298-59-2,462.54,Apoptosis; Autophagy; mTOR,Apoptosis; Autophagy; PI3K/Akt/mTOR,Vistusertib (AZD2014) is an ATP competitive mTOR inhibitor with an IC50 of 2.81 nM. AZD2014 inhibits both mTORC1 and mTORC2 complexes.,C25H30N6O3,DMSO : ≥ 50 mg/mL (108.10 mM),10mM,Cancer,Phase 2,O=C(NC)C1=CC=CC(C2=CC=C3C(N=C(N4[C@@H](C)COCC4)N=C3N5[C@@H](C)COCC5)=N2)=C1
GDC-0349,,1207360-89-1,452.55,Autophagy; mTOR,Autophagy; PI3K/Akt/mTOR,GDC-0349 is a potent and selective ATP-competitive mTOR inhibitor with a Ki of 3.8 nM. GDC-0349 inhibits of both mTORC1 and mTORC2 complexes.,C24H32N6O3,DMSO : ≥ 100 mg/mL (220.97 mM),10mM,Cancer,Phase 1,O=C(NCC)NC(C=C1)=CC=C1C2=NC3=C(CCN(C4COC4)C3)C(N5[C@@H](C)COCC5)=N2
BMS-911543,,1271022-90-2,432.52,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"BMS-911543 is a selective JAK2 inhibitor, with IC50s of 1.1 nM, less selective at JAK1, JAK3 and TYK2 (IC50, 75, 360, 66 nM, respectively).",C23H28N8O,DMSO : 25 mg/mL (57.80 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=CC2=C(N(C)C=N3)C3=C(NC4=NN(C)C(C)=C4)N=C2N1CC)N(C5CC5)C6CC6
Utidelone,Epothilone D; UTD1; KOS 862,189453-10-9,491.68,Antibiotic; Bacterial; Fungal; Microtubule/Tubulin,Anti-infection; Cell Cycle/DNA Damage; Cytoskeleton,Utidelone (Epothilone D) is a potent microtubule stabilizer.,C27H41NO5S,DMSO : ≥ 100 mg/mL (203.38 mM),10mM,Cancer; Infection,Phase 2,O=C1C[C@H](O)C(C)(C)C([C@H](C)[C@@H](O)[C@@H](C)CCC/C(C)=C/C[C@@H](/C(C)=C/C2=CSC(C)=N2)O1)=O
GSK2292767,,1254036-66-2,512.58,PI3K,PI3K/Akt/mTOR,"GSK2292767 is a potent and selective inhibitor of PI3Kδ, with a pIC50 of 10.1. GSK2292767 showing greater than 500-fold selective over the other PI3K isoforms. GSK2292767 can be used for the research of respiratory disease[1].",C24H28N6O5S,DMSO : 125 mg/mL (243.86 mM; ultrasonic and warming and heat to 60°C),10mM,Inflammation/Immunology,Phase 1,CS(=O)(NC1=CC(C2=CC3=C(C(C4=NC=C(CN5C[C@@H](C)O[C@@H](C)C5)O4)=C2)C=NN3)=CN=C1OC)=O
Darizmetinib,HRX-0215,2369583-33-3,457.45,JNK; MDM-2/p53; NF-κB; p38 MAPK,Apoptosis; MAPK/ERK Pathway; NF-κB,"Darizmetinib (HRX-0215) is an orally active, potent and selective inhibitor of mitogen-activated protein kinase kinase 4 (MKK4). Darizmetinib leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration. Darizmetinib is promising for research of preventing liver failure after extensive oncological liver resections or transplantation of small liver grafts[1][2][3].",C21H17F2N5O3S,DMSO : 175 mg/mL (382.56 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(C1=CC=C(C(NS(=O)(CCC)=O)=C1F)F)C2=NNC3=NC=C(C4=CC=NC=C4)C=C32
MAX-10181,PD-1/PD-L1-IN-30,2171558-14-6,527.53,PD-1/PD-L1,Immunology/Inflammation,"MAX-10181 (PD-1/PD-L1-IN-30) is a PD-1/PD-L1 binding inhibitor, with an IC50 value of 0.018 μM. MAX-10181 can be used for research of cancers and other related diseases[1].",C29H28F3NO5,DMSO : 100 mg/mL (189.56 mM; Need ultrasonic),10mM,Cancer,Phase 1,CC1=C(C=CC=C1/C=C/C2=C(C=CC(CNC(CO)(C)C(O)=O)=C2)C(F)(F)F)C3=CC=C(OCCO4)C4=C3
Larotinib,,1438072-11-7,488.94,Btk; EGFR; IRAK,Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,Larotinib is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target with an IC50 of 0.6 nM[1].,C24H26ClFN4O4,DMSO : 125 mg/mL (255.66 mM; Need ultrasonic),10mM,Cancer,Phase 2,COC(C(OCCCN1C[C@]2([H])[C@](OCCO2)([H])C1)=C3)=CC4=C3C(NC5=CC(Cl)=C(C=C5)F)=NC=N4
Larotinib (mesylate hydrate),,2097129-93-4,699.17,Btk; EGFR; IRAK,Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,Larotinib mesylate hydrate is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target with an IC50 of 0.6 nM[1].,C26H36ClFN4O11S2,DMSO : 25 mg/mL (35.76 mM; Need ultrasonic),10mM,Cancer,Phase 2,COC(C(OCCCN1C[C@]2([H])[C@](OCCO2)([H])C1)=C3)=CC4=C3C(NC5=CC(Cl)=C(C=C5)F)=NC=N4.CS(=O)(O)=O.CS(=O)(O)=O.O
WP1066,,857064-38-1,356.22,Apoptosis; JAK; STAT,Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"WP1066 is an inhibitor of JAK2 and STAT3, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3.",C17H14BrN3O,DMSO : ≥ 44 mg/mL (123.52 mM); Ethanol : 16.67 mg/mL (46.80 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(N[C@H](C1=CC=CC=C1)C)/C(C#N)=C/C2=NC(Br)=CC=C2
Baricitinib,LY3009104; INCB028050,1187594-09-7,371.42,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.",C16H17N7O2S,DMSO : 25 mg/mL (67.31 mM; Need ultrasonic and warming),10mM,Inflammation/Immunology,Launched,N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(S(=O)(CC)=O)C1
Baricitinib (phosphate),LY3009104 (phosphate); INCB028050 (phosphate),1187595-84-1,469.41,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable JAK1/JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, respectively.",C16H20N7O6PS,DMSO : 250 mg/mL (532.58 mM; Need ultrasonic),10mM,Inflammation/Immunology,Launched,N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(S(=O)(CC)=O)C1.O=P(O)(O)O
Silevertinib,BDTX-1535; EGFR-IN-76,2607829-38-7,561.05,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"BDTX-1535 (EGFR-IN-76) is an orally available, blood-brain permeable, selective EGFR inhibitor with anti-tumor activity. BDTX-1535 is indicated in a variety of models including non-small cell lung cancer, glioblastoma patient-derived tumors, and intracranial tumors[1][2][3].",C30H30ClFN6O2,DMSO : 100 mg/mL (178.24 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(/C=C/CN1CCOCC1)NC2=CC3=C(N=CN=C3NC4=C(C(Cl)=CC=C4)F)C=C2C#C[C@]56[C@](CN(C6)C)([H])C5
MRT-2359,,2803881-11-8,495.38,Apoptosis,Apoptosis,"MRT-2359 is a potent, orally active and selective GSPT1 depressant (IC50: >30 nM and <300 nM) that specifically induces apoptosis dependent on protein translation. MRT-2359 exhibits significant and preferred anti-proliferative activity in a variety of cancer cell lines, especially MYC-driven cell lines, such as non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) with high expression of N-Myc or L-Myc. MRT-2359 inhibits the growth of drug-resistant NSCLC and SCLC cells, making it suitable for cancer research[1][2][3][4][5].",C22H17F4N3O6,DMSO : 100 mg/mL (201.87 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC(OC(F)(F)F)=CC=C1F)OCC2=CC=C3C(C(N(C4C(NC(CC4)=O)=O)C3)=O)=C2
TNG260,,2935964-98-8,383.44,HDAC,Cell Cycle/DNA Damage; Epigenetics,"TNG260 is a selective, orally effective inhibitor of HDAC1 and CoREST complex, with a 10-fold selectivity for HDAC1 over HDAC3 and a 500-fold selectivity for CoREST complex over NuRD and Sin3 complex. TNG260 reshapes the tumor immune microenvironment, reduces immunosuppressive neutrophil infiltration, promotes effector T cell recruitment, and reverses anti-PD-1 resistance caused by STK11 deficiency by inhibiting the activity of the CoREST-HDAC1 complex. TNG260 induces durable tumor regression in combination with α-PD1 in MC38 tumor-bearing mice with STK11 mutations, and has lower toxicity to bone marrow cells than non-selective HDAC inhibitors[1].",C20H18FN3O2S,DMSO : 2.22 mg/mL (5.79 mM; ultrasonic and warming and heat to 60°C),2mM,Cancer,Phase 2,NC1=CC=C(C2=CC=C(F)C=C2)C=C1NC(C3=CC=C([S@](=O)(C)=N)C=C3)=O
Copanlisib (dihydrochloride),BAY 80-6946 (dihydrochloride),1402152-13-9,553.44,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity[1].",C23H30Cl2N8O4,H2O : 50 mg/mL (90.34 mM; Need ultrasonic); DMSO : 5 mg/mL (9.03 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(C1=CN=C(N)N=C1)NC2=NC3=C(OC)C(OCCCN4CCOCC4)=CC=C3C5=NCCN25.[H]Cl.[H]Cl
Lucitanib,E-3810,1058137-23-7,443.49,FGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Lucitanib (E-3810) is a novel dual inhibitor of VEGFR and FGFR, potently and selectively inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1 and FGFR2 with IC50s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively[1][2][3].",C26H25N3O4,DMSO : ≥ 20.83 mg/mL (46.97 mM),10mM,Cancer,Phase 3,O=C(NC)C1=CC=CC2=C1C=CC(OC3=CC=NC4=CC(OCC5(N)CC5)=C(OC)C=C43)=C2
Capivasertib,AZD5363,1143532-39-1,428.92,Akt; Autophagy,Autophagy; PI3K/Akt/mTOR,"Capivasertib (AZD5363) is an orally active and potent pan-AKT kinase inhibitor with IC50 of 3, 7 and 7 nM for Akt1,Akt2 and Akt3, respectively.",C21H25ClN6O2,DMSO : 125 mg/mL (291.43 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(C1(N)CCN(C2=C3C(NC=C3)=NC=N2)CC1)N[C@H](C4=CC=C(Cl)C=C4)CCO
Triciribine,API-2; NSC 154020; TCN,35943-35-2,320.30,Akt; DNA/RNA Synthesis; HIV,Anti-infection; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"Triciribine is a DNA synthesis inhibitor, also inhibits Akt and HIV-1/2 with IC50 of 130 nM, and 0.02-0.46 μM, respectively.",C13H16N6O4,DMSO : 100 mg/mL (312.21 mM; Need ultrasonic),10mM,Cancer,Phase 2,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N2C3=NC=NC4=C3C(C(N)=NN4C)=C2
Cabazitaxel,XRP6258; RPR-116258A; taxoid XRP6258,183133-96-2,835.93,Autophagy; Microtubule/Tubulin,Autophagy; Cell Cycle/DNA Damage; Cytoskeleton,Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.,C45H57NO14,DMSO : ≥ 100 mg/mL (119.63 mM),10mM,Cancer,Launched,CC1=C([C@@H](OC)C([C@@]2(C)[C@@]3([H])[C@](OC(C)=O)(CO4)[C@H]4C[C@@H]2OC)=O)C(C)(C)[C@@]([C@H]3OC(C5=CC=CC=C5)=O)(O)C[C@@H]1OC([C@H](O)[C@H](C6=CC=CC=C6)NC(OC(C)(C)C)=O)=O
Izorlisib,CH5132799,1007207-67-1,377.42,PI3K,PI3K/Akt/mTOR,"Izorlisib (CH5132799) is a selective class I PI3K inhibitor. Izorlisib inhibits class I PI3Ks, particularly PI3Kα, with an IC50 of 14 nM.",C15H19N7O3S,DMSO : 4.55 mg/mL (12.06 mM; Need ultrasonic),10mM,Cancer,Phase 1,NC1=NC=C(C2=C3C(N(S(=O)(C)=O)CC3)=NC(N4CCOCC4)=N2)C=N1
AG-13958,AG-013958,319460-94-1,467.50,VEGFR,Protein Tyrosine Kinase/RTK,"AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD)[1].",C26H22FN7O,DMSO : 5 mg/mL (10.70 mM; ultrasonic and warming and heat to 60°C),10mM,Cardiovascular Disease,Phase 2,O=C(C1=CC(C)=NN1C)NC2=CC(NC3=CC4=C(C=C3)C(/C=C/C5=NC=CC=C5)=NN4)=CC=C2F
RGB-286638,,784210-87-3,618.55,CDK; GSK-3; JAK; MEK,Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC50s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC50s of  3, 5, 50, and 54 nM.",C29H37Cl2N7O4,H2O : 25 mg/mL (40.42 mM; Need ultrasonic); DMSO : ≥ 150 mg/mL (242.50 mM),10mM,Cancer,Phase 1,O=C(NN1CCOCC1)NC2=CC=CC(C3=C4C(C5=CC=C(CN6CCN(CCOC)CC6)C=C5)=NN3)=C2C4=O.[H]Cl.[H]Cl
RGB-286638 (free base),,784210-88-4,545.63,CDK; GSK-3; JAK; MEK,Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC50s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC50s of  3, 5, 50, and 54 nM.",C29H35N7O4,DMSO : 2.6 mg/mL (4.77 mM; Need ultrasonic); Ethanol : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),2mM,Cancer,Phase 1,O=C(NN1CCOCC1)NC2=CC=CC(C3=C4C(C5=CC=C(CN6CCN(CCOC)CC6)C=C5)=NN3)=C2C4=O
RWJ-67657,JNJ 3026582,215303-72-3,425.50,p38 MAPK,MAPK/ERK Pathway,"RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity[1].",C27H24FN3O,DMSO : 125 mg/mL (293.77 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Inflammation/Immunology; Cardiovascular Disease,Phase 1,OCCC#CC1=NC(C2=CC=C(F)C=C2)=C(C3=CC=NC=C3)N1CCCC4=CC=CC=C4
TAK-593,,1005780-62-0,445.47,PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"TAK-593 is a potent VEGFR and PDGFR family inhibitor with IC50s of 3.2, 0.95, 1.1, 4.3 and 13 nM for VEGFR1, VEGFR2, VEGFR3, PDFGRα and PDFGRβ, respectively.",C23H23N7O3,DMSO : ≥ 48.5 mg/mL (108.87 mM),10mM,Cancer,Phase 1,O=C(C1=CC(C)=NN1C)NC2=CC(OC3=NN4C(C=C3)=NC(NC(C5CC5)=O)=C4)=CC=C2C
Semapimod (tetrahydrochloride),CNI-1493; CPSI-2364 (tetrahydrochloride),164301-51-3,890.74,Interleukin Related; p38 MAPK; TNF Receptor,Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway,"Semapimod tetrahydrochloride (CNI-1493), an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6. Semapimod tetrahydrochloride inhibits TLR4 signaling (IC50≈0.3 μM). Semapimod tetrahydrochloride inhibits p38 MAPK and nitric oxide production in macrophages. Semapimod tetrahydrochloride has potential in a variety of inflammatory and autoimmune disorders[1][2][3].",C34H56Cl4N18O2,H2O : 2.17 mg/mL (2.44 mM; ultrasonic and warming and heat to 60°C),2mM,Cancer; Inflammation/Immunology,Phase 2,O=C(NC1=CC(/C(C)=N/NC(N)=N)=CC(/C(C)=N/NC(N)=N)=C1)CCCCCCCCC(NC2=CC(/C(C)=N/NC(N)=N)=CC(/C(C)=N/NC(N)=N)=C2)=O.Cl.Cl.Cl.Cl
Merestinib,LY2801653,1206799-15-6,552.53,c-Met/HGFR; Discoidin Domain Receptor; FLT3; ROS Kinase,Protein Tyrosine Kinase/RTK,"Merestinib (LY2801653) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib (LY2801653) also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM)[1][2].",C30H22F2N6O3,DMSO : ≥ 32 mg/mL (57.92 mM),10mM,Cancer,Phase 2,O=C(C1=CC=C(C)N(C2=CC=C(F)C=C2)C1=O)NC3=CC=C(OC4=CC5=C(N(C)N=C5)C=C4C6=CNN=C6)C(F)=C3
Merestinib dihydrochloride,LY2801653 (dihydrochloride),1206801-37-7,625.45,c-Met/HGFR; Discoidin Domain Receptor; FLT3; ROS Kinase,Protein Tyrosine Kinase/RTK,"Merestinib dihydrochloride (LY2801653 dihydrochloride) is a potent, orally bioavailable c-Met inhibitor (Ki=2 nM) with anti-tumor activities. Merestinib dihydrochloride also has potent activity against MST1R (IC50=11 nM), FLT3 (IC50=7 nM), AXL (IC50=2 nM), MERTK (IC50=10 nM), TEK (IC50=63 nM), ROS1, DDR1/2 (IC50=0.1/7 nM) and MKNK1/2 (IC50=7 nM)[1][2].",C30H24Cl2F2N6O3,DMSO : ≥ 100 mg/mL (159.88 mM),10mM,Cancer,Phase 2,[H]Cl.[H]Cl.O=C(C1=CC=C(C)N(C2=CC=C(F)C=C2)C1=O)NC3=CC=C(OC4=CC5=C(N(C)N=C5)C=C4C6=CNN=C6)C(F)=C3
APG-2449,,2196186-84-0,640.24,Anaplastic lymphoma kinase (ALK); Apoptosis; FAK; ROS Kinase,Apoptosis; Protein Tyrosine Kinase/RTK,"APG-2449 is an orally active inhibitor for BCL-2 and multikinase (ALK/FAK/ROS1) with potent antitumor activities. APG-2449 reduces cell viability and enhances apoptosis in acute myeloid leukemia cells in vitro. APG-2449 decreases activation of FAK and its downstream effectors. APG-2449 can be studied in research for mesothelioma tumor, non-small cell lung cancer, ovarian cancer, hematologic and solid malignancies[1][2][3][4].",C33H42ClN5O4S,DMSO : 25 mg/mL (39.05 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=S(C1=C(NC2=NC(NC3=CC(C)=C(C4=CCN(C5CCOCC5)CC4)C=C3OC(C)C)=NC=C2Cl)C=CC=C1)(C(C)C)=O
Podofilox,Podophyllotoxin,518-28-5,414.41,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,Podofilox (Podophyllotoxin) is a potent inhibitor of microtubule assembly and DNA topoisomerase II.,C22H22O8,DMSO : 100 mg/mL (241.31 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1OC[C@]2([H])[C@@H](O)C3=C(C=C4OCOC4=C3)[C@@H](C5=CC(OC)=C(OC)C(OC)=C5)[C@]21[H]
Taltobulin,HTI-286; SPA-110,228266-40-8,473.65,ADC Payload; Apoptosis; Microtubule/Tubulin,Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,"Taltobulin (HTI-286), a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Taltobulin inhibits the polymerization of purified tubulin, disrupts microtubule organization in cells, and induces mitotic arrest, as well as apoptosis[1].",C27H43N3O4,DMSO : ≥ 100 mg/mL (211.13 mM),10mM,Cancer,Phase 1,CC(C)(C)[C@H](NC([C@H](C(C)(C1=CC=CC=C1)C)NC)=O)C(N([C@@H](C(C)C)/C=C(C(O)=O)\C)C)=O
Ceritinib,LDK378,1032900-25-6,558.14,Anaplastic lymphoma kinase (ALK); IGF-1R; Insulin Receptor,Protein Tyrosine Kinase/RTK,"Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib (LDK378) also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib (LDK378) shows great antitumor potency[1][2].",C28H36ClN5O3S,DMSO : 12.5 mg/mL (22.40 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Endocrinology,Launched,CC(C)OC1=CC(C2CCNCC2)=C(C)C=C1NC3=NC=C(Cl)C(NC4=CC=CC=C4S(=O)(C(C)C)=O)=N3
Irpagratinib,ABSK011,2230974-62-4,570.59,FGFR,Protein Tyrosine Kinase/RTK,"Irpagratinib (ABSK011) is an orally active FGFR4 inhibitor (IC50<10 nM). Irpagratinib inhibits FGFR4 autophosphorylation and blocks signaling from FGFR4 to downstream pathway activation. Irpagratinib has shown high exposure in PK studies in mice, rats, and dogs, and also demonstrated antitumor activity in a subcutaneous xenograft tumor model[1][2].",C28H32F2N6O5,DMSO : 100 mg/mL (175.26 mM; Need ultrasonic),10mM,Cancer,Phase 2,FC(C(OC)=CC(OC)=C1F)=C1C2=CC(C=N3)=C(C(N4CC(C)(C4)OC)=N2)N=C3N[C@H]5[C@H](CCOC5)NC(C=C)=O
Nedometinib,NFX-179,2252314-46-6,470.24,MEK; p38 MAPK; PERK,Cell Cycle/DNA Damage; MAPK/ERK Pathway,"Nedometinib (NFX-179) is a specific MEK1 inhibitor with an IC50 of 135 nM. Nedometinib inhibits p-ERK, MAPK. Nedometinib exerts anticancer activity against squamous cell carcinoma. Nedometinib can be used for research in dermatosis, neurofibromatosis[1][2].",C17H16FIN4O3,DMSO : 100 mg/mL (212.66 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=C(NC2=CC=C(C=C2F)I)N(C)C3=C1C=CC=N3)NOCCO
Vorbipiprant,CR6086,1417742-86-9,472.50,Interleukin Related; MMP; PD-1/PD-L1; Prostaglandin Receptor,GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease,"Vorbipiprant (CR6086) is an orally active EP4 receptor antagonist with high selectivity for the human EP4 receptor (Ki: 16.6 nM). Vorbipiprant has immunomodulatory, anti-inflammatory, antitumor, and anti-angiogenic activities. Vorbipiprant can inhibit the expression of multiple pro-inflammatory cytokines and the activation of immune cells, and convert ""cold"" tumors unresponsive to immune checkpoint inhibitors into ""hot"" tumors. Vorbipiprant is used in the research of diseases such as rheumatoid arthritis and colon cancer[1][2].",C26H27F3N2O3,DMSO : 200 mg/mL (423.28 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Cardiovascular Disease,Phase 2,O=C(C1=CC=C(C2(CC2)NC(C3N(CCC4(C3)CC4)CC5=CC=C(C(F)(F)F)C=C5)=O)C=C1)O
Tersolisib,STX-478,2883540-92-7,401.29,PI3K,PI3K/Akt/mTOR,STX-478 (compound 80) is an oral CNS-penetrant allosteric mutant-selective PI3Kα inhibitor. STX-478 shows robust and durable tumor regression and can be used in cancer research[1].,C16H12F5N5O2,DMSO : 100 mg/mL (249.20 mM; Need ultrasonic),10mM,Cancer,Phase 2,NC1=NC=C(C=N1)NC(N[C@H](C2=C(C3=CC(F)=CC(F)=C3O2)C)C(F)(F)F)=O
Zoldonrasib,RMC-9805; KRAS G12D inhibitor 18,2922732-54-3,1168.44,Apoptosis; Ras,Apoptosis; GPCR/G Protein; MAPK/ERK Pathway,Zoldonrasib (RMC-9805) is a potent and orally active KRAS G12D inhibitor.Zoldonrasib induces apoptosis in KRAS G12D mutant cancer cells. Zoldonrasib has the potential for the research of KRAS G12D mutant cancer[1][2].,C63H88F3N11O7,DMSO : 100 mg/mL (85.58 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C([C@H]1NN(C([C@@H](NC([C@@H](N2C[C@]3(CN(C([C@@H]4N(C)[C@@H]4C5CC5)=O)CC3)CC2)C6CCCC6)=O)C[C@H]7CN8CCO7)=O)CCC1)OCC(C)(C)CC9=[C@@]([C@@]%10=C([C@@H](OC)C)N=CC(N%11CCN(C%12CC%12)CC%11)=C%10)N(CC(F)(F)F)C%13=C9C=C8C=C%13
Cadefrecitinib,GLPG3667,2308520-97-8,443.46,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Cadefrecitinib (GLPG3667) is a reversible, ATP-competitive and orally active TYK2 inhibitor with an IC50 of 2.3 nM. Cadefrecitinib inhibits IFNα/pSTAT1, and the IC50 values ??in human peripheral blood mononuclear cell (PBMC) and whole blood assays are 70 nM and 623 nM, respectively. Cadefrecitinib has the potential for the study of inflammatory and autoimmune diseases[1].",C22H21N9O2,DMSO : 50 mg/mL (112.75 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 2,N#CC1=NC=C(C(C)=C1)OC2=CC(NC3=NN=C(N4CCOCC4)C=C3)=C(N=CN5C)C5=N2
STX-721,,2765525-82-2,587.11,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,STX-721 is a mutant-selective inhibitor of EGFR and HER2 Exon 20 insertion (ex20ins) mutants[1].,C32H35ClN6O3,DMSO : 100 mg/mL (170.33 mM; Need ultrasonic),10mM,Others,Phase 2,O=C(N1CCC[C@]1(C)C#CC2=C(C=CN=C2)C3=C(C4=C(N3)CCNC4=O)NC5=CC=CC(Cl)=C5OC)/C=C/CN(C)C
Afuresertib,GSK2110183; LAE002,1047644-62-1,427.32,Akt; PKC; ROCK,Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad,"Afuresertib (GSK2110183) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3, respectively[1][2].",C18H17Cl2FN4OS,DMSO : 100 mg/mL (234.02 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(C1=CC(C2=C(Cl)C=NN2C)=C(Cl)S1)N[C@@H](CC3=CC=CC(F)=C3)CN
Afuresertib (hydrochloride),GSK2110183 (hydrochloride); LAE002 (hydrochloride),1047645-82-8,463.78,Akt; PKC; ROCK,Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad,"Afuresertib hydrochloride (GSK 2110183 hydrochloride) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with Kis of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively[1][2].",C18H18Cl3FN4OS,H2O : 12.5 mg/mL (26.95 mM; Need ultrasonic); DMSO : 250 mg/mL (539.05 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(C1=CC(C2=C(Cl)C=NN2C)=C(Cl)S1)N[C@@H](CC3=CC=CC(F)=C3)CN.[H]Cl
Radotinib,IY-5511,926037-48-1,530.50,Apoptosis; Bcr-Abl; JAK; Prion Protein; STAT,Apoptosis; Epigenetics; JAK/STAT Signaling; Neuronal Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases[1][2][3].",C27H21F3N8O,DMSO : 6.25 mg/mL (11.78 mM; Need ultrasonic),10mM,Cancer; Infection; Neurological Disease,Launched,O=C(NC1=CC(C(F)(F)F)=CC(N2C=C(C)N=C2)=C1)C3=CC=C(C)C(NC4=NC=CC(C5=NC=CN=C5)=N4)=C3
Rociletinib,CO-1686; AVL-301; CNX-419,1374640-70-6,555.55,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Rociletinib (CO-1686) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.",C27H28F3N7O3,DMSO : 125 mg/mL (225.00 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,C=CC(NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(C)=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1)=O
Rociletinib hydrobromide,CO-1686 (hydrobromide); AVL-301 hydrobromide; CNX-419 hydrobromide,1446700-26-0,636.46,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.",C27H29BrF3N7O3,DMSO : ≥ 59 mg/mL (92.70 mM); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Phase 3,C=CC(NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(C)=O)CC4)C=C3OC)=NC=C2C(F)(F)F)=C1)=O.[H]Br
Poziotinib,HM781-36B; NOV120101,1092364-38-9,491.34,Apoptosis; EGFR,Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Poziotinib (HM781-36B) is an orally active, irreversible pan-HER inhibitor, which effectively inhibits EGFRwt, HER-2 and HER-4 with IC50s of 3.2, 5.3 and 23.5 nM, respectively. Poziotinib (HM781-36B) also shows excellent inhibitory activities against mutated EGFRs, including EGFRT790M and EGFRL858R/T790M, with IC50s of 4.2 and 2.2 nM, respectively. Excellent antitumor activity[1][2].",C23H21Cl2FN4O3,DMSO : 50 mg/mL (101.76 mM; Need ultrasonic),10mM,Cancer,Phase 3,C=CC(N1CCC(OC2=CC3=C(NC4=CC=C(Cl)C(Cl)=C4F)N=CN=C3C=C2OC)CC1)=O
Osimertinib,AZD-9291; Mereletinib,1421373-65-0,499.61,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[1].",C28H33N7O2,DMSO : 100 mg/mL (200.16 mM; Need ultrasonic),10mM,Cancer,Launched,C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C)=O
Osimertinib (mesylate),AZD-9291 (mesylate); Mereletinib (mesylate),1421373-66-1,595.71,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[1].",C29H37N7O5S,DMSO : 11.67 mg/mL (19.59 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C)=O.CS(=O)(O)=O
SAR-260301,,1260612-13-2,354.40,PI3K,PI3K/Akt/mTOR,SAR-260301 is an orally available and selective PI3Kβ inhibitor with an IC50 of 23 nM[1][2].,C19H22N4O3,DMSO : 100 mg/mL (282.17 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C1N=C(CC(N2[C@@H](C)CC3=C2C=CC=C3)=O)NC(N4CCOCC4)=C1
Flupentixol (dihydrochloride),Flupenthixol (dihydrochloride),2413-38-9,507.44,Apoptosis; Dopamine Receptor; PI3K,Apoptosis; GPCR/G Protein; Neuronal Signaling; PI3K/Akt/mTOR,"Flupentixol is an orally active D1/D2 dopamine receptor antagonist and new PI3K inhibitor (PI3Kα IC50=127 nM). Flupentixol shows anti-proliferative activity to cancer cells and induces apoptosis. Flupentixol can also be used in schizophrenia, anxiolytic and depressive research[1][2][3].",C23H27Cl2F3N2OS,H2O : 100 mg/mL (197.07 mM; Need ultrasonic); DMSO : 33.33 mg/mL (65.68 mM; Need ultrasonic),10mM,Cancer; Neurological Disease,Launched,OCCN1CCN(CC/C=C2C3=C(SC4=C/2C=CC=C4)C=CC(C(F)(F)F)=C3)CC1.[H]Cl.[H]Cl
Voxtalisib,XL765; SAR245409,934493-76-2,270.29,mTOR; PI3K,PI3K/Akt/mTOR,"Voxtalisib (XL765) is a potent PI3K inhibitor, which has a similar activity toward class I PI3K (IC50s=39, 113, 9 and 43 nM for p110α, p110β, p110γ and p110δ, respectively), also inhibits DNA-PK (IC50=150 nM) and mTOR (IC50=157 nM). Voxtalisib (XL765) inhibits mTORC1 and mTORC2 with IC50s of 160 and 910 nM, respectively.",C13H14N6O,DMSO : 10 mg/mL (37.00 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1C(C2=NNC=C2)=CC3=C(C)N=C(N)N=C3N1CC
5-BrdU,BrdU; 5-Bromo-2'-deoxyuridine; BUdR,59-14-3,307.10,DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog,Cell Cycle/DNA Damage,5-BrdU (BrdU) is a nucleoside analog that competes with thymidine for incorporation into DNA. 5-BrdU is commonly used in the detection of proliferating cells.,C9H11BrN2O5,H2O : 2 mg/mL (6.51 mM; ultrasonic and warming and heat to 60°C); DMSO : 250 mg/mL (814.07 mM; Need ultrasonic),10mM,Cancer,Phase 2,O[C@H]1C[C@H](N2C(NC(C(Br)=C2)=O)=O)O[C@@H]1CO
HRS-4642,,2836263-09-1,632.68,Ras,GPCR/G Protein; MAPK/ERK Pathway,HRS-4642 is a selective KRAS(G12D) inhibitor (Kd=0.083 nM) with anti-cancer activity. HRS-4642 synergizes with Carfilzomib (HY-10455) and exhibits significant in vivo potency to reshape the tumor microenvironment into an immune-activating microenvironment.,C34H35F3N6O3,DMSO : ≥ 100 mg/mL (158.06 mM),10mM,Cancer,Phase 2,OC(C=C1C2=C(F)C(N=C(OC[C@@]3(CCC4)N4C[C@H](F)C3)N=C5N(C[C@@H]6N[C@H]7CC6)[C@@H]7CO8)=C5C8=N2)=CC9=C1C(CC)=C(F)C=C9
Savolitinib,Volitinib; HMPL-504; AZD-6094,1313725-88-0,345.36,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable c-Met inhibitor with IC50 s of 5 nM and 3 nM for c-Met and p-Met, respectively. Savolitinib (AZD-6094) selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. Antineoplastic activity[1][2].",C17H15N9,DMSO : ≥ 20.83 mg/mL (60.31 mM),10mM,Cancer,Launched,CN1N=CC(C2=CN=C3C(N([C@H](C4=CN5C(C=C4)=NC=C5)C)N=N3)=N2)=C1
Uprosertib,GSK2141795,1047634-65-0,429.25,Akt,PI3K/Akt/mTOR,"Uprosertib (GSK2141795) is a potent and selective pan-Akt inhibitor with IC50 values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.",C18H16Cl2F2N4O2,DMSO : 50 mg/mL (116.48 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=CC(C2=C(Cl)C=NN2C)=C(Cl)O1)N[C@@H](CC3=CC=C(F)C(F)=C3)CN
Cerdulatinib,PRT062070; PRT2070,1198300-79-6,445.54,JAK; Syk,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Cerdulatinib (PRT062070) is a selective Tyk2 inhibitor with an IC50 of 0.5 nM. Cerdulatinib (PRT062070) also is a dual JAK and SYK inhibitor with IC50s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively.",C20H27N7O3S,DMSO : ≥ 30 mg/mL (67.33 mM),10mM,Cancer,Phase 3,O=S(N(CC1)CCN1C2=CC=C(NC3=NC=C(C(N)=O)C(NC4CC4)=N3)C=C2)(CC)=O
Cerdulatinib (hydrochloride),PRT062070 (hydrochloride); PRT2070 (hydrochloride),1369761-01-2,482.00,JAK; Syk,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC50s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies[1][2].",C20H28ClN7O3S,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 20 mg/mL (41.49 mM; ultrasonic and warming and heat to 80°C),10mM,Cancer,Phase 3,O=S(N(CC1)CCN1C2=CC=C(NC3=NC=C(C(N)=O)C(NC4CC4)=N3)C=C2)(CC)=O.Cl
Ilorasertib,ABT-348,1227939-82-3,488.54,Aurora Kinase; PDGFR; VEGFR,Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK,"Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)[1][2].",C25H21FN6O2S,DMSO : 41.67 mg/mL (85.29 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC=CC(F)=C1)NC2=CC=C(C3=CSC4=C3C(N)=NC=C4C5=CN(CCO)N=C5)C=C2
Ilorasertib (hydrochloride),ABT-348 (hydrochloride),1847485-91-9,525.00,Aurora Kinase; PDGFR; VEGFR,Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK,"Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)[1][2].",C25H22ClFN6O2S,DMSO : 41.67 mg/mL (79.37 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC=CC(F)=C1)NC2=CC=C(C3=CSC4=C3C(N)=NC=C4C5=CN(CCO)N=C5)C=C2.[H]Cl
AC-430 (hydrobromide),,1359828-49-1,430.27,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,AC-430 hydrobromide (example 1) is a potent JAK2 inhibitor. AC-430 hydrobromide can be used for the research of myeloproliferative disorders and cancer[1].,C19H17BrFN5O,DMSO : 50 mg/mL (116.21 mM; Need ultrasonic),10mM,Cancer,Phase 1,FC1=CC=C(C(C2=NC(NC3=NNC(C)=C3)=C4C=CC=CC4=N2)O)C=C1.Br
EOC317,ACTB-1003,939805-30-8,591.53,FGFR; VEGFR,Protein Tyrosine Kinase/RTK,"EOC317 (ACTB-1003) is an oral kinase inhibitor with IC50s of 6, 2 and 4 nM for FGFR1, VEGFR2 and Tie-2.",C27H26F5N7O3,DMSO : 25 mg/mL (42.26 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(NC1=CC(C(F)(F)F)=CC=C1F)NC2=CC=C(C3=C4C(N)=NC=NN4C(CN5CCOCC5)=C3COC)C=C2F
Tucatinib,Irbinitinib; ARRY-380; ONT-380,937263-43-9,480.52,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Tucatinib (Irbinitinib) is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM.",C26H24N8O2,DMSO : 41.67 mg/mL (86.72 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC5=CC6=NC=NN6C=C5
Tucatinib (hemiethanolate),Irbinitinib (hemiethanolate); ARRY-380 (hemiethanolate); ONT-380 (hemiethanolate),1429755-56-5,503.57,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM.",C26H24N8O2.1/2C2H6O,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 125 mg/mL (248.23 mM; Need ultrasonic),10mM,Cancer,Launched,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC5=CC6=NC=NN6C=C5.CCO
AT13148,,1056901-62-2,313.78,Akt; PKA; Ribosomal S6 Kinase (RSK); ROCK,Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad,"AT13148 is an orally active and ATP-competitive, multi-AGC kinase inhibitor with IC50s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.",C17H16ClN3O,DMSO : 50 mg/mL (159.35 mM; Need ultrasonic),10mM,Cancer,Phase 1,ClC1=CC=C([C@](C2=CC=C(C3=CNN=C3)C=C2)(O)CN)C=C1
BNT411,,2296821-50-4,439.55,Toll-like Receptor (TLR),Immunology/Inflammation,"BNT411 is a selective TLR7 agonist that can induce the release of IFNa both in vivo and in vitro. BNT411 has anticancer activity and can be used in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC)[1].",C24H33N5O3,DMSO : 10 mg/mL (22.75 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=C(C)N(C1CCOCC1)CCCCN2C(CCOC)=NC3=C2C4=C(C=CC=C4)N=C3N
GDC-3280,AK3287; AKEX0011,1590403-33-0,389.33,ASK1; p38 MAPK,Apoptosis; MAPK/ERK Pathway,GDC-3280 (AK3287; AKEX0011) is an orally active compound based on Pirfenidone (HY-B0673)'s phenyl pyridone scaffold. GDC-3280 alleviates the inflammatory and fibrotic reaction of silicosis by inhibiting the ASK1-p38 MAPK pathway and regulating macrophage polarization. GDC-3280 exhibits anti-inflammatory and anti-fibrotic effects[1].,C18H14F3N5O2,DMSO : 31.25 mg/mL (80.27 mM; ultrasonic and warming and heat to 60°C),10mM,Inflammation/Immunology,Phase 1,O=C1C2=C(C(C3=CN(C)N=C3)=CN1C4=CC=C(C=C4)OC(F)(F)F)N(C)C=N2
SYHA1813,,1807466-30-3,410.44,c-Fms; VEGFR,Protein Tyrosine Kinase/RTK,SYHA1813 is a dual inhibitor of CSF1R and VEGFR. SYHA1813 has potent antitumor activity against GBM[1].,C25H19FN4O,DMSO : 100 mg/mL (243.64 mM; Need ultrasonic),10mM,Cancer,Phase 2,NC1=NNC2=C1C(C3=CC=C4C(C=CC=C4C(NC5=CC=C(F)C(C)=C5)=O)=C3)=CC=C2
BNC105,,945771-74-4,372.37,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,BNC105 is a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.,C20H20O7,DMSO : 25 mg/mL (67.14 mM; Need ultrasonic),10mM,Cancer,Phase 2,COC1=CC(C(C2=C(C)OC3=C(O)C(OC)=CC=C23)=O)=CC(OC)=C1OC
Carboxyamidotriazole,L-651582; CAI,99519-84-3,424.67,Calcium Channel; NF-κB; NO Synthase; p38 MAPK,Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Neuronal Signaling; NF-κB,"Carboxyamidotriazole (L-651582) is an orally active cytostatic inhibitor of nonvoltage-operated calcium channels and calcium channel-mediated signaling pathways. Carboxyamidotriazole inhibits NF-κB, MAPK activation and NO production. Carboxyamidotriazole has anti-angiogenic and anti-inflammatory activities. Carboxyamidotriazole has anticancer activity against liver cancer, lung cancer and leukemia[1][2][3][4][5][6][7][8][9][10][11][12][13].",C17H12Cl3N5O2,DMSO : 100 mg/mL (235.48 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Cardiovascular Disease,Phase 3,O=C(C1=C(N)N(CC2=CC(Cl)=C(C(C3=CC=C(Cl)C=C3)=O)C(Cl)=C2)N=N1)N
Cilengitide,EMD 121974,188968-51-6,588.66,Apoptosis; Autophagy; Integrin; PD-1/PD-L1; STAT,Apoptosis; Autophagy; Cytoskeleton; Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt,"Cilengitide (EMD 121974) is a potent integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers[1][2][3].",C27H40N8O7,DMSO : ≥ 44 mg/mL (74.75 mM); H2O : 40 mg/mL (67.95 mM; adjust pH to 1 with 1 M HCL),10mM,Cancer,Phase 3,O=C(NCC(N[C@H](C(N[C@H](CC1=CC=CC=C1)C(N([C@H]2C(C)C)C)=O)=O)CC(O)=O)=O)[C@H](CCCNC(N)=N)NC2=O
Ethynylcytidine,ECyD; TAS-106; 3'-C-Ethynylcytidine,180300-43-0,267.24,DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog,Cell Cycle/DNA Damage,"Ethynylcytidine (ECyD), a nucleoside analog and a potent inhibitor of RNA synthesis, inhibits RNA polymerases I, II and II. Ethynylcytidine has robust antitumor activity in a wide range of models of cancer[1][2][3]. Ethynylcytidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.",C11H13N3O5,DMSO : 250 mg/mL (935.49 mM; Need ultrasonic),10mM,Cancer,Phase 2,OC[C@@H]1[C@](O)(C#C)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1
Forodesine (hydrochloride),BCX-1777 (hydrochloride); Immucillin-H (hydrochloride),284490-13-7,302.71,Apoptosis; Nucleoside Antimetabolite/Analog,Apoptosis; Cell Cycle/DNA Damage,"Forodesine hydrochloride (BCX-1777 hydrochloride) is a highly potent and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC50 values ranging from 0.48 to 1.57 nM for human, mouse, rat, monkey and dog PNP. Forodesine hydrochloride is a potent human lymphocyte proliferation inhibitor. Forodesine hydrochloride could induce apoptosis in leukemic cells by increasing the dGTP levels[1][2].",C11H15ClN4O4,H2O : 100 mg/mL (330.34 mM; Need ultrasonic); DMSO : 10 mg/mL (33.03 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1C(NC=C2[C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)=C2NC=N1.Cl
Forodesine,BCX-1777; Immucillin-H,209799-67-7,266.25,Apoptosis; Nucleoside Antimetabolite/Analog,Apoptosis; Cell Cycle/DNA Damage,"Forodesine (BCX-1777) is a highly potent and orally active purine nucleoside phosphorylase (PNP) inhibitor with IC50 values ranging from 0.48 to 1.57 nM for human, mouse, rat, monkey and dog PNP. Forodesine is a potent human lymphocyte proliferation inhibitor. Forodesine could induce apoptosis in leukemic cells by increasing the dGTP levels[1][2].",C11H14N4O4,DMSO : 100 mg/mL (375.59 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1C(NC=C2[C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)=C2NC=N1
Genz-644282,,529488-28-6,407.42,Topoisomerase,Cell Cycle/DNA Damage,"Genz-644282 is a non-camptothecin topoisomerase I inhibitor, used for cancer research.",C22H21N3O5,DMSO : 3.64 mg/mL (8.93 mM; ultrasonic and warming and heat to 75°C),2mM,Cancer,Phase 1,O=C1N(CCNC)C2=C(C=NC(C2=C3)=CC4=C3OCO4)C5=CC(OC)=C(OC)C=C15
JI-101,,900573-88-8,466.33,Ephrin Receptor; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"JI-101 is an orally available multi-kinase inhibitor of VEGFR2, PDGFRβ and EphB4 with potent anti-cancer activity.",C22H20BrN5O2,DMSO : ≥ 100 mg/mL (214.44 mM),10mM,Cardiovascular Disease; Cancer,Phase 2,O=C(NC1=CC(Br)=CC=C1OC)NC2=CC=CC3=C2C=CN3CC4=CC(N)=NC=C4
BOLD-100,NKP-1339; IT-139; KP-1339,197723-00-5,502.14,Apoptosis; DNA/RNA Synthesis,Apoptosis; Cell Cycle/DNA Damage,"BOLD-100 (NKP-1339; IT-139) is the first-in-class ruthenium-based anticancer agent in development against solid cancer with limited side effects. BOLD-100 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. BOLD-100 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu[1].",C14H12Cl4N4NaRu,DMSO : ≥ 59 mg/mL (117.50 mM),10mM,Cancer,Phase 2,[Cl-][Ru+3]([Cl-])([Cl-])([N]1=CC2=C(N1)C=CC=C2)([N]3=CC4=C(N3)C=CC=C4)[Cl-].[Na+]
Pacritinib,SB1518,937272-79-2,472.58,FLT3; JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,Pacritinib (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM).,C28H32N4O3,DMSO : 10 mg/mL (21.16 mM; ultrasonic and warming and heat to 60°C); 0.1 M HCl : 2 mg/mL (4.23 mM; Need ultrasonic); 1 M HCl : ≥ 100 mg/mL (211.60 mM),10mM,Cancer,Launched,C1(COC/C=C/COCC2=C(OCCN3CCCC3)C=CC4=C2)=CC=CC(C5=N/C(NC=C5)=N\4)=C1
Pacritinib (citrate),SB1518 (citrate),1228923-42-9,664.70,FLT3; JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,Pacritinib (SB1518) citrate is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib citrate also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM). Pacritinib citrate can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF)[1][2][3].,C34H40N4O10,DMSO : 30 mg/mL (45.13 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,OC(CC(CC(O)=O)(C(O)=O)O)=O.C1(COC/C=C/COCC2=C(OCCN3CCCC3)C=CC4=C2)=CC=CC(C5=N/C(NC=C5)=N\4)=C1
Phenformin (hydrochloride),Phenethylbiguanide hydrochloride,834-28-6,241.72,AMPK; Autophagy,Autophagy; Epigenetics; PI3K/Akt/mTOR,"Phenformin hydrochloride is an anti-diabetic agent from the biguanide class, can activate AMPK activity.",C10H16ClN5,DMSO : 10 mg/mL (41.37 mM; Need ultrasonic); H2O : 12.5 mg/mL (51.71 mM; Need ultrasonic),10mM,Cancer,Launched,NC(NC(NCCC1=CC=CC=C1)=N)=N.Cl
Pipobroman,,54-91-1,356.05,DNA Alkylator/Crosslinker; DNA/RNA Synthesis,Cell Cycle/DNA Damage,"Pipobroman is a bromide derivative of piperazine and acts as an alkylating agent. Pipobroman plays its role by inhibiting DNA and RNA polymerase or by reducing pyrimidine nucleotide incorporation into DNA. Pipobroman can be used for the cancer research, including polycythemia vera, myeloproliferative neoplasm, and AML et.al[1].",C10H16Br2N2O2,DMSO : ≥ 36 mg/mL (101.11 mM),10mM,Cancer,Launched,O=C(N1CCN(C(CCBr)=O)CC1)CCBr
PR-104,,851627-62-8,579.27,DNA Alkylator/Crosslinker,Cell Cycle/DNA Damage,"PR-104 is a selective hypoxia-activated DNA cross-linking agent and can be used for the research of multiple tumor xenograft models. PR-104, as a nitrogen mustard pre-proagent, is converted efficiently to the more lipophilic dinitrobenzamide mustards alcohol PR-104A[1].",C14H20BrN4O12PS,DMSO : 100 mg/mL (172.63 mM; Need ultrasonic); H2O : 31.25 mg/mL (53.95 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,O=C(NCCOP(O)(O)=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1N(CCBr)CCOS(=O)(C)=O
Pebezertinib,BLU 451; LNG-451,2769954-39-2,497.45,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,Pebezertinib (BLU 451) is an orally active inhibitor for EGFR. Pebezertinib exhibits the ability to penetrate the central nervous system (CNS). Pebezertinib can be used for research about non-small cell lung cancer carrying EGFR exon 20 insertion[1].,C24H19F4N7O,DMSO : 116.67 mg/mL (234.54 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(NC1=CC=C(C(NC2=C(C3=CC=C(C(F)(F)F)C=C3)C=NC(NC4=CN(C)N=C4)=N2)=C1)F)C=C
RRx-001,Nibrozetone,925206-65-1,268.02,Apoptosis; CD47; Parasite,Anti-infection; Apoptosis; Immunology/Inflammation,"RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity[1]. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α[2]. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity[3].",C5H6BrN3O5,DMSO : ≥ 100 mg/mL (373.11 mM),10mM,Cancer; Infection; Inflammation/Immunology,Phase 3,BrCC(N1CC([N+]([O-])=O)([N+]([O-])=O)C1)=O
Sutetinib,,1259519-20-4,439.51,EGFR; PDGFR; VEGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Sutetinib is an orally active inhibitor for tyrosine kinase, that is associated with tumor growth and angiogenesis, such as VEGFR (Ki= 0.009 μM for VEGFR-1/2/3), PDGFR (Ki= 0.008 μM for PDGFR-α/β) and proto-oncogene cKIT. Sutetinib inhibits the proliferation, migration, and tubular structure formation of endothelial cells and fibroblasts, and exhibits board-spectrum antitumor efficacy in vitro and in vivo[1].",C26H25N5O2,DMSO : 100 mg/mL (227.53 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,CCOC(C(NC(/C=C/CN(C)C)=O)=C1)=CC2=C1C(NC3=CC(C#C)=CC=C3)=C(C#N)C=N2
Tegafur-gimeracil-oteracil (potassium),S-1; TS-1,150863-82-4,540.89,Nucleoside Antimetabolite/Analog; Xanthine Oxidase,Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Tegafur-gimeracil-oteracil potassium (TS-1) is an oral anticancer agent composed of Tegafur (HY-17400), Gimeracil (HY-17469), and Oteracil potassium (HY-17511) at a molar ratio of 1:0.4:1. TS-1 can be utilized in research on the peritoneal dissemination of gastric cancer[1].",C17H15ClFKN6O9,,10mM,Cancer,Phase 4,O=C(C1=NC(NC(N1)=O)=O)O[K].O=C2C=C(C(Cl)=CN2)O.O=C3NC(N(C4OCCC4)C=C3F)=O
Sapacitabine,CS682; CYC682,151823-14-2,490.64,Nucleoside Antimetabolite/Analog,Cell Cycle/DNA Damage,Sapacitabine is an orally available nucleoside analog proagent that is structurally related to cytarabine.,C26H42N4O5,DMSO : 33.33 mg/mL (67.93 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(N=C(NC(CCCCCCCCCCCCCCC)=O)C=C1)N1[C@H]2[C@@H](C#N)[C@H](O)[C@@H](CO)O2
SAR125844,,1116743-46-4,550.63,Akt; Apoptosis; c-Met/HGFR; MEK; PI3K,Apoptosis; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK,"SAR125844 is a potent, selective, and ATP-competitive MET kinase inhibitor with the value of IC50 is 4.2 nM and Ki is 2.8 nM. SAR125844 has antitumor activity and can be used for the research of cancer[1][2][3].",C25H23FN8O2S2,DMSO : 45 mg/mL (81.72 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NCCN1CCOCC1)NC2=NC3=CC=C(SC4=NN=C5C=CC(C6=CC=C(F)C=C6)=NN54)C=C3S2
Trifluridine/tipiracil hydrochloride mixture,TAS-102; FTD/TPI,733030-01-8,435.76,Nucleoside Antimetabolite/Analog; Thymidylate Synthase,Apoptosis; Cell Cycle/DNA Damage,"Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a potent and orally active nucleoside antitumor agent. The composition of Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a 1:0.5 mixture (on a molar basis) of alpha,alpha,alpha-tri-fluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI). Trifluridine/tipiracil hydrochloride mixture (TAS-102) shows the antitumor activity mainly via the inhibition of thymidylate synthase (TS) and incorporation into DNA[1][2].",C10H11F3N2O5.1/2C9H11ClN4O2.1/2HCl,DMSO : 50 mg/mL (114.74 mM; ultrasonic and warming and heat to 60°C); H2O : 100 mg/mL (229.48 mM; Need ultrasonic); DMF : 20 mg/mL (45.90 mM; Need ultrasonic),10mM,Cancer,Launched,O=C1N([C@H]2C[C@H](O)[C@@H](CO)O2)C=C(C(F)(F)F)C(N1)=O.O=C3NC(CN4CCCC4=N)=C(Cl)C(N3)=O.[1/2].Cl
Treosulfan,NSC 39069; Treosulphan,299-75-2,278.30,DNA Alkylator/Crosslinker,Cell Cycle/DNA Damage,Treosulfan (NSC 39069) is a bifunctional alkylating agent with activity in ovarian cancer and other solid tumor types.,C6H14O8S2,DMSO : ≥ 100 mg/mL (359.32 mM); H2O : 50 mg/mL (179.66 mM; Need ultrasonic),10mM,Cancer,Launched,O[C@H]([C@@H](O)COS(C)(=O)=O)COS(C)(=O)=O
VAL-083,Dianhydrodulcitol; Dianhydrogalactitol,23261-20-3,146.14,DNA Alkylator/Crosslinker,Cell Cycle/DNA Damage,"VAL-083 is an alkylating agent that creates N7 methylation on DNA, with antitumor activity.",C6H10O4,H2O : 70 mg/mL (478.99 mM; Need ultrasonic),10mM,Cancer,Launched,O[C@H]([C@H](O)[C@]1(OC1)[H])[C@@]2([H])CO2
Voreloxin (Hydrochloride),SNS-595 Hydrochloride; Vosaroxin Hydrochloride; AG 7352 Hydrochloride,175519-16-1,437.90,Apoptosis; Topoisomerase,Apoptosis; Cell Cycle/DNA Damage,"Voreloxin Hydrochloride is a first-in-class topoisomerase II inhibitor that intercalates DNA and induces site-selective DNA DSB, G2 arrest, and apoptosis.",C18H20ClN5O4S,DMSO : 2 mg/mL (4.57 mM; ultrasonic and warming and heat to 60°C); H2O : 2 mg/mL (4.57 mM; ultrasonic and warming and heat to 60°C),2mM,Cancer,Phase 3,[H]Cl.O=C(C1=CN(C2=NC=CS2)C3=C(C=CC(N4C[C@H](OC)[C@@H](NC)C4)=N3)C1=O)O
Pilaralisib,XL-147; SAR245408,934526-89-3,541.02,PI3K,PI3K/Akt/mTOR,"Pilaralisib (XL147; SAR245408) is a potent and highly selective class I PI3Ks inhibitor with IC50s of 39 nM, 383 nM, 23 nM and 36 nM for PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ.",C25H25ClN6O4S,DMSO : ≥ 100 mg/mL (184.84 mM),10mM,Cancer,Phase 2,CC(C)(N)C(NC1=CC=CC(S(=O)(NC2=NC3=CC=CC=C3N=C2NC4=CC(OC)=CC=C4Cl)=O)=C1)=O
Camptothecin,Campathecin; (S)-(+)-Camptothecin; CPT,7689-03-4,348.36,ADC Payload; Antibiotic; Apoptosis; Fungal; Influenza Virus; MicroRNA; Topoisomerase,Antibody-drug Conjugate/ADC Related; Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics,"Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM[1]. Camptothecin (CPT) exhibits powerful antineoplastic activity against colorectal, breast, lung and ovarian cancers, modulates hypoxia-inducible factor-1α (HIF-1α) activity by changing microRNAs (miRNA) expression patterns in human cancer cells[2][3].",C20H16N2O4,DMSO : 6.25 mg/mL (17.94 mM; Need ultrasonic); 1M NaOH : 10 mg/mL (28.71 mM; ultrasonic and adjust pH to 11 with NaOH),10mM,Cancer; Infection,Launched,O=C1C2=C([C@@](O)(CC)C(OC2)=O)C=C(N1C3)C(C3=C4)=NC5=C4C=CC=C5
Irinotecan,(+)-Irinotecan; CPT-11; VAL-413(free base),97682-44-5,586.68,Autophagy; Topoisomerase,Autophagy; Cell Cycle/DNA Damage,"Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex[1].",C33H38N4O6,DMSO : 25 mg/mL (42.61 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@@]7(CC)O)=O)=C7C=C65)=O)=C(CC)C4=C3
Irinotecan (hydrochloride),(+)-Irinotecan (hydrochloride); CPT-11 (hydrochloride); VAL-413,100286-90-6,623.14,Autophagy; Topoisomerase,Autophagy; Cell Cycle/DNA Damage,Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer[1].,C33H39ClN4O6,DMSO : 125 mg/mL (200.60 mM; Need ultrasonic); H2O : 3.33 mg/mL (5.34 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@@]7(CC)O)=O)=C7C=C65)=O)=C(CC)C4=C3.[H]Cl
Irinotecan (hydrochloride trihydrate),(+)-Irinotecan (hydrochloride trihydrate); CPT-11 (hydrochloride trihydrate),136572-09-3,677.18,Autophagy; Topoisomerase,Autophagy; Cell Cycle/DNA Damage,Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity[1].,C33H45ClN4O9,H2O : 1.52 mg/mL (2.24 mM; Need ultrasonic and warming); Ethanol : 3.33 mg/mL (4.92 mM; Need ultrasonic); DMSO : 50 mg/mL (73.84 mM; Need ultrasonic),10mM,Cancer,Launched,[H]Cl.O=C(N1CCC(N2CCCCC2)CC1)OC3=CC=C4N=C5C(CN6C(C(COC([C@@]7(CC)O)=O)=C7C=C65)=O)=C(CC)C4=C3.O.O.O
Colchicine,,64-86-8,399.44,Apoptosis; Autophagy; Microtubule/Tubulin; NOD-like Receptor (NLR),Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton; Immunology/Inflammation,"Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research[1][2][3][4][5].",C22H25NO6,DMSO : 100 mg/mL (250.35 mM; Need ultrasonic); H2O : ≥ 33.33 mg/mL (83.44 mM),10mM,Cancer,Launched,CC(N[C@H](C1=C2)CCC3=CC(OC)=C(OC)C(OC)=C3C1=CC=C(OC)C2=O)=O
VS-5584,SB2343,1246560-33-7,354.41,mTOR; PI3K,PI3K/Akt/mTOR,"VS-5584 is a pan-PI3K/mTOR kinase inhibitor with IC50s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 simultaneously blocks mTORC2 as well as mTORC1.",C17H22N8O,DMSO : 33.33 mg/mL (94.04 mM; Need ultrasonic),10mM,Cancer,Phase 1,NC1=NC=C(C2=C3N=C(C)N(C(C)C)C3=NC(N4CCOCC4)=N2)C=N1
X-376,,1365267-27-1,547.41,Anaplastic lymphoma kinase (ALK); c-Met/HGFR,Protein Tyrosine Kinase/RTK,X-376 is a potent and highly specific ALK tyrosine kinase inhibitor (TKI) (IC50=0.61 nM). X-376 is a less potent inhibitor of MET (IC50=0.69 nM). X-376 displays potent anti-tumor activity[1].,C25H25Cl2FN6O3,DMSO : 100 mg/mL (182.68 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=NN=C(N)C(O[C@@H](C2=C(Cl)C=CC(F)=C2Cl)C)=C1)NC3=CC=C(C(N4CCN(C)CC4)=O)C=C3
Acumapimod,BCT197,836683-15-9,385.42,Autophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,"Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC50 of less than 1 μM for p38α.",C22H19N5O2,DMSO : ≥ 50 mg/mL (129.73 mM),10mM,Inflammation/Immunology,Phase 2,O=C(NC1CC1)C2=CC=C(C)C(N3N=CC(C(C4=CC=CC(C#N)=C4)=O)=C3N)=C2
Gepotidacin,GSK2140944,1075236-89-3,448.52,Antibiotic; Bacterial; Topoisomerase,Anti-infection; Cell Cycle/DNA Damage,Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor.,C24H28N6O3,DMSO : 7.14 mg/mL (15.92 mM; Need ultrasonic),10mM,Infection,Launched,O=C(C=NC(C=C1)=C23)N3[C@H](CN4CCC(NCC5=CC(CCCO6)=C6C=N5)CC4)CN2C1=O
Gepotidacin (mesylate hydrate),,1624306-20-2,580.65,Antibiotic; Bacterial; Topoisomerase,Anti-infection; Cell Cycle/DNA Damage,Gepotidacin mesylate hydrate is an orally active triazaacenaphthylene antibiotic and bacterial type II topoisomerase inhibitor. Gepotidacin mesylate hydrate inhibits bacterial DNA replication by blocking topoisomerase enzymes. Gepotidacin mesylate hydrate selectively inhibits topoisomerase IV and the B subunit of DNA gyrase[1][2].,C25H36N6O8S,DMSO : 233.33 mg/mL (401.84 mM; Need ultrasonic),10mM,Infection,Phase 3,O=C(C=NC(C=C1)=C23)N3[C@H](CN4CCC(NCC5=CC(CCCO6)=C6C=N5)CC4)CN2C1=O.CS(=O)(O)=O.O.O
Seletalisib,UCB5857,1362850-20-1,482.85,PI3K,PI3K/Akt/mTOR,Seletalisib (UCB5857) is potent and selective PI3Kδ inhibitor with an IC50 of 12 nM.,C23H14ClF3N6O,DMSO : ≥ 83.3 mg/mL (172.52 mM),10mM,Inflammation/Immunology,Phase 2,FC(F)(F)[C@H](NC1=C2C(C=CC=N2)=NC=N1)C3=CC4=CC=CC(Cl)=C4N=C3C5=CC=C[N+]([O-])=C5
Solcitinib,GSK-2586184; GLPG-0778,1206163-45-2,389.45,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Solcitinib is an orally active, competitive, potent, selective JAK1 inhibitor, with an IC50 of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.",C22H23N5O2,DMSO : 16.67 mg/mL (42.80 mM; ultrasonic and warming and heat to 60°C),10mM,Inflammation/Immunology,Phase 2,O=C(C1CC1)NC2=NN3C(C4=CC=C(C(N5CC(C)(C)C5)=O)C=C4)=CC=CC3=N2
Censavudine,Festinavir; BMS-986001; OBP-601,634907-30-5,248.24,HIV; Nucleoside Antimetabolite/Analog; Reverse Transcriptase,Anti-infection; Cell Cycle/DNA Damage,"Censavudine (OBP-601; BMS-986001), a nucleoside analog, is a nucleoside reverse transcriptase inhibitor. Censavudine is a potent HIV inhibitor with EC50 ranges from 30 nM to 81 nM and 450 nM to 890 nM for HIV-2 and HIV-1, respectively[1][2]. Censavudine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.",C12H12N2O4,DMSO : 52 mg/mL (209.48 mM; Need ultrasonic); H2O : 10 mg/mL (40.28 mM; ultrasonic and warming and heat to 60°C),10mM,Infection,Phase 2,C#C[C@@]1(O[C@](N(C=C2C)C(NC2=O)=O)([H])C=C1)CO
Pexmetinib,ARRY-614,945614-12-0,556.63,Autophagy; p38 MAPK; Tie,Autophagy; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC50s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.",C31H33FN6O3,DMSO : ≥ 125 mg/mL (224.57 mM),10mM,Cancer,Phase 2,O=C(NCC1=CC(F)=CC=C1OC2=CC3=C(N(CCO)N=C3)C=C2)NC4=CC(C(C)(C)C)=NN4C5=CC=C(C)C=C5
Onatasertib,CC-223; ATG-008,1228013-30-6,397.47,Apoptosis; mTOR,Apoptosis; PI3K/Akt/mTOR,"Onatasertib (CC-223) is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, with an IC50 value for mTOR kinase of 16 nM. Onatasertib inhibits both mTORC1 and mTORC2.",C21H27N5O3,DMSO : ≥ 27 mg/mL (67.93 mM),10mM,Cancer,Phase 2,O=C1CNC2=NC=C(C3=CC=C(C(C)(O)C)N=C3)N=C2N1[C@H]4CC[C@H](OC)CC4
Sitravatinib,MGCD516; MG-516,1123837-84-2,629.68,c-Kit; Discoidin Domain Receptor; FLT3; Trk Receptor; VEGFR,Neuronal Signaling; Protein Tyrosine Kinase/RTK,"Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM,  6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively[1]. Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment[2].",C33H29F2N5O4S,DMSO : ≥ 32 mg/mL (50.82 mM),10mM,Cancer; Inflammation/Immunology,Phase 3,O=C(C1(C(NC2=CC=C(F)C=C2)=O)CC1)NC3=CC=C(OC4=C5C(C=C(C6=NC=C(CNCCOC)C=C6)S5)=NC=C4)C(F)=C3
CC-115,,1228013-15-7,336.35,DNA-PK; mTOR,Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"CC-115 is a potent and dual  DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.",C16H16N8O,DMSO : 20 mg/mL (59.46 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C1CN=C2C(N1CC)=NC(C3=C(C)N=C(C4=NN=CN4)C=C3)=CN2
CC-115 (hydrochloride),,1300118-55-1,372.81,DNA-PK; mTOR,Cell Cycle/DNA Damage; PI3K/Akt/mTOR,"CC-115 hydrochloride is a potent and dual  DNA-PK and mTOR kinase inhibitor with IC50s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling.",C16H17ClN8O,DMSO : ≥ 30 mg/mL (80.47 mM); H2O : 50 mg/mL (134.12 mM; Need ultrasonic),10mM,Cancer,Phase 1,[H]Cl.O=C1CN=C2C(N1CC)=NC(C3=C(C)N=C(C4=NN=CN4)C=C3)=CN2
Darolutamide,ODM-201; BAY-1841788,1297538-32-9,398.85,Androgen Receptor,Vitamin D Related/Nuclear Receptor,Darolutamide (ODM-201;BAY-1841788) is a potent androgen receptor (AR) antagonist with an IC50 of 26 nM in in vitro assay.,C19H19ClN6O2,DMSO : 100 mg/mL (250.72 mM; Need ultrasonic),10mM,Cancer,Launched,ClC1=C(C#N)C=CC(C2=NN(C[C@H](C)NC(C3=NNC(C(O)C)=C3)=O)C=C2)=C1
Itacitinib,INCB039110,1334298-90-6,553.51,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,Itacitinib (INCB039110) is an orally active and selective inhibitor of JAK1 with an IC50 of 2 nM for human JAK1. Itacitinib shows >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis[1][2].,C26H23F4N9O,DMSO : ≥ 30 mg/mL (54.20 mM),10mM,Cancer,Phase 3,N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(C5CCN(C(C6=C(F)C(C(F)(F)F)=NC=C6)=O)CC5)C1
Itacitinib adipate,,1334302-63-4,699.66,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,Itacitinib adipate is an orally bioavailable and selective JAK1 inhibitor which has been tested for efficacy and safety in a phase II trial in myelofibrosis.,C32H33F4N9O5,DMSO : ≥ 137.5 mg/mL (196.52 mM),10mM,Cancer,Phase 3,N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(C5CCN(C(C6=C(F)C(C(F)(F)F)=NC=C6)=O)CC5)C1.O=C(O)CCCCC(O)=O
Saquinavir (mesylate),Ro 31-8959/003,149845-06-7,766.95,Apoptosis; Calcium Channel; HIV; HIV Protease; Interleukin Related; JNK; NO Synthase; p38 MAPK; Reactive Oxygen Species (ROS); Toll-like Receptor (TLR),Anti-infection; Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB,Saquinavir (Ro 31-8959) mesylate is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir mesylate also has anti-inflammatory activity and can induce apoptosis of human red blood cells[1][2][3].,C39H54N6O8S,DMSO : 16.67 mg/mL (21.74 mM; Need ultrasonic),10mM,Infection; Inflammation/Immunology; Cardiovascular Disease,Launched,CS(=O)(O)=O.O=C(C1=NC2=C(C=CC=C2)C=C1)N[C@@H](CC(N)=O)C(N[C@@H](CC3=CC=CC=C3)[C@H](O)CN4[C@@H](C[C@@]5([H])[C@@](CCCC5)([H])C4)C(NC(C)(C)C)=O)=O
Saquinavir,Ro 31-8959,127779-20-8,670.84,Apoptosis; Calcium Channel; HIV; HIV Protease; Interleukin Related; JNK; NO Synthase; p38 MAPK; Reactive Oxygen Species (ROS); Toll-like Receptor (TLR),Anti-infection; Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB,Saquinavir (Ro 31-8959) is an orally active HIV protease inhibitor that can be used in the research of AIDS. Saquinavir also has anti-inflammatory activity and can induce apoptosis of human red blood cells[1][2][3].,C38H50N6O5,DMSO : 100 mg/mL (149.07 mM; Need ultrasonic),10mM,Infection; Inflammation/Immunology; Cardiovascular Disease,Launched,O=C(N[C@@H](CC(N)=O)C(N[C@@H](CC1=CC=CC=C1)[C@H](O)CN2[C@H](C(NC(C)(C)C)=O)C[C@@](CCCC3)([H])[C@@]3([H])C2)=O)C4=NC5=CC=CC=C5C=C4
Dofequidar,MS-209 (free base),129716-58-1,481.59,P-glycoprotein,Membrane Transporter/Ion Channel,"Dofequidar (MS-209 free base) is an orally active quinoline compoundthat blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1). Dofequidar has highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar competitively inhibits ABCB1/P-gp, ABCC1/MRP-1, blocks the efflux of chemotherapeutic agents, increases the drug concentration in cancer cells, and enhances the chemotherapeutic effect[1][2].",C30H31N3O3,DMSO : 50 mg/mL (103.82 mM; Need ultrasonic),10mM,Cancer,Phase 1,OC(COC1=C2C=CC=NC2=CC=C1)CN3CCN(C(C(C4=CC=CC=C4)C5=CC=CC=C5)=O)CC3
Dofequidar (fumarate),MS-209,153653-30-6,597.66,P-glycoprotein,Membrane Transporter/Ion Channel,"Dofequidar fumarate (MS-209) is an orally active quinoline compoundthat blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1). Dofequidar fumarate has highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar fumarate competitively inhibits ABCB1/P-gp, ABCC1/MRP-1, blocks the efflux of chemotherapeutic agents, increases the drug concentration in cancer cells, and enhances the chemotherapeutic effect[1][2].",C34H35N3O7,DMSO : 100 mg/mL (167.32 mM; Need ultrasonic); H2O : 1 mg/mL (1.67 mM; Need ultrasonic),10mM,Cancer,Phase 3,OC(COC1=C2C=CC=NC2=CC=C1)CN3CCN(C(C(C4=CC=CC=C4)C5=CC=CC=C5)=O)CC3.O=C(O)/C=C/C(O)=O
Peramivir (trihydrate),RWJ 270201 trihydrate; BCX 1812 trihydrate,1041434-82-5,382.45,ERK; IKK; Influenza Virus; JNK; p38 MAPK; STAT,Anti-infection; JAK/STAT Signaling; MAPK/ERK Pathway; NF-κB; Stem Cell/Wnt,"Peramivir trihydrate (RWJ-270201 trihydrate) is a highly potent, selective and orally active influenza virus neuraminidase (NA) inhibitor, with IC50 values ranging from 0.9 to 4.3 nM for nine NA subtypes[1][2][3].",C15H34N4O7,H2O : 5 mg/mL (13.07 mM; Need ultrasonic); DMSO : < 1 mg/mL (ultrasonic) (insoluble or slightly soluble),10mM,Infection; Inflammation/Immunology,Launched,O[C@H]1[C@]([C@H](C(CC)CC)NC(C)=O)([H])[C@H](NC(N)=N)C[C@@H]1C(O)=O.[H]O.[H]O.[H]O
Peramivir,RWJ-270201; BCX-1812,330600-85-6,328.41,ERK; IKK; JNK; p38 MAPK; STAT,JAK/STAT Signaling; MAPK/ERK Pathway; NF-κB; Stem Cell/Wnt,Peramivir is an novel cyclopentane neuraminidase inhibitor of influenza virus. Peramivir has antiviral activity and anti-cytokines stom effects. Peramivir can be used for the research of COVID-19[1][2][3].,C15H28N4O4,1 M HCl : ≥ 100 mg/mL (304.50 mM); DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble or slightly soluble),2mM,Infection; Inflammation/Immunology,Launched,O[C@H]1[C@]([C@H](C(CC)CC)NC(C)=O)([H])[C@H](NC(N)=N)C[C@@H]1C(O)=O
Gemcitabine,LY 188011,95058-81-4,263.20,Apoptosis; Autophagy; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog,Apoptosis; Autophagy; Cell Cycle/DNA Damage,"Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[1][2].",C9H11F2N3O4,DMSO : 200 mg/mL (759.88 mM; Need ultrasonic); Ethanol : 12.5 mg/mL (47.49 mM; Need ultrasonic); H2O : 6.25 mg/mL (23.75 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,NC(C=CN1[C@H]2C(F)(F)[C@H](O)[C@@H](CO)O2)=NC1=O
Epothilone B,EPO 906; Patupilone,152044-54-7,507.68,Antibiotic; Apoptosis; Bacterial; Fungal; Microtubule/Tubulin,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,Epothilone B is a microtubule stabilizer with a Ki of 0.71μM. It acts by binding to the αβ-tubulin heterodimer subunit which causes decreasing of αβ-tubulin dissociation.,C27H41NO6S,DMSO : 116.67 mg/mL (229.81 mM; Need ultrasonic),10mM,Cancer; Infection,Phase 3,O=C(C[C@H](O)C1(C)C)O[C@H](/C(C)=C/C2=CSC(C)=N2)C[C@]3([H])O[C@]3(C)CCC[C@H](C)[C@H](O)[C@@H](C)C1=O
Pirenzepine (dihydrochloride),LS 519; Pirenzepin (dihydrochloride); Gastrozepin (dihydrochloride),29868-97-1,424.32,mAChR,GPCR/G Protein; Neuronal Signaling,"Pirenzepine (LS 519) dihydrochloride is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine dihydrochloride reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine dihydrochloride shows anti-proliferative activity to cancer cells[1][2].",C19H23Cl2N5O2,H2O : 50 mg/mL (117.84 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease,Launched,O=C1NC2=CC=CN=C2N(C(CN3CCN(C)CC3)=O)C4=CC=CC=C14.[H]Cl.[H]Cl
Pirenzepine,LS 519 (free base); Pirenzepin; Gastrozepin,28797-61-7,351.40,mAChR,GPCR/G Protein; Neuronal Signaling,"Pirenzepine (LS 519 free base) is a selective M1 mAChR (muscarinic acetylcholine receptor) antagonist. Pirenzepine reduces gastric acid secretion and reduces muscle spasm, can be used in peptic ulcers research. Pirenzepine shows anti-proliferative activity to cancer cells[1][2].",C19H21N5O2,DMSO : 100 mg/mL (284.58 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Metabolic Disease,Launched,O=C1NC2=CC=CN=C2N(C(CN3CCN(C)CC3)=O)C4=CC=CC=C14
Duvelisib,IPI-145; INK1197,1201438-56-3,416.86,PI3K,PI3K/Akt/mTOR,"Duvelisib (IPI-145) is a selectivite p100δ inhibitor with IC50 of 2.5 nM, 27.4 nM, 85 nM and 1602 nM for p110δ, P110γ, p110β and p110α, respectively[1][2].",C22H17ClN6O,DMSO : 100 mg/mL (239.89 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)C)=CC5=C1C(Cl)=CC=C5
Enozertinib (hemihydrate),ORIC-114 (hemihydrate),,669.77,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,Enozertinib (ORIC-114) hemihydrate is the inhibitor for EGFR that exhibits antineoplastic activity[1].,C35H42F2N8O3.1/2H2O,,10mM,Cancer,Phase 2,C=CC(NC1=C(N2CCC(N3CCN(C4CC4)CC3)CC2)C=C(C(NC5=NC=NC(N6[C@@H](C7=CC(F)=CC(F)=C7)CCO6)=C5)=C1)OC)=O.O.[0.5]
Idarubicin (hydrochloride),4-Demethoxydaunorubicin hydrochloride,57852-57-0,533.95,Antibiotic; Autophagy; Bacterial; c-Myc; DNA/RNA Synthesis; Fungal; Topoisomerase,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage,Idarubicin hydrochloride is an anthracycline antileukemic agent. It inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin hydrochloride inhibits the growth of bacteria and yeasts.,C26H28ClNO9,DMSO : 83.33 mg/mL (156.06 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,OC(C(C(C1=CC=CC=C21)=O)=C3C2=O)=C4[C@H](C[C@@](C(C)=O)(O)CC4=C3O)O[C@@](O[C@@H](C)[C@H]5O)([H])C[C@@H]5N.Cl
Idarubicin,4-Demethoxydaunorubicin,58957-92-9,497.49,Antibiotic; Autophagy; Bacterial; c-Myc; DNA/RNA Synthesis; Fungal; Topoisomerase,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage,Idarubicin is an orally active and potent anthracycline antileukemic agent. Idarubicin inhibits the topoisomerase II interfering with the replication of DNA and RNA transcription. Idarubicin shows induction of DNA damage. Idarubicin inhibits DNA synthesis and of c-myc expression. Idarubicin inhibits the growth of bacteria and yeasts[1][2][3][4][5].,C26H27NO9,10 mM in DMSO,10mM,Cancer; Infection,Launched,OC(C(C(C1=CC=CC=C21)=O)=C3C2=O)=C4[C@H](C[C@@](C(C)=O)(O)CC4=C3O)O[C@@](O[C@@H](C)[C@H]5O)([H])C[C@@H]5N
Tegafur,FT 207; NSC 148958,17902-23-7,200.17,Nucleoside Antimetabolite/Analog,Cell Cycle/DNA Damage,Tegafur (FT 207; NSC 148958) is a chemotherapeutic 5-FU proagent used in the treatment of cancers; is a component of tegafur-uracil.,C8H9FN2O3,DMSO : ≥ 48 mg/mL (239.80 mM); H2O : ≥ 20 mg/mL (99.92 mM),10mM,Cancer,Launched,O=C1NC(C(F)=CN1C2OCCC2)=O
Ifosfamide,,3778-73-2,261.09,DNA Alkylator/Crosslinker,Cell Cycle/DNA Damage,Ifosfamide is an alkylating chemotherapeutic agent with activity against a wide range of tumors.,C7H15Cl2N2O2P,DMSO : ≥ 125 mg/mL (478.76 mM),10mM,Cancer,Launched,ClCCN1P(OCCC1)(NCCCl)=O
Fosbretabulin (disodium),CA 4DP; CA 4P; Combretastatin A4 disodium phosphate,168555-66-6,440.29,Apoptosis; Microtubule/Tubulin,Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,"Fosbretabulin disodium (CA 4DP) is a tubulin destabilizing agent. Fosbretabulin disodium is the Combretastatin A4 proagent that selectively targets endothelial cells, induces regression of nascent tumour neovessels, reduces tumour blood flow and causes central tumour necrosis[1][3].",C18H19Na2O8P,H2O : 4.5 mg/mL (10.22 mM; Need ultrasonic and warming); DMF : < 1 mg/mL (insoluble),10mM,Cancer,Phase 3,COC1=C(OC)C(OC)=CC(/C=C\C2=CC=C(OC)C(OP(O[Na])(O[Na])=O)=C2)=C1
Garenoxacin (Mesylate hydrate),BMS284756 (Mesylate hydrate),223652-90-2,540.53,Antibiotic; Bacterial; DNA/RNA Synthesis; Topoisomerase,Anti-infection; Cell Cycle/DNA Damage,"Garenoxacin (BMS284756) Mesylate hydrate is an orally active quinolone antibiotic and has a broad spectrum of activity against a wide array of gram-positive and gram-negative bacteria, anaerobes, and fastidious organisms[1].",C24H26F2N2O8S,DMSO : 100 mg/mL (185.00 mM; Need ultrasonic); H2O : 12.5 mg/mL (23.13 mM; Need ultrasonic),10mM,Infection,Launched,O=C(C1=CN(C2CC2)C3=C(C=CC(C4=CC5=C([C@@H](C)NC5)C=C4)=C3OC(F)F)C1=O)O.CS(=O)(O)=O.O
Metformin (hydrochloride),"1,1-Dimethylbiguanide (hydrochloride)",1115-70-4,165.62,AMPK; Apoptosis; Autophagy; Mitophagy; mTOR,Apoptosis; Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo[1][2][3][4][5][6][7].",C4H12ClN5,DMSO : ≥ 1.7 mg/mL (10.26 mM); H2O : ≥ 100 mg/mL (603.79 mM),10mM,Metabolic Disease; Cardiovascular Disease; Cancer,Launched,NC(NC(N(C)C)=N)=N.Cl
2'-Deoxycytidine (hydrochloride),2'-Deoxycytidine monohydrochloride; Deoxycytidine hydrochloride; NSC 83251,3992-42-5,263.68,Endogenous Metabolite; Nucleoside Antimetabolite/Analog,Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,2'-Deoxycytidine hydrochloride is composed of the purine nucleoside guanine linked by its N9 nitrogen to the C1 carbon of deoxyribose.,C9H14ClN3O4,H2O : ≥ 41 mg/mL (155.49 mM); DMSO : 25 mg/mL (94.81 mM; ultrasonic and warming and heat to 80°C),10mM,Others; Cancer,Launched,OC[C@@H]1[C@@H](O)C[C@H](N2C(N=C(N)C=C2)=O)O1.Cl
Thio-TEPA,,52-24-4,189.22,Antibiotic; Bacterial; DNA Alkylator/Crosslinker,Anti-infection; Cell Cycle/DNA Damage,"Thio-TEPA is a DNA alkylating agent, with antitumor activity.",C6H12N3PS,H2O : < 0.1 mg/mL (ultrasonic) (insoluble); DMSO : 100 mg/mL (528.49 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,S=P(N1CC1)(N2CC2)N3CC3
Berberine (chloride hydrate),Natural Yellow 18 (chloride hydrate),68030-18-2,389.83,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; Parasite; Reactive Oxygen Species (ROS); Topoisomerase,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,Berberine chloride hydrate (Natural Yellow 18 chloride hydrate) is an alkaloid that acts as an antibiotic. Berberine chloride hydrate induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties[1].,C20H20ClNO5,DMSO : ≥ 3.9 mg/mL (10.00 mM); H2O : 1 mg/mL (2.57 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.[Cl-].O
Griseofulvin,,126-07-8,352.77,Antibiotic; Apoptosis; Bcl-2 Family; Caspase; Endogenous Metabolite; Fungal; Microtubule/Tubulin; Wee1,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Metabolic Enzyme/Protease,"Griseofulvin is an orally active antifungal antibiotic with antitumor activity. Griseofulvin induces apoptosis and G2/M cell cycle arrest in cancer cells. Griseofulvin also has cardiovascular modulatory activity, reducing angina pectoris, relieving hand artery spasm associated with onychomycosis, and peripheral vascular diseases such as shoulder-hand syndrome[1][2][3][4][5][6].",C17H17ClO6,DMSO : 33.33 mg/mL (94.48 mM; Need ultrasonic),10mM,Cancer; Infection; Cardiovascular Disease,Launched,O=C1[C@]2(C(OC)=CC(C[C@H]2C)=O)OC3=C(Cl)C(OC)=CC(OC)=C13
Mebendazole,,31431-39-7,295.29,Apoptosis; Microtubule/Tubulin; Parasite,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,"Mebendazole is a highly effective, broad-spectrum antihelmintic against nematode infestations. Mebendazole also exhibits inhibitory effect against glioblastoma multiforme (GBM), inhibits Hedgehog pathway and tubulin polymerization. Mebendazole is orally active and can cross CNS penetration[1][2][3].",C16H13N3O3,DMSO : 4.17 mg/mL (14.12 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Infection; Cancer,Launched,O=C(OC)NC1=NC2=CC=C(C(C3=CC=CC=C3)=O)C=C2N1
Alofanib,RPT835,1612888-66-0,413.40,Apoptosis; FGFR,Apoptosis; Protein Tyrosine Kinase/RTK,Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). Anticancer and antiangiogenic activity[1][2].,C19H15N3O6S,DMSO : ≥ 30.1 mg/mL (72.81 mM),10mM,Cancer; Cardiovascular Disease,Phase 1,O=C(O)C1=CC=CC(S(=O)(NC2=CC(C3=CC=CN=C3)=C(C)C=C2[N+]([O-])=O)=O)=C1
Nastorazepide,Z-360,209219-38-5,520.62,Akt; Cholecystokinin Receptor; Ephrin Receptor; HIF/HIF Prolyl-Hydroxylase; Interleukin Related; VEGFR,GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; Neuronal Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK,"Nastorazepide (Z-360) is an orally active 1,5-benzodiazepine derivative and gastrin/CCK-2 receptor antagonist. Nastorazepide inhibits the specific binding of [3H]CCK-8 to the human CCK-2 receptor with a Ki value of 0.47 nM. Nastorazepide inhibits IL-1β, ephrin B1, VEGF, and HIF-1alpha, reduces Akt and NR2B phosphorylation. Nastorazepide has antitumor activity against pancreatic cancer. Nastorazepide inhibits colorectal cancer liver metastasis and relieves pain[1][2][3][4][5][6][7].",C29H36N4O5,DMSO : ≥ 32 mg/mL (61.47 mM),10mM,Cancer; Neurological Disease,Phase 2,O=C(O)C1=CC=CC(NC(N[C@H]2C(N(CC(C(C)(C)C)=O)C3=CC=CC=C3N(C4CCCCC4)C2)=O)=O)=C1
Tarloxotinib (bromide),TH-4000,1636180-98-7,681.77,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,Tarloxotinib bromide (TH-4000) is an irreversible EGFR/HER2 inhibitor.,C24H24Br2ClN9O3,DMSO : ≥ 33 mg/mL (48.40 mM),10mM,Cancer,Phase 2,BrC1=C(Cl)C=CC(NC2=NC=NC3=C2C=C(NC(/C=C/C[N+](C)(C)CC4=C([N+]([O-])=O)N=CN4C)=O)N=C3)=C1.[Br-]
Leniolisib,CDZ173,1354690-24-6,450.46,PI3K,PI3K/Akt/mTOR,Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor. Leniolisib has the potential for immunodeficiency disorders treatment.,C21H25F3N6O2,DMSO : 100 mg/mL (222.00 mM; Need ultrasonic),10mM,Inflammation/Immunology,Launched,CCC(N1C[C@@H](NC2=C(CN(C3=CC(C(F)(F)F)=C(OC)N=C3)CC4)C4=NC=N2)CC1)=O
Leniolisib (phosphate),CDZ173 (phosphate),1354691-97-6,548.45,PI3K,PI3K/Akt/mTOR,Leniolisib (CDZ173) phosphate is a potent and selective PI3Kδ inhibitor. Leniolisib phosphate has the potential for immunodeficiency disorders treatment.,C21H28F3N6O6P,DMSO : 100 mg/mL (182.33 mM; Need ultrasonic),10mM,Inflammation/Immunology,Launched,CCC(N1C[C@H](CC1)NC2=C3CN(CCC3=NC=N2)C4=CC(C(F)(F)F)=C(N=C4)OC)=O.O=P(O)(O)O
Tenalisib,RP6530,1639417-53-0,415.42,PI3K,PI3K/Akt/mTOR,"Tenalisib (RP6530) is a novel, potent, and selective PI3Kδ and PI3Kγ inhibitor with IC50 values of 25 and 33 nM, respectively.",C23H18FN5O2,DMSO : ≥ 100 mg/mL (240.72 mM),10mM,Cancer,Phase 2,O=C1C(C2=CC=CC(F)=C2)=C([C@@H](NC3=C4NC=NC4=NC=N3)CC)OC5=CC=CC=C15
Quercetin,,117-39-5,302.24,Apoptosis; Autophagy; Mitophagy; PI3K; Reactive Oxygen Species (ROS),Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR,"Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC50 of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H10O7,Ethanol : 16.67 mg/mL (55.15 mM; Need ultrasonic); DMSO : 100 mg/mL (330.86 mM; Need ultrasonic),10mM,Cancer,Launched,OC1=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C3C1=O
Atopaxar,E5555; ER-172594-00,751475-53-3,527.63,Apoptosis; JAK; Protease Activated Receptor (PAR),Apoptosis; Epigenetics; GPCR/G Protein; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Atopaxar (E5555) is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar, an antiplatelet agent, interferes with platelet signaling. Atopaxar can be used for the research of atherothrombotic disease[1][2].",C29H38FN3O5,DMSO : 50 mg/mL (94.76 mM; Need ultrasonic),10mM,Cancer; Cardiovascular Disease,Phase 2,COC1=C(N2CCOCC2)C=C(C(CN(CC3=C4C(F)=C(OCC)C(OCC)=C3)C4=N)=O)C=C1C(C)(C)C
Ombrabulin (hydrochloride),AVE8062 (hydrochloride); AC7700 (hydrochloride),253426-24-3,438.90,Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"Ombrabulin hydrochloride is a derivative of CA-4 phosphate, which is known to exhibit antivascular effects through selective disruption of the tubulin cytoskeleton of endothelial cells.",C21H27ClN2O6,DMSO : 100 mg/mL (227.84 mM; Need ultrasonic); H2O : 20 mg/mL (45.57 mM; Need ultrasonic),10mM,Cancer; Cardiovascular Disease,Phase 3,O=C(NC1=CC(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)=CC=C1OC)[C@@H](N)CO.[H]Cl
Berberine (chloride),Natural Yellow 18 (chloride),633-65-8,371.81,Antibiotic; Autophagy; Bacterial; Endogenous Metabolite; Parasite; Reactive Oxygen Species (ROS); Topoisomerase,Anti-infection; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,Berberine chloride is an alkaloid that acts as an antibiotic. Berberine chloride induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Antineoplastic properties[1].,C20H18ClNO4,DMSO : 8.33 mg/mL (22.40 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Cancer,Launched,COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.[Cl-]
Filgotinib,GLPG0634,1206161-97-8,425.50,HIV; JAK,Anti-infection; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Filgotinib (GLPG0634) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. Filgotinib can effectively inhibit the activities of JAK1, JAK2, JAK3 and TYK2 with IC50 values of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib can be used in the study of rheumatoid arthritis and inflammatory bowel disease[1][2][3].",C21H23N5O3S,DMSO : 25 mg/mL (58.75 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,O=C(C1CC1)NC2=NN3C(C4=CC=C(CN5CCS(CC5)(=O)=O)C=C4)=CC=CC3=N2
Filgotinib (maleate),GLPG0634 (maleate),1802998-75-9,541.58,HIV; JAK,Anti-infection; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Filgotinib maleate (GLPG0634 maleate) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. Filgotinib maleate can effectively inhibit the activities of JAK1, JAK2, JAK3 and TYK2 with IC50 values ??of 10 nM, 28 nM, 810 nM and 116 nM, respectively. Filgotinib maleate also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. Filgotinib maleate can be used in the study of rheumatoid arthritis and inflammatory bowel disease[1][2][3].",C25H27N5O7S,DMSO : 35 mg/mL (64.63 mM; ultrasonic and warming and heat to 60°C),10mM,Inflammation/Immunology,Launched,OC(/C=C\C(O)=O)=O.O=C(C1CC1)NC2=NN3C(C4=CC=C(C=C4)CN5CCS(=O)(CC5)=O)=CC=CC3=N2
AMG-337,,1173699-31-4,463.46,Apoptosis; Caspase; c-Met/HGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"AMG-337 is a potent, orally active, selective MET kinase inhibitor with IC50 values of 1, 1, 4.7, 5, 21.5, 1077 and >4000 nM of WT MET, H1094R MET, M1250T MET, HGF-stimulated pMET (PC3 cells) MET, V1092I MET, Y1230H MET, and D1228H MET, respectively. AMG 337 inhibits the phosphorylation of MET and downstream effectors in MET-amplified cancer cell lines, resulting in an inhibition of MET-dependent cell proliferation and induction of apoptosis[1][2].",C23H22FN7O3,DMSO : 100 mg/mL (215.77 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1C2=C(N=CC(OCCOC)=C2)C=CN1[C@@H](C3=NN=C4C(F)=CC(C5=CN(C)N=C5)=CN43)C
Erdafitinib,JNJ-42756493,1346242-81-6,446.54,Apoptosis; FGFR,Apoptosis; Protein Tyrosine Kinase/RTK,"Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC50s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.",C25H30N6O2,DMSO : 62.5 mg/mL (139.97 mM; Need ultrasonic),10mM,Cancer,Launched,CN1N=CC(C2=NC3=CC(N(C4=CC(OC)=CC(OC)=C4)CCNC(C)C)=CC=C3N=C2)=C1
Zorifertinib,AZD3759,1626387-80-1,459.90,Apoptosis; EGFR,Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Zorifertinib (AZD3759) is a potent, orally active, central nervous system-penetrant, EGFR inhibitor. At Km ATP concentrations, the IC50s are 0.3, 0.2, and 0.2 nM for EGFRwt, EGFRL858R, and EGFRexon 19Del, respectively. Zorifertinib induces cancer cell apoptosis. Zorifertinib has antitumor activity, and can be used for NSCLC, HCC etc. research[1].",C22H23ClFN5O3,DMSO : ≥ 50 mg/mL (108.72 mM),10mM,Cancer,Phase 3,ClC1=CC=CC(NC2=NC=NC3=CC(OC)=C(OC(N4[C@H](C)CN(C)CC4)=O)C=C23)=C1F
FR 167653,FR 167653 sulfate,158876-66-5,525.51,Autophagy; p38 MAPK,Autophagy; MAPK/ERK Pathway,"FR 167653 (FR 167653 sulfate), an orally active and selective p38 MAPK inhibitor, is a potent suppressor of TNF-α and IL-1β production via specific inhibition of p38 MAPK activity. FR 167653 (FR 167653 sulfate) is effective in treating inflammation, relieving trauma and ischemia-reperfusion injury in vivo[1][2][3].",C24H20FN5O6S,DMSO : 100 mg/mL (190.29 mM; Need ultrasonic),10mM,Endocrinology,Phase 1,O=C(N1NC2=C(C3=CC=NC=C3)C(C4=CC=C(F)C=C4)=NN2CC1)C(C5=CC=CC=C5)=O.O=S(O)(O)=O
6-Thio-2'-Deoxyguanosine,6-thio-dG; β-TGdR,789-61-7,283.31,DNA/RNA Synthesis,Cell Cycle/DNA Damage,6-Thio-2'-Deoxyguanosine is a nucleoside analogue that can be incorporated into de novo-synthesized telomeres by telomerase.,C10H13N5O3S,DMSO : 50 mg/mL (176.49 mM; Need ultrasonic),10mM,Cancer,Phase 3,OC[C@@H]1[C@H](C[C@H](N2C=NC3=C2NC(N)=NC3=S)O1)O
PF-03715455,,1056164-52-3,700.27,p38 MAPK,MAPK/ERK Pathway,PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease)[1][2].,C35H34ClN7O3S2,DMSO : 50 mg/mL (71.40 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 2,CC(C)(C1=NN(C2=CC=C(O)C(Cl)=C2)C(NC(NCC3=CC=CC=C3SC4=CN5C(C6=CC=CC=C6SCCO)=NN=C5C=C4)=O)=C1)C
Lifirafenib,BGB-283,1446090-79-4,478.42,EGFR; Raf,JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK,"Lifirafenib (BGB-283) is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively.",C25H17F3N4O3,DMSO : ≥ 100 mg/mL (209.02 mM),10mM,Cancer,Phase 1,O=C1NC2=NC=CC(OC3=CC=C(O[C@@]4([H])[C@]5([H])[C@@H]4C6=NC7=CC=C(C(F)(F)F)C=C7N6)C5=C3)=C2CC1
Merbarone,NSC 336628,97534-21-9,263.27,Topoisomerase,Cell Cycle/DNA Damage,Merbarone (NSC 336628) is an orally active inhibitor of topoisomerase II. Merbarone acts primarily by blocking topoisomerase II-mediated DNA cleavage without stabilizing topo II-DNA covalent complexes. Merbarone is an anticancer agent[1][2][4].,C11H9N3O3S,DMSO : 12.5 mg/mL (47.48 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C(C(N1)=O)C(NC1=S)=O)NC2=CC=CC=C2
Ceralasertib,AZD6738,1352226-88-0,412.51,ATM/ATR,Cell Cycle/DNA Damage; PI3K/Akt/mTOR,Ceralasertib (AZD6738) is an orally active and bioavailable inhibitor of ATR kinase with an IC50 of 1 nM.,C20H24N6O2S,DMSO : 70 mg/mL (169.69 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=[S@@](C1(CC1)C2=NC(C3=C4C(NC=C4)=NC=C3)=NC(N5CCOC[C@H]5C)=C2)(C)=N
Erenapurstat,E3330; APX-3330,136164-66-4,378.46,AP-1; DNA/RNA Synthesis; HIF/HIF Prolyl-Hydroxylase; NF-κB; Reactive Oxygen Species (ROS); VEGFR,Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Protein Tyrosine Kinase/RTK,"Erenapursta (E3330) is a direct, orally active and selective inhibitor of Ape-1 (apurinic/apyrimidinic endonuclease 1)/Ref-1 (redox factor-1) redox. Erenapursta is able to impair tumor growth and blocks the activity of NF-κB, AP-1, and HIF-1α in pancreatic cancer. Erenapursta shows anticancer activities[1][2][3][4][5].",C21H30O6,DMSO : 120 mg/mL (317.07 mM; Need ultrasonic),10mM,Cancer; Neurological Disease; Cardiovascular Disease,Phase 2,CCCCCCCCC/C(C(O)=O)=C\C1=C(C)C(C(OC)=C(OC)C1=O)=O
SCH 58261,,160098-96-4,345.36,Adenosine Receptor,GPCR/G Protein,"SCH 58261 is a potent, selective and competitive antagonist of adenosine A2A receptor with an IC50 of 15 nM, and displays 323-, 53- and 100-fold more selective for A2A receptor than A1, A2B, and A3 receptors, respectively[1][2][3].",C18H15N7O,DMSO : ≥ 34 mg/mL (98.45 mM),10mM,Cancer,Phase 3,NC1=NC(N(CCC2=CC=CC=C2)N=C3)=C3C4=NC(C5=CC=CO5)=NN14
Nemiralisib,GSK2269557 (free base),1254036-71-9,440.54,PI3K,PI3K/Akt/mTOR,Nemiralisib (GSK2269557 free base) is a potent and highly selective PI3Kδ inhibitor with a pKi of 9.9.,C26H28N6O,DMSO : 33.33 mg/mL (75.66 mM; Need ultrasonic),10mM,Cancer,Phase 2,CC(N1CCN(CC2=CN=C(C3=CC(C4=CC=CC5=C4C=CN5)=CC6=C3C=NN6)O2)CC1)C
Peficitinib,ASP015K; JNJ-54781532,944118-01-8,326.39,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Peficitinib (ASP015K) is an orally active JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively[1].",C18H22N4O2,DMSO : 58.33 mg/mL (178.71 mM; Need ultrasonic),10mM,Inflammation/Immunology,Launched,O[C@](C[C@@H]1C[C@H]2C3)(C2)C[C@@H]3[C@H]1NC4=C5C(NC=C5)=NC=C4C(N)=O
Upadacitinib,ABT-494,1310726-60-3,380.37,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research[1][2].",C17H19F3N6O,DMSO : 100 mg/mL (262.90 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology,Launched,O=C(N1C[C@@H](CC)[C@@H](C2=CN=C3C=NC(NC=C4)=C4N32)C1)NCC(F)(F)F
Ilginatinib (maleate),NS-018 (maleate),1354799-87-3,505.50,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM).",C25H24FN7O4,DMSO : ≥ 30 mg/mL (59.35 mM); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Phase 2,CN1N=CC(C2=CC(N[C@H](C3=CC=C(F)C=C3)C)=NC(NC4=NC=CN=C4)=C2)=C1.O=C(O)/C=C\C(O)=O
Ilginatinib,NS-018,1239358-86-1,389.43,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ilginatinib (NS-018) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM).",C21H20FN7,DMSO : 100 mg/mL (256.79 mM; Need ultrasonic),10mM,Cancer,Phase 2,CN1N=CC(C2=CC(N[C@H](C3=CC=C(F)C=C3)C)=NC(NC4=NC=CN=C4)=C2)=C1
Ilginatinib hydrochloride,NS-018 hydrochloride,1239358-85-0,425.89,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM).",C21H21ClFN7,DMSO : ≥ 35 mg/mL (82.18 mM); H2O : 2 mg/mL (4.70 mM; Need ultrasonic),10mM,Cancer,Phase 2,[H]Cl.CN1N=CC(C2=CC(N[C@H](C3=CC=C(F)C=C3)C)=NC(NC4=NC=CN=C4)=C2)=C1
Glesatinib (hydrochloride),MGCD265 hydrochloride,1123838-51-6,656.17,c-Met/HGFR; TAM Receptor,Protein Tyrosine Kinase/RTK,"Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent MET/SMO dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC)[1][2].",C31H28ClF2N5O3S2,DMSO : 50 mg/mL (76.20 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 2,O=C(NC(NC1=CC=C(OC2=C3C(C=C(C4=NC=C(CNCCOC)C=C4)S3)=NC=C2)C(F)=C1)=S)CC5=CC=C(F)C=C5.Cl
Apomine,SR-45023A; SR 9223i; SK&F-99085,126411-13-0,562.66,Apoptosis; HMG-CoA Reductase (HMGCR),Apoptosis; Metabolic Enzyme/Protease,"Apomine (SR-45023A) is an orally active antineoplastic agent that inhibits the mevalonate/isoprenoid pathway in cholesterol synthesis. Apomine can accelerate the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR). Apomine can also inhibit the growth of various types of cancer cells, including lung cancer, colon cancer, breast cancer, and skin cancer.  Apomine is able to induce apoptosis in tumor cell lines derived from leukemia, colon cancer, liver cancer, ovarian cancer, and breast cancer[1][2].",C28H52O7P2,DMSO : 20 mg/mL (35.55 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,CC(C)(C)C1=C(O)C(C(C)(C)C)=CC(CC(P(OC(C)C)(OC(C)C)=O)P(OC(C)C)(OC(C)C)=O)=C1
Miransertib,ARQ-092,1313881-70-7,432.52,Akt; Parasite,Anti-infection; PI3K/Akt/mTOR,"Miransertib (ARQ-092) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research[1]. Miransertib is effective against Leishmania[2].",C27H24N6,DMSO : 12.5 mg/mL (28.90 mM; Need ultrasonic),10mM,Cancer; Infection,Phase 2,NC1=NC=CC=C1C2=NC3=CC=C(C4=CC=CC=C4)N=C3N2C5=CC=C(C6(N)CCC6)C=C5
Miransertib (hydrochloride),ARQ-092 (hydrochloride),1313883-00-9,468.98,Akt; Parasite,Anti-infection; PI3K/Akt/mTOR,"Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research[1]. Miransertib hydrochloride is effective against Leishmania[2].",C27H25ClN6,DMSO : 50 mg/mL (106.61 mM; Need ultrasonic),10mM,Cancer; Infection,Phase 2,NC1=NC=CC=C1C2=NC3=CC=C(C4=CC=CC=C4)N=C3N2C5=CC=C(C6(N)CCC6)C=C5.[H]Cl
Naquotinib,ASP8273,1448232-80-1,562.71,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Naquotinib (ASP8273) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.",C30H42N8O3,DMSO : 100 mg/mL (177.71 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(C1=NC(CC)=C(O[C@H]2CN(C(C=C)=O)CC2)N=C1NC3=CC=C(N4CCC(N5CCN(C)CC5)CC4)C=C3)N
Olmutinib,HM61713; BI 1482694,1353550-13-6,486.59,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,Olmutinib (HM61713; BI-1482694) is an orally active and irreversible third EGFR tyrosine kinase inhibitor that binds to a cysteine residue near the kinase domain. Olmutinib  is used for NSCLC[1][2].,C26H26N6O2S,DMSO : 125 mg/mL (256.89 mM; Need ultrasonic),10mM,Cancer,Launched,C=CC(NC1=CC=CC(OC2=C3C(C=CS3)=NC(NC4=CC=C(N5CCN(C)CC5)C=C4)=N2)=C1)=O
Triazavirin,,928659-17-0,286.20,DNA/RNA Synthesis; Influenza Virus; Nucleoside Antimetabolite/Analog,Anti-infection; Cell Cycle/DNA Damage,Triazavirin is a nucleoside analogue of nucleic acid and an antiviral agent. Triazavirin works by inhibiting the synthesis of viral RNA and DNA and replication of genomic fragments. Triazavirin is also an effective protective agent on the transmission stage of influenza[1].,C5H7N6NaO5S,DMSO : 125 mg/mL (436.76 mM; Need ultrasonic); H2O : 50 mg/mL (174.70 mM; Need ultrasonic),10mM,Infection,Phase 4,O=C1N([N-]C(SC)=N2)C2=NN=C1[N+]([O-])=O.[H]O[H].[H]O[H].[Na+]
Ifupinostat,BEBT-908,1235449-52-1,507.57,PI3K,PI3K/Akt/mTOR,"Ifupinostat is a selective PI3Kα inhibitor extracted from patent US/20120088764A1, Compound 243, has an IC50<0.1 μM, PI3Kα inhibitor 1 also inhibits HDAC (0.1 μM≤IC50≤1 μM) .",C23H25N9O3S,DMSO : ≥ 37 mg/mL (72.90 mM),10mM,Cancer,Phase 3,CN(CC1=CC(N=C(C2=CN=C(NC)C=C2)N=C3N4CCOCC4)=C3S1)C5=NC=C(C(NO)=O)C=N5
Naquotinib (mesylate),ASP8273 (mesylate),1448237-05-5,658.81,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective and irreversible EGFR inhibitor; with IC50s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.",C31H46N8O6S,DMSO : 12.5 mg/mL (18.97 mM; Need ultrasonic and warming),10mM,Cancer,Phase 3,O=C(C1=NC(CC)=C(O[C@H]2CN(C(C=C)=O)CC2)N=C1NC3=CC=C(N4CCC(N5CCN(C)CC5)CC4)C=C3)N.CS(=O)(O)=O
Olafertinib,CK-101; RX518,1660963-42-7,530.57,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Olafertinib (CK-101) is an orally available, third generation and irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Olafertinib selectively inhibits both EGFR-TKI-sensitizing and resistance mutations with minimal activity on wild-type EGFR. Olafertinib can be used in research for non-small cell lung cancer (NSCLC) with EGFR mutations and other advanced malignancies[1][2].",C29H28F2N6O2,DMSO : 125 mg/mL (235.60 mM; Need ultrasonic),10mM,Cancer,Phase 2,OCCN1CCN(C2=C(F)C(F)=C(NC3=NC=C4C(C(C5=CC(NC(C=C)=O)=CC=C5)=CC=C4)=N3)C=C2)CC1
Avitinib,Abivertinib; AC0010,1557267-42-1,487.53,Apoptosis; Btk; EGFR,Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Avitinib (Abivertinib) is a third-generation, irreversible and orally active selective EGFR inhibitor, with IC50 values of 0.18 nM, 0.18 nM, 7.68 nM and against EGFR L858R, EGFR T790M and wild-type EGFR. Avitinib is also a BTK inhibitor that induces apoptosis and inhibits phosphorylation of BTK in mantle cell lymphoma. Avitinib shows anticancer effects[1][2].",C26H26FN7O2,DMSO : 83.33 mg/mL (170.92 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(C=C)NC1=CC=CC(OC2=NC(NC3=CC(F)=C(N4CCN(C)CC4)C=C3)=NC5=C2C=CN5)=C1
Avitinib (maleate),Abivertinib (maleate); AC0010 (maleate),1557268-88-8,603.60,Apoptosis; Btk; EGFR,Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Avitinib (Abivertinib) maleate is a third-generation, irreversible and orally active selective EGFR inhibitor, with IC50 values of 0.18 nM, 0.18 nM, 7.68 nM and against EGFR L858R, EGFR T790M and wild-type EGFR. Avitinib maleate is also a BTK inhibitor that induces apoptosis and inhibits phosphorylation of BTK in mantle cell lymphoma. Avitinib maleate shows anticancer effects[1][2].",C30H30FN7O6,DMSO : ≥ 100 mg/mL (165.67 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Phase 3,O=C(O)/C=C\C(O)=O.O=C(C=C)NC1=CC=CC(OC2=NC(NC3=CC(F)=C(N4CCN(C)CC4)C=C3)=NC5=C2C=CN5)=C1
Burixafor (hydrobromide),TG-0054 (hydrobromide),1191450-19-7,769.01,CXCR; VEGFR,GPCR/G Protein; Immunology/Inflammation; Protein Tyrosine Kinase/RTK,"Burixafor (TG-0054) hydrobromide is a selective, orally active CXCR4 antagonist that effectively blocks the interaction between CXCR4 and its ligand, stromal cell-derived factor SDF-1. Burixafor hydrobromide interferes with the SDF-1/CXCR4 signaling pathway, prompting the release of bone marrow stem cells into the peripheral circulation, exerting immunomodulatory and anti-inflammatory activities. Burixafor hydrobromide can be used in the study of cancer, Intraocular neovascular diseases (such as choroidal neovascularization), myocardial infarction and other diseases, with the potential to mobilize stem cells, improve cardiac function and reduce inflammatory responses[1][2][3].",C27H51N8O3P.5/2HBr,H2O : 50 mg/mL (65.02 mM; Need ultrasonic),10mM,Cancer; Endocrinology; Inflammation/Immunology; Cardiovascular Disease,Phase 2,NC1=CC(N2CCN(CCP(O)(O)=O)CC2)=NC(NC[C@H]3CC[C@H](CNCCCNC4CCCCC4)CC3)=N1.[H]Br
4SC-203,,895533-09-2,642.77,FLT3; VEGFR,Protein Tyrosine Kinase/RTK,"4SC-203 is a potent multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively FLT3/STK1, FLT3 mutated forms, and VEGFRs[1].",C33H38N8O4S,DMSO : 125 mg/mL (194.47 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(NC1=NC2=CC=C(NC3=C4C=C(OC)C(OCCCN5CCN(C)CC5)=CC4=NC=N3)C=C2S1)NC6=CC(C)=CC=C6OC
NRC-2694,,936446-61-6,418.49,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"NRC-2694 is an epidermal growth factor receptor (EGFR) antagonist with anti-cancer and anti-proliferative properties. NRC-2694 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.",C24H26N4O3,DMSO : 250 mg/mL (597.39 mM; Need ultrasonic),10mM,Cancer,Phase 2,COC1=CC2=NC=NC(NC3=CC=CC(C#C)=C3)=C2C=C1OCCCN4CCOCC4
Fruquintinib,HMPL-013,1194506-26-7,393.39,VEGFR,Protein Tyrosine Kinase/RTK,"Fruquintinib (HMPL-013) is a highly potent and selective VEGFR 1/2/3 inhibitor with IC50s of 33, 0.35, and 35 nM, respectively.",C21H19N3O5,DMSO : 5 mg/mL (12.71 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(C1=C(C)OC2=CC(OC3=C4C=C(OC)C(OC)=CC4=NC=N3)=CC=C12)NC
Lisavanbulin,BAL-101553,1263384-43-5,515.57,Checkpoint Kinase (Chk); Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"Lisavanbulin (BAL-101553) is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin is a BBB-penetrant and orally active antitumor agent, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin is also a spindle assembly checkpoint activator. Lisavanbulin induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma[1][2][3][4].",C26H29N9O3,DMSO : 100 mg/mL (193.96 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC=C(C(CN2C3=CC=CC=C3N=C2C4=NON=C4NCCC#N)=O)C=C1)[C@@H](N)CCCCN
Lisavanbulin (dihydrochloride),BAL-101553 (dihydrochloride),1387574-54-0,588.49,Checkpoint Kinase (Chk); Microtubule/Tubulin,Cell Cycle/DNA Damage; Cytoskeleton,"Lisavanbulin (BAL-101553) dihydrochloride is the prodrug of the microtubule targeting agent Avanbulin (BAL 27862) (HY-106008). Lisavanbulin dihydrochloride exhibits antitumor activity, especially in tumors that express high levels of end-binding protein 1. Lisavanbulin dihydrochloride has ability to target tumor cell proliferation and affects the tumor microenvironment by reducing tumor microvasculature. Lisavanbulin dihydrochloride is also a spindle assembly checkpoint activator. Lisavanbulin dihydrochloride induces cell cycle arrest and subsequent death or aberrant chromosome segregation. Lisavanbulin dihydrochloride can be studied in research for diffuse large B cell lymphoma (DLBCL) and glioblastoma[1][2][3][4].",C26H31Cl2N9O3,DMSO : 125 mg/mL (212.41 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(NC1=CC=C(C(CN2C3=CC=CC=C3N=C2C4=NON=C4NCCC#N)=O)C=C1)[C@@H](N)CCCCN.Cl.Cl
Pifusertib,TAS-117,1402602-94-1,424.49,Akt; Apoptosis; Autophagy,Apoptosis; Autophagy; PI3K/Akt/mTOR,"Pifusertib (TAS-117) is a potent, selective, orally active allosteric Akt inhibitor (with IC50s of 4.8, 1.6, and 44 nM for Akt1, 2, and 3, respectively). Pifusertib triggers anti-myeloma activities and enhances fatal endoplasmic reticulum (ER) stress induced by proteasome inhibition. Pifusertib induces apoptosis and autophagy[1].",C26H24N4O2,10 mM in DMSO,10mM,Cancer,Phase 2,C[C@@](C1)(O)C[C@]1(N)C2=CC=C(C3=C(N(COC4=CC=NC=C45)C5=N3)C6=CC=CC=C6)C=C2
Pifusertib (hydrochloride),TAS-117 (hydrochloride),2930090-28-9,460.96,Akt; Apoptosis; Autophagy,Apoptosis; Autophagy; PI3K/Akt/mTOR,"Pifusertib (TAS-117) hydrochloride is a potent, selective, orally active allosteric Akt inhibitor (with IC50s of 4.8, 1.6, and 44 nM for Akt1, 2, and 3, respectively). Pifusertib hydrochloride triggers anti-myeloma activities and enhances fatal endoplasmic reticulum (ER) stress induced by proteasome inhibition. Pifusertib hydrochloride induces apoptosis and autophagy[1].",C26H25ClN4O2,DMSO : 62.5 mg/mL (135.59 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,C[C@@](C1)(O)C[C@]1(N)C2=CC=C(C3=C(N(COC4=CC=NC=C45)C5=N3)C6=CC=CC=C6)C=C2.[H]Cl
Zoligratinib,Debio 1347; CH5183284,1265229-25-1,356.38,FGFR,Protein Tyrosine Kinase/RTK,"Zoligratinib (Debio 1347) is an orally available and selective FGFR inhibitor with IC50s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.",C20H16N6O,DMSO : 25 mg/mL (70.15 mM; ultrasonic and warming and heat to 50°C),10mM,Cancer,Phase 2,O=C(C1=C(N)N(C2=CC=C3N=C(C)NC3=C2)N=C1)C(N4)=CC5=C4C=CC=C5
Paxalisib,GDC-0084,1382979-44-3,382.42,mTOR; PI3K,PI3K/Akt/mTOR,"Paxalisib (GDC-0084) is a brain penetrant inhibitor of PI3K and mTOR, with Kis of 2 nM, 46 nM, 3 nM, 10 nM and 70 nM for PI3Kα PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively[1].",C18H22N8O2,DMSO : 7.69 mg/mL (20.11 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,NC1=NC=C(C2=NC(N3CCOCC3)=C4N=C(C(C)(C)OCC5)N5C4=N2)C=N1
Derazantinib,ARQ-087,1234356-69-4,468.57,FGFR,Protein Tyrosine Kinase/RTK,"Derazantinib (ARQ-087) is an ATP competitive and orally activeFGFR inhibitor (IC50s: 1.8 nM for FGFR2, 4.5 nM for FGFR1 and 3 nM). Derazantinib inhibits FGFR phosphorylation. Derazantinib inhibits tumor growth in multiple xenograft models[1][2].",C29H29FN4O,DMSO : 25 mg/mL (53.35 mM; Need ultrasonic),10mM,Cancer,Phase 3,COCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C5=CC=CC=C5C3=N2)=CC=C1
ASP5878,,1453208-66-6,407.37,FGFR,Protein Tyrosine Kinase/RTK,"ASP5878 is an oral active inhibitor of FGFR 1, 2, 3, and 4, with IC50 values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity[1].",C18H19F2N5O4,DMSO : ≥ 250 mg/mL (613.69 mM),10mM,Cancer,Phase 1,OCCN1N=CC(NC2=NC=C(OCC3=C(F)C(OC)=CC(OC)=C3F)C=N2)=C1
PF-06459988,,1428774-45-1,431.88,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"PF-06459988 is an orally activity, irreversible and mutant-selective inhibitor of EGFR mutant forms. PF-06459988 demonstrates high potency and specificity to the T790M-containing double mutant EGFRs. PF-06459988 can be used for the research of cancer[1].",C19H22ClN7O3,DMSO : 50 mg/mL (115.77 mM; Need ultrasonic),10mM,Cancer,Phase 2,C=CC(N1C[C@H](COC2=C3C(NC=C3Cl)=NC(NC4=CN(C)N=C4)=N2)[C@@H](OC)C1)=O
Pictilisib (dimethanesulfonate),GDC-0941 (dimethanesulfonate) ; GDC-0941 (2 MeSO3H salt),957054-33-0,705.85,Apoptosis; Autophagy; PI3K,Apoptosis; Autophagy; PI3K/Akt/mTOR,"Pictilisib dimethanesulfonate (GDC-0941 dimethanesulfonate) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).",C25H35N7O9S4,H2O : 7.14 mg/mL (10.12 mM; ultrasonic and warming and heat to 60°C); DMSO : 7.14 mg/mL (10.12 mM; Need ultrasonic and warming),10mM,Cancer,Phase 2,O=S(N1CCN(CC1)CC2=CC3=C(S2)C(N4CCOCC4)=NC(C5=CC=CC6=C5C=NN6)=N3)(C)=O.O=S(O)(C)=O.O=S(O)(C)=O
Pelitinib,EKB-569; WAY-EKB 569,257933-82-7,467.92,EGFR; Src,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Pelitinib (EKB-569;WAY-EKB 569) is an irreversible inhibitor of EGFR with an IC50 of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC50s of 282, 800, and 1255 nM, respectively. ",C24H23ClFN5O2,DMSO : 25 mg/mL (53.43 mM; Need ultrasonic),10mM,Cancer,Phase 2,N#CC1=C(C2=CC(NC(/C=C/CN(C)C)=O)=C(OCC)C=C2N=C1)NC3=CC(Cl)=C(C=C3)F
Neratinib,HKI-272,698387-09-6,557.04,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Neratinib (HKI-272) is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively[1].",C30H29ClN6O3,DMSO : 13.33 mg/mL (23.93 mM; Need ultrasonic),10mM,Cancer,Launched,ClC1=C(OCC2=NC=CC=C2)C=CC(NC3=C(C#N)C=NC4=CC(OCC)=C(NC(/C=C/CN(C)C)=O)C=C43)=C1
Neratinib (maleate),HKI-272 (maleate),915942-22-2,673.11,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Neratinib (HKI-272) maleate is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively[1].",C34H33ClN6O7,DMSO : 250 mg/mL (371.41 mM; Need ultrasonic),10mM,Cancer,Launched,OC(/C=C\C(O)=O)=O.CCOC(C(NC(/C=C/CN(C)C)=O)=C1)=CC2=C1C(NC3=CC(Cl)=C(C=C3)OCC4=CC=CC=N4)=C(C#N)C=N2
Tofacitinib,Tasocitinib; CP-690550,477600-75-2,312.37,Apoptosis; JAK,Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.",C16H20N6O,DMSO : 125 mg/mL (400.17 mM; Need ultrasonic); Ethanol : 2.5 mg/mL (8.00 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Launched,O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1
Tofacitinib (citrate),Tasocitinib (citrate); CP-690550 (citrate),540737-29-9,504.49,Apoptosis; Bacterial; Fungal; Influenza Virus; JAK,Anti-infection; Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Tofacitinib citrate is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.",C22H28N6O8,DMSO : 41.67 mg/mL (82.60 mM; Need ultrasonic); H2O : 3.33 mg/mL (6.60 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1.O=C(CC(C(O)=O)(O)CC(O)=O)O
"(3R,4S)-Tofacitinib",,1092578-46-5,312.37,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"(3R,4S)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC50 of 1 nM.",C16H20N6O,DMSO : 100 mg/mL (320.13 mM; Need ultrasonic),10mM,Inflammation/Immunology,Launched,CN(C1=NC=NC2=C1C=CN2)[C@@H]3[C@@H](C)CCN(C(CC#N)=O)C3
Pictilisib,GDC-0941,957054-30-7,513.64,Apoptosis; Autophagy; PI3K,Apoptosis; Autophagy; PI3K/Akt/mTOR,"Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with an IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).",C23H27N7O3S2,DMSO : 100 mg/mL (194.69 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 2,CS(N1CCN(CC2=CC3=C(C(N4CCOCC4)=NC(C5=CC=CC6=C5C=NN6)=N3)S2)CC1)(=O)=O
AT9283,,896466-04-9,381.43,Apoptosis; Aurora Kinase; Autophagy; Bcr-Abl; FLT3; JAK,Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo[1][2].",C19H23N7O2,DMSO : ≥ 100 mg/mL (262.17 mM),10mM,Cancer,Phase 3,O=C(NC1CC1)NC2=CNN=C2C3=NC4=CC=C(C=C4N3)CN5CCOCC5
JNJ-38877605,,943540-75-8,377.35,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"JNJ-38877605 is an orally active ATP-competitive inhibitor of c-Met with an IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases[1][2]. JNJ-38877605 inhibits c-Met phosphorylation and regulates lipid accumulation. JNJ-38877605 can be used for tumor and metabolic disease reseach[3][4][5].",C19H13F2N7,DMSO : 25 mg/mL (66.25 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease,Phase 1,FC(F)(C1=NN=C2C=CC(C3=CN(C)N=C3)=NN21)C4=CC5=C(N=CC=C5)C=C4
Tivantinib,"ARQ 197; (3R,4R)-ARQ 198",905854-02-6,369.42,Apoptosis; c-Met/HGFR,Apoptosis; Protein Tyrosine Kinase/RTK,Tivantinib is a highly selective c-Met tyrosine kinase inhibitor with a Ki of 355 nM.,C23H19N3O2,DMSO : 100 mg/mL (270.69 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(NC1=O)[C@@H](C2=CN3C4=C(C=CC=C42)CCC3)[C@@H]1C5=CNC6=C5C=CC=C6
MK-2461,,917879-39-1,495.55,c-Met/HGFR,Protein Tyrosine Kinase/RTK,"MK-2461 is an ATP-competitive, selective and orally active wild-type and mutant c-Met inhibitor (IC50s: 0.4-2.5 nM). MK-2461 also inhibits Ron (IC50 of 7 nM) and Flt1 (IC50 of 10 nM),  MK-2461 shows selective for c-MET over other kinases (lC50s = 22-7800 nM). MK-2461 can be used for the study of cancer, such as gastric cancer[1].",C24H25N5O5S,DMSO : ≥ 31 mg/mL (62.56 mM),10mM,Cancer,Phase 2,O=S(N(C)C[C@H]1OCCOC1)(NC2=CC=C3C=CC(C(C(C3=C2)=O)=C4)=NC=C4C5=CN(N=C5)C)=O
Linifanib,ABT-869; AL-39324,796967-16-3,375.40,Apoptosis; Autophagy; c-Fms; c-Kit; FLT3; PDGFR; VEGFR,Apoptosis; Autophagy; Protein Tyrosine Kinase/RTK,"Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis[1][2].",C21H18FN5O,DMSO : 13.16 mg/mL (35.06 mM; Need ultrasonic),10mM,Cancer,Phase 3,O=C(NC1=CC=C(C2=C3C(N)=NNC3=CC=C2)C=C1)NC4=C(C=CC(C)=C4)F
Avagacestat,BMS-708163,1146699-66-2,520.89,Notch; γ-secretase,Neuronal Signaling; Stem Cell/Wnt,"Avagacestat (BMS-708163) is a potent inhibitor of γ-secretase, with IC50s of 0.27 nM and 0.30 nM for Aβ42 and Aβ40 inhibition; Avagacestat (BMS-708163) also inhibits NICD (Notch IntraCellular Domain) with IC50 of 0.84 nM and shows weak inhibition of CYP2C19, with IC50 of 20 μM. Avagacestat can be used for Alzheimer disease research.",C20H17ClF4N4O4S,DMSO : ≥ 100 mg/mL (191.98 mM),10mM,Cancer,Phase 2,O=S(N([C@@H](C(N)=O)CCC(F)(F)F)CC1=CC=C(C2=NOC=N2)C=C1F)(C3=CC=C(Cl)C=C3)=O
ZSTK474,,475110-96-4,417.41,Autophagy; PI3K,Autophagy; PI3K/Akt/mTOR,"ZSTK474 is an ATP-competitive pan-class I PI3K inhibitor with IC50s of 16 nM, 44 nM, 4.6 nM and 49 nM for PΙ3Κα, PI3Kβ, PI3Kδ and PI3Kγ, respectively.",C19H21F2N7O2,DMSO : 33.33 mg/mL (79.85 mM; Need ultrasonic),10mM,Cancer,Phase 1,FC(C1=NC2=C(N1C3=NC(N4CCOCC4)=NC(N5CCOCC5)=N3)C=CC=C2)F
Ruxolitinib,INCB18424,941678-49-5,306.37,Apoptosis; Autophagy; JAK; Mitophagy,Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC50s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3[1]. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy[3].",C17H18N6,DMSO : ≥ 100 mg/mL (326.40 mM); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Cancer,Launched,N#CC[C@H](C1CCCC1)N2N=CC(C3=C4C=CNC4=NC=N3)=C2
Ruxolitinib (S enantiomer),S-Ruxolitinib; S-INCB18424,941685-37-6,306.37,JAK,Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ruxolitinib (S enantiomer) (S-Ruxolitinib) is the S-enantiomer of Ruxolitinib (HY-50856). Ruxolitinib (S enantiomer) is an orally active, potent JAK inhibitor[1][2].",C17H18N6,DMSO : ≥ 100 mg/mL (326.40 mM); 1M HCl : 50 mg/mL (163.20 mM; ultrasonic and adjust pH to 1 with HCl),10mM,Cancer,Launched,N#CC[C@@H](C1CCCC1)N2N=CC(C3=NC=NC4=C3C=CN4)=C2
Ruxolitinib (phosphate),INCB018424 phosphate,1092939-17-7,404.36,Autophagy; JAK; Mitophagy,Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.",C17H21N6O4P,DMSO : 220 mg/mL (544.07 mM; Need ultrasonic); H2O : 10 mg/mL (24.73 mM; Need ultrasonic),10mM,Cancer,Launched,N#CC[C@H](C1CCCC1)N2N=CC(C3=C4C=CNC4=NC=N3)=C2.O=P(O)(O)O
Bafetinib,INNO-406; NS-187,859212-16-1,576.62,Apoptosis; Bcr-Abl; Src,Apoptosis; Protein Tyrosine Kinase/RTK,"Bafetinib is an orally active Lyn/Bcr-Abl tyrosine kinase inhibitor. Bafetinib enhances the activity of several pro-apoptotic Bcl-2 homology (BH) 3-pure proteins (Bim, Bad, Bmf, and Bik) through intrinsic apoptotic pathways regulated by the Bcl-2 family, and induces apoptosis of Ph+ leukemia cells. Bafetinib has antitumor activity[1][2][3].",C30H31F3N8O,DMSO : 100 mg/mL (173.42 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C(C1=CC=C(C(C(F)(F)F)=C1)CN2C[C@@H](N(C)C)CC2)NC3=CC=C(C)C(NC4=NC=CC(C5=CN=CN=C5)=N4)=C3
Crizotinib,PF-02341066,877399-52-5,450.34,Anaplastic lymphoma kinase (ALK); Autophagy; c-Met/HGFR; ROS Kinase,Autophagy; Protein Tyrosine Kinase/RTK,"Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition[1][2][3].",C21H22Cl2FN5O,DMSO : 20 mg/mL (44.41 mM; ultrasonic and warming and heat to 60°C); H2O : < 0.1 mg/mL (ultrasonic) (insoluble),10mM,Cancer,Launched,ClC1=C(F)C=CC(Cl)=C1[C@H](OC2=CC(C3=CN(N=C3)C4CCNCC4)=CN=C2N)C
Crizotinib (hydrochloride),PF-02341066 (hydrochloride),1415560-69-8,486.80,Anaplastic lymphoma kinase (ALK); Autophagy; c-Met/HGFR; ROS Kinase,Autophagy; Protein Tyrosine Kinase/RTK,"Crizotinib hydrochloride (PF-02341066 hydrochloride) is an orally bioavailable, selective, and ATP-competitive dual ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib hydrochloride (PF-02341066 hydrochloride) inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. It is also a ROS proto-oncogene 1 (ROS1) inhibitor. Crizotinib hydrochloride (PF-02341066 hydrochloride) has effective tumor growth inhibition[1][2][3].",C21H23Cl3FN5O,DMSO : ≥ 4.9 mg/mL (10.07 mM); H2O : 50 mg/mL (102.71 mM; Need ultrasonic),10mM,Cancer,Launched,ClC1=C(F)C=CC(Cl)=C1[C@H](OC2=CC(C3=CN(N=C3)C4CCNCC4)=CN=C2N)C.Cl
Gefitinib,ZD1839,184475-35-2,446.90,Apoptosis; Autophagy; EGFR,Apoptosis; Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer [1][2][5].",C22H24ClFN4O3,DMSO : 100 mg/mL (223.76 mM; Need ultrasonic),10mM,Cancer,Launched,ClC1=C(C=CC(NC2=NC=NC3=C2C=C(C(OC)=C3)OCCCN4CCOCC4)=C1)F
Gefitinib (hydrochloride),ZD-1839 hydrochloride,184475-55-6,483.36,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Gefitinib hydrochloride (ZD1839 hydrochloride) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib hydrochloride selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib hydrochloride also induces autophagy. Gefitinib hydrochloride has antitumour activity[1][2].",C22H25Cl2FN4O3,DMSO : 0.227 mg/mL (0.47 mM; Need ultrasonic and warming); H2O : 6.25 mg/mL (12.93 mM; Need ultrasonic),10mM,Cancer,Launched,ClC1=C(C=CC(NC2=NC=NC3=C2C=C(C(OC)=C3)OCCCN4CCOCC4)=C1)F.[H]Cl
Erlotinib,CP-358774; NSC 718781; OSI-774,183321-74-6,393.44,Autophagy; EGFR,Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer[1]. Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.",C22H23N3O4,DMSO : 3.94 mg/mL (10.01 mM; ultrasonic and warming and heat to 40°C),10mM,Cancer,Launched,C#CC1=CC=CC(NC2=NC=NC3=C2C=C(C(OCCOC)=C3)OCCOC)=C1
Lapatinib,GW572016; GW2016,231277-92-2,581.06,Autophagy; EGFR; Ferroptosis,Apoptosis; Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].",C29H26ClFN4O4S,DMSO : 125 mg/mL (215.12 mM; ultrasonic and warming and heat to 06°C),10mM,Cancer,Launched,O=S(CCNCC1=CC=C(C2=CC=C3C(C(NC4=CC(Cl)=C(C=C4)OCC5=CC(F)=CC=C5)=NC=N3)=C2)O1)(C)=O
Lapatinib (ditosylate),GW572016 (ditosylate); GW2016 (ditosylate),388082-77-7,925.46,Autophagy; EGFR; Ferroptosis,Apoptosis; Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Lapatinib ditosylate (GW572016 ditosylate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].",C43H42ClFN4O10S3,DMSO : 125 mg/mL (135.07 mM; Need ultrasonic),10mM,Cancer,Launched,O=S(CCNCC1=CC=C(C2=CC=C3C(C(NC4=CC(Cl)=C(C=C4)OCC5=CC(F)=CC=C5)=NC=N3)=C2)O1)(C)=O.O=S(C6=CC=C(C)C=C6)(O)=O.O=S(C7=CC=C(C)C=C7)(O)=O
Lapatinib (ditosylate monohydrate),GW572016 (ditosylate monohydrate); GW2016 (ditosylate monohydrate),388082-78-8,943.48,Autophagy; EGFR; Ferroptosis,Apoptosis; Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].",C43H44ClFN4O11S3,DMSO : 50 mg/mL (53.00 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=S(CCNCC1=CC=C(C2=CC3=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)N=CN=C3C=C2)O1)(C)=O.O=S(C6=CC=C(C)C=C6)(O)=O.O=S(C7=CC=C(C)C=C7)(O)=O.O
Nintedanib,BIBF 1120,656247-17-5,539.62,FGFR; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.",C31H33N5O4,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 5.83 mg/mL (10.80 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C1NC2=CC(C(OC)=O)=CC=C2/C1=C(NC3=CC=C(N(C(CN4CCN(C)CC4)=O)C)C=C3)\C5=CC=CC=C5
Dovitinib,CHIR-258; TKI258,405169-16-6,392.43,c-Fms; c-Kit; FGFR; FLT3; PDGFR; VEGFR,Protein Tyrosine Kinase/RTK,"Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib has potent antitumor activity[1][2].",C21H21FN6O,DMSO : 23.33 mg/mL (59.45 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 3,O=C1NC(C=CC=C2F)=C2C(N)=C1C3=NC4=CC=C(N5CCN(C)CC5)C=C4N3
Perifosine,KRX-0401; NSC 639966; D21266,157716-52-4,461.66,Akt; Apoptosis; Autophagy,Apoptosis; Autophagy; PI3K/Akt/mTOR,Perifosine is an oral Akt inhibitor which inhibits proliferation of different tumor cell lines with IC50s of 0.6-8.9 μM.,C25H52NO4P,H2O : 100 mg/mL (216.61 mM; Need ultrasonic); DMSO : < 1 mg/mL (insoluble or slightly soluble); DMF : < 1 mg/mL (insoluble),10mM,Cancer,Phase 3,[O-]P(OC1CC[N+](C)(CC1)C)(OCCCCCCCCCCCCCCCCCC)=O
Temsirolimus,CCI-779,162635-04-3,1030.29,Apoptosis; Autophagy; Bacterial; mTOR,Anti-infection; Apoptosis; Autophagy; PI3K/Akt/mTOR,Temsirolimus is an inhibitor of mTOR with an IC50 of 1.76 μM. Temsirolimus activates autophagy and prevents deterioration of cardiac function in animal model[8].,C56H87NO16,DMSO : 100 mg/mL (97.06 mM; Need ultrasonic),10mM,Cancer,Launched,O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)OC)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](OC(C(C)(CO)CO)=O)CC4)OC)C)=O)=O
Tacedinaline,N-acetyldinaline; CI-994; Goe-5549,112522-64-2,269.30,Apoptosis; HDAC,Apoptosis; Cell Cycle/DNA Damage; Epigenetics,"Tacedinaline (N-acetyldinaline) is an inhibitor of the histone deacetylase (HDAC) with IC50s of 0.9, 0.9, 1.2 μM for recombinant HDAC 1, 2 and 3 respectively.",C15H15N3O2,DMSO : ≥ 50 mg/mL (185.67 mM),10mM,Cancer,Phase 3,O=C(NC1=C(N)C=CC=C1)C2=CC=C(NC(C)=O)C=C2
GSK-1070916,GSK-1070916A,942918-07-2,507.63,Apoptosis; Aurora Kinase,Apoptosis; Cell Cycle/DNA Damage; Epigenetics,"GSK-1070916 is a potent and selective ATP-competitive inhibitor of aurora B and aurora C with Kis of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A.",C30H33N7O,DMSO : 16.67 mg/mL (32.84 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Phase 1,O=C(NC1=CC=C(C2=NN(C=C2C3=C4C(NC(C5=CC=CC(CN(C)C)=C5)=C4)=NC=C3)CC)C=C1)N(C)C
Buparlisib,BKM120; NVP-BKM120,944396-07-0,410.39,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Buparlisib (BKM120; NVP-BKM120) is a pan-class I PI3K inhibitor, with IC50s of 52, 166, 116 and 262 nM for p110α, p110β, p110δ and p110γ, respectively.",C18H21F3N6O2,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : 100 mg/mL (243.67 mM; Need ultrasonic),10mM,Cancer,Phase 3,FC(F)(C1=C(C2=CC(N3CCOCC3)=NC(N4CCOCC4)=N2)C=NC(N)=C1)F
Osimertinib (dimesylate),AZD-9291 (dimesylate); Mereletinib (dimesylate),2070014-82-1,691.82,EGFR,JAK/STAT Signaling; Protein Tyrosine Kinase/RTK,"Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective EGFR inhibitor with IC50s of 12 and 1 nM against EGFRL858R and EGFRL858R/T790M, respectively.",C30H41N7O8S2,DMSO : 2.63 mg/mL (3.80 mM; Need ultrasonic); H2O : 100 mg/mL (144.55 mM; Need ultrasonic),10mM,Cancer,Launched,CS(=O)(O)=O.C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(CCN(C)C)C)=O.CS(=O)(O)=O
5-Fluorouracil,5-FU,51-21-8,130.08,Apoptosis; Endogenous Metabolite; HIV; Nucleoside Antimetabolite/Analog,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. 5-Fluorouracil induces apoptosis and can be used as a chemical sensitizer[1][2]. 5-Fluorouracil also inhibits HIV[3].,C4H3FN2O2,DMSO : 50 mg/mL (384.38 mM; Need ultrasonic); 1 M Ammonium hydroxide : 50 mg/mL (384.38 mM; Need ultrasonic); H2O : 10 mg/mL (76.88 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,O=C(N1)NC=C(F)C1=O
Decitabine,5-Aza-2'-deoxycytidine; 5-AZA-CdR; NSC 127716,2353-33-5,228.21,Apoptosis; DNA Methyltransferase; Nucleoside Antimetabolite/Analog,Apoptosis; Cell Cycle/DNA Damage; Epigenetics,Decitabine (NSC 127716) is an orally active deoxycytidine analogue antimetabolite and a DNA methyltransferase inhibitor. Decitabine incorporates into DNA in place of cytosine can covalently trap DNA methyltransferase to DNA causing irreversible inhibition of the enzyme. Decitabine induces cell G2/M arrest and cell apoptosis. Decitabine has potent anticancer activity[1][2].,C8H12N4O4,H2O : 20 mg/mL (87.64 mM; Need ultrasonic); DMSO : ≥ 50 mg/mL (219.10 mM),10mM,Cancer,Launched,O[C@H]1C[C@H](N2C(N=C(N)N=C2)=O)O[C@@H]1CO
Clofarabine,,123318-82-1,303.68,Apoptosis; Autophagy; Nucleoside Antimetabolite/Analog,Apoptosis; Autophagy; Cell Cycle/DNA Damage,"Clofarabine, a nucleoside analogue for research of cancer, is a potent inhibitor of ribonucleotide reductase (IC50=65 nM) by binding to the allosteric site on the regulatory subunit[1].",C10H11ClFN5O3,DMSO : ≥ 50 mg/mL (164.65 mM),10mM,Metabolic Disease; Cancer,Launched,O[C@H]1[C@H](F)[C@H](N(C=N2)C3=C2C(N)=NC(Cl)=N3)O[C@@H]1CO
Darifenacin (hydrobromide),UK-88525 (hydrobromide),133099-07-7,507.46,Akt; mAChR; p38 MAPK,GPCR/G Protein; MAPK/ERK Pathway; Neuronal Signaling; PI3K/Akt/mTOR,Darifenacin (UK-88525) hydrobromide is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9.  Darifenacin hydrobromide binds >20-fold more specifically to M3R than to other muscarinic receptors.  Darifenacin hydrobromide can be used in the study of urinary incontinence and other symptoms of overactive bladder.  Darifenacin hydrobromide inhibits tumor growth in colorectal cancer cells and has anti-tumor effects[1][2][3][4][5][6].,C28H31BrN2O2,DMSO : 33.33 mg/mL (65.68 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Neurological Disease,Launched,O=C(C(C1=CC=CC=C1)([C@@H]2CCN(CCC3=CC4=C(OCC4)C=C3)C2)C5=CC=CC=C5)N.Br
Darifenacin,UK-88525,133099-04-4,426.55,Akt; mAChR; p38 MAPK,GPCR/G Protein; MAPK/ERK Pathway; Neuronal Signaling; PI3K/Akt/mTOR,Darifenacin (UK-88525) is a selective and orally active M3 muscarinic receptor (M3R) antagonist with a pKi of 8.9.  Darifenacin binds >20-fold more specifically to M3R than to other muscarinic receptors. Darifenacin can be used in the study of urinary incontinence and other symptoms of overactive bladder.  Darifenacin inhibits tumor growth in colorectal cancer cells and has anti-tumor effects[1][2][3][4][5][6].,C28H30N2O2,DMSO : 100 mg/mL (234.44 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Neurological Disease,Launched,O=C(N)C(C1=CC=CC=C1)([C@H]2CN(CCC3=CC=C(OCC4)C4=C3)CC2)C5=CC=CC=C5
Nifuratel,NF 113; SAP 113; Methylmercadone,4936-47-4,285.28,Antibiotic; Apoptosis; Bacterial; Fungal; Interleukin Related; Parasite; STAT; TNF Receptor,Anti-infection; Apoptosis; Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt,"Nifuratel (NF 113) is an orally active broad-spectrum antibiotic with antiprotozoal, antibacterial, anticancer and anti-inflammatory activities, and has good inhibitory effects on Candida and Trichomonas. Nifuratel is also a STAT3 inhibitor, which significantly inhibits the growth and proliferation of human gastric cancer cells and induces apoptosis. In addition, Nifuratel also inhibits mast cell-mediated antigen hypersensitivity reactions and can be used in the study of IgE-mediated allergic diseases[1][2][3][4][5][6][7][8].",C10H11N3O5S,H2O : < 0.1 mg/mL (insoluble); DMSO : 50 mg/mL (175.27 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C1OC(CSC)CN1/N=C/C2=CC=C([N+]([O-])=O)O2
Trifluridine,Trifluorothymidine; 5-Trifluorothymidine; TFT,70-00-8,296.20,Apoptosis; Autophagy; DNA/RNA Synthesis; HSV; Nucleoside Antimetabolite/Analog; Orthopoxvirus; Thymidylate Synthase,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage,"Trifluridine (Trifluorothymidine) is an irreversible and orally active thymidylate synthase inhibitor, and thereby suppressing DNA synthesis. Trifluridine is an antiviral molecule used for research of HSV, rhabdovirus and orthopoxvirus infection. Trifluridine induces cell apoptosis and autophagy. Trifluridine is also an anticancer agent used in studies of metastatic colorectal cancer, gastrointestinal tumors[1][2][3][4].",C10H11F3N2O5,H2O : 33.33 mg/mL (112.53 mM; ultrasonic and warming and heat to 60°C); DMSO : ≥ 100 mg/mL (337.61 mM),10mM,Cancer,Launched,O[C@H]1C[C@H](N2C(NC(C(C(F)(F)F)=C2)=O)=O)O[C@@H]1CO
Tipiracil (hydrochloride),,183204-72-0,279.12,Nucleoside Antimetabolite/Analog,Cell Cycle/DNA Damage,"Tipiracil (hydrochloride) is a thymidine phosphorylase inhibitor (TPI), used for cancer research.",C9H12Cl2N4O2,H2O : 50 mg/mL (179.13 mM; Need ultrasonic); DMSO : < 1 mg/mL (insoluble or slightly soluble); DMF : < 1 mg/mL (insoluble),10mM,Cancer,Launched,[H]Cl.O=C1C(Cl)=C(CN2C(CCC2)=N)NC(N1)=O
Tipiracil,,183204-74-2,242.66,Nucleoside Antimetabolite/Analog; Thymidylate Synthase,Apoptosis; Cell Cycle/DNA Damage,Tipiracil is a thymidine phosphorylase (TPase) inhibitor.,C9H11ClN4O2,DMSO : < 1 mg/mL (ultrasonic;warming) (insoluble or slightly soluble); H2O : 1 mg/mL (4.12 mM; Need ultrasonic),2mM,Cancer,Launched,O=C1NC(C(Cl)=C(CN2C(CCC2)=N)N1)=O
Histamine (phosphate),Histamine diphosphate,51-74-1,307.14,Akt; Apoptosis; Endogenous Metabolite; Histamine Receptor; p38 MAPK; Reactive Oxygen Species (ROS),Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB; PI3K/Akt/mTOR,"Histamine phosphate is the agonist for histamine receptor and a vasodilator. Histamine phosphate is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine phosphate affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine phosphate can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma[1][2][3][4][5][6][7].",C5H15N3O8P2,H2O : 100 mg/mL (325.58 mM; Need ultrasonic); DMSO : 1.43 mg/mL (4.66 mM; Need ultrasonic),10mM,Cancer; Endocrinology; Inflammation/Immunology; Neurological Disease,Launched,NCCC1=CNC=N1.O=P(O)(O)O.O=P(O)(O)O
Etilefrine,,709-55-7,181.23,Adrenergic Receptor; Akt; AMPK,Epigenetics; GPCR/G Protein; Neuronal Signaling; PI3K/Akt/mTOR,"Etilefrine is a sympathetic nerve agonist and AMPK activator that selectively targets α1/β1 adrenergic receptors. Etilefrine stimulates α1 adrenergic receptors, leading to contraction of vascular smooth muscle and increased peripheral resistance. Etilefrine also stimulates β1 receptors to enhance myocardial contractility and increase heart rate, thereby increasing blood pressure and improving cardiac output. Etilefrine also bidirectionally regulates the AMPK/Akt pathway and modulates the phosphorylation levels. Etilefrine can be used in cardiovascular research, such as postural hypotension, chylothorax, and improving low cardiac output[1][2][3].",C10H15NO2,DMSO : 40 mg/mL (220.71 mM; Need ultrasonic),10mM,Cardiovascular Disease,Launched,OC(CNCC)C1=CC=CC(O)=C1
Etilefrine (hydrochloride),,943-17-9,217.70,Adrenergic Receptor; Akt; AMPK,Epigenetics; GPCR/G Protein; Neuronal Signaling; PI3K/Akt/mTOR,"Etilefrine hydrochloride is a sympathetic nerve agonist and AMPK activator that selectively targets α1/β1 adrenergic receptors. Etilefrine hydrochloride stimulates α1 adrenergic receptors, leading to contraction of vascular smooth muscle and increased peripheral resistance. Etilefrine hydrochloride also stimulates β1 receptors to enhance myocardial contractility and increase heart rate, thereby increasing blood pressure and improving cardiac output. Etilefrine hydrochloride also bidirectionally regulates the AMPK/Akt pathway and modulates the phosphorylation levels. Etilefrine hydrochloride can be used in cardiovascular research, such as postural hypotension, chylothorax, and improving low cardiac output[1][2][3].",C10H16ClNO2,DMSO : 100 mg/mL (459.36 mM; Need ultrasonic),10mM,Cardiovascular Disease,Phase 2,OC(CNCC)C1=CC=CC(O)=C1.[H]Cl
4-Phenylbutyric acid,4-PBA; Benzenebutyric acid,1821-12-1,164.20,HDAC; Virus Protease,Anti-infection; Cell Cycle/DNA Damage; Epigenetics,"4-Phenylbutyric acid (4-PBA) is an inhibitor of HDAC and endoplasmic reticulum (ER) stress, used in cancer and infection research.",C10H12O2,H2O : 2 mg/mL (12.18 mM; Need ultrasonic); DMSO : 100 mg/mL (609.01 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,O=C(O)CCCC1=CC=CC=C1
Gemcitabine (hydrochloride),LY 188011 (hydrochloride),122111-03-9,299.66,Apoptosis; Autophagy; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog,Apoptosis; Autophagy; Cell Cycle/DNA Damage,"Gemcitabine Hydrochloride (LY 188011 Hydrochloride) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine Hydrochloride inhibits DNA synthesis and repair, resulting in autophagyand apoptosis[1][2].",C9H12ClF2N3O4,H2O : 25 mg/mL (83.43 mM; Need ultrasonic); DMSO : 62.5 mg/mL (208.57 mM; ultrasonic and warming and heat to 60°C); DMF : 2.5 mg/mL (8.34 mM; Need ultrasonic),10mM,Cancer,Launched,O[C@H]1C(F)(F)[C@H](N2C(N=C(N)C=C2)=O)O[C@@H]1CO.Cl
Sulindac,MK-231,38194-50-2,356.41,NF-κB; PD-1/PD-L1,Immunology/Inflammation; NF-κB,"Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer[1][2].",C20H17FO3S,DMSO : 50 mg/mL (140.29 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,Launched,O=C(CC(C1=C2C=CC(F)=C1)=C(/C2=C/C3=CC=C(C=C3)S(C)=O)C)O
Docetaxel,RP-56976,114977-28-5,807.88,Apoptosis; Endogenous Metabolite; Microtubule/Tubulin,Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Metabolic Enzyme/Protease,"Docetaxel (RP-56976) is a microtubule?depolymerization inhibitor, with an IC50 of 0.2 μM. Docetaxel attenuates the effects of?bcl-2 and bcl-xL gene expression. Docetaxel arrests the cell cycle at G2/M and leads to cell apoptosis. Docetaxel has anti-cancer activity[1][3].",C43H53NO14,DMSO : 100 mg/mL (123.78 mM; Need ultrasonic); Ethanol : 50 mg/mL (61.89 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(OC(C)(C)C)N[C@@H](C1=CC=CC=C1)[C@H](C(O[C@@H]2C(C)=C([C@@H](O)C([C@@]3(C)[C@]([C@@](CO4)(OC(C)=O)[C@@]4([H])C[C@@H]3O)([H])[C@@H]5OC(C6=CC=CC=C6)=O)=O)C(C)(C)[C@@]5(O)C2)=O)O
Docetaxel (Trihydrate),RP-56976 (Trihydrate),148408-66-6,861.93,Apoptosis; Microtubule/Tubulin,Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,Docetaxel Trihydrate (RP-56976 Trihydrate) is an antineoplastic agent and inhibits microtubule?depolymerization with an IC50 value of 0.2 μM[1]. Docetaxel Trihydrate is a semisynthetic analog of taxol and attenuates the effects of?bcl-2?and?bcl-xL?gene expression. Docetaxel Trihydrate arrests the cell cycle at G2/M and leads to cell apoptosis[1][3].,C43H59NO17,Ethanol : 50 mg/mL (58.01 mM; Need ultrasonic); DMSO : 250 mg/mL (290.05 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(OC(C)(C)C)N[C@H]([C@H](C(O[C@@H]1C(C)=C([C@@H](O)C([C@@]2(C)[C@]([C@@](CO3)(OC(C)=O)[C@@]3([H])C[C@@H]2O)([H])[C@@H]4OC(C5=CC=CC=C5)=O)=O)C(C)(C)[C@@]4(O)C1)=O)O)C6=CC=CC=C6.O.O.O
Paclitaxel,,33069-62-4,853.91,ADC Payload; Apoptosis; Autophagy; Microtubule/Tubulin,Antibody-drug Conjugate/ADC Related; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton,Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy[1][2].,C47H51NO14,H2O : < 0.1 mg/mL (insoluble); DMSO : 100 mg/mL (117.11 mM; Need ultrasonic),10mM,Cancer; Cardiovascular Disease,Launched,O=C(C1=CC=CC=C1)N[C@@H](C2=CC=CC=C2)[C@H](C(O[C@@H]3C(C)=C([C@@H](OC(C)=O)C([C@@]4(C)[C@]([C@@](CO5)(OC(C)=O)[C@@]5([H])C[C@@H]4O)([H])[C@@H]6OC(C7=CC=CC=C7)=O)=O)C(C)(C)[C@@]6(O)C3)=O)O
Capecitabine,,154361-50-9,359.35,Apoptosis; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog,Apoptosis; Cell Cycle/DNA Damage,"Capecitabine is an oral proagent that is converted to its active metabolite, 5-FU, by thymidine phosphorylase.",C15H22FN3O6,H2O : 12.5 mg/mL (34.79 mM; ultrasonic and warming and heat to 60°C); DMSO : 250 mg/mL (695.70 mM; Need ultrasonic),10mM,Cancer,Launched,O[C@H]1[C@@H](O)[C@H](N2C=C(C(NC(OCCCCC)=O)=NC2=O)F)O[C@@H]1C
Ceftiofur (hydrochloride),,103980-44-5,560.02,Antibiotic; Bacterial; Interleukin Related; NF-κB; p38 MAPK; TNF Receptor,Anti-infection; Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB,"Ceftiofur hydrochloride is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur hydrochloride exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur hydrochloride also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6[1][2][3].",C19H18ClN5O7S3,DMSO : 175 mg/mL (312.49 mM; Need ultrasonic),10mM,Infection,Launched,[H]Cl.O=C(C(N12)=C(CSC(C3=CC=CO3)=O)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O
Fludarabine (phosphate),NSC 118218 (phosphate),75607-67-9,365.21,Apoptosis; Nucleoside Antimetabolite/Analog,Apoptosis; Cell Cycle/DNA Damage,"Fludarabine (phosphate) is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.",C10H13FN5O7P,DMSO : ≥ 100 mg/mL (273.82 mM); H2O : 5 mg/mL (13.69 mM; Need ultrasonic),10mM,Cancer,Launched,NC1=C2C(N([C@H]3[C@@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O3)C=N2)=NC(F)=N1
Fludarabine,F-ara-A; NSC 118218,21679-14-1,285.24,Apoptosis; DNA/RNA Synthesis; Nucleoside Antimetabolite/Analog; STAT,Apoptosis; Cell Cycle/DNA Damage; JAK/STAT Signaling; Stem Cell/Wnt,Fludarabine (NSC 118218) is a DNA synthesis inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes[1][2][3][4].,C10H12FN5O4,DMSO : 25 mg/mL (87.65 mM; Need ultrasonic),10mM,Cancer,Launched,O[C@H]1[C@H](O)[C@H](N2C(N=C(F)N=C3N)=C3N=C2)O[C@@H]1CO
Tropisetron,SDZ-ICS-930 (free base),89565-68-4,284.36,5-HT Receptor; AP-1; JAK; nAChR; NF-κB; Nuclear Factor of activated T Cells (NFAT); p38 MAPK,Epigenetics; GPCR/G Protein; Immunology/Inflammation; JAK/STAT Signaling; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Neuronal Signaling; NF-κB; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Tropisetron is an orally active 5-HT3R antagonist (Ki = 5.3 nM) as well as being a potent and selective α7 nicotinic partial agonist (EC50 = 1.3 μM). Tropisetron prevents phosphorylation and activation of the p38 MAPK. Tropisetron inhibits both IL-2 gene transcription and IL-2 synthesis in stimulated T cells. Tropisetron inhibits the binding to DNA and the transcriptional activity of NFAT and AP-1. Tropisetron is anti-inflammatory and antiemetic. Tropisetron has antitumor and neuroprotective effects. Tropisetron can be studied in research for diseases including hemorrhagic cystitis, chronic joint inflammation, lung cancer and chronic cerebral hypoperfusion[1][2][3][4][5][6].",C17H20N2O2,H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble or slightly soluble),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,O=C(C1=CNC2=C1C=CC=C2)O[C@H]3C[C@H]4CC[C@H](N4C)C3
Bendamustine (hydrochloride),SDX-105,3543-75-7,394.72,Apoptosis; DNA Alkylator/Crosslinker,Apoptosis; Cell Cycle/DNA Damage,"Bendamustine hydrochloride (SDX-105), a purine analogue, is a DNA cross-linking agent. Bendamustine hydrochloride activats DNA-damage stress response and apoptosis. Bendamustine hydrochloride has potent alkylating, anticancer and antimetabolite properties[1].",C16H22Cl3N3O2,DMSO : 100 mg/mL (253.34 mM; Need ultrasonic); H2O : 10 mg/mL (25.33 mM; Need ultrasonic),10mM,Cancer,Launched,CN1C(C=CC(N(CCCl)CCCl)=C2)=C2N=C1CCCC(O)=O.Cl
Dacarbazine,Imidazole Carboxamide,4342-03-4,182.18,Apoptosis; Nucleoside Antimetabolite/Analog,Apoptosis; Cell Cycle/DNA Damage,"Dacarbazine is a nonspecific antineoplastic (antineoplastic) alkylating agent. Dacarbazine inhibits T and B lymphocyte responses with IC50 of 50 and 10 μg/mL, respectively. Dacarbazine can be used in the study of metastatic malignant melanoma[1][2][3][4][5].",C6H10N6O,DMSO : 5 mg/mL (27.45 mM; ultrasonic and warming and heat to 60°C); 0.1 M HCl : 20 mg/mL (109.78 mM; ultrasonic and warming and heat to 60°C); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,O=C(C1=C(/N=N/N(C)C)NC=N1)N
Artemisinin,Qinghaosu; NSC 369397,63968-64-9,282.34,Akt; Ferroptosis; HCV; Parasite,Anti-infection; Apoptosis; PI3K/Akt/mTOR,"Artemisinin (Qinghaosu), a sesquiterpene lactone,  is an anti-malarial agent isolated from the aerial parts of Artemisia annua L. plants[1]. Artemisinin inhibits AKT signaling pathway by decreasing pAKT in a dose-dependent manner. Artemisinin reduces cancer cell proliferation, migration, invasion, tumorigenesis and metastasis and has neuroprotective effects[2].",C15H22O5,H2O : < 0.1 mg/mL (ultrasonic) (insoluble); DMSO : 50 mg/mL (177.09 mM; Need ultrasonic),10mM,Cancer; Infection; Neurological Disease,Launched,O=C1[C@H](C)[C@]2([H])CC[C@@H](C)[C@]3([H])CC[C@@](O4)(C)OO[C@]32[C@]4([H])O1
Floxuridine,5-Fluorouracil 2'-deoxyriboside,50-91-9,246.19,Apoptosis; Bacterial; CMV; DNA/RNA Synthesis; HSV; Nucleoside Antimetabolite/Analog,Anti-infection; Apoptosis; Cell Cycle/DNA Damage,Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis[1][2]. Floxuridine has antiviral effects against HSV and CMV[3].,C9H11FN2O5,DMSO : 125 mg/mL (507.74 mM; Need ultrasonic); H2O : ≥ 50 mg/mL (203.10 mM),10mM,Cancer; Infection,Launched,OC[C@@H]1[C@@H](O)C[C@H](N2C(NC(C(F)=C2)=O)=O)O1
Stavudine,d4T,3056-17-5,224.22,Apoptosis; Autophagy; HIV; NOD-like Receptor (NLR); Nucleoside Antimetabolite/Analog; Reverse Transcriptase,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation,Stavudine (d4T) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Stavudine has activity against HIV-1 and HIV-2. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA). Stavudine reduces NLRP3 inflammasome activation and modulates Amyloid-β autophagy. Stavudine induces apoptosis[1][2][3][4].,C10H12N2O4,DMSO : 125 mg/mL (557.49 mM; Need ultrasonic); H2O : 16.67 mg/mL (74.35 mM; Need ultrasonic),10mM,Infection,Launched,OC[C@H]1O[C@@H](N2C=C(C)C(NC2=O)=O)C=C1
Perindopril,S-9490,82834-16-0,368.47,Angiotensin-converting Enzyme (ACE); NF-κB; Sirtuin; STAT,Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt,"Perindopril (S-9490) is an orally available, long-acting angiotensin-converting enzyme (ACE) inhibitor. Perindopril inhibits inflammatory cell influx and intimal thickening, preserving elastin on the inside of the aorta. Perindopril effectively inhibits experimental abdominal aortic aneurysm (AAA) formation in a rat model and reduces pulmonary vasoconstriction in rats with pulmonary hypertension[1][2][3][4].",C19H32N2O5,H2O : 100 mg/mL (271.39 mM; ultrasonic and warming and heat to 80°C),10mM,Cancer; Neurological Disease; Cardiovascular Disease,Launched,O=C([C@H]1N(C([C@@H](N[C@H](C(OCC)=O)CCC)C)=O)[C@@]2([H])CCCC[C@@]2([H])C1)O
Perindopril (erbumine),Perindopril (tert-butylamine salt); S-9490 (erbumine),107133-36-8,441.60,Angiotensin-converting Enzyme (ACE); NF-κB; Sirtuin; STAT,Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt,Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NF-κB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure[1][2][3][4].,C23H43N3O5,DMSO : 10 mg/mL (22.64 mM; Need ultrasonic); H2O : ≥ 50 mg/mL (113.22 mM),10mM,Cardiovascular Disease; Cancer,Launched,O=C([C@H]1N(C([C@@H](N[C@H](C(OCC)=O)CCC)C)=O)[C@@]2([H])CCCC[C@@]2([H])C1)O.CC(C)(C)N
Pefloxacin,Pefloxacinium,70458-92-3,333.36,Antibiotic; Bacterial; DNA/RNA Synthesis; Parasite; Topoisomerase,Anti-infection; Cell Cycle/DNA Damage,"Pefloxacin is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC50 of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC90s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies[1][2][3][4][5][6][7][8][9].",C17H20FN3O3,DMSO : 1 mg/mL (3.00 mM; ultrasonic and warming and heat to 60°C),2mM,Infection; Inflammation/Immunology,Launched,O=C(C1=CN(CC)C2=C(C=C(F)C(N3CCN(C)CC3)=C2)C1=O)O
Cytidine,Cytosine β-D-riboside; Cytosine-1-β-D-ribofuranoside,65-46-3,243.22,Endogenous Metabolite; Nucleoside Antimetabolite/Analog,Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function[1][2][3].",C9H13N3O5,H2O : ≥ 50 mg/mL (205.58 mM); DMSO : 50 mg/mL (205.58 mM; Need ultrasonic),10mM,Neurological Disease,Launched,O[C@H]1[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O[C@@H]1CO
Altretamine,ENT-50852; RB-1515; WR-95704,645-05-6,210.28,DNA Alkylator/Crosslinker,Cell Cycle/DNA Damage,Altretamine is an alkylating antineoplastic agent.,C9H18N6,DMSO : 8.33 mg/mL (39.61 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Launched,CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1
Carmofur,HCFU,61422-45-5,257.26,Ceramidase; FAAH; Glutathione Peroxidase; Nucleoside Antimetabolite/Analog; SARS-CoV; Virus Protease,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Neuronal Signaling,"Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI)[1][2][3].",C11H16FN3O3,DMSO : 83.33 mg/mL (323.91 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C(N(C(N1)=O)C=C(F)C1=O)NCCCCCC
Albendazole,SKF-62979,54965-21-8,265.33,Antibiotic; Apoptosis; Autophagy; Bacterial; HIF/HIF Prolyl-Hydroxylase; Microtubule/Tubulin; Parasite; Reactive Oxygen Species (ROS); VEGFR,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Protein Tyrosine Kinase/RTK,"Albendazole (SKF-62979) is an orally active and broad-spectrum parasiticide with high effectiveness and low host toxicity, is used for the research of gastrointestinal parasites in humans and animals. Albendazole induces apoptosis and autophagy in cancer cells. Albendazole also inhibits tubulin polymerization and HIF-1α, VEGF expression, has antioxidant activity, and inhibits the glycolytic process in cancer cells[1][2][3][4][5].",C12H15N3O2S,DMSO : 20 mg/mL (75.38 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer; Infection,Launched,O=C(OC)NC1=NC2=CC=C(SCCC)C=C2N1
Busulfan,,55-98-1,246.30,Apoptosis; DNA Alkylator/Crosslinker,Apoptosis; Cell Cycle/DNA Damage,Busulfan is a potent alkylating antineoplastic agent. Busulfan causes DNA damage by cross-linking DNAs and DNA and proteins. Busulfan inhibits thioredoxin reductase. Busulfan induces apoptosis. Busulfan is an immunosuppressive and myeloablative chemotherapeutic agent[1][2][3].,C6H14O6S2,DMSO : 50 mg/mL (203.00 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble); Methanol : 1 mg/mL (4.06 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Inflammation/Immunology,Launched,CS(=O)(OCCCCOS(C)(=O)=O)=O
Thiabendazole,Tiabendazole; 2-(4-Thiazolyl)benzimidazole,148-79-8,201.25,Caspase; CDK; Interleukin Related; MDM-2/p53; Mitochondrial Metabolism; Parasite; VEGFR,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,Thiabendazole is an orally available benzimidazole fungicide with repellent and anticancer activities. Thiabendazole can result in developmental malformations. Thiabendazole can be used for modeling[1][2][3][4][5].,C10H7N3S,H2O : < 0.1 mg/mL (ultrasonic) (insoluble); DMSO : 50 mg/mL (248.45 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease,Launched,C1(C2=CSC=N2)=NC3=CC=CC=C3N1
Vidarabine,Ara-A; Adenine Arabinoside; 9-β-D-Arabinofuranosyladenine,5536-17-4,267.25,Antibiotic; HSV; Nucleoside Antimetabolite/Analog; Orthopoxvirus,Anti-infection; Cell Cycle/DNA Damage,Vidarabine (Ara-A) an antiviral agent which is active against herpes simplex and varicella zoster viruses[1][2]. Vidarabine has IC50s of 9.3 μg/ml for HSV-1 and 11.3 μg/ml for HSV-2[2]. Vidarabine also has anti-orthopoxvirus activity[3].,C10H13N5O4,DMSO : 50 mg/mL (187.09 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Infection,Launched,OC[C@@H]1[C@@H](O)[C@H](O)[C@H](N2C3=NC=NC(N)=C3N=C2)O1
Flubendazole,,31430-15-6,313.28,Apoptosis; Autophagy; MDM-2/p53; Microtubule/Tubulin; Parasite; STAT,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton; JAK/STAT Signaling; Stem Cell/Wnt,"Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites[1][2].",C16H12FN3O3,DMSO : 4.17 mg/mL (13.31 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,O=C(OC)NC1=NC2=CC=C(C(C3=CC=C(F)C=C3)=O)C=C2N1
Tioconazole,UK-20349,65899-73-2,387.71,Akt; Antibiotic; Autophagy; Fungal; mTOR; Parasite; PI3K,Anti-infection; Autophagy; PI3K/Akt/mTOR,"Tioconazole (UK-20349) is a broad-spectrum antifungal imidazole derivative. Tioconazole inhibits several dermatophytes and yeasts, with MIC50 values of less than 3.12 mg/L and 9 mg/L, respectively. Additionally, Tioconazole exhibits anti-parasitic activity. Tioconazole exerts anticancer activity by inhibiting the PI3K/AKT/mTOR signaling pathway and blocking autophagy. Tioconazole is applicable for research in the fields of anti-infection and anticancer therapy[1][2][3][4][5].",C16H13Cl3N2OS,DMSO : ≥ 100 mg/mL (257.92 mM); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer; Infection,Launched,ClC1=CC=C(C(OCC2=C(Cl)SC=C2)CN3C=CN=C3)C(Cl)=C1
Levofloxacin,(-)-Ofloxacin,100986-85-4,361.37,Antibiotic; Bacterial; DNA/RNA Synthesis; Orthopoxvirus; Topoisomerase,Anti-infection; Cell Cycle/DNA Damage,"Levofloxacin ((-)-Ofloxacin) is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin inhibits the DNA gyrase and topoisomerase IV.  Levofloxacin can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin shows anti-orthopoxvirus activity[1][2][3][4][5].",C18H20FN3O4,DMSO : 10 mg/mL (27.67 mM; Need ultrasonic); H2O : ≥ 5 mg/mL (13.84 mM),10mM,Infection; Cancer,Launched,O=C(C(C1=O)=CN2[C@@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O
Levofloxacin (hydrate),Levofloxacin hemihydrate,138199-71-0,370.38,Antibiotic; Bacterial; DNA/RNA Synthesis; Orthopoxvirus; Topoisomerase,Anti-infection; Cell Cycle/DNA Damage,"Levofloxacin hydrate (Levofloxacin hemihydrate) is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrate inhibits the DNA gyrase and topoisomerase IV.  Levofloxacin hydrate can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin hydrate shows anti-orthopoxvirus activity[1][2][3][4].",C18H20FN3O4.1/2H2O,DMSO : 50 mg/mL (135.00 mM; ultrasonic and warming and heat to 60°C); H2O : 10 mg/mL (27.00 mM; Need ultrasonic),10mM,Infection; Cancer,Launched,O=C(C(C1=O)=CN2[C@@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O.[0.5H2O]
Levofloxacin (hydrochloride),(-)-Ofloxacin (hydrochloride),177325-13-2,397.83,Antibiotic; Apoptosis; Bacterial; DNA/RNA Synthesis; Orthopoxvirus; Topoisomerase,Anti-infection; Apoptosis; Cell Cycle/DNA Damage,"Levofloxacin hydrochloride is an orally active antibiotic. Levofloxacin inhibits DNA gyrase and topoisomerase IV activity, inducing Apoptosis. Levofloxacin hydrochloride has antibacterial activity against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride exhibits anticancer activity against lung cancer. Levofloxacin hydrochloride has anti-acnegenic, anxiogenic, and analgesic effects. Levofloxacin hydrochloride shortens sleep duration in mice. Levofloxacin hydrochloride can be used in the research of infectious diseases (such as tuberculosis, chronic periodontitis, bacterial infections associated with stable COPD, and BK viremia) and lung cancer[1][2][3][4][5][6][7][8][9][10].",C18H21ClFN3O4,H2O : 20 mg/mL (50.27 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Infection; Neurological Disease,Launched,[H]Cl.O=C(C(C1=O)=CN2[C@@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O
Ciprofloxacin (hydrochloride monohydrate),Bay-09867 (hydrochloride monohydrate),86393-32-0,385.82,Antibiotic; Apoptosis; Bacterial; Mitochondrial Metabolism; Reactive Oxygen Species (ROS); Topoisomerase,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Ciprofloxacin (Bay-09867) hydrochloride monohydrate is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin hydrochloride monohydrate induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin hydrochloride monohydrate has anti-proliferative activity and induces apoptosis. Ciprofloxacin hydrochloride monohydrate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity[1][2][3][4].",C17H21ClFN3O4,H2O : 20 mg/mL (51.84 mM; Need ultrasonic); DMSO : 5 mg/mL (12.96 mM; ultrasonic and warming and heat to 60°C),10mM,Infection; Cancer,Launched,[H]O[H].[H]Cl.O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CCNCC4)=C3)C1=O)O
Trimebutine,,39133-31-8,387.47,Akt; Apoptosis; Calcium Channel; ERK; IRAK; JNK; NF-κB; Opioid Receptor; Potassium Channel; Toll-like Receptor (TLR),Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Neuronal Signaling; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt,"Trimebutine is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine inhibits L-type Ca2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS)[1][2][3][4][5][6].",C22H29NO5,DMSO : 100 mg/mL (258.08 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease,Launched,O=C(OCC(C1=CC=CC=C1)(N(C)C)CC)C2=CC(OC)=C(OC)C(OC)=C2
Trimebutine (maleate),,34140-59-5,503.54,Akt; Apoptosis; Calcium Channel; ERK; IRAK; JNK; NF-κB; Opioid Receptor; Potassium Channel; Toll-like Receptor (TLR),Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Neuronal Signaling; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt,"Trimebutine maleate is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine maleate inhibits L-type Ca2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine maleate also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine maleate also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine maleate also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS)[1][2][3][4][5][6].",C26H33NO9,DMSO : 100 mg/mL (198.59 mM; Need ultrasonic); H2O : 25 mg/mL (49.65 mM; Need ultrasonic),10mM,Cancer; Metabolic Disease; Inflammation/Immunology; Neurological Disease,Launched,O=C(O)/C=C\C(O)=O.O=C(OCC(C1=CC=CC=C1)(N(C)C)CC)C2=CC(OC)=C(OC)C(OC)=C2
Nalidixic acid,,389-08-2,232.24,Antibiotic; Bacterial; Topoisomerase,Anti-infection; Cell Cycle/DNA Damage,"Nalidixic acid, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria[1].",C12H12N2O3,DMSO : 6 mg/mL (25.84 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); 0.1 M NaOH : 10 mg/mL (43.06 mM; Need ultrasonic),10mM,Infection,Launched,O=C(C1=CN(CC)C2=C(C=CC(C)=N2)C1=O)O
Nalidixic acid (sodium salt),,3374-05-8,254.22,Antibiotic; Bacterial; Topoisomerase,Anti-infection; Cell Cycle/DNA Damage,"Nalidixic acid sodium salt, a quinolone antibiotic, is effective against both gram-positive and gram-negative bacteria. Nalidixic acid acts in a bacteriostatic manner in lower concentrations and is bactericidal in higher concentrations. Nalidixic acid inhibits a subunit of DNA gyrase and topoisomerase IV and reversibly blocks DNA replication in susceptible bacteria[1][2].",C12H11N2NaO3,H2O : 116.67 mg/mL (458.93 mM; Need ultrasonic),10mM,Infection,Launched,O=C(C1=CN(CC)C2=NC(C)=CC=C2C1=O)O[Na]
Mycophenolic acid,Mycophenolate,24280-93-1,320.34,Antibiotic; Apoptosis; Bacterial; Dengue Virus; Endogenous Metabolite; Flavivirus; Fungal,Anti-infection; Apoptosis; Metabolic Enzyme/Protease,Mycophenolic acid is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 μM.?Mycophenolic acid demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid is an immunosuppressive agent. Antiangiogenic and antitumor effects[1][2].,C17H20O6,H2O : < 0.1 mg/mL (ultrasonic) (insoluble); DMSO : ≥ 100 mg/mL (312.17 mM),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C(O)CC/C(C)=C/CC1=C(O)C2=C(COC2=O)C(C)=C1OC
Mycophenolic acid (sodium),Mycophenolate (sodium),37415-62-6,342.32,Antibiotic; Apoptosis; Bacterial; Dengue Virus; Endogenous Metabolite; Flavivirus; Fungal,Anti-infection; Apoptosis; Metabolic Enzyme/Protease,Mycophenolic acid sodium is a potent uncompetitive inosine monophosphate dehydrogenase (IMPDH) inhibitor with an EC50 of 0.24 μM. Mycophenolic acid sodium demonstrates antiviral effects against a wide range of RNA viruses including influenza. Mycophenolic acid sodium is an immunosuppressive agent. Antiangiogenic and antitumor effects[1][2].,C17H19NaO6,DMSO : 175 mg/mL (511.22 mM; Need ultrasonic); H2O : 100 mg/mL (292.12 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C(O[Na])CC/C(C)=C/CC1=C(O)C2=C(COC2=O)C(C)=C1OC
Roxithromycin,RU-28965,80214-83-1,837.05,Antibiotic; Apoptosis; Bacterial; NF-κB; p38 MAPK,Anti-infection; Apoptosis; MAPK/ERK Pathway; NF-κB,"Roxithromycin (RU-28965) is an orally active semi-synthethic macrolide antibiotic. Roxithromycin inhibits protein biosynthesis in the elongation step by binding to 50S bacterial ribosome. Roxithromycin has antimicrobial, antiproliferative, anti-inflammatory, tumour vasculature inhibiting and lung injury ameliorating effects[1][2][3][4][5][6][7][8][9][10][11].",C41H76N2O15,H2O : < 0.1 mg/mL (insoluble); DMSO : ≥ 100 mg/mL (119.47 mM),10mM,Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease,Launched,C[C@H]([C@H]([C@](O)(C[C@H](/C1=N\OCOCCOC)C)C)O[C@@](O[C@H](C)C[C@@H]2N(C)C)([H])[C@@H]2O)[C@]([C@H](C(O[C@@H]([C@@](O)([C@H](O)[C@H]1C)C)CC)=O)C)([H])O[C@@](O[C@@H](C)[C@@H]3O)([H])C[C@@]3(C)OC
Naphazoline (hydrochloride),Naphthazoline (hydrochloride),550-99-2,246.74,Adrenergic Receptor; Interleukin Related; TNF Receptor; VEGFR,Apoptosis; GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Protein Tyrosine Kinase/RTK,"Naphazoline (Naphthazoline) hydrochloride is a potent α-adrenergic receptor agonist. Naphazoline hydrochloride reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline hydrochloride reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF. Naphazoline hydrochloride can be used for non-bacterial conjunctivitis research[1][2].",C14H15ClN2,H2O : 50 mg/mL (202.64 mM; Need ultrasonic); DMSO : ≥ 25 mg/mL (101.32 mM),10mM,Inflammation/Immunology; Cardiovascular Disease; Cancer,Launched,C1(CC2=NCCN2)=CC=CC3=CC=CC=C13.Cl
Lomefloxacin (hydrochloride),SC47111A (hydrochloride); NY-198 (hydrochloride),98079-52-8,387.81,Antibiotic; Apoptosis; Bacterial; Reactive Oxygen Species (ROS); Topoisomerase,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB,"Lomefloxacin hydrochloride (NY-198 hydrochloride) is an orally active difluoroquinolone antibiotic. Lomefloxacin hydrochloride prevents DNA supercoiling and replication by inhibiting bacterial topoisomerase II. Lomefloxacin hydrochloride induces ROS production and Apoptosis. Lomefloxacin hydrochloride has broad-spectrum bactericidal activity against Gram-positive and Gram-negative bacteria. Lomefloxacin hydrochloride has anticancer effects against melanoma. Lomefloxacin hydrochloride can be used in the study of systemic bacterial infections (such as Salmonella typhimurium infections), skin and melanoma [1][2][3][4][5][6].",C17H20ClF2N3O3,H2O : 7.14 mg/mL (18.41 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Infection; Endocrinology,Launched,CCN(C=C(C(O)=O)C1=O)C(C1=CC(F)=C2N(CCN3)CC3C)=C2F.Cl
Lonidamine,AF-1890; Diclondazolic Acid; DICA,50264-69-2,321.16,Apoptosis; Hexokinase; Mitochondrial Metabolism; Parasite,Anti-infection; Apoptosis; Metabolic Enzyme/Protease,"Lonidamine (AF-1890) is a hexokinase and mitochondrial pyruvate carrier inhibitor (Ki: 2.5 μM). Lonidamine also inhibits aerobic glycolysis in cancer cells. Lonidamine can be used in the research of mitochondrial metabolism and inflammation, such as pulmonary fibrosis[1][2][3].",C15H10Cl2N2O2,DMSO : 50 mg/mL (155.69 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Phase 3,O=C(C1=NN(CC2=CC=C(Cl)C=C2Cl)C3=C1C=CC=C3)O
Niflumic acid,,4394-00-7,282.22,Chloride Channel; COX,Immunology/Inflammation; Membrane Transporter/Ion Channel,Niflumic acid is a calcium-activated chloride channel blocker and COX-2 inhibitor with the IC50 value of 100 nM. Niflumic acid induces apoptosis through caspase-8/Bid/Bax pathway in lung cancer cells. Niflumic acide exhibits anti-tumor activity by affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Niflumic acid has orally bioactivity. Niflumic acid acts on rheumatoid arthritis[1][2][3][4][5][6][7][8].,C13H9F3N2O2,H2O : < 0.1 mg/mL (insoluble); DMSO : ≥ 100 mg/mL (354.33 mM),10mM,Inflammation/Immunology; Cancer,Launched,O=C(C1=CC=CN=C1NC2=CC=CC(C(F)(F)F)=C2)O
Niclosamide,BAY2353,50-65-7,327.12,Antibiotic; Parasite; STAT,Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt,"Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells[2][3][5].",C13H8Cl2N2O4,DMSO : 4.55 mg/mL (13.91 mM; Need ultrasonic); DMF : 5 mg/mL (15.28 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Infection; Cancer,Launched,O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2O
Niclosamide (olamine),BAY2353 (olamine),1420-04-8,388.20,Antibiotic; Parasite; STAT,Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt,"Niclosamide (BAY2353) olamine is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide olamin is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide olamin has biological activities against cancer, and inhibits DNA replication in Vero E6 cells[2][3][5].",C15H15Cl2N3O5,DMSO : 125 mg/mL (322.00 mM; Need ultrasonic),10mM,Cancer; Infection,Launched,O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2O.NCCO
Carbimazole,,22232-54-8,186.23,p38 MAPK,MAPK/ERK Pathway,"Carbimazole is an orally active antithyroid agent which rapidly converts to Methimazole after absorption and prevents thyroid peroxidase enzyme from iodinating and coupling the tyrosine residues on thyroglobulin, hence reducing the production of thyroxine. Carbimazole also displays anti-inflammatory and neuronal-protective activities, suggesting its application for hyperthyroidism and neurological research[1][2][3].",C7H10N2O2S,DMSO : 100 mg/mL (536.97 mM; Need ultrasonic),10mM,Endocrinology; Neurological Disease,Launched,O=C(N1C=CN(C)C1=S)OCC
Lercanidipine,,100427-26-7,611.73,Apoptosis; Calcium Channel; NF-κB; p38 MAPK; Reactive Oxygen Species (ROS),Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB,"Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research[1][2][3][4][5].",C36H41N3O6,DMSO : 100 mg/mL (163.47 mM; Need ultrasonic),10mM,Neurological Disease; Cardiovascular Disease,Launched,O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OC(C)(C)CN(CCC(C3=CC=CC=C3)C4=CC=CC=C4)C
Lercanidipine (hydrochloride),,132866-11-6,648.19,Apoptosis; Calcium Channel; NF-κB; p38 MAPK; Reactive Oxygen Species (ROS),Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB,"Lercanidipine is a third-generation, lipophilic, brain-penetrant, vascular-selective and orally active dihydropyridine-calcium channel blocker with a pIC50 of 7.74 (converts from μM). Lercanidipine has long lasting antihypertensive action as well as reno- and neuro-protective effect. Lercanidipine also shows anti-oxidant, anti-inflammatory and anti-apoptotic properties. Lercanidipine can be used in cardiovascular and neurological research[1][2][3][4][5].",C36H42ClN3O6,DMSO : 50 mg/mL (77.14 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble),10mM,Neurological Disease; Cardiovascular Disease,Launched,O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OC(C)(C)CN(CCC(C3=CC=CC=C3)C4=CC=CC=C4)C.[H]Cl
Metformin,"1,1-Dimethylbiguanide",657-24-9,129.17,AMPK; Apoptosis; Autophagy; Mitophagy; mTOR,Apoptosis; Autophagy; Epigenetics; PI3K/Akt/mTOR,"Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo[1][2][3][4][5][6][7].",C4H11N5,H2O : 50 mg/mL (387.09 mM; Need ultrasonic); DMSO : 25 mg/mL (193.54 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease,Launched,NC(NC(N(C)C)=N)=N
Butylphthalide,3-n-Butylphthalide; 3-Butylphthalide,6066-49-5,190.24,p38 MAPK,MAPK/ERK Pathway,Butylphthalide (3-n-Butylphthalide) is an active molecule against cerebral ischemia. It was originally isolated from celery species and has been shown to be effective in stroke animal models.,C12H14O2,DMSO : 250 mg/mL (1314.13 mM; Need ultrasonic),10mM,Neurological Disease,Launched,O=C1OC(CCCC)C2=C1C=CC=C2
Balsalazide,,80573-04-2,357.32,Interleukin Related; STAT,Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt,"Balsalazide is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway[1][2][3].",C17H15N3O6,1M NaOH : 50 mg/mL (139.93 mM; ultrasonic and adjust pH to 12 with NaOH); DMSO : 100 mg/mL (279.86 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Launched,O=C(O)C1=CC(/N=N/C2=CC=C(C(NCCC(O)=O)=O)C=C2)=CC=C1O
Balsalazide (sodium hydrate),Balsalazide disodium dihydrate,150399-21-6,437.31,Interleukin Related; STAT,Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt,"Balsalazide sodium hydrate is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway[1][2][3].",C17H17N3Na2O8,H2O : 100 mg/mL (228.67 mM; Need ultrasonic); DMSO : 125 mg/mL (285.84 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Launched,O=C(O)C1=CC(/N=N/C2=CC=C(C(NCCC(O[Na])=O)=O)C=C2)=CC=C1O[Na].O.O
Ceftriaxone,Ro 13-9904 (free acid),73384-59-5,554.58,Antibiotic; Aurora Kinase; Bacterial; GSK-3,Anti-infection; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR; Stem Cell/Wnt,"Ceftriaxone (Ro 13-9904 free acid) is a broad spectrum β-lactam third-generation cephalosporin antibiotic, which has good antibacterial activity against a variety of gram-negative and positive bacteria. Ceftriaxone is a covalent inhibitor of GSK3β with IC50 value of 0.78 μM. Ceftriaxone is an inhibitor of Aurora B. Ceftriaxone has anti-inflammatory, antitumor and antioxidant activities.  Ceftriaxone can be used in the study of bacterial infections and meningitis[1][2][3][4][5][6][7].",C18H18N8O7S3,DMSO : 31.25 mg/mL (56.35 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C(C(N12)=C(CSC(N(C)NC3=O)=NC3=O)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O
Histamine (dihydrochloride),,56-92-8,184.07,Akt; Apoptosis; Endogenous Metabolite; Histamine Receptor; p38 MAPK; Reactive Oxygen Species (ROS),Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB; PI3K/Akt/mTOR,"Histamine dihydrochloride is the agonist for histamine receptor and a vasodilator. Histamine dihydrochloride is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine dihydrochloride affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine dihydrochloride can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma[1][2][3][4][5][6][7].",C5H11Cl2N3,DMSO : 100 mg/mL (543.27 mM; Need ultrasonic),10mM,Cancer; Endocrinology; Inflammation/Immunology; Neurological Disease,Launched,NCCC1=CN=CN1.Cl.Cl
Sertaconazole (nitrate),FI7056,99592-39-9,500.78,Apoptosis; Autophagy; Fungal; Microtubule/Tubulin; p38 MAPK,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway,"Sertaconazole nitrate (FI7056) is a broad-spectrum topical antifungal agent, exhibits anti-inflammatory activity via activation of a p38-COX-2-PGE2 pathway. Sertaconazole nitrate is also a microtubule inhibitor, shows antiproliferative effect, induces apoptosis and autophagy, and can also inhibit the migration of cells[1][2][3][4].",C20H16Cl3N3O4S,DMSO : ≥ 100 mg/mL (199.69 mM),10mM,Infection; Cancer,Launched,ClC1=CC=C(C(OCC2=CSC3=C(Cl)C=CC=C32)CN4C=CN=C4)C(Cl)=C1.O[N+]([O-])=O
Bicyclol,SY801,118159-48-1,390.34,Apoptosis; Autophagy; Bcl-2 Family; CDK; Cyclin G-associated Kinase (GAK); ERK; Ferroptosis; Glutathione S-transferase; HBV; HCV; HSP; Interleukin Related; JNK; Microtubule/Tubulin; mTOR; NF-κB; p38 MAPK; P-glycoprotein; Reactive Oxygen Species (ROS); TNF Receptor,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Cytoskeleton; Immunology/Inflammation; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt,"Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the Ras/Raf/MEK/ERK pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma[1][2][3][4][5][6][7][8].",C19H18O9,DMSO : 100 mg/mL (256.19 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Launched,O=C(C1=CC(OC)=C(OCO2)C2=C1C3=C4OCOC4=C(OC)C=C3CO)OC
Altiratinib,DCC-2701,1345847-93-9,510.46,c-Met/HGFR; FLT3; Trk Receptor; VEGFR,Neuronal Signaling; Protein Tyrosine Kinase/RTK,"Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC50s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3 respectively.",C26H21F3N4O4,DMSO : 25 mg/mL (48.98 mM; Need ultrasonic),10mM,Cancer,Phase 1,O=C(C1(C(NC2=CC=C(F)C=C2)=O)CC1)NC3=CC(F)=C(OC4=CC(NC(C5CC5)=O)=NC=C4)C=C3F
AZ7550,,1421373-99-0,485.58,Drug Metabolite; EGFR; IGF-1R,JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,AZ7550 is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.,C27H31N7O2,DMSO : 83.33 mg/mL (171.61 mM; ultrasonic and adjust pH to 5 with 1 M HCL),10mM,Cancer; Endocrinology,Phase 1,C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(C)CCNC)=O
AZ7550 Mesylate,AZ7550 trimesylate salt,2319837-99-3,773.90,Drug Metabolite; EGFR; IGF-1R,JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,AZ7550 Mesylate is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.,C30H43N7O11S3,DMSO : 25 mg/mL (32.30 mM; Need ultrasonic),10mM,Cancer; Endocrinology,Phase 1,CN1C=C(C2=NC(NC3=CC(NC(C=C)=O)=C(N(CCNC)C)C=C3OC)=NC=C2)C4=CC=CC=C41.O=S(O)(C)=O.O=S(O)(C)=O.O=S(O)(C)=O
Oxaprozin,Oxaprozinum; Wy21743,21256-18-8,293.32,Akt; Apoptosis; COX; IKK; NF-κB,Apoptosis; Immunology/Inflammation; NF-κB; PI3K/Akt/mTOR,"Oxaprozin is an orally active and potent COX inhibitor, with IC50 values of 2.2 μM for human platelet COX-1 and and 36 μM for IL-1-stimulated human synovial cell COX-2, respectively. Oxaprozin also inhibits the activation of NF-κB. Oxaprozin induces cell apoptosis. Oxaprozin shows anti-inflammatory activity. Oxaprozin-mediated inhibition of the Akt/IKK/NF-κB pathway contributes to its anti-inflammatory properties[1][2].",C18H15NO3,DMSO : ≥ 100 mg/mL (340.92 mM),10mM,Inflammation/Immunology; Cancer,Launched,O=C(O)CCC1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)O1
Suramin (sodium salt),Suramin (hexasodium salt),129-46-4,1429.17,Apoptosis; Parasite; Phosphatase; Reverse Transcriptase; SARS-CoV; Sirtuin; Topoisomerase,Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease,"Suramin sodium salt	(Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor[1]. Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM)[2]. Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM)[3][4]. Suramin sodium salt is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor[5]. Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent[6][7][8].",C51H34N6Na6O23S6,DMSO : 83.33 mg/mL (58.31 mM; Need ultrasonic); H2O : 50 mg/mL (34.99 mM; Need ultrasonic),10mM,Cancer; Infection; Cardiovascular Disease,Launched,O=C(NC1=CC(C(NC2=CC(C(NC3=CC=C(S(=O)(O[Na])=O)C4=CC(S(=O)(O[Na])=O)=CC(S(=O)(O[Na])=O)=C34)=O)=CC=C2C)=O)=CC=C1)NC5=CC(C(NC6=CC(C(NC7=CC=C(S(=O)(O[Na])=O)C8=CC(S(=O)(O[Na])=O)=CC(S(=O)(O[Na])=O)=C78)=O)=CC=C6C)=O)=CC=C5
Ceftiofur (sodium),sodium ceftiofur,104010-37-9,545.54,Antibiotic; Bacterial; Interleukin Related; NF-κB; p38 MAPK; TNF Receptor,Anti-infection; Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB,"Ceftiofur sodium is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur sodium exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur sodium also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6[1][2][3].",C19H16N5NaO7S3,DMSO : 50 mg/mL (91.65 mM; Need ultrasonic),10mM,Infection,Launched,O=C(O[Na])C(N12)=C(CSC(C3=CC=CO3)=O)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O
Acenocoumarol,,152-72-7,353.33,Akt; Apoptosis; ERK; GSK-3; JNK; NF-κB; p38 MAPK; PKA; VD/VDR,Apoptosis; MAPK/ERK Pathway; NF-κB; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad; Vitamin D Related/Nuclear Receptor,"Acenocoumarol is an anticoagulant that functions as a Vitamin K antagonist. Acenocoumarol inhibits MAPK/ERK/JNK signaling pathway, reduces the nuclear translocation of NF-κB p65, activates Akt/GSK3β signaling pathway. Acenocoumarol induces apoptosis in cell A549, arrests cell cycle at S phase[1][2][3][4].",C19H15NO6,DMSO : 100 mg/mL (283.02 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Cardiovascular Disease,Launched,O=C1C(C(C2=CC=C([N+]([O-])=O)C=C2)CC(C)=O)=C(O)C3=CC=CC=C3O1
Gemifloxacin (mesylate),SB-265805S; LB-20304a,210353-53-0,485.49,Antibiotic; Bacterial; DNA/RNA Synthesis; Topoisomerase,Anti-infection; Cell Cycle/DNA Damage,"Gemifloxacin mesylate (SB-265805S; LB-20304a) is an orally active broad-spectrum quinolone antibacterial antibiotic. Gemifloxacin mesylate inhibits DNA synthesis by inhibiting DNA gyrase and Topoisomerase IV activities. Gemifloxacin mesylate has potent antibacterial activities against gram-positive bacteria in vitro efficacy study, particularly Streptococci and Staphylococci. Gemifloxacin mesylate has been used in the research of respiratory tract infections[1][2][3].",C19H24FN5O7S,DMSO : 100 mg/mL (205.98 mM; Need ultrasonic); H2O : 50 mg/mL (102.99 mM; Need ultrasonic),10mM,Infection,Launched,O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4CC(CN)/C(C4)=N/OC)=N3)C1=O)O.CS(=O)(O)=O
Gliquidone,AR-DF 26,33342-05-1,527.63,COX; ERK; Interleukin Related; NF-κB; Potassium Channel; Reactive Oxygen Species (ROS); STAT,Immunology/Inflammation; JAK/STAT Signaling; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt,"Gliquidone can bind to the pancreatic β-cells and increases insulin release to regulate blood glucose levels. Gliquidone significantly decreases LPS (HY-D1056)-induced proinflammatory responses and inhibits ERK/STAT3/NF-κB phosphorylation in BV2 microglial cells. Gliquidone can suppress microgliosis, microglial hypertrophy mediated by LPS, and proinflammatory cytokine COX-2 and IL-6 levels in murine model. Gliquidone also exhibits good anticancer activity in lung carcinoma cells. Gliquidone has antioxidant property. Gliquidone can be studied in research for type 2 diabetes and cancers[1][2].",C27H33N3O6S,H2O : < 0.1 mg/mL (insoluble); DMSO : 50 mg/mL (94.76 mM; Need ultrasonic),10mM,Metabolic Disease,Launched,O=S(C1=CC=C(CCN(C(C(C)(C)C2=C3C=C(OC)C=C2)=O)C3=O)C=C1)(NC(NC4CCCCC4)=O)=O
Trioxsalen,Trisoralen; Trioxysalen; TMP,3902-71-4,228.25,DNA Alkylator/Crosslinker,Cell Cycle/DNA Damage,"Trioxsalen (Trisoralen), a psoralen derivative, is a photochemical DNA crosslinker. Trioxsalen only works after photoactivation with near ultraviolet light. Trioxsalen is a photosensitizer that can be used for the research of vitiligo and hand eczema. Trioxsalen is used for visualization of genomic interstrand cross-links localized by laser photoactivation[1][2][3].",C14H12O3,DMSO : 2 mg/mL (8.76 mM; Need ultrasonic); H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 80°C) (insoluble),2mM,Inflammation/Immunology,Launched,O=C1C=C(C)C2=CC3=C(OC(C)=C3)C(C)=C2O1
Nitroxoline,8-Hydroxy-5-nitroquinoline; 5-Nitro-8-quinolinol,4008-48-4,190.16,Antibiotic; Apoptosis; Autophagy; Bacterial,Anti-infection; Apoptosis; Autophagy,"Nitroxoline (8-Hydroxy-5-nitroquinoline), an antibiotic, is an orally active antibiofilm agent. Nitroxoline reduces the formation and induces the dispersal of Pseudomonas aeruginosa biofilms by chelation of iron and zinc. Nitroxoline can be used for the urinary tract infections and cancer research[1][2][3].",C9H6N2O3,DMSO : 50 mg/mL (262.94 mM; Need ultrasonic),10mM,Infection; Cancer,Launched,OC1=C2N=CC=CC2=C([N+]([O-])=O)C=C1
Terfenadine,(±)-Terfenadine; MDL-991,50679-08-8,471.67,Apoptosis; Caspase; Histamine Receptor; Na+/Ca2+ Exchanger; Potassium Channel,Apoptosis; GPCR/G Protein; Immunology/Inflammation; Membrane Transporter/Ion Channel; Neuronal Signaling,"Terfenadine ((±)-Terfenadine) is a potent open-channel blocker of hERG with an IC50 of 204 nM[1]. Terfenadine, an H1 histamine receptor antagonist, acts as a potent apoptosis inducer in melanoma cells through modulation of Ca2+ homeostasis. Terfenadine induces ROS-dependent apoptosis, simultaneously activates Caspase-4, -2, -9[2].",C32H41NO2,DMSO : ≥ 50 mg/mL (106.01 mM); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer; Inflammation/Immunology; Endocrinology,Launched,OC(C1=CC=C(C(C)(C)C)C=C1)CCCN2CCC(C(C3=CC=CC=C3)(O)C4=CC=CC=C4)CC2
Fludrocortisone,9α-Fludrocortisone; 9α-Fluorcortisol,127-31-1,380.45,Mineralocorticoid Receptor; Sodium Channel,Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor,Fludrocortisone inhibits natriuresis. Fludrocortisone is a synthetic mineralocorticoid with anti-inflammatory activity. Fludrocortisone can be studied in research for small cell lung cancer with profound hyponatremia and acute neurological symptoms as well as aneurysmal subarachnoid hemorrhage[1][2].,C21H29FO5,DMSO : 100 mg/mL (262.85 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer,Launched,C[C@@]12[C@](C(CO)=O)(O)CC[C@@]1([H])[C@]3([H])CCC4=CC(CC[C@]4(C)[C@@]3(F)[C@@H](O)C2)=O
Histamine,Ergamine,51-45-6,111.15,Akt; Apoptosis; Endogenous Metabolite; Histamine Receptor; p38 MAPK; Reactive Oxygen Species (ROS),Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Neuronal Signaling; NF-κB; PI3K/Akt/mTOR,"Histamine is the agonist for histamine receptor and a vasodilator. Histamine is an organic nitrogen compound that participates in local immune responses, regulates intestinal physiological functions, and acts as a neurotransmitter. Histamine affects p38 MAPK/Akt signaling pathway, exhibits antitumor, antioxidant and anti-inflammatory activities. Histamine can be used in the research of acute myeloid leukemia, malignant melanoma, and renal cell carcinoma[1][2][3][4][5][6][7].",C5H9N3,H2O : 125 mg/mL (1124.61 mM; Need ultrasonic),10mM,Cancer; Endocrinology; Inflammation/Immunology; Neurological Disease,Launched,NCCC1=CN=CN1
Anethole trithione,,532-11-6,240.36,mAChR,GPCR/G Protein; Neuronal Signaling,"Anethole trithione, a sulfur heterocyclic choleretic, is a bile secretion-stimulating agent. Anethole trithione enhances salivary secretion and increases mAChRs, and can be used for dry mouth research[1][2].",C10H8OS3,DMSO : 12.5 mg/mL (52.01 mM; Need ultrasonic),10mM,Cancer; Neurological Disease,Launched,S=C1SSC(C2=CC=C(OC)C=C2)=C1
Chloropyramine hydrochloride,,6170-42-9,326.26,FAK; Histamine Receptor; VEGFR,GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Protein Tyrosine Kinase/RTK,Chloropyramine hydrochloride is a histamine receptor H1 antagonist which can also inhibit the biochemical function of  VEGFR-3 and FAK.,C16H21Cl2N3,DMSO : 30 mg/mL (91.95 mM; Need ultrasonic and warming); H2O : 100 mg/mL (306.50 mM; Need ultrasonic),10mM,Cancer; Endocrinology,Launched,CN(C)CCN(CC1=CC=C(Cl)C=C1)C2=NC=CC=C2.[H]Cl
Meclofenamic acid (sodium),Meclofenamate (sodium),6385-02-0,318.13,Endogenous Metabolite; Fat Mass and Obesity-associated Protein (FTO); Gap Junction Protein,Cytoskeleton; Metabolic Enzyme/Protease,Meclofenamic acid (Meclofenamate) sodium is a non-steroidal anti-inflammatory agent (NSAID). Meclofenamic acid sodium is a non-selective gap-junction blocker and a highly selective inhibitor of fat - and obesity-related enzyme (FTO). Meclofenamic acid sodium has anti-inflammatory and antitumor activities[1][2][3].,C14H10Cl2NNaO2,H2O : 100 mg/mL (314.34 mM; Need ultrasonic); DMSO : 125 mg/mL (392.92 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology,Launched,O=C(O[Na])C1=CC=CC=C1NC2=C(Cl)C=CC(C)=C2Cl
Nifuroxazide,,965-52-6,275.22,Antibiotic; Bacterial; STAT,Anti-infection; JAK/STAT Signaling; Stem Cell/Wnt,"Nifuroxazide is an effective inhibitor of STAT3, also exerts potent anti-tumor and anti-metastasis activity. Nifuroxazide is an orally active nitrofuran antibiotic.",C12H9N3O5,DMSO : ≥ 155 mg/mL (563.19 mM),10mM,Cancer; Infection,Launched,O=C(N/N=C/C1=CC=C([N+]([O-])=O)O1)C2=CC=C(O)C=C2
Uridine,β-Uridine,58-96-8,244.20,Endogenous Metabolite; NF-κB; Nucleoside Antimetabolite/Analog,Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; NF-κB,"Uridine (β-Uridine) is a nucleoside compound composed of uracil and a ribose ring, which are connected by a β-N1-glycosidic bond[1].",C9H12N2O6,H2O : ≥ 100 mg/mL (409.50 mM); DMSO : 50 mg/mL (204.75 mM; Need ultrasonic),10mM,Cancer,Launched,O[C@H]1[C@@H](O)[C@H](N2C(NC(C=C2)=O)=O)O[C@@H]1CO
Benzoin,DL-Benzoin; Desyl alcohol; (±)-2-Hydroxy-2-phenylacetophenone,119-53-9,212.25,PI3K,PI3K/Akt/mTOR,"Benzoin (DL-Benzoin), a natural balsamic resin, is a PI3Kα inhibitor with anticancer effects. Benzoin inihits the growth of colon cancer cell line (HCT-116). Benzoin can be used as a food additive[1][2].",C14H12O2,DMSO : 50 mg/mL (235.57 mM; Need ultrasonic),10mM,Cancer,Launched,OC(C1=CC=CC=C1)C(C2=CC=CC=C2)=O
Fursultiamine,,804-30-8,398.54,Ferroportin; Mitochondrial Metabolism; NF-κB; VEGFR,Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; NF-κB; Protein Tyrosine Kinase/RTK,"Fursultiamine is a vitamin B1 derivative, has anti-nociceptive and antineoplastic activity. Fursultiamine can be used for vitamin B1 deficiency, osteoarthritis (OA) and cancer research[1][2].",C17H26N4O3S2,DMSO : 106.7 mg/mL (267.73 mM; Need ultrasonic and warming); H2O : ≥ 6.67 mg/mL (16.74 mM),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,O=CN(CC1=CN=C(C)N=C1N)/C(C)=C(SSCC2OCCC2)\CCO
Bromisoval,Bromovalerylurea,496-67-3,223.07,STAT,JAK/STAT Signaling; Stem Cell/Wnt,Bromisoval has anti-inflammatory effects.,C6H11BrN2O2,DMSO : 300 mg/mL (1344.87 mM; Need ultrasonic and warming),10mM,Inflammation/Immunology; Neurological Disease,Launched,CC(C)C(Br)C(NC(N)=O)=O
Thymoquinone,,490-91-5,164.20,Akt; Apoptosis; PI3K; VEGFR,Apoptosis; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK,"Thymoquinone is an orally active natural product isolated from N. sativa Thymoquinone down-regulates the VEGFR2-PI3K-Akt pathway. Thymoquinone has antioxidant, anti-inflammatory, anticancer, antiviral, anticonvulsant, antifungal, antiviral, antiangiogenic activity and hepatoprotective effects. Thymoquinone can be used to study Alzheimer's disease, cancer, cardiovascular disease, infectious disease and inflammation [1][2][3][4][5].",C10H12O2,DMSO : 100 mg/mL (609.01 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease,Phase 3,O=C1C(C)=CC(C(C(C)C)=C1)=O
Honokiol,NSC 293100,35354-74-6,266.33,Akt; Autophagy; ERK; HCV,Anti-infection; Autophagy; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt,"Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt. Honokiol can readily cross the blood brain barrier[1][2][3][4].",C18H18O2,DMSO : ≥ 50 mg/mL (187.74 mM),10mM,Cancer,Phase 3,OC1=C(CC=C)C=C(C2=CC(CC=C)=CC=C2O)C=C1
Oridonin,NSC-250682; Isodonol,28957-04-2,364.43,Akt; Bacterial,Anti-infection; PI3K/Akt/mTOR,"Oridonin (NSC-250682), a diterpenoid isolated from Rabdosia rubescens, acts as an inhibitor of AKT, with IC50s of 8.4 and 8.9 μM for AKT1 and AKT2; Oridonin possesses anti-tumor, anti-bacterial and anti-inflammatory effects.",C20H28O6,DMSO : 62.5 mg/mL (171.50 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology,Phase 4,O[C@@H]1[C@]2(CO3)[C@@]([C@H](O)[C@]3(O)[C@]45[C@@]2([H])CC[C@](C(C5=O)=C)([H])[C@@]4([H])O)([H])C(C)(C)CC1
Ferulic acid,Coniferic acid,1135-24-6,194.19,Endogenous Metabolite; FGFR,Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,"Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.",C10H10O4,DMSO : 100 mg/mL (514.96 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(O)/C=C/C1=CC=C(O)C(OC)=C1
Ferulic acid (sodium),Coniferic acid (sodium),24276-84-4,216.17,Endogenous Metabolite; FGFR; Reactive Oxygen Species (ROS),Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Protein Tyrosine Kinase/RTK,"Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.",C10H9NaO4,DMSO : 33.33 mg/mL (154.18 mM; Need ultrasonic); H2O : 100 mg/mL (462.60 mM; Need ultrasonic),10mM,Cardiovascular Disease; Cancer,Launched,O=C(O[Na])/C=C/C1=CC=C(O)C(OC)=C1
(S)-10-Hydroxycamptothecin,10-HCPT; 10-Hydroxycamptothecin,19685-09-7,364.35,Apoptosis; Topoisomerase,Apoptosis; Cell Cycle/DNA Damage,"(S)-10-Hydroxycamptothecin (10-HCPT;10-Hydroxycamptothecin) is a DNA topoisomerase I inhibitor of isolated from the Chinese plant Camptotheca accuminata.  (S)-10-Hydroxycamptothecin exhibits a remarkable apoptosis-inducing effect. (S)-10-Hydroxycamptothecin has the potential for hepatoma, gastric carcinoma, colon cancer and leukaemia treatment[1][2][3][4].",C20H16N2O5,DMSO : 50 mg/mL (137.23 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=CC5=CC(O)=CC=C5N=C4C3=C2)=O
Dihydromyricetin,Ampelopsin; Ampeloptin,27200-12-0,320.25,Autophagy; DNA/RNA Synthesis; Influenza Virus; mTOR,Anti-infection; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR,Dihydromyricetin is a potent inhibitor with an IC50 of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting mTOR signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2). Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC50 of 22 μM.,C15H12O8,DMSO : ≥ 100 mg/mL (312.26 mM),10mM,Cancer; Infection,Phase 2,O=C1[C@H](O)[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13
Parthenolide,(-)-Parthenolide,20554-84-1,248.32,Apoptosis; Autophagy; Mitophagy; NF-κB,Apoptosis; Autophagy; NF-κB,Parthenolide is a sesquiterpene lactone found in the medicinal herb Feverfew. Parthenolide exhibits anti-inflammatory activity by inhibiting NF-κB activation; also inhibits HDAC1 protein without affecting other class I/II HDACs.,C15H20O3,H2O : < 0.1 mg/mL (ultrasonic) (insoluble); DMSO : ≥ 100 mg/mL (402.71 mM),10mM,Cancer,Phase 2,C/C1=C\CC[C@@](C)(O2)[C@H]2[C@@H](OC(C3=C)=O)[C@H]3CC1
Quercetin (dihydrate),,6151-25-3,338.27,Apoptosis; PI3K,Apoptosis; PI3K/Akt/mTOR,"Quercetin dihydrate, a natural flavonoid, is a stimulator of recombinant SIRT1 and a PI3K inhibitor with IC50s of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively[1].",C15H14O9,DMSO : 100 mg/mL (295.62 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Inflammation/Immunology; Cancer,Launched,O=C1C(O)=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13.[H]O[H].[H]O[H]
Oleanolic acid,Oleanic acid; Caryophyllin,508-02-1,456.70,Autophagy; Endogenous Metabolite; HIV; MAP3K,Anti-infection; Autophagy; MAPK/ERK Pathway; Metabolic Enzyme/Protease,Oleanolic acid (Caryophyllin) is a natural compound from plants with anti-tumor activities.,C30H48O3,DMSO : 5 mg/mL (10.95 mM; Need ultrasonic); DMF : 45.45 mg/mL (99.52 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer,Launched,C[C@]([C@@]1([H])[C@]2(CC[C@@H]3O)C)(CC[C@@]2([H])C3(C)C)[C@@](C4=CC1)(CC[C@]5(C(O)=O)[C@@]4([H])CC(C)(C)CC5)C
Orotic acid,6-Carboxyuracil; Vitamin B13,65-86-1,156.10,Endogenous Metabolite; Nucleoside Antimetabolite/Analog,Cell Cycle/DNA Damage; Metabolic Enzyme/Protease,"Orotic acid (6-Carboxyuracil), a precursor in biosynthesis of pyrimidine nucleotides and RNA, is released from the mitochondrial dihydroorotate dehydrogenase (DHODH) for conversion to UMP by the cytoplasmic UMP synthase enzyme. Orotic acid is a marker for measurement in routine newborn screening for urea cycle disorders. Orotic acid can induce hepatic steatosis and hepatomegaly in rats[1][2][3].",C5H4N2O4,DMSO : 50 mg/mL (320.31 mM; ultrasonic and warming and heat to 60°C); H2O : < 0.1 mg/mL (insoluble),10mM,Metabolic Disease,Launched,O=C(C(NC1=O)=CC(N1)=O)O
Luteolin,Luteoline; Luteolol; Digitoflavone,491-70-3,286.24,Apoptosis; Autophagy; Endogenous Metabolite; Keap1-Nrf2,Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB,"Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells[1][2][3].",C15H10O6,DMSO : ≥ 100 mg/mL (349.36 mM),10mM,Cancer; Inflammation/Immunology,Launched,O=C1C=C(C2=CC=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13
Matrine,Matridin-15-one; Vegard; α-Matrine,519-02-8,248.37,Apoptosis; Autophagy; Ferroptosis; Mitophagy; Opioid Receptor; PINK1/Parkin,Apoptosis; Autophagy; GPCR/G Protein; Neuronal Signaling,"Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI)[1][2][3][4][5].",C15H24N2O,H2O : 20 mg/mL (80.53 mM; Need ultrasonic); DMSO : ≥ 50 mg/mL (201.31 mM),10mM,Cancer; Inflammation/Immunology,Launched,O=C1CCC[C@]2([H])[C@@]3([H])CCCN4[C@@]3([H])[C@](CCC4)([H])CN21
Hesperetin,,520-33-2,302.28,Apoptosis; Autophagy; Bcl-2 Family; NF-κB; p38 MAPK; Reactive Oxygen Species (ROS),Apoptosis; Autophagy; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB,"Hesperetin is a natural flavanone that can be found in citrus, and acts as a potent and orally active broad-spectrum inhibitor against human UGT activity. Hesperetin induces apoptosis via p38 MAPK activation. Hesperetin displays a range of bioactivities including antioxidant, anti-inflammatory, and anti-cancer. Hesperetin is found to induce cell-cycle arrest at G2/M phase. Hesperetin can reduce Bcl-2 and enhance BaxM. Hesperetin induces apoptosis through inhibiting NF-κB receptor[1][2][3][4].",C16H14O6,DMSO : 125 mg/mL (413.52 mM; Need ultrasonic),10mM,Neurological Disease; Cancer,Phase 1,O=C1C[C@@H](C2=CC=C(OC)C(O)=C2)OC3=CC(O)=CC(O)=C13
Artesunate,,88495-63-0,384.42,Ferroptosis; Parasite; STAT; Virus Protease,Anti-infection; Apoptosis; JAK/STAT Signaling; Stem Cell/Wnt,Artesunate is an inhibitor of both STAT-3 and exported protein 1 (EXP1).,C19H28O8,H2O : < 0.1 mg/mL (insoluble); 7.5% Sodium bicarbonate : 2 mg/mL (5.20 mM; ultrasonic and warming and heat to 60°C); DMSO : 83.33 mg/mL (216.77 mM; Need ultrasonic),10mM,Cancer,Launched,O=C(O[C@H]1[C@H](C)[C@]2([H])CC[C@@H](C)[C@]3([H])CC[C@@](O4)(C)OO[C@]32[C@]4([H])O1)CCC(O)=O
Bakuchiol,(S)-(+)-Bakuchiol,10309-37-2,256.38,Autophagy; Carboxylesterase (CES); p38 MAPK; UGT,Autophagy; MAPK/ERK Pathway; Metabolic Enzyme/Protease,"Bakuchiol is a phytoestrogen that can be obtained from psoralen seeds. Bakuchiol has been proven to be a non-competitive inhibitor of multiple enzymes, including UDP-glucuronosyltransferase 2B7 (UGT2B7) [2] and human carboxylesterase 2 (hCE2) [3], with IC50s values of 40.9 μM and 7.28 μM, respectively. Bakuchiol exhibits significant research and application potential in areas such as anti-inflammatory[5], antibacterial[4], antitumor[1] therapies, as well as drug metabolism regulation.",C18H24O,DMSO : 62.5 mg/mL (243.78 mM; Need ultrasonic),10mM,Cancer; Infection; Metabolic Disease; Inflammation/Immunology,Phase 1,OC1=CC=C(/C=C/[C@](C)(C=C)CC/C=C(C)\C)C=C1
Daphnetin,"7,8-Dihydroxycoumarin",486-35-1,178.14,Akt; AMPK; Apoptosis; Autophagy; Bcl-2 Family; Caspase; EGFR; mTOR; Parasite; PARP; PKA; PKC; Reactive Oxygen Species (ROS),Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt; TGF-beta/Smad,"Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative can be found in plants of the Genus Daphne, is a potent, oral active protein kinase inhibitor, with IC50s of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively. Daphnetin triggers ROS-induced cell apoptosis and induces cytoprotective autophagy by modulating the AMPK/Akt/mTOR pathway. Daphnetin has anti-inflammation activitity and inhibits TNF-α, IL-1β, ROS, and MDA production. Daphnetin has schizontocidal activity against malaria parasites. Daphnetin can be used for rheumatoid arthritis , cancer and anti-malarian research[1][2][3][4].",C9H6O4,H2O : < 0.1 mg/mL (ultrasonic) (insoluble); DMSO : 50 mg/mL (280.68 mM; Need ultrasonic),10mM,Inflammation/Immunology; Cancer; Cardiovascular Disease,Launched,O=C1C=CC2=CC=C(O)C(O)=C2O1
Demecolcine,,477-30-5,371.43,Apoptosis; Microtubule/Tubulin,Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,Demecolcine is a potent mitotic inhibitor with an IC50 value of 2.4 μM for inhibition of tubulin polymerization. Colcemid (Demecolcine) can interact with tubulin dimers to induce anti-mitotic action and inhibit microtubule growth. Colcemid (Demecolcine) can be used for inflammatory disorders and cancer research[1][2].,C21H25NO5,H2O : 5 mg/mL (13.46 mM; ultrasonic and warming and heat to 60°C); DMSO : 25 mg/mL (67.31 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Inflammation/Immunology,Launched,O=C1C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=CC=C1OC
Asiaticoside,,16830-15-2,959.12,Apoptosis; Endogenous Metabolite; p38 MAPK; Reactive Oxygen Species (ROS); TGF-beta/Smad,Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt; TGF-beta/Smad,"Asiaticoside, a trisaccaride triterpene from Centella asiatica, suppresses TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts; Asiaticoside shows antioxidant, anti-inflammatory, and anti-ulcer properties.",C48H78O19,DMSO : 100 mg/mL (104.26 mM; Need ultrasonic),10mM,Inflammation/Immunology; Neurological Disease; Cardiovascular Disease; Cancer,Phase 3,C[C@@H]1CC[C@@]2(C(O[C@@H]3O[C@H](CO[C@H]4[C@H](O)[C@@H](O)[C@H](O[C@@]5([H])[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O5)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@H]3O)=O)[C@@](C6=CC[C@@]([C@](C[C@@H](O)[C@H](O)[C@]7(CO)C)(C)[C@@]7([H])CC8)([H])[C@]8(C)[C@]6(C)CC2)([H])[C@H]1C
8-Gingerol,,23513-08-8,322.44,Akt; Apoptosis; Autophagy; Bacterial; Caspase; EGFR; MMP; mTOR; PERK; PI3K; STAT; TRP Channel,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; JAK/STAT Signaling; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"8-Gingerol can be found in the rhizome of ginger (Z. officinale) and has oral bioactivity. It activates TRPV1, with an EC50 value of 5.0 μM. 8-Gingerol inhibits COX-2 and also suppresses the growth of H. pylori in vitro. Additionally, 8-Gingerol exhibits anticancer, antioxidant, and anti-inflammatory properties by inhibiting the epidermal growth factor receptor (EGFR) and modulating its downstream STAT3/ERK pathway to suppress the proliferation, migration, and invasion of colorectal cancer cells. 8-Gingerol also exerts immunosuppressive effects by inhibiting oxidative stress, inducing cell cycle arrest, promoting apoptosis, and regulating autophagy. Furthermore, 8-Gingerol has cardioprotective effects. 8-Gingerol is promising for research in the fields of cancer, infection, immunosuppression, and cardiovascular diseases.",C19H30O4,DMSO : ≥ 100 mg/mL (310.14 mM),10mM,Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease,Launched,CCCCCCC[C@H](O)CC(CCC1=CC=C(O)C(OC)=C1)=O
Vincristine (sulfate),Leurocristine (sulfate); NSC-67574 (sulfate); 22-Oxovincaleukoblastine (sulfate),2068-78-2,923.04,Apoptosis; Microtubule/Tubulin,Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton,"Vincristine sulfate is an antitumor vinca alkaloid which inhibits microtubule formation in mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. It binds to microtubule with a Ki of 85 nM.",C46H58N4O14S,DMSO : 83.33 mg/mL (90.28 mM; ultrasonic and warming and heat to 80°C); H2O : 50 mg/mL (54.17 mM; Need ultrasonic),10mM,Cancer,Launched,CC[C@@]1(C=CCN2CC3)[C@@]2([H])[C@@]3(C4=CC([C@](C5=C6C7=CC=CC=C7N5)(C[C@](C[C@](CC)(O)C8)([H])C[N@@]8CC6)C(OC)=O)=C(OC)C=C4N9C=O)[C@]9([H])[C@](C(OC)=O)(O)[C@@H]1OC(C)=O.O=S(O)(O)=O
Taurocholic acid (sodium),Sodium taurocholate; N-Choloyltaurine (sodium),145-42-6,537.68,Endogenous Metabolite; VEGFR,Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK,Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect[1].,C26H44NNaO7S,DMSO : ≥ 100 mg/mL (185.98 mM); H2O : 100 mg/mL (185.98 mM; Need ultrasonic),10mM,Inflammation/Immunology,Phase 2,C[C@H](CCC(NCCS(=O)(O[Na])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C
Icaritin,Anhydroicaritin,118525-40-9,368.38,Apoptosis; Autophagy; JAK,Apoptosis; Autophagy; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC50  of 8 μM) and primary CML cells (IC50  of 13.4 μM for CML-CP and 18 μM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis[1][2][3.",C21H20O6,DMSO : 15.62 mg/mL (42.40 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble),10mM,Cancer,Phase 4,O=C1C(O)=C(C2=CC=C(OC)C=C2)OC3=C(C/C=C(C)\C)C(O)=CC(O)=C13
Crocin,Crocin I,42553-65-1,976.96,Apoptosis; Endogenous Metabolite; JAK,Apoptosis; Epigenetics; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt,"Crocin (Crocin I) is an orally active natural product that can be isolated from the stigma of Crocus sativus. Crocin inhibits tumor cell proliferation and promotes apoptosis through JAK pathway. Crocin has anti-inflammatory, antioxidant and antitumor activities [1][2].",C44H64O24,DMSO : 125 mg/mL (127.95 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease,Launched,O[C@@H]([C@H](O)[C@H]1O)[C@H](O[C@H]1OC(/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C(O[C@@H]([C@@H]([C@@H](O)[C@@H]2O)O)O[C@@H]2CO[C@@H]([C@@H]([C@@H](O)[C@@H]3O)O)O[C@@H]3CO)=O)=O)CO[C@@H]([C@@H]([C@@H](O)[C@@H]4O)O)O[C@@H]4CO
Berberine (hemisulfate),Natural Yellow 18 (hemisulfate),316-41-6,384.40,Akt; Antibiotic; AP-1; Apoptosis; Autophagy; Bacterial; Caspase; JNK; NF-κB; PI3K; Reactive Oxygen Species (ROS); Topoisomerase,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR,"Berberine hemisulfate is the hemisulfate form of Berberine (HY-N0716). Berberine hemisulfate is an alkaloid isolated from the Chinese herbal medicine Huanglian. Berberine hemisulfate exhibits anti-inflammatory, antibiobic, antitumor, cardiovascular protective and neuroprotective activity[1][2][3][4][5][6].",C20H18NO4.1/2O4S,H2O : 200 mg/mL (520.29 mM; Need ultrasonic); DMSO : 2 mg/mL (5.20 mM; ultrasonic and warming and heat to 60°C),10mM,Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease,Launched,O=S([O-])([O-])=O.COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.[0.5]
Berberine (sulfate),Natural Yellow 18 (sulfate),633-66-9,433.43,Akt; Antibiotic; AP-1; Apoptosis; Autophagy; Bacterial; Caspase; JNK; NF-κB; Parasite; PI3K; Reactive Oxygen Species (ROS); Topoisomerase,Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR,"Berberine sulfate is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an antibiotic. Berberine sulfate induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Berberine sulfate has antineoplastic properties. The sulfate form improves bioavailability[1][2].",C20H19NO8S,DMSO : 0.5 mg/mL (1.15 mM; ultrasonic and warming and heat to 60°C); H2O : 50 mg/mL (115.36 mM; Need ultrasonic),10mM,Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease,Launched,COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.O=S(O)([O-])=O
Cinobufotalin,,1108-68-5,458.54,Others,Others,"Cinobufotalin is a cardiotonic steroids or bufadienolides, is extracted from the skin secretions of the giant toads. Cinobufotalin has been used as a cardiotonic, diuretic and a hemostatic agent, Cinobufotalin is also a potential anti-lung cancer agent[1].",C26H34O7,DMSO : 125 mg/mL (272.60 mM; Need ultrasonic),10mM,Cancer,Launched,C[C@]([C@@H](C(C=C1)=COC1=O)[C@H]2OC(C)=O)(CC[C@@]3([H])[C@@]4([H])CC[C@@]5(O)[C@@]3(CC[C@H](O)C5)C)[C@@]64[C@@H]2O6
Ergothioneine,L-(+)-Ergothioneine,497-30-3,229.31,Akt; Endogenous Metabolite; Keap1-Nrf2; NF-κB; p38 MAPK,MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR,"Ergothioneine is an imidazole-2-thione derivative with orally active histidine betaine. Ergothioneine is a specific inhibitor of p38-MAPK and Akt, which plays a protective role in cell apoptosis induced by stress. Ergothioneine has antioxidant activity[1][2].",C9H15N3O2S,H2O : 125 mg/mL (545.13 mM; Need ultrasonic),10mM,Others,Phase 3,S=C1NC(C[C@@H](C([O-])=O)[N+](C)(C)C)=CN1
D-chiro-Inositol,,643-12-9,180.16,Endogenous Metabolite; FOXO; Microtubule/Tubulin; NF-κB; TNF Receptor,Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; Metabolic Enzyme/Protease; NF-κB,"D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome[1][2][3][4][5][6][7][8][9].",C6H12O6,H2O : 75 mg/mL (416.30 mM; Need ultrasonic),10mM,Metabolic Disease,Phase 4,O[C@H]1[C@@H]([C@@H]([C@H]([C@@H]([C@H]1O)O)O)O)O
Sonolisib,PX-866,502632-66-8,525.59,PI3K,PI3K/Akt/mTOR,"Sonolisib (PX-866), an improved Wortmannin analogue, is an oral, irreversible, and pan-isoform inhibitor of PI3K (IC50=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)). Antitumor activity[1][2].",C29H35NO8,DMSO : 100 mg/mL (190.26 mM; Need ultrasonic),10mM,Cancer,Phase 2,O=C1C([C@@](CC2)([H])[C@@]3(C)C2=O)=C([C@H](OC(C)=O)C3)[C@]4(C)C(/C(C(O[C@@H]4COC)=O)=C\N(CC=C)CC=C)=C1O
Guaiazulene,,489-84-9,198.30,Akt; Apoptosis; Bacterial; Caspase; Fungal; mTOR; Reactive Oxygen Species (ROS),Anti-infection; Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR,"Guaiazulene is a bicyclic sesquiterpene that can cross the blood-brain barrier. Guaiazulene exhibits various biological activities such as anti-inflammatory, antioxidant, hepatoprotective, antibacterial, and anti-tumor properties. Guaiazulene is also commonly used as a colorant in cosmetics.  Guaiazulene shows in vitro cytotoxicity to rat neuronal cells and N2a neuroblastoma cells at high concentrations[1][2][3][4].",C15H18,DMSO : 50 mg/mL (252.14 mM; Need ultrasonic),10mM,Cancer; Infection; Inflammation/Immunology; Neurological Disease,Launched,CC(C1=CC2=C(C)C=CC2=C(C)C=C1)C
Perillyl alcohol,,536-59-4,152.24,Akt; Apoptosis; Caspase; Ras; Reactive Oxygen Species (ROS),Apoptosis; GPCR/G Protein; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; PI3K/Akt/mTOR,"Perillyl alcohol is an orally active monoterpene. Perillyl alcohol exhibits multiple activities such as analgesic, anti-inflammatory, anti-tumor, anti-angiogenic, and anti-nociceptive effects. Perillyl alcohol can induce apoptosis and cell cycle arrest in tumor cells[1][2][3][4].",C10H16O,DMSO : 100 mg/mL (656.86 mM; Need ultrasonic),10mM,Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease,Phase 1,OCC1=CCC(C(C)=C)CC1
Ceftiofur,,80370-57-6,523.56,Antibiotic; Bacterial; Interleukin Related; NF-κB; p38 MAPK; TNF Receptor,Anti-infection; Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; NF-κB,"Ceftiofur is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6[1][2][3].",C19H17N5O7S3,DMSO : 100 mg/mL (191.00 mM; Need ultrasonic),10mM,Infection,Launched,O=C(C(N12)=C(CSC(C3=CC=CO3)=O)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O
Disitertide (diammonium),P144 (diammonium),,1614.88,Apoptosis; PI3K; TGF-beta/Smad,Apoptosis; PI3K/Akt/mTOR; Stem Cell/Wnt; TGF-beta/Smad,Disitertide (P144) diammonium is a peptidic  transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide diammonium is also a PI3K inhibitor and an apoptosis inducer[1][2][3][4][5].,C68H115N19O22S2,DMSO : 10 mg/mL (6.19 mM; Need ultrasonic); H2O : 9.09 mg/mL (5.63 mM; ultrasonic and adjust pH to 9 with NH3·H2O),2mM,Cancer,Phase 2,O=C([C@@H](N)[C@@H](C)O)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C([O-])=O)CC(N)=O)=O)CCC(N)=O)=O)CCSC)=O)CCSC)=O)C)=O)CC1=CNC2=CC=CC=C12)=O)[C@H](CC)C)=O)[C@H](CC)C)=O)CO)=O)C)=O)CC([O-])=O)=O)CC(C)C)=O)CO.[NH4+].[NH4+]
LMP744,MJ-III65; NSC706744,308246-52-8,452.46,Topoisomerase,Cell Cycle/DNA Damage,LMP744 (MJ-III65) is a DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity[1].,C24H24N2O7,DMSO : ≥ 4.17 mg/mL (9.22 mM),2mM,Cancer,Phase 1,OCCNCCCN1C2=C(C(C3=CC(OCO4)=C4C=C23)=O)C5=CC(OC)=C(OC)C=C5C1=O
Fumaric acid,,110-17-8,116.07,Endogenous Metabolite; NF-κB; p38 MAPK,MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB,"Fumaric acid is an unsaturated dicarbonic acid, an intermediate product of the citric acid cycle that provides intracellular energy in the form of ATP. Fumaric acid exerts anti-inflammatory effects by inhibiting the NF-κB signaling pathway dependent on p38 MAPK. Fumaric acid can be used in the study of pregnancy-induced hypertension[1][2][3].",C4H4O4,H2O : 11.11 mg/mL (95.72 mM; Need ultrasonic); DMSO : 25 mg/mL (215.39 mM; Need ultrasonic),10mM,Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease,Launched,O=C(O)/C=C/C(O)=O
Glycine,,56-40-6,75.07,Endogenous Metabolite; iGluR; VEGFR,Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling; Protein Tyrosine Kinase/RTK,"Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis[1][2][3][4][5][6].",C2H5NO2,DMSO : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble or slightly soluble); Methanol : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble); H2O : 25 mg/mL (333.02 mM; Need ultrasonic),10mM,Neurological Disease,Launched,NCC(O)=O
